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Abstract 
In recent years, two G protein coupled receptors have been de-orphanised 
which respond to long chain free fatty acids (FFAs), and so are able to mediate 
the signalling of these important nutrient molecules. FFA1 (GPR40) is 
predominantly expressed in pancreatic -cells, while the expression profile of 
GPR120 includes gut endocrine cells and adipose tissue. These distributions, 
together with the potential of both receptors to stimulate insulin and incretin 
hormone secretion, singled them out as potential drug targets for type 2 
diabetes and obesity. The aim of this thesis was to evaluate the pharmacology 
of these receptors and their signalling properties, including the development 
of fluorescent FFA receptor ligands to evaluate agonist binding using imaging 
techniques.  
GPR120 has been identified to exist as two splice isoforms in humans, 
differing by a short insertion in the third intracellular loop, but no full isoform 
specific characterisation of receptor signalling and trafficking had been 
undertaken. This work therefore studied the GPR120S and GPR120L isoforms 
in terms of both G protein dependent and arrestin dependent signalling, 
and trafficking. It was found that the long GPR120L isoform exhibited reduced 
G protein signalling, but similar -arrestin recruitment and lysosomal 
intracellular trafficking profiles as GPR120S. Potentially, expression of the long 
GPR120 isoform provides a mechanism to direct signalling to the -arrestin 
pathway, for example to produce anti-inflammatory effects in macrophages. 
As the expression profile of GPR120 overlaps with that of FFA1, for example in 
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colonic endocrine cells, a series of constrained GPR120 homo-dimers and 
GPR120:FFA1 heterodimers were created using irreversible bimolecular 
fluorescence complementation, and the potential for novel pharmacology was 
investigated by monitoring dimer internalisation. However, there was no 
evidence that such dimerisation altered the pharmacology of the ligands 
tested. Second, a model of the GPR120S ligand binding site was tested using 
point mutagenesis of the receptor. This mutagenesis validated key features of 
the model, including the role of Arg99 in co-ordinating the agonist carboxylate 
group, and interactions of the agonists with the conserved transmembrane VI 
dƌƉ  “ƚŽŐŐůĞ-ƐǁŝƚĐŚ ? involved in receptor activation. Another mutation 
(Asn215) provided evidence for ligand-specific binding modes within the 
pocket. This study showed the complexity of testing mutants designed to 
interfere with ligand binding indirectly through signalling assays and 
highlighted the requirement for a FFA receptor binding assay to measure 
ligand affinity directly.  
In the absence of radioligands of suitable selectivity and affinity,  a novel 
fluorescent ligand, based on the FFA1/GPR120 agonist GW9508, was used to 
successfully develop a whole cell FFA1 competition binding assay for the first 
time, obtaining FFA1 affinity estimates for a range of synthetic ligands. 
Fluorescent ligand binding was further investigated using fluorescence 
correlation spectroscopy and photon counting histogram analysis, defining 
the diffusion characteristics of FFA1 receptors in the membrane of single 
living cells, and providing preliminary evidence for their dimerisation. 
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Chapter One: Introduction 
1.1 Fatty acids 
Fatty acid nutrients are classically seen as an important energy source, as their 
ɴŽǆŝĚĂƚŝŽŶŝŶƚŚĞŵŝƚŽĐŚŽŶĚƌŝĂǇŝĞůĚƐĞŶĞƌŐǇ(Yaney and Corkey, 2003). Fatty 
acids are also central to the synthesis and composition of other cellular lipids, 
for example the phospholipids that make up the plasma membrane (Williams 
et al., 2012).  
Increasingly however, free fatty acids (FFAs) ?ǁŚĞƌĞ “ĨƌĞĞ ?ƌĞĨĞƌƐƚŽĨĂƚƚǇĂĐŝĚƐ
that are not bound to carrier proteins such as albumin in plasma, have been 
shown to play diverse roles in intracellular signalling. Originally, these 
signalling roles were thought to be fulfilled indirectly via effects on 
metabolism and through nuclear localised peroxisome proliferator-activated 
receptors (PPARs) (Michalik et al., 2006). More recently, this signalling has 
also been shown to be elicited through membrane localised receptors, such as 
the fatty acid receptor family of G protein-coupled receptors (GPCRs) 
(Stoddart et al., 2008). 
Understanding these FFA signalling pathways is critical in unravelling the 
complex picture of the roles different types of FFA play in nutrition, and in 
targeting such pathways therapeutically. Some dietary fatty acids are seen as 
 “ďĞŶĞĨŝĐŝĂů ? ?ƐƵĐŚĂƐʘ-3 polyunsaturated fatty acids in fish oils, for example in 
having a neuroprotective ĞĨĨĞĐƚ ŝŶůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞ  ?ƚŚĞ ŶŽŵĞŶĐůĂƚƵƌĞŽĨ
fatty acids is covered in section 1.4.1). Unfortunately, evidence can be either 
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for (Hashimoto and Hossain, 2011), ŽƌĂŐĂŝŶƐƚŝŶĐƌĞĂƐŝŶŐʘ-3 fatty acids in the 
diet (Yip et al., 2013). Other FFAs are seen as damaging, for example 
ƐƵƉƉůĞŵĞŶƚŝŶŐƚŚĞĚŝĞƚǁŝƚŚʘ-6 unsaturated fatty acids such as linoleic acid 
has been shown to increase the risk of cardiovascular disease mortality 
(Ramsden et al., 2013). Some work has suggested that the ratio of dietary 
&&Ɛ ?Ğ ?Ő ?ʘ- ? Pʘ-6 unsaturated FFAs) is key for a beneficial effect upon fertility 
(Yan et al., 2013). Equally the dual action of different types of fatty acids as 
nutrients and as signalling molecules is linked to the pathogenesis and 
possible treatment of metabolic diseases, for example obesity (Buckley and 
Howe, 2010) and type II diabetes (Petit et al., 2012). In this introduction, the 
different mechanisms by which FFAs elicit intracellular signalling are briefly 
reviewed, before focusing on the potential physiological roles and signalling 
mechanisms of the recently identified FFA GPCRs, which are the subject of this 
thesis. 
1.2 Types of FFA signalling 
1.2.1 Effects via metabolism and as signalling precursors 
ɴŽǆŝĚĂƚŝŽŶŝŶƚŚĞŵŝƚŽĐŚŽŶĚƌŝĂŝƐƚŚĞƉƌŽĐĞƐƐǁŚŝĐŚďƌĞĂŬƐĚŽǁŶĨĂƚƚǇĂĐŝĚƐ
into acetyl-Coenzyme A (CoA) for entry into the tricarboxylic acid cycle. This 
yields reduced NADH (nicotinamide adenine dinucleotide) and FADH2 (flavin 
adenine dinucleotide) which can then enter the electron transport chain to 
generate energy in the form of adenosine triphosphate (ATP) (Porter and 
Brand, 1995). The ratio of acetyl-CoA to CoA fluctuates depending on the 
metabolic status of the cell, and therefore signals the nutrient status of the 
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cell. For example if there is a high level of nutrients, there will be a higher 
level of acetyl-CoA. Acetylation has also been shown to regulate both the 
activity of metabolic enzymes and the expression of their genes (Wellen and 
Thompson, 2012). Meanwhile, malonyl-CoA is produced from the 
carboxylation of acetyl-CoA, and regulates the activity of carnitine 
acyltransferase, preventing long chain fatty acids being taken up into the 
ŵŝƚŽĐŚŽŶĚƌŝĂĨŽƌɴŽǆŝĚĂƚŝŽŶ(Graciano et al., 2011). 
The relationship between the cellular uptake and -oxidation of fatty acids 
must be balanced, as intracellular accumulation outweighing -oxidation can 
lead to the engagement of alternative metabolic pathways which for example, 
may contribute to insulin resistance (Zhang et al., 2010a). One such process in 
skeletal muscle cells involved the metabolism of the saturated FFA palmitate 
into the inflammatory molecule ceramide (Sabin et al., 2007). Free fatty acids 
are also precursors which can affect production of many other lipophilic 
signalling molecules, such as cannabinoids (Kim et al., 2011), prostaglandins 
(Hellmann et al., 2013), leukotrienes (Norris and Dennis, 2012), and 
sphingosine (Huwiler and Pfeilschifter, 2009). 
1.2.2 The influence of FFAs on cellular membranes 
The plasma membrane is made up of a phospholipid bilayer, formed due to 
the nature of the phospholipids. They are made up of a hydrophilic phosphate 
headgroup (orientated towards the aqueous environment) and two 
hydrophobic fatty acid tails. The different types of fatty acids incorporated 
into phospholipids present in the plasma membrane can influence membrane 
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fluidity. Phospholipids containing saturated fatty acids (rigid, lacking double 
bonds) can aggregate in lipid rafts (that also contain the lipid cholesterol), 
whilst unsaturated fatty acid tails have rotation around their double bonds, 
and form a more fluid membrane excluding cholesterol (the structures of FFAs 
are covered in section 1.4.1) (Williams et al., 2012). Saturated lipid rafts have 
ƌĞĐĞŝǀĞĚ ĂƚƚĞŶƚŝŽŶ ĂƐ  “ŵŝĐƌŽĚŽŵĂŝŶƐ ? ǁŝƚŚŝŶ ƚŚĞ ƉůĂƐŵĂ ŵĞŵďƌĂŶĞ ƚŚĂƚ
might organise protein signalling complexes, for example containing G protein 
coupled receptors (Bjork and Svenningsson, 2011). 
There are several examples of how different fatty acids can have a modulatory 
role upon membrane receptors, by their incorporation into lipids to influence 
the plasma membrane environment. It was found that a higher concentration 
ŽĨ ƉŚŽƐƉŚĂƚŝĚǇůĐŚŽůŝŶĞ ĐŽŶƚĂŝŶŝŶŐ ʘ- ? ĨĂƚƚǇ ĂĐŝĚ  ?ĐŽŵƉĂƌĞĚ ƚŽ ʘ-3) in the 
plasma membrane caused a reduction in G protein-coupled signalling from 
the light receptor rhodopsin. This was thought to be due to the double bond 
Ăƚʘ- ?ĚŽĐŽƐĂƉĞŶƚĂĞŶŽŝĐĂĐŝĚ  ?W ) ŝŶƐƚĞĂĚŽĨĂƚʘ-3 docosahexaenoic acid 
(DHA), that appears to directly impact the conformation changes associated 
with rhodopsin activation (Mitchell et al., 2012) Also, DHA and DPA 
supplementation of cells expressing Toll-like receptor (TLR)-4, found that the 
subsequent activation of TLR-4 led to the increased release of fatty acids from 
membrane lipids (via lipase activity) that selectively inhibited cyclooxygenase 
pathways, therefore having an anti-inflammatory effect (Norris and Dennis, 
2012). It has also been found that fatty acids can modulate the activity of 
potassium and sodium ion channels and that this can be exploited 
therapeutically in the treatment of epilepsy. The presence of polyunsaturated 
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fatty acids (PUFAs) in the diet, such as DHA, resulted in the hyperpolarisation 
of the plasma membrane in isolated pyramidal neurones, preventing the 
hyper excitability associated with epileptic seizures (Tigerholm et al., 2012). 
ʘ-3 fatty acids have also been shown to play a direct and indirect signalling 
role upon transient receptor potential (TRP) channels in neurodegeneration 
(Leonelli et al., 2011). Interestingly, FFAs have a diverse range of effects upon 
TRP channels. They can act both directly upon these channels or can modulate 
TRP activity indirectly by having an effect upon the plasma membrane lipids. 
For example DHA was found to be a potent agonist, whilst linolenic acid was 
an antagonist directly at TRPV1 (Matta et al., 2007). On the other hand, these 
effects could be mediated by the fact that PUFAs alter the composition of 
plasma membrane lipids around the receptor (Bruno et al., 2007). 
In addition to the plasma membrane, the presence of different dietary FFAs 
can alter the composition of other cellular membrane bilayers with functional 
significance. For example cardiolipin is a dimeric phospholipid (with four acyl 
fatty acid tails) found in the inner mitochondrial membrane. It is thought to be 
required for various mitochondria functions, and that its effects can be 
regulated by cardiolipin remodelling with different fatty acids. For example 
supplementation of DHA has been shown to have a positive effect in 
preventing mitochondrial cell death, thought to be due to it having an 
unsaturating effect upon cardiolipin composition (Khairallah et al., 2012). 
Potentially, this could be used in treating mitochondrial dysfunction in various 
ĚŝƐŽƌĚĞƌƐ ? ƐƵĐŚ ĂƐ WĂƌŬŝŶƐŽŶ ?Ɛ(Chao et al., 2012) ? ůǌŚĞŝŵĞƌ ?Ɛ(Eckert et al., 
2012) and cardiovascular disease (Stanley et al., 2012). 
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1.2.3 The PPAR family of nuclear receptors 
The PPAR family of receptors are ligand activated transcription factors. 
Arguably, they were the first free fatty acid receptors to be identified, 
responding intracellularly to the fatty acids and their derivatives. Following 
activation by lipid ligands in the cytoplasm, PPARs translocate to the nucleus 
and form heterodimers with the retinoid x receptor. Using a de-repression 
mechanism, these heterodimers then activate the expression of genes related 
to lipid homeostasis and metabolism, which lower circulating lipid levels and 
increase insulin sensitivity. They activate or suppress genes involved in 
metabolism, but the activity of which specific genes they modulate depends 
ŽŶƚŚĞ ƐƵďƚǇƉĞ ŝŶƋƵĞƐƚŝŽŶ ?ŽĨǁŚŝĐŚ ƚŚĞƌĞ ĂƌĞ  ? Pɲ ?ɴ ɷĂŶĚɶ(Sugden and 
Holness, 2008). 
The endogenous ligands for the PPARɲ subtype include fatty acids and other 
ŵĞĚŝĂƚŽƌƐ ƐƵĐŚ ĂƐ ƉƌŽƐƚĂŐůĂŶĚŝŶƐ ? dŚŝƐ ƐƵďƚǇƉĞ ƉůĂǇƐ Ă ƌŽůĞ ŝŶ ƌĞŐƵůĂƚŝŶŐ ɴ-
oxidation of fatty acids in the liver and skeletal muscle, adapting metabolism 
in response to a change in nutrition. These genes are involved in lipid 
catabolism and homeostasis, and their activation results in increasing the 
oxidation and uptake of fat, and decreasing the synthesis of fatty acids (Cook 
et al., 2000). It is a clinical target for dyslipidaemia (Nicholls and Uno, 2012), 
using synthetic agonists such as clofibric acid, and was also surprisingly found 
to be a modulator of inflammation (Belfort et al., 2010). 
The PPARɴ ?ɷ subtype is found in all tissues, but the least is known about this 
subtype. Its activation represses genes involved in lipid metabolism to 
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increase fat oxidation (Roberts et al., 2011). Selective agonists suggest a 
clinical role in improving insulin sensitivity and perhaps a use in the treatment 
of diabetes (Salvado et al., 2012). 
There are two subtypes of PPARɶ found in pancreas and skeletal muscle, and 
adipose tissue. Its activation modulates genes involved in insulin signalling, 
glucose and lipid homeostasis (Herzig et al., 2003) and lipid storage, playing a 
role in adipocyte differentiation (Floyd and Stephens, 2012; Roberts et al., 
2011; Virtue et al., 2012). Its activation also has an anti-inflammatory effect 
(Liao et al., 2007) ? WWZɶ ĂŐŽŶŝƐƚƐ ? ƐƵĐŚ ĂƐ ƚŚŝĂǌŽůŝĚŝŶĞĚŝŽŶĞƐ  ?dƐ ) ŚĂǀĞ 
been used in the past as insulin sensitisers in type II diabetes, but recently 
these have also been associated with an increased cardiovascular risk (see 
section 1.4.4.1.1.4). 
1.2.4 Fatty acid receptor family of GPCRs 
More recently, FFA mediated signalling has also been shown to be elicited 
through plasma membrane localised GPCRs (Stoddart et al., 2008). One FFA 
family of GPCRs is found in a cluster present on chromosome 19q13.1. This 
cluster contains GPR40, also known as free fatty acid receptor 1 (FFA1) along 
with GPR41 (FFA3), GPR42 (an inactive pseudogene in man) and GPR43 
(FFA2). FFA2 and FFA3 are activated by short chain FFAs (Brown et al., 2003; 
Le Poul et al., 2003; Nilsson et al., 2003). FFA2 is expressed in the immune 
cells (Le Poul et al., 2003), adipose tissue (Brown et al., 2003; Nilsson et al., 
2003) and the gastrointestinal (GI) tract (Karaki et al., 2006; Karaki et al., 
2008). FFA2 plays a role in the stimulation of adipogenesis and inhibition of 
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lipolysis (Ge et al., 2008; Hong et al., 2005). Meanwhile, FFA3 is also expressed 
in the adipose tissue (Brown et al., 2003), the immune cells (Brown et al., 
2003; Le Poul et al., 2003) and the GI tract (Tazoe et al., 2009), and has been 
shown to be involved in the production of the anorexigenic hormone, leptin 
(Xiong et al., 2004). 
FFA1 receptors (Briscoe et al., 2003; Itoh et al., 2003; Kotarsky et al., 2003), 
together with the distantly related GPR120 found on chromosome 10q23.33 
(Fredriksson et al., 2003a), are activated by medium to long chain FFAs 
(Hirasawa et al., 2005) ?&& ?ŝƐƉƌĞĚŽŵŝŶĂŶƚůǇĞǆƉƌĞƐƐĞĚŝŶƉĂŶĐƌĞĂƚŝĐɴĐĞůůƐ
and GI tract (Briscoe et al., 2003; Itoh et al., 2003; Kotarsky et al., 2003) and 
one of its key roles is the potentiation of glucose stimulated insulin secretion 
 ?'^/^ )ĨƌŽŵɴĐĞůůƐ(Briscoe et al., 2003). GPR120 is predominantly expressed 
in intestinal enteroendocrine cells (e.g. L cells), as well as in the lungs and 
adipose tissue (Gotoh et al., 2007; Hirasawa et al., 2005) and is thought to 
play a role in the secretion of satiety gut hormones, also known as incretins, 
such as cholecystokinin (CCK) (Tanaka et al., 2008a) and glucagon-like peptide-
1 (GLP-1) (Tanaka et al., 2008b). These two receptors will be discussed in 
more detail later in the introduction (section 1.4). 
There are two more unrelated receptors which respond to fatty acids or their 
close derivatives: GPR84 and GPR119. GPR84 is expressed on macrophages, 
and has been postulated to be a pro-inflammatory receptor (Suzuki et al., 
2013). It is activated by medium chain fatty acids (C9-14) (Nagasaki et al., 
2012), and this amplifies the production of pro-inflammatory cytokines, for 
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example in macrophages (Suzuki et al., 2013) ?dƵŵŽƵƌŶĞĐƌŽƐŝƐĨĂĐƚŽƌ ?dE& )ɲ
has been shown to upregulate expression of GPR84 in adipocytes, suggesting 
its participation in metabolic inflammation contributing to the vicious cycle 
between obesity and type II diabetes (Nagasaki et al., 2012). 
GPR119, on the other hand, responds to ethanolamide derivatives of fatty 
acids and phospholipids (Soga et al., 2005). It is expressed in the paŶĐƌĞĂƚŝĐɴ
cell (Soga et al., 2005) and in intestinal endocrine L cells in the GI tract (Lauffer 
et al., 2009). Its actŝǀĂƚŝŽŶŝŶƚŚĞƉĂŶĐƌĞĂƚŝĐɴĐĞůůůĞĂĚƐƚŽŐůƵĐŽƐĞĚĞƉĞŶĚĞŶƚ
insulin secretion, through coupling to Gs to cause an increase in cyclic 
adenosine monophosphate (cAMP) levels (Soga et al., 2005), whilst activation 
in the L cell leads to the release of GLP-1 and other peptide hormones (Lauffer 
et al., 2009). Both oleoylethanolamide and a synthetic agonist at GPR119 
were found to suppress food intake and reduce body weight in rodents 
(Overton et al., 2006). A summary of the ligands of FFAs at the FFA family of 
receptors is shown in Figure 1.1. 
There are also other families of lipid GPCRs which are not phylogenetically 
related, but can still share related agonist pharmacology, for example the 
cannabinoid receptors and the sphingosine-1-phosphate receptor subtypes. 
There are two cannabinoid receptors, CB1 and CB2. CB2 is involved in immune 
responses, whilst CB1 is expressed both centrally and peripherally, and is 
involved in glucose and lipid metabolism (Cavuoto et al., 2007). They are 
activated by lipid derived endocannabinoids such as anandamide (also shown 
in Figure 1.1), which are endogenously produced from phospholipids 
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containing arachidonic acid present in the plasma membrane of cells 
(Newman et al., 2007). In relation to the therapeutic opportunities presented 
by other fatty acid receptors (discussed in section 1.4.4), the CB1 receptor has 
been a target for obesity treatments (the inverse agonist rimonabant, now 
withdrawn for its depressant side effects (Despres et al., 2005)), as centrally 
expressed receptors play a role in controlling appetite (Kim et al., 2013b). The 
five sphingosine-1-phosphate (S1P) receptor subtypes are activated by S1P 
and lysophosphatidic acid (Rosen et al., 2009). S1P is a lipid mediator 
generated from sphingomyelin, thought to play in a role in the positive 
cardiovascular effects of high density lipoprotein (HDL) (Rodriguez et al., 
2009). Interestingly, blockade of S1P receptor signalling was also found to 
slow the onset of streptozotocin induced diabetes (Imasawa et al., 2010). 
Also, treatment with immunomodulatory drug fingolimod (FTY720; an S1P 
receptor 1 agonist following its phosphorylation by sphingosine kinase), 
prevented weight gain and increased insulin sensitivity in mice, implicating 
this receptor as another possible therapeutic target in type II diabetes 
(Kendall and Hupfeld, 2008).  
11 
 
 
Figure 1.1 Structures of ligands at fatty acid receptors 
Structures of the various ligands at members of the FFA receptor family. Short 
chain FFAs at FFA2 and FFA3; medium to long chain FFAs at FFA1 and GPR120; 
and FFA derivatives at GPR119. Also included is anandamide, the agonist for 
the cannabinoid receptor,  ? ? dŚĞ ʘ-x nomenclature for unsaturated FFAs 
derives from the first position of the double bond(s) relative to the terminal 
methyl of the acyl chain; i.e. ʘ-3 (3rd ďŽŶĚ ? ƐƵĐŚ ĂƐ , ) ? ʘ-6 (6th bond; 
ĂƌĂĐŚŝĚŽŶŝĐĂĐŝĚ ?ůŝŶŽůĞŝĐĂĐŝĚ ) ?ʘ-9 (9th bond; oleic acid).  
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1.3 G protein-coupled receptors 
The FFA plasma membrane GPCRs are part of a receptor family of more than 
800 distinct proteins, contributing to approximately 1-2 % of the human 
genome (Fredriksson et al., 2003b). This great number of GPCRs allows for 
them as a whole to respond to a great variety of ligands such as photons, 
amino acids, peptides, proteins, lipids, carbohydrates and other small organic 
compounds (Lagerstrom and Schioth, 2008). Thus GPCRs play a fundamental 
role in cell to cell communication between different cell types in the body, 
essential for whole body homeostasis. GPCRs are also already well-
represented as drug targets. They are the object of 25-30 % of current drugs 
(Overington et al., 2006), though these only target only a small number of 
GPCRs, ~30 (Wise et al., 2004). As a group, GPCRs have similarities, but also 
contain differences which allow for their division into families by functional 
and structural similarity. 
1.3.1 Classification 
The first attempt to classify GPCRs assigned them into six groups, A - F 
(Kolakowski, 1994). This classification system has been further embellished 
over the years, condensing into five groups (Bockaert and Pin, 1999; 
Fredriksson et al., 2003b). This latest classification system is called the GRAFS 
system and relates to the non-sensory GPCRs, giving families based on 
phylogenetic analysis: glutamate (also called class C), rhodopsin (class A), 
adhesion, frizzled and secretin (class B) (Fredriksson et al., 2003b). 
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Class A comprises of rhodopsin-like GPCRs, which is the largest group, 
containing almost 700 GPCRs (~400 olfactory GPCRs, with the other ~300 
being non-sensory GPCRs). Receptors within this group typically have short 
amino termini and are activated by the ligand binding within the TM helices or 
the extracellular loops (Bockaert and Pin, 1999). This group can be further 
ƐƉůŝƚ ŝŶƚŽ  ? ƐŵĂůůĞƌ ŐƌŽƵƉƐ ?dŚĞ ɲ ƐƵďŐƌŽƵƉĐŽntains many pharmaceutically 
ƌĞůĞǀĂŶƚŵŽŶŽĂŵŝŶĞƌĞĐĞƉƚŽƌƐ ?ƐƵĐŚĂƐƚŚĞɴadrenoceptors, the muscarinic 
receptors, the histamine receptors, the dopamine receptors and the serotonin 
receptors. The small amine ligands bind within the transmembrane (TM) 
helices of these receptors (Rosenbaum et al., 2007). The fatty acid receptors 
ĂůƐŽ ďĞůŽŶŐ ƚŽ ƚŚŝƐ ŐƌŽƵƉ ? dŚĞ ɴ ƐƵďŐƌŽƵƉ ƉƌĞĚŽŵŝŶĂŶƚůǇ ĐŽntains peptide 
receptors such as the neuropeptide Y family of receptors, the oxytocin 
receptor and the neurokinin-1 receptor. These peptide ligands also bind 
within the TM helices, but with additional involvement from the extracellular 
loops (ECLs) (Fong et al., 1992) ? DĞĂŶǁŚŝůĞ ? ƚŚĞ ɶ ƐƵďŐƌŽƵƉ ŝŶĐůƵĚĞƐ ďŽƚŚ
peptide receptors and lipid receptors such as the opioid receptors and the 
chemokine receptors; whilst glycoprotein and olfactory receptors belong to 
ƚŚĞɷƐƵď-group (Fredriksson et al., 2003b).  
Class B is an amalgamation of the secretin-like group of receptors and the 
adhesion group of receptors. The secretin-like peptide receptors include the 
secretin receptor, the glucagon receptor, the glucagon-like peptide receptor 
and the gastric inhibitory polypeptide receptor. They typically contain a large 
amino terminus which contain six cysteine residues that form disulphide 
bridges, thought to be key for forming the ligand binding domain for peptide 
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hormones (Grace et al., 2004; Lisenbee et al., 2005). Meanwhile, the adhesion 
receptors also have a large amino terminus (Bjarnadottir et al., 2004), but 
differ from the secretin receptors by the fact their amino termini may contain 
proteolytic domains, and that they also bind extracellular matrix molecules 
(Krasnoperov et al., 2002).  
Class C receptors are the metabotropic receptors, that respond to 
neurotransmitters glutamate and ɶ-aminobutyric acid (GABA), calcium, and to 
sweet and unami taste molecules. They also contain a large globular amino 
terminus motif called a Venus fly trap (VFT) motif, containing two domains 
that in between them form a cleft. Once the agonist binds within, the two 
domains close together, not too dissimilar to a Venus fly trap (Kunishima et 
al., 2000); these receptors are also known for characteristically forming 
dimers, in part via interactions through the VFT domains (see section 1.6.5). 
The final class of receptors is known as the frizzled/taste2 group, which 
contains the group of 10 frizzled receptors (FZD 1-10) and the smoothened 
(SMO) receptor (Davies et al., 2007; Kolakowski, 1994), both of which are 
involved in development. Frizzled receptors respond to secreted glycoproteins 
associated with Wnt signalling (Malbon, 2004). Meanwhile, SMO is involved in 
sonic hedgehog (SH) signalling, for example during developmental responses 
(Polizio et al., 2011).  
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1.4 Long chain fatty acid GPCRs, FFA1 and GPR120 
The fatty acid receptors described in 1.2.4 are all class A GPCRs. FFA1 is an 
intron-less gene (Sawzdargo et al., 1997), whilst GPR120 contains four exons 
and has two splice variants (Figure 1.2). The short isoform contains 361 
residues, whilst the long isoform contains 16 additional residues between 
positions 231 and 247 in intracellular loop (ICL) 3. 
1.4.1 FFA GPCR pharmacology 
As a group, FFA GPCRs are distinguished predominantly by their selectivity for 
endogenous FFAs of different chain length. FFA2 and FFA3 are both activated 
by C2-6 short chain fatty acids (Brown et al., 2003; Le Poul et al., 2003; Nilsson 
et al., 2003), but differ in their order of potency: FFA2 is C3>C4=C2>C6>C5, 
whilst FFA3 is C3>C4>C6>C5>C2 (Le Poul et al., 2003). GPR120 is activated by 
long chain fatty acids: C14-18 saturated, C16-22 mono- and poly-unsaturated 
(Hirasawa et al., 2005). FFA1 is activated by medium to long chain fatty acids: 
C6-18 saturated and C10 W22 unsaturated (Briscoe et al., 2003; Itoh et al., 
2003; Kotarsky et al., 2003). As discussed above, GPR119 is activated by 
ethanolamide derivatives of fatty acids and phospholipids rather than fatty 
acids themselves (Soga et al., 2005), and most potently by 
oleoylethanolamide (Overton et al., 2006); thus unlike FFA1 and GPR120, free 
carboxylic acid groups present in FFAs are not required for GPR119 activity. 
FFA1 and GPR120 are activated by all types of fatty acids including saturated, 
unsaturated, polyunsaturated and conjugated fatty acids. Saturated fatty 
acids contain no double bonds i.e. they are saturated with hydrogens, whilst 
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unsaturated fatty acids contain one double bond. PUFAs contain multiple 
double bonds, and conjugated fatty acids contain a pair of double bonds that 
are separated by only one single bond (Figure 1.1). Fatty acids can also be 
ŶĂŵĞĚĨŽƌ ƚŚĞƉŽƐŝƚŝŽŶŽĨ ƚŚĞ ĚŽƵďůĞ ďŽŶĚ ? ĨŽƌĞǆĂŵƉůĞ ʘ-3 fatty acids are 
named such because the double bond is placed at the third carbon from the 
terminal methyl of the carbon chain (the opposite end of the fatty acid from 
the carboxyl group). 
Additionally, both FFA1 and GPR120 are activated by the synthetic agonist 
GW9508, whilst only FFA1 is inhibited by the antagonist GW1100 (Briscoe et 
al., 2006). These and other synthetic ligands will be discussed in more depth in 
chapter 4. 
1.4.2 Polymorphisms found in FFA1 and GPR120 
Three single nucleotide polymorphisms of FFA1 have been identified in 
humans: D175N found in ECL2 (Hamid et al., 2005); R211H found in ICL3 (Haga 
et al., 2002; Hamid et al., 2005; Ogawa et al., 2005) and G180S found in TM 5 
(Vettor et al., 2008). These polymorphisms have principally been explored as 
risk factors for type II diabetes (see also section 1.4.3). 
Both D175A and R211H are caused by guanine to adenine substitutions. 
Studies on both Danish (Hamid et al., 2005) and Italian subjects (Vettor et al., 
2008) found that these mutations had no effect upon markers for type II 
diabetes. In vitro signalling studies found both R211H and D175N mutants to 
have similar agonist potency values to FFA1 wild type (WT), but D175N had a 
maximum efficacy lower than WT and R211H (Hamid et al., 2005). Conversely 
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however, a study on Japanese subjects found a sliding scale of phenotype. The 
Arg homozygotes had the lowest measurements, in terms of levels of insulin 
secretion and values determined using the homeostasis models of insulin 
ƌĞƐŝƐƚĂŶĐĞ ĂŶĚ ɴ-cell function, whilst the His homozygotes had the highest, 
and the heterozygotes were intermediate. They postulated that the H211 
FFA1 phenotype predisposes to insulin resistance (Ogawa et al., 2005). 
Interestingly, the prevalence of the FFA1 G180S mutation increased with body 
mass index, suggesting a link between the mutation, and the likelihood to 
become obese. Carriers of the Ser allele were found to have significantly 
lower insulin secretion in response to lipids. Additionally, in vitro studies also 
found the Ser180 FFA1 receptors to have a significantly lower signalling 
response to fatty acids (Vettor et al., 2008). However, more recent work on 
these mutations using recombinant cell lines found no difference in signalling 
or potency to agonists (Smith et al., 2009). 
A recent study has also found a human GPR120 polymorphism present in 
European populations. R270H was found to inhibit intracellular signalling 
mediated by long chain fatty acids and increased the risk of obesity in both 
mice and humans (Ichimura et al., 2012).  
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Figure 1.2 Structures of FFA1 and GPR120. 
Structures of FFA1 and GPR120, with the site of the 16 residue insert in the 
long isoform of GPR120 also shown (*). The most conserved residue in each 
TM helix, characteristic of class A GPCRs, is shown in a blue box.  In 
Ballesteros-Weinstein labelling (Ballesteros and Weinstein, 1995), this residue 
is x.50 (where x is the number of the TM domain). Asparagine mediated 
glycosylation sites are shown in black; potential cysteine disulphide bridges 
are shown in grey; and palmitoylation sites are shown in red.  
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1.4.3 Physiological roles of FFA1 and GPR120 
The following section will deal with the physiology of FFA1 and GPR120 and 
their potential roles as nutrient sensors. 
1.4.3.1 Insulin secretion and ƉĂŶĐƌĞĂƚŝĐɴĐĞůů function 
Most of the initial work on FFA1 focused on its high levels of expression in 
ƉĂŶĐƌĞĂƚŝĐɴĐĞůůƐ ?ǁŚŝĐŚĐĂŶďĞĨƵƌƚŚĞƌŝŶĐƌĞĂƐĞĚ ?ďǇ&& ?ŐĞŶĞƚƌĂŶƐĐƌŝƉƚŝŽŶ )
under conditions of high glucose (Kebede et al., 2012) ? /ŶƉĂŶĐƌĞĂƚŝĐɴĐĞůůƐ ?
FFA1 rapidly potentiates GSIS in the presence of FFAs. FFA1 mediates these 
acute affects of FFAs, by increasing intracellular calcium signalling, to increase 
insulin secretion (Itoh et al., 2003; Matsuda-Nagasumi et al., 2013). FFA1 has 
also been implicated in mediating the chronic effects of fatty acids that can 
lead to lipotoxicity (Steneberg et al., 2005); however, these studies on FFA1 
and lipotoxicity have been controversial. Two studies concluded that FFA1 
was not responsible for the chronic effects that lead to ůŝƉŽƚŽǆŝĐŝƚǇ ŝŶɴ cells 
(Latour et al., 2007; Tan et al., 2008). 
In fact, lipotoxicity could simply be due to excess ɴ ŽǆŝĚĂƚŝŽŶ ŝŶ ƚŚĞ
mitochondria. Chronic excess fatty acids can lead to defects in this process in 
ƚŚĞŵŝƚŽĐŚŽŶĚƌŝĂ ?ůĞĂĚŝŶŐƚŽɴĐĞůůĨĂŝůƵƌĞ(Joseph et al., 2004; Lu et al., 2010). 
Thus, FFA1 knockout mice have shown impaired GSIS in  cells (Alquier et al., 
2009), but this knock out has not been shown to prevent the development of 
insulin resistance in other cell types (Kebede et al., 2008; Lan et al., 2008), or 
glucose intolerance, even on a high fat diet or diabetes background (Matsuda-
Nagasumi et al., 2013). Additionally, the FFA1 knock out animals did not 
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ĚŝƐƉůĂǇ ĂůƚĞƌĞĚ ɴ ĐĞůů ĂƌĐŚŝƚĞĐƚƵƌĞ (Matsuda-Nagasumi et al., 2013). Also, in 
one study, transgenic over-expression of FFA1 actually led to improved 
glucose tolerance and increased insulin secretion (Nagasumi et al., 2009), 
suggesting that FFA1 activity may even have a positive effect in the long term.  
These sets of conflicting studies led to a long debate on whether an agonist 
(Nagasumi et al., 2009) or antagonist (Steneberg et al., 2005; Vettor et al., 
2008) would be best as a potential treatment for type II diabetes. The 
published findings of agonist TAK-875 (Sasaki et al., 2011) concluded that 
FFA1 does not mediate the chronic effects of FFAs that cause lipotoxicity 
(Tsujihata et al., 2011), with clinical trials showing that in terms of treating 
diabetic patients at least (Kaku et al., 2013), FFA1 agonists are the way 
forward (Leifke et al., 2012). This does not rule out antagonists though, in 
perhaps playing a role in blocking the pancreatic effects of chronically 
elevated levels of FFAs, or perhaps for improving insulin secretion (Hu et al., 
2009; Zhang et al., 2010b). 
PPARɶ is also found in pancreas, and like the fatty acid receptors is activated 
by fatty acids. Its activation results in the transcription of genes involved in 
insulin signalling, glucose and lipid homeostasis (Herzig et al., 2003). There is 
ĂůƐŽĞǀŝĚĞŶĐĞƚŚĂƚWWZɶĂĐƚŝǀĂƚŝŽŶŵĂǇŝŶĐƌĞĂƐĞƚŚĞĞǆƉƌĞƐƐŝŽŶŽĨ&& ?(Kim 
et al., 2013a), further suggesting an relevant role for FFA1 in fatty acid control 
in the ƉĂŶĐƌĞĂƚŝĐɴĐĞůů ? 
There have also been suggestions of GPR120 expression in both the 
ƉĂŶĐƌĞĂƚŝĐɴ ĐĞůůƐ (Morgan and Dhayal, 2009) ĂŶĚ ƚŚĞ ɲĐĞůůƐ ? ǁŚŝĐŚ ƌĞůĞĂƐĞ
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ŐůƵĐĂŐŽŶ ? /ƚǁĂƐƉŽƐƚƵůĂƚĞĚƚŚĂƚ'WZ ? ? ? ŝŶƚŚĞɲĐĞůůŵĂǇƉůĂǇĂƌŽůĞ in FFA 
potentiation of glucagon release, as shown by the attenuation of glucagon 
release in GPR120 KO cells (CP Briscoe, Janssen Pharmaceuticals, personal 
communication). 
As discussed below, increased incretin hormone levels mediated through 
GPR120 (and possibly FFA1) in gut endocrine cells has been shown to enhance 
GSIS and increase ƉƌŽůŝĨĞƌĂƚŝŽŶ ŽĨ ƉĂŶĐƌĞĂƚŝĐ ɴ cells (Tanaka et al., 2008b). 
WĞƌŚĂƉƐƚŚŝƐŝŶĐƌĞĂƐĞŝŶɴĐĞůůŶƵŵďĞƌŝƐŝŶƉĂƌƚĚƵĞƚŽGPR120 also having a 
role in the inhibition of fatty acid induced, but not glucose induced islet 
apoptosis (Katsuma et al., 2005; Taneera et al., 2012). 
1.4.3.2 FFA1 and GPR120 in  intestinal endocrine cells 
FFA1 is also expressed by the K, L and I endocrine cells in the gut. The K cells 
are found in the duodenum and jejunum, and secrete glucose-dependent 
insulinotropic peptide (GIP) (Parker et al., 2009). Due to its action as a GI 
hormone that causes insulin release, GIP is called an incretin (Thorens, 1995). 
K cells have been found to release GIP following the activation of FFA1 (Luo et 
al., 2012). The L cells are found in the small intestine and colon (Reimann et 
al., 2008), and are associated with the release of GLP-1 and peptide YY (PYY). 
GLP-1 is also an incretin (Thorens, 1995). FFA1 activation was also found to 
mediate the secretion of GLP-1 (Habib et al., 2013; Li et al., 2013; Luo et al., 
2012; Xiong et al., 2013). Additionally, the I cells are found in the duodenum 
and small intestine, and secrete CCK. These cells have also been found to 
express FFA1 (Sykaras et al., 2012), whose activation has also shown to cause 
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CCK release (Liou et al., 2011). This involvement and action of FFA1 is of 
interest because all incretins (CCK, GIP, GLP-1 and PYY) increase insulin 
secretion from ɴ cells (Edfalk et al., 2008; Luo et al., 2012), as well as playing a 
role in promoting satiety (Naslund et al., 1998). 
However, assignment of a specific role of FFA1 in intestinal endocrine 
secretion is complicated by the fact that GPR120 is also predominantly 
expressed in the gut endocrine cells. GPR120 has also been found to be 
expressed in the same sets of K cells (Parker et al., 2009), I cells (Sykaras et al., 
2012) and L cells (Habib et al., 2013) as FFA1. GPR120 mediates GLP-1 release 
(Hirasawa et al., 2005; Tanaka et al., 2008b), with the G protein alpha subunit 
gustducin implicated in the coupling mechanism between GPR120 and GLP-1 
secretion (Li et al., 2013). Indeed, in studies using the intestinal endocrine cell 
line STC-1, GPR120 but not FFA1 siRNA mediated knockdown was capable of 
preventing FFA-stimulated incretin release (Hirasawa et al., 2005). In the I 
cells, GPR120 activation was found to cause CCK release (Tanaka et al., 
2008a). Additionally, GPR120 has also been postulated to play a role in 
regulating the production of acylated-ghrelin in secretory cells of the stomach 
and small intestine, which is known as the only peripheral hormone to 
stimulate appetite (Janssen et al., 2012). 
1.4.3.3 GPR120 In the adipocyte 
GPR120 is also expressed in adipose tissue, and thought to have a role in 
adipogenesis, allowing adipocyte maturation and differentiation (Gotoh et al., 
2007). GPR120 has also been shown to increase glucose uptake though 
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intracellular calcium signalling (Oh da et al., 2010) and also play a role in 
regulating glucose metabolism in these cells (Liu et al., 2012a). 
1.4.3.4 Other sites of interest 
GPR120 is expressed in the lingual cells on the tongue, which in conjunction 
with expression in the gut, gives the picture of GPR120 being a dietary lipid 
sensor (Matsumura et al., 2007). Additionally, GPR120 is expressed in 
macrophages and has been shown to have an anti-inflammatory role (Oh da 
et al., 2010). There is also evidence for an anti-inflammatory role for FFA1 
(Fujita et al., 2011). 
Both FFA1 and GPR120 have found to be expressed in bone, with GPR120 
being found in osteoblasts and FFA1 in osteoclasts. It was found that long 
chain fatty acids inhibit osteoclastogenesis and stimulate osteoblast function, 
contributing to a positive effect upon bone density (Cornish et al., 2008). This 
has been corroborated by more recent work which also showed that the 
activation of FFA1 was found to protect against bone loss by preventing the 
differentiation of osteoclasts (Wauquier et al., 2013). Interestingly though, the 
activation of FFA1 by TZD treatment has been shown to increase the incidence 
of bone fractures (Mieczkowska et al., 2012). 
FFA1 is substantially expressed in brain tissue (Briscoe et al., 2003), but its 
functions remain largely unclear. One group found FFA1 to play a role in 
antinociception (Nakamoto et al., 2012). Another group postulated that FFA1 
may have a role in PUFAs, such as DHA, being neuroprotective (Boneva et al., 
2011). 
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1.4.4 FFA1 and GPR120 as targets for diabetes and obesity 
1.4.4.1 Type II diabetes 
The world-wide prevalence of type II diabetes is predicted to increase from 
approximately 171 million in 2000 to 366 million in 2030 (Wild et al., 2004). 
Diabetes can be classified as type I or type II. Type I typically presents in the 
young (<20 years), is characterised by the autoimmune destruction of 
ƉĂŶĐƌĞĂƚŝĐɴĐĞůůƐǁŚŝĐŚĐĂƵƐĞƐĂůĂĐŬŽĨŝŶƐƵůŝŶƉƌŽĚƵĐƚŝŽŶĂŶĚƐĞĐƌĞƚŝŽŶ ?ĂŶĚ
is treated by exogenous insulin. Type II typically presents in the older 
population, >50 years. The root cause is thought to be hyperglycaemia, which 
leads to an increase in insulin secretion to counteract this, which also gives 
rise to hyperinsulinaemia. Over time, a lack of insulin sensitivity develops 
within target tissues such as the liver, muscle and adipose tissue, which 
results in further hyperinsulinaemia to compensate for the lack of action. 
ǀĞŶƚƵĂůůǇ ? ƚŚŝƐ ĐĂƵƐĞƐ ɴ ĐĞůů ĚĞĂƚŚ ? ůĞĂĚŝŶŐ ƚŽ Ă ůĂĐŬ ŽĨ ŝŶƐƵůŝŶ ƉƌŽĚƵĐƚŝŽŶ
(Prentki and Nolan, 2006). Lipotoxicity can therefore be seen as the 
ĚĞƚƌŝŵĞŶƚĂů ĞĨĨĞĐƚƐ ƵƉŽŶ ƚŚĞ ĨƵŶĐƚŝŽŶ ŽĨ ƉĂŶĐƌĞĂƚŝĐ ɴ ĐĞůůƐ caused by 
sustained elevation of glucose and fatty acids (Poitout et al., 2009). Combined 
prolonged elevated fatty acids and glucose levels have been linked with 
inhibition of insulin biosynthesis (Harmon et al., 2001) and inhibition of GSIS 
(Briaud et al., 2002) ĂŶĚ ŝŶĐƌĞĂƐĞĚ ɴ cell apoptosis (El-Assaad et al., 2003), 
also potentially leading to type II diabetes. 
There are other short and long term effects of uncontrolled hyperglycaemia, 
both due to an increase in glycosylation products such as glycosylated 
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haemoglobin (Ramasamy et al., 2011). The shorter term effects appear to be 
in the macrovascular vessels, causing atherosclerosis (Madonna and De 
Caterina, 2011; Wang et al., 2009). The longer term effects of hyperglycaemia 
involve the microvascular system, such as capillaries and can result in 
retinopathy, nephropathy and neuropathy. (Campos, 2012). Type II diabetes 
can be treated with diet, exercise and/or drugs, which will now be discussed 
prior to considering approaches through targeting FFA1 and/or GPR120. 
1.4.4.1.1 Treatments for type II diabetes 
1.4.4.1.1.1 Diet/exercise 
Both weight loss (or more specifically, the loss of adipose tissue) using a 
calorie controlled diet especially by avoiding sugar rich foods to prevent 
spikes in plasma glucose (Albu et al., 2010), and exercise (De Feyter et al., 
2007) ĐĂŶ ŝŵƉƌŽǀĞ ɴ ĐĞůů ĨƵŶĐƚŝŽŶ ĂŶĚ ŝŵƉƌŽǀĞ ĨĂƐƚŝŶŐ Őůucose levels and 
insulin sensitivity. 
1.4.4.1.1.2 Insulin and sulphonylureas 
Traditionally, both sulphonylureas and insulin have been used to treat type II 
diabetes. Injection of exogenous insulin, is used to maintain normal glycaemia 
in type II diabetics (Mudaliar and Edelman, 2001), but can lead to either hypo- 
or hyperglycaemia (Kourtoglou, 2011). Sulphonylureas are sometimes used in 
conjunction with insulin therapeutically (Kabadi and Kabadi, 2003). 
Sulphonylureas stimulate iŶƐƵůŝŶ ƌĞůĞĂƐĞ ĨƌŽŵ ƚŚĞ ɴ ĐĞůůƐ ? ďǇ ďŝŶĚŝŶŐ ƚŽ ĂŶĚ
inhibiting KATP channels, causing depolarisation of the plasma membrane, 
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activating Ca2+ channels and thus stimulating insulin release (Remedi and 
Nichols, 2008). Unfortunately, two major side effects with both insulin and 
sulphonylureas are hypoglycaemia and weight gain (Ahren, 2013). 
1.4.4.1.1.3 Metformin 
Another drug is the oral biguanide, metformin. It suppresses glucose 
production in the liver, has a low risk of hypoglycaemia (Hundal et al., 2000) 
and also improves insulin sensitivity (Collier et al., 2006). It is thought to be 
superior to other antidiabetic drugs due to a decrease in cardiovascular 
complications (Holman et al., 2008), but it does have GI side effects (Bolen et 
al., 2007). 
1.4.4.1.1.4 Thiazolidinediones 
TZDs were another class of drugs used in the treatment of type II diabetes, 
and are WWZɶĂŐŽŶists that improve insulin sensitivity in the muscle, whilst 
causing a decrease in plasma levels of glucose, lipids and insulin (Lehmann et 
al., 1995). TZDs were prescribed for treatment of type II diabetes, but were 
later withdrawn due to safety concerns. Troglitazone was the first to be 
withdrawn in 2000, after being shown to cause fatal hepatoxicity (Saha et al., 
2010). Next, a large study showed rosiglitazone to significantly increase the 
risk of myocardial infarction (Nissen and Wolski, 2007), and was followed by 
its withdrawal from Europe and its restriction in the US in 2010 (Pouwels and 
van Grootheest, 2012). Studies on pioglitazone have shown it to decrease the 
risk of cardiovascular complications (Dormandy et al., 2005), but more recent 
work has shown it to increase the risk of bladder cancer (Sato et al., 2011). As 
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discussed in chapters 3 and 4, TZDs are now known to have additional 
mechanisms of action including binding and activation of FFA1 receptors 
(Kotarsky et al., 2003; Smith et al., 2009). 
1.4.4.1.1.5 GLP-1 
GLP-1 activates a class B GPCR from the secretin-like family, GLP-1R, whose 
activation enhances GSIS (Naslund et al., 1998). GLP-1 administration has 
ďĞĞŶ ƐŚŽǁŶ ƚŽ ĞŶŚĂŶĐĞ ɴ ĐĞůů ƉƌŽůŝĨĞƌĂƚŝŽŶ ? ĐĂƵƐĞ ĂŶ ŝŶĐƌĞĂƐĞ ŝŶ ŝŶƐƵůŝŶ
secretion and enhance glucose tolerance (Perfetti et al., 2000), decrease 
glucagon levels (Buse et al., 2009) and inhibit food intake both in rats (Turton 
et al., 1996) and humans (Flint et al., 1998). In man, GLP-1 suppresses 
appetite and promotes satiety (Toft-Nielsen et al., 1999), and leads to weight 
loss (Vilsboll et al., 2012). GLP-1 analogues, exendin-4 (Egan et al., 2002) and 
Liraglutide (Buse et al., 2009) have been investigated for their potential use in 
the treatment of type II diabetes, but have been found to have the side effect 
of nausea (Sun et al., 2012). Unfortunately, from the point of view of drug 
development, GLP-1 itself has a short half-life in vivo, but modifications can be 
made to make the peptides more resistant to degradation (Buse et al., 2009). 
In addition, the degradative enzyme dipeptidyl peptidase (DPP)-4 can be 
targeted by inhibitors to prevent the breakdown of endogenous GLP-1, and 
this also has the positive effect of a decreased incidence of nausea (Scheen, 
2013). 
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1.4.5 Evaluation of FFA1 and GPR120 as therapeutic targets 
FFA1 and GPR120 are seen as therapeutic targets for type II diabetes. This 
short section will quickly summarise what is already known about the 
potential drugs for these receptors, and whether from a drug discovery 
perspective, they would work as a pharmaceutical treatment for type II 
diabetes. 
FFA1 has been shown to potentiate GSIS in the presence of FFAs, from the 
ƉĂŶĐƌĞĂƚŝĐ ɴ ĐĞůls (Stoddart et al., 2008), and the majority of the evidence 
presented above suggest that FFA1 does not mediate any lipotoxic effects 
long term (section 1.4.3.1), making it a good target. A range of FFA1 agonists 
have been synthesised (which will be covered in chapter 4). These have also 
been optimised for their pharmacokinetic profiles, as well receptor agonist 
properties. 
The most prominent example of an FFA1 agonist is TAK-875. It has been 
shown in clinical trials to be successful at improving the glyceamic control in 
type II diabetic patients (Kaku et al., 2013). 
Another example is TUG 424, which had nanomolar potency in increasing GSIS 
(Christiansen et al., 2008). Further optimisation of this compound has lead to 
complete bioavailability and low micromolar efficacy in improving glucose 
tolerance in mice (Christiansen et al., 2013). 
Finally, there are the Amgen compounds, including the partial agonist AMG-
837, which had a good pharmacokinetic profile as well as evidence of it being 
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a glucose-dependent insulin secretagogue (Houze et al., 2012). Another duo 
of full agonists from the same group are AM-1638 and AM-6226, whom have 
been shown to promote insulin secretion, but also act upon the 
enteroendocrine system to elicit GLP-1 and GIP secretion (Luo et al., 2012). In 
fact, this group suggested combination therapy of both the partial and full 
agonists to engage both the satiety effects from activating the 
ĞŶƚĞƌŽĞŶĚŽĐƌŝŶĞ ĐĞůůƐ ? ĂŶĚ ĂůƐŽ ƚŚĞ ŝŶĐƌĞĂƐĞ ŝŶ ŝŶƐƵůŝŶ ƐĞĐƌĞƚŝŽŶ ĨƌŽŵ ƚŚĞ ɴ
cell in the treatment of type II diabetes. 
There is also evidence that GPR120 agonists could be a target for type II 
diabetes treatments, because the activation of GPR120 has been shown to 
stimulate incretin release, such as GLP-1 (Hirasawa et al., 2005) and CCK 
(Tanaka et al., 2008a). Additionally, GPR120 has been shown to exert anti-
ŝŶĨůĂŵŵĂƚŽƌǇ ĂĐƚŝŽŶƐ ? ǁŚŝĐŚ ǁŽƵůĚ ĐŽƵŶƚĞƌ ƚŚĞ  “ŵĞƚĂďŽůŝĐ ŝŶĨůĂŵŵĂƚŝŽŶ ?
that also contributes to type II diabetes (Oh et al., 2010). 
1.4.5.1 Obesity 
There is an increasing prevalence in obesity in the Western world (Ogden et 
al., 2006; Rennie and Jebb, 2005). One estimate puts the worldwide rate at 
over 1.5 billion individuals being overweight or obese (Nguyen and Lau, 2012; 
Simpson et al., 2009). In the UK and US, being overweight is classified as 
having a BMI 25  W 30, whilst being obese is to have a of BMI 30+. BMI is a 
simple tool to measure weight, where body mass index equals mass (kg) 
divided by height (m)2, but BMI classifications may actually underestimate 
obesity (Shah and Braverman, 2012). Obesity predisposes to other co-
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morbidities such as hypertension, cardiovascular diseases (Nguyen and Lau, 
2012), type II diabetes (Wild et al., 2004) and cancer (Schottenfeld et al., 
2013). 
Weight gain occurs with an energy imbalance, when food intake is greater 
than energy expenditure (due to either exercise or basal metabolism) 
(Redinger, 2009). Less simple to explain is the complex interplay of appetite 
ĂŶĚ “ƌĞǁĂƌĚ ?ƐŝŐŶĂůůŝŶŐŝŶƚŚĞďƌĂŝŶŝŶƌĞůĂƚŝŽŶƚŽĂƉƉĞƚŝƚĞ ?^ŝŵƉůŝƐƚŝĐĂůůǇ ?ƚŚĞ
gut brain axis of control of food intake is as follows: a decrease in food intake 
leads to an increase in circulating levels of ghrelin released from the stomach, 
which also causes release of orexigenic neuropeptide Y (NPY) from 
hypothalamic arcuate neurones. Via its receptors in the hypothalamus, NPY 
acts to inhibit POMC (pro-opiomelanocortin) and CART (cocaine and 
amphetamine related transcript) satiety neurones and causes an increase in 
appetite. Conversely, food intake causes release of GLP-1, CCK and PYY from 
the gut, which activate their respective receptors in the hypothalamus, inhibit 
NPY neurones, and stimulate POMC/CART neurones to promote satiety 
(Redinger, 2009; Simpson et al., 2009). Equally leptin (released from adipose 
tissue) (Feng et al., 2012), and insulin (from the pancreas) (Shiraishi et al., 
2011) are negative regulators of the hypothalamic appetite circuits. 
Hypothalamic food intake is also modulated by other central pathways, for 
example those recognising reward, and this may involve other mediators such 
as endocannabinoids (Gardner and Vorel, 1998). Endocannabinoids are also 
an orexigenic signal via their activation of CB1 receptors, to stimulate appetite 
(Pagotto et al., 2006). 
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1.4.5.2 Current therapeutic strategies 
1.4.5.2.1 Lifestyle interventions 
The least aggressive treatment for obesity is to undertake a calorie controlled 
diet in conjunction with exercise, which along with weight loss has been 
shown to improve other factors such as cardiovascular risk (Unick et al., 
2013). 
1.4.5.2.2 Bariatric surgery 
Currently, the only effective treatment for long term weight loss for the 
morbidly obese (defined as BMI >40) is bariatric surgery, which not only 
decreases body weight (Borg et al., 2006), but has also been shown to 
improve type II diabetes (Pournaras et al., 2012). It has been suggested that 
bariatric surgery is particularly successful because it alters the secretion of gut 
hormones (Pournaras et al., 2012). A challenge now is to emulate this 
pharmacologically. One gut hormone of interest is PYY, which is released from 
the L endocrine cells and has been shown to reduce food intake and promote 
satiety (Stanley et al., 2004) by acting on the hypothalamus (Zhang et al., 
2011a). One study on PYY found that intravenous PYY caused an equivalent 
satiety in both obese and lean subjects, therefore it was suggested that 
obesity is not associated with a resistance to PYY, but rather perhaps there is 
a lower postprandial release of PYY or some other sort of deficiency in 
circulating PYY (Batterham et al., 2003), but these results could not be 
replicated by other groups (Boggiano et al., 2005). 
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Also of interest, is the combination of hormones to emulate the post prandial 
state, for example when PYY3-36 is combined with another gut hormone such 
as oxyntomodulin (also a GLP-1 homologue and agonist) they are additive as 
anorectic signals and require lower doses, therefore avoiding side effects such 
as nausea (Field et al., 2010). This strengthens the argument that the 
combination of both GLP-1 and Y2 agonists may be an attractive target for 
obesity drugs (Neary et al., 2005; Talsania et al., 2005). 
1.4.5.2.3 Current drugs and potential FFA receptor agonists as anti-obesity 
agents 
Two obesity medications have been withdrawn due to deleterious side 
effects. Rimonabant is a CB1 antagonist, which blocked orexigenic signalling, 
but it was associated with increased risk of depression and suicide (Despres et 
al., 2005). Sibutramine is a 5-HT uptake inhibitor, which decreased food intake 
(Heal et al., 1998), but had cardiovascular side effects (James et al., 2010; 
Rucker et al., 2007). The only drug currently still on the market is orlistat, a 
pancreatic lipase inhibitor. It prevents the breakdown of ingested fat and its 
absorption from the gut, but has the unpleasant side effect of steatorrhea 
(Filippatos et al., 2008). 
The fact that only one drug is left on the market shows the clinical need for 
new drugs at new targets. GPR120 is a good target for novel anti-obesity 
therapies. Its activation causes incretin release, which by their nature confer 
satiety signals, and as discussed above have beneficial actions on insulin 
secretion that reduce the risk of associated type II diabetes. Additionally, due 
33 
 
to its lumenal localisation on the intestinal endocrine cells, any drugs 
targeting GPR120 do not require systemic absorption. Also, GPR120 has also 
been shown to elicit anti-inflammatory effects (Oh da et al., 2010), which 
would also be advantageous for obese patients as they often have systemic 
ůŽǁŐƌĂĚĞŝŶĨůĂŵŵĂƚŝŽŶ ?ƚĞƌŵĞĚ “ŵĞƚĂ-ŝŶĨůĂŵŵĂƚŝŽŶ ?(Talukdar et al., 2011). 
Many of these beneficial advantages are in principle also shared by FFA1 
agonists, as this receptor is also found on similar populations of intestinal 
endocrine cells; however GPR120 has received most attention to date in this 
respect, because of the early evidence that GPR120, rather than FFA1 
signalling appears most relevant for stimulating incretin release from L cells 
(Hirasawa et al., 2005). 
1.5 The general molecular pharmacology of GPCRs 
In this section, the overall common themes in GPCR ligand binding, signalling 
and regulation are discussed. More detailed information on the ligand binding 
and activation of FFA1 and GPR120 receptors will be covered in Chapters 3 
and 4. 
1.5.1 Structure and activation of class A GPCRs 
Although GPCRs can be split into 5 groups, they still all share the common 
feature of a structure that traverses the plasma membrane with seven helical 
domains (e.g. Figure 1.2), forming a predicted serpentine structure which was 
then confirmed by their crystallisation. The first GPCR to be crystallised was 
rhodopsin, which is comprised of the protein opsin covalently bound to a 
vitamin A derivative, 11-cis-retinal that acts as an inverse agonist. Once 
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activated by photons, this ligand becomes all trans and behaves as an agonist 
to alter receptor conformation, allowing vision (Palczewski et al., 2000). This 
initially gave a template upon which to propose structures for other GPCRs. 
dŚĞ ɴ2 ĂĚƌĞŶŽĐĞƉƚŽƌ  ?ɴ2AR) was crystallised next in the presence of partial 
inverse agonist carazolol (Cherezov et al., 2007; Rosenbaum et al., 2007). In 
the following six years, a rapid expansion has occurred and 18 GPCRs now 
have an x-ray structure reported for them (Venkatakrishnan et al., 2013). 
These have shown that all GPCRs can be split into 3 segments: the 
extracellular domain which modulates ligand access; the TM helical bundle 
that forms the core of the GPCR, and allows for conformational change to be 
transmitted from the agonist binding pocket to the intracellular face; and the 
intracellular face which interacts with effector signalling proteins. 
1.5.1.1 Common themes in ligand binding 
These structures have uncovered some common themes of ligand binding 
within the receptors, such as the involvement of ECL2 in controlling ligand 
access and the formation of a transmembrane binding pocket for small 
molecule ligands. 
1.5.1.1.1 Extracellular loop 2 
From comparison of the current x-ray structures, there appears to be 2 
different types of extracellular domain, defined principally by ECL2. One type 
allows for water-accessible, downwards ligand access and examples of these 
domains are quite variable; whilst the other type prevents access to the 
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binding pocket, and these receptors have hydrophobic ligands, thought to 
bind the receptor transversely through the plasma membrane. 
The receptors that allow for downwards access appear to have an ECL2 that 
contains secondary structure composed of alpha helices, such as tŚĞ ɴ
adrenoceptors ĂŶĚĂĚĞŶŽƐŝŶĞ ƌĞĐĞƉƚŽƌƐ ?dŚĞ ɴ2AR has a fairly large, solvent 
exposed ECL2 that holds itself out of the binding pocket, in part by disulphide 
bonds, for example one disulphide bridge links ECL2 to TM 3, constraining the 
structure. This allows the small ligands access to the binding site deep within 
the TM helices (Cherezov et al., 2007) ?^ŝŵŝůĂƌƚŽƚŚĞɴ2AR, ƚŚĞɴ1 subtype also 
contains alpha helical structure within ECL2. In this case, ECL2 is thought to 
contribute to the binding pocket and helps to define what ligands bind with 
high affinity. Despite very similar residues within the TM binding pocket, the 
ĂŵŝŶŽ ĂĐŝĚ ƐĞƋƵĞŶĐĞ ŽĨ ɴ1 ƌĞĐĞƉƚŽƌƐ ĚŝĨĨĞƌƐ ŵĂƌŬĞĚůǇ ĨƌŽŵ ɴ2 in the ECL2 
region, which alters the charge distribution and shape of the entrance to the 
binding pocket. This may explain some of the differences in ligand specificity 
between the two (Warne et al., 2008). The crystal structure of A2A adenosine 
receptor ƐŚŽǁĞĚƚŚĂƚŝƚƐ> ?ǁĂƐŵŽƌĞĚŝƐŽƌĚĞƌĞĚƚŚĂŶɴ2, with no elements 
of secondary structure. There was however, a network of disulphide bonds 
that hold ECL2 in a position that allowed the ligand binding pocket to be 
readily accessible to solvent, and presumably also for small diffusible ligands 
such as adenosine (Jaakola et al., 2008). 
In the muscarinic receptor class, ECL2 also appears to be key in regulating 
ligand entry into the binding pocket. In the x-ray structure of the M3 receptor 
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it was found that Leu225 in ECL2 creates a pocket that does not exist in M2 
(Leu225 substituted with Phe181) which is thought to contribute to the 
altered binding of the M3 selective antagonist tiotropium (Kruse et al., 2012). 
Other experimental approaches have also shown the importance of ECL2 in 
dictating ligand binding in other GPCRs (Avlani et al., 2007; Shi and Javitch, 
2004), and as discussed in Chapter 4, there is evidence that it regulates ligand 
binding and activation of FFA1. 
Interestingly, ECL2 structures in rhodopsin (with a covalently bound ligand), 
and the S1P receptor (with a hydrophobic ligand) are substantially different. 
The ECL2 of rhodopsin occludes the binding poĐŬĞƚďǇ ĨŽƌŵŝŶŐĂ  ? ƐƚƌĂŶĚɴ
sheet structure with the receptor amino terminus, holding 11-cis-retinal 
within the TM domains. This structure is probably due to the fact that the 
ligand does not have to diffuse into the binding pocket (Palczewski et al., 
2000). The S1PR also has a binding pocket occluded by ECL2 and the amino 
terminus (described in more detail in Chapter 4). This is predicted to result in 
its hydrophobic ligands activating laterally from within the lipid bilayer 
(Hanson et al., 2012). 
1.5.1.1.2 Binding pocket 
&ƌŽŵ ƚŚĞ ĐůĂƐƐ  'WZƐƚƌƵĐƚƵƌĞƐ ƐŽ ĨĂƌ ? Ă  “ůŝŐĂŶĚďŝŶĚŝŶŐ ĐƌĂĚůĞ ? ŚĂƐďĞĞŶ
postulated (Venkatakrishnan et al., 2013). This is formed by interactions with 
diverse ligands mediated at residues in similar positions within TM 3 (e.g. 
3.32, 3.36), 6 (e.g. 6.48, 6.51) and 7 (e.g. 7.39; see Figure 1.2 for information 
on Ballesteros Weinstein numbering). While some of these residues are highly 
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conserved (e.g. Trp 6.48 is part of the toggle switch activation mechanism, see 
section 1.5.1.3.2 below), the amino acid identities at others can be variable. 
Although this suggests a consensus GPCR scaffold structure for recognising 
ligands, naturally all binding pockets vary slightly depending upon ligand 
(Venkatakrishnan et al., 2013). In the x-ƌĂǇƐƚƌƵĐƚƵƌĞŽĨɴ2AR, the cleft formed 
in the binding site carries an overall negative charge (Cherezov et al., 2007), 
centred around Asp 3.32, which makes contact with the positive amine of the 
agonists (Strader et al., 1988). 
The opioid receptor family, with larger endogenous peptide ligands than 
amine receptoƌƐ ? ĐŽŶƐŝƐƚƐ ŽĨ ɷ ? ʅ ĂŶĚ ʃ ƐƵďƚǇƉĞƐ ? KƉŝŽŝĚ ƌĞĐĞƉƚŽƌƐ ǁĞƌĞ
ƚŚĞŽƌŝƐĞĚ ƚŽ ŚĂǀĞ  “ŵĞƐƐĂŐĞ-ĂĚĚƌĞƐƐ ? ƉŚĂƌŵĂĐŽůŽŐǇ ? ǁŚĞƌĞ ŽŶĞ ƉĞƉƚŝĚĞ
agonist can contain two discrete parts: message (efficacy: ability to activate 
the receptor by changing its conformation), thought to be mediated by the 
morphinan group found in opioid agonists (Zhang et al., 2011b); whilst the 
 “ĂĚĚƌĞƐƐ ?ƉĂƌƚĐŽŶĨĞƌƐƐĞůĞĐƚŝǀŝƚǇďĞƚǁĞĞŶƚŚĞƚŚƌĞĞƐƵďƚǇƉĞƐ ? 
dŚĞ ĐƌǇƐƚĂů ƐƚƌƵĐƚƵƌĞ ŽĨ ƚŚĞ ʅ ŽƉŝŽŝĚ ƌĞĐĞƉƚŽƌ ƐŚŽǁĞĚ ƚŚĞ ĂŶƚĂŐŽŶŝƐƚ
morphinan in the binding pocket, interacting with residues also found in the 
other opioid subtypes (Manglik et al., 2012) ? dŚĞ ɷ ŽƉŝŽŝĚ ƌĞĐĞƉƚŽƌ ǁĂƐ
crystallised with selective antagonist naltrindole, and binds in a deep but 
easily solvent-accessible pocket. Selectivity at this receptor is mediated by the 
indole group of natrindole interacting with Leu300 found in the upper binding 
pocket. In contrast, residues at this position in the other receptor subtypes 
prevent natrindole binding (Granier et al., 2012). A similar story is highlighted 
38 
 
ďǇ ƚŚĞ ƐƚƌƵĐƚƵƌĞ ŽĨ ƚŚĞ ʃ ŽƉŝŽŝĚ ƌĞĐĞƉƚŽƌ ? dŚĞ ďĂƐŝƐ ŽĨ ŝƚƐ ƐĞůĞĐƚŝǀŝƚǇ ĨŽƌ ƚŚĞ
antagonist JDTic is again in the upper part of pocket, mediated by Glu297 (Wu 
et al., 2012). 
1.5.1.1.3 Differences in class A GPCR x-ray structures 
While there are evidently conserved elements in the x-ray structures so far, 
the individual nature of many GPCRs is illustrated by the structure of the 
chemokine receptor CXCR4, which shows multiple differences to the 
ƐƚƌƵĐƚƵƌĞƐ ŽĨ ƚŚĞ ɴ2AR and the A2A adenosine receptor. For example, when 
compared to these receptors, CXCR4 contains a tighter turn in TM 2, adapting 
the helix to allow conserved residues to face the binding pocket (Wu et al., 
2010). Also, CXCR4 contains only a partial helix 8, important for G protein 
activation (Wu et al., 2010). This illustrates some of the potential limitations 
when modelling receptor sequences, on even closely related GPCR structures 
(see also Chapter 4). 
1.5.1.1.4 Helical bundle 
Comparison of all known x-ray structures demonstrate that the 7TM helical 
domains have structural similarity, forming a common core (Venkatakrishnan 
et al., 2013). All seven transmembrane helices form a circular arrangement 
with TM helices 1-4 forming a central, stable core with TM 3 tilted across the 
centre of this core whilst helices 5-7 interact with the core but are much less 
densely packed (Patel et al., 2005). 
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1.5.1.2 dŚĞ ƌŽůĞ ŽĨ  “ĐůĂƐƐ  ? ĐŽŶƐĞƌǀĞĚ ƌĞƐŝĚƵĞƐ ĂŶĚ ŵŽƚŝĨƐ ŝŶ ƚŚĞ ŝŶĂĐƚŝǀĞ
state 
GPCRs are thought to be constrained in the inactive state through a variety of 
non-covalent interactions, including those mediated by conserved class A 
motifs identified in part by the core amino acids in Figure 1.2. Interactions 
between the central core of TM 1-4 and TM 5-7 include two conserved class A 
motifs. 
1.5.1.2.1 TM 3: DRY motif 
Firstly, the Glu/Asp-Arg-Tyr (E/DRY) motif is found at the bottom of TM 3 
centred on Arg 3.50 (Figure 1.2). This forms a stabilising ionic salt bridge 
within itself between the Asp/Glu and Arg, but Arg also constrains the 
receptor in an inactive conformation by interacting with residues found at the 
bottom of TM 6, which in rhodopsin are Asp and Thr (Palczewski et al., 2000; 
Scheerer et al., 2008). The role of the DRY motif has been extensively studied 
by mutagenesis in GPCRs, and arguments have been made for two groups 
defined by its different effects on receptor activation (Rovati et al., 2007). 
In the first group the DRY motif holds the receptor in the inactive state, and 
mutations cause constitutive receptor activation in the absence of agonist 
(Scheer et al., 2000). One example of this group is of ƚŚĞ ɴ2AR, in which an 
ionic lock is proposed between the Arg of the DRY and a Glu found at the 
bottom of TM 6 (Ballesteros et al., 2001). However, this interaction was not 
present in the inactive crystal structure (Cherezov et al., 2007). This may be 
due to the methods employed to crystallise receptors, for example large 
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protein modifications to the receptor or the particular conformation adopted 
using the particular ligands employed for crystallisation. 
The second group are thought to be resistant to induced constitutive activity 
following mutation, and instead the DRY motif appears to play more of a role 
in interacting with and activating the G protein (Rovati et al., 2007). For 
ĞǆĂŵƉůĞ ?ŝŶƚŚĞŚƵŵĂŶŚŝƐƚĂŵŝŶĞ, ?ƌĞĐĞƉƚŽƌƚŚĞZz “ůŽĐŬ ?ƉĂƌƚŶĞƌƌĞƐŝĚƵĞ
at the bottom of TM 6 is missing (an uncharged Ala). Whilst it was postulated 
that this may be why the H4 receptor has a high constitutive activity, the 
inactive receptor was not stabilised when engineered to contain a negative 
amino acid at the key TM6 position; in fact this substitution also prevented G 
protein activation (Schneider et al., 2010). 
1.5.1.2.2 TM VII: NPxxY motif 
Another stabilising interaction that holds the receptor in an inactive state is 
Asn-Pro-X-X-Tyr (NPxxY) motif present in TM 7 (centred on Pro7.50), which 
forms a network of stabilising interactions with residues in TM 2 (Balaraman 
et al., 2010) and helix 8 (Park et al., 2008). The Tyr in the NPxxY motif interacts 
with a conserved Phe found in helix 8 (Park et al., 2008). Meanwhile, in the 
ɴ1AR, mutation at Phe 7.48 led to an alteration of the interaction between 
NPxxY and TM 2 and helix 8. This mutant had lower constitutive activity, 
though to be due to a stabilisation of the inactive state (Balaraman et al., 
2010). Also, in the inactive state, the NPxxY motif interacts with Trp 6.48 in 
the CWxP motif (including Pro 6.50) in TM 6. (Bhattacharya et al., 2008b). 
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1.5.1.3 Structural changes in GPCR activation that transduce the signal to the 
intracellular face 
GPCR activation requires structural change between inactive and active 
conformations. Agonists stabilise an active receptor conformation, whilst 
inverse agonist ligands stabilise the inactive receptor state (thereby reducing 
its constitutive activation, if present). Early studies supported this inverse 
structural relationship between agonist activation and inverse agonist effects. 
For example, a fluorescence based assay used purified ɴ2AR labelled at 
cysteine residues using a compound sensitive to the polarity of its 
environment (i.e. the fluorescence increased when the polarity of the 
environment decreased). This study showed that agonist binding caused an 
agonist specific, dose-dependent decrease in fluorescence (i.e. fluorophore is 
moved to a more hydrophobic environment in the centre of the receptor 
protein core). Meanwhile, inverse agonists produced a small increase in 
fluorescence, suggesting that receptor activation and inactivation are elicited 
by the same but opposite changes in receptor conformation (Gether et al., 
1995). This theory has been backed up by later studies using fluorescence 
resonance energy transfer (FRET) (Zurn et al., 2009). 
During activation, structural receptor interactions between key residues are 
modulated and changed, probably through a simultaneous whole receptor 
rearrangement, rather than a step by step rearrangement.  
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1.5.1.3.1 DRY motif 
Following activation, the Asp or the DRY lock becomes protonated and the Arg 
no longer forms a salt bridge with negative residues found at the bottom of 
TM 6, (Farrens et al., 1996), instead interacting with TM 5 Tyr, moving TM 3 
and 5 relative to each other (Patel et al., 2005; Scheerer et al., 2008), but 
these interactions are not present in the crystal structures (Rasmussen et al., 
2011a; Rasmussen et al., 2011b). 
1.5.1.3.2 CWxP molecular switch 
The breaking of the ionic lock also causes TM 3 and TM 6 to move apart 
(Rasmussen et al., 1999). The centre of this change is the TM 6 CWǆW “ƚŽŐŐůĞ
switcŚ ? ?dŚĞWƌŽ6.50 bend in TM 6 is increased such that the extracellular end 
of this helix does not move, but the intracellular end moves outward relative 
to TM 3 (Bhattacharya et al., 2008b). It is thought that when agonists bind to 
ɴ2AR, they interact with the Trp contained in the CWxP motif, causing this 
molecular switch to occur (Bhattacharya et al., 2008a). Activation of the CWxP 
molecular switch on TM 6 also leads to its movement towards TM 5 and a 
tighter interaction with the NPxxY motif on TM 7 (this movement is covered in 
more depth in section 1.5.1.3.3) (Liu et al., 2004; Rasmussen et al., 2011a). 
1.5.1.3.3 Change in TM 6 due to Pro kink 
dŚŝƐ  “ƐĞĞ-ƐĂǁ ? ŵŽƚŝŽŶ ĂƌŽƵŶĚ ƚŚĞ ƉƌŽůŝŶĞ ŬŝŶŬ(Altenbach et al., 2008) is 
ƚŚĞƌĞĨŽƌĞ ĂůƐŽ ƉĂƌƚ ŽĨ ƚŚĞ  “ƚŽŐŐůĞ-ƐǁŝƚĐŚ ŵŽĚĞů ?(Schwartz et al., 2006). In 
addition, TM 6 has been shown undergo a twisting motion clockwise away 
from the TM 3 DRY motif, out of the receptor core upon activation (Jensen et 
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al., 2001), and towards TM  ? ŝŶ ďŽƚŚ ɴ2AR (Ghanouni et al., 2001) and 
rhodopsin (Dunham and Farrens, 1999). TM 5 and 6 rearrange their side 
chains to stabilise this conformational change (Patel et al., 2005) by aromatic 
stacking interactions forming a lock between Phe in TM 5 and Trp in the CWxP 
motif of TM 6 (Holst et al., 2010). 
Cross-linking studies on TM 6 have shown its movement as important in 
receptor activation not only for rhodopsin (Cai et al., 1999; Farrens et al., 
1996) ĂŶĚɴ2AR (Bhattacharya et al., 2008a), but even for a family B GPCR, the 
parathyroid hormone receptor (Sheikh et al., 1999), which is surprising 
because class B GPCRs do not contain the same conserved residues as class A. 
This shows that a global model for receptor activation may be a common 
feature, evolutionarily shared for all GPCRs, not just specific for family A 
receptors. 
1.5.1.3.4 TM 7 (7.50): another Pro rearrangement 
The see-saw action of TM 6, and TM 7 which also contains a conserved Pro 
residue, causes an inwards movement of the top portions of the TM helices, 
towards TM 3. This closes the entrance to the binding site in the structures of 
both the A2A ĂŶĚɴ2AR (Cherezov et al., 2007; Jaakola et al., 2008; Rosenbaum 
et al., 2007), and opens up the intracellular face for effector proteins to bind. 
1.5.1.3.5 Movement of NPxxY from helix 8 to TM 6 
This tighter interaction in the extracellular portion of the receptor is probably 
due to a breaking of the interaction between NPxxY and helix 8. The Tyr of 
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NPxxY forms a new interaction with the hydrophobic patch found on the 
intracellular portion of TM 6 (Fritze et al., 2003; Park et al., 2008).  
1.5.1.3.6 Other conserved residues 
There are some other highly conserved residues among class A GPCRs (Figure 
1.2), which may not be involved in activation, but may still play a role in 
maintaining the conformation of the receptor. 
1.5.1.3.6.1 TM 1: Asn 1.50 
Although generally speaking TM 1 is not involved in receptor activation, the 
highly conserved Asn 1.50 has been shown to be key in mediating in the 
interaction between TM 1, TM 2 and TM 7 in a non class A GPCR (Singh et al., 
2011). 
1.5.1.3.6.2 TM 2: Asp 2.50 
This highly conserved residue is thought to interact with a sodium ion in a 
water cluster, which stabilised the A2A receptor (Liu et al., 2012b). In many 
receptors, this residue is thought to be responsible for sensitivity of agonist 
binding and G protein activation to the sodium ion concentration (Costa et al., 
1990). 
1.5.1.3.6.3 TM 5: Pro 5.50 
The highly conserved proline in TM 5 plays a similar role to the proline in TM 6 
in kinking the transmembrane helix, but does not undergo such a significant 
movement upon receptor activation (Bhattacharya et al., 2008b; Deupi, 2012). 
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The rearrangements discussed above cause concomitant movements in ICL2, 
/> ?ĂŶĚƚŚĞĐĂƌďŽǆǇůƚĂŝů ?ĂůůŽǁŝŶŐĞĨĨĞĐƚŽƌƐƐƵĐŚĂƐɴ-arrestins (Marion et al., 
2006) and G proteins to bind in a pocket formed by TM 3, 6 and 7 on the 
intracellular side of the receptor (Gerber et al., 2001; Nygaard et al., 2009). 
dŚĞɴ2AR x-ray structure showed the cytoplasmic face of the receptor to carry 
a positive charge overall, which could also be involved in G protein binding 
and activation (Cherezov et al., 2007; Lebon et al., 2011). 
1.6 Signalling & Trafficking 
1.6.1 G proteins 
Next, the principal GPCR effector protein, the G protein, will be discussed. 
1.6.1.1 Activation of the G protein and the G protein cycle 
The conformational changes elicited by agonist binding result in classical 
signal transduction, via coupling with heterotrimeric guanine nucleotide-
binding proteins (G proteins), for which GPCRs are named. The G protein 
heterotrimer is made up of an ɲsubunit (16 encoding genes, although when 
ŝŶĐůƵĚŝŶŐ ƐƉůŝĐĞ ǀĂƌŝĂŶƚƐ ? ŽǀĞƌ  ? ? 'ɲ ƉƌŽƚĞŝŶ ƐƵďƵŶŝƚƐ ĂƌĞ ĞǆƉƌĞƐƐĞĚ ? dĂďůĞ
1.1) bound to guanosine diphosphate (GDP); a ɴ subunit (5 genes); and a ɶ
subunit (12 genes) (Simon et al., 1991).  
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Main class Effector Signalling outcome Types 
Gs Stimulation of adenylyl cyclase  A?ĐDW ɲƐ ?ɲŽůĨ 
 Gi/o Inhibition of adenylyl cyclase A?ĐDW ɲŝ ? ?ɲŝ ? ?ɲŝ ? ? 
 
ĐƚŝǀĂƚŝŽŶŽĨƉŚŽƐƉŚŽůŝƉĂƐĞɴ A?ĂůĐŝƵŵ ɲŽĂ ?ɲŐƵƐƚ ?ɲǌ 
Gq/11 ĐƚŝǀĂƚŝŽŶŽĨƉŚŽƐƉŚŽůŝƉĂƐĞɴ ?
causes cleavage of PIP2 to release 
IP3 and DAG 
A?ĂůĐŝƵŵĨƌŽŵ
intracellular stores 
(IP3) and PKC (DAG) 
activation 
ɲƋ ?ɲ ? ? ?ɲ ? ? ?ɲ ? ? 
G12/13 Activation of RhoGEF, leading to 
activation of small monomeric 
GTPase RhoA 
A?DW<, 
cytoskeletal 
rearrangement 
ɲ ? ? ?ɲ ? ?
Transducins 
Activation of cGMP 
phosphodiesterase 
A? cGMP ɲƚ ? ?ɲƚ ? 
Table 1.1 dŚĞŵĂŝŶĐůĂƐƐĞƐŽĨ'ɲ ?  
dŚĞ ƚǇƉĞƐ ŽĨ 'ɲ, the effectors and signalling associated with them. cAMP, cyclic adenosine monophosphate; PIP2, phosphatidylinositol 4,5-
bisphosphate; IP3, inositol 1,4,5-trisphosphate; DAG, diacyl glycerol; MAPK, mitogen activated protein kinase; RhoGEF, Rho guanine nucleotide 
exchange factor. 
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There are two models to how G proteins associate with the receptor; pre-
coupling and collisional. BRET studies have shown evidence for the pre-
coupling model (Gales et al., 2006), where the G protein and receptor are pre-
assembled in an inactive form that is only activated once the ligand has bound 
to the receptor (Hu et al., 2010; Qin et al., 2011). On the other hand, free 
collision coupling states that the G protein:receptor complex is only formed 
after a ligand has bound to the receptor. Evidence for this collisional model 
has been provided using FRET studies (Hein et al., 2005). 
1.6.1.2 G protein cycle 
Once activated, the receptor acts as a guanine nucleotide exchange factor 
(GEF) upon the G protein. Receptor and G protein coupling causes GDP to be 
released ? ĂŶĚ ŐƵĂŶŽƐŝŶĞ ƚƌŝƉŚŽƐƉŚĂƚĞ  ?'dW ) ƚŽ ďĞĐŽŵĞ ďŽƵŶĚ ƚŽŚĞ 'ɲ
ƐƵďƵŶŝƚ ? dŚŝƐ ĂĐƚŝǀĂƚĞƐ ƚŚĞ ' ƉƌŽƚĞŝŶ ? ĂƐ ƚŚĞ ƉƌĞƐĞŶĐĞ ŽĨ ƚŚĞ ɶ ƉŚŽƐƉŚĂƚĞ
elicits conformational changes within the G protein in the 3 flexible loops 
named switches I, II and III (Lambright et al., 1994) ?ĐĂƵƐŝŶŐ'ɲƚŽdissociate 
ĨƌŽŵďŽƚŚƚŚĞ'WZĂŶĚƚŚĞɴɶƐƵďƵŶŝƚ ?ĂŶĚƚŽĂĐƚŝǀĂƚĞĞĨĨĞĐƚŽƌƉƌŽƚĞŝŶƐĂŶĚ
secondary messengers.  
G protein activity is regulatĞĚďǇ'ɲ GTPase activity; the hydrolysis of bound 
GTP to GDP allows heterotrimer reformation. GTPase activating proteins, such 
as regulators of G protein signalling (RGS) proteins hasten this intrinsic GTPase 
activity (Oldham and Hamm, 2008). 
48 
 
1.6.1.3 Ternary complex 
In pharmacological terms, GPCR activation of the G protein (or other 
effectors) is most commonly described by the ternary complex model which 
considers agonist (A), receptor (R), and G protein (G). When a receptor is 
activated by an agonist, it forms a low affinity AR complex (agonist:receptor), 
which then causes the receptor to couple with a G protein, thus forming a 
high affinity ARG ternary complex (ligand:receptor:G protein). Therefore, it 
was postulated that ligands are agonists because their binding selectively 
promotes and stabilises this high affinity state, leading to the activation of 
effector proteins which causes the cellular response. This model also allows 
for the formation of the RG complex spontaneously (generating constitutive 
activity or agonist-independent receptor activity as previously described, for 
example for the GPCR DRY motif mutations in section 1.5.1.2.1). Neutral 
antagonists can bind to either form equally (as these do not stabilise the 
ternary complex, but prevent agonist binding). This model describes 
interactions solely based on ligand affinity (ability to bind the receptor), 
assuming that intrinsic efficacy (ability to activate the receptor once bound) 
can be treated as a separate independent parameter (De Lean et al., 1980; 
Stephenson, 1956). 
This theory was then embellished into the extended ternary complex model. 
This stated that the receptor can also exist in two forms: R and R*, where R* is 
the activated receptor. In this model, agonists stabilise the activated receptor, 
and only the activated receptor R* can interact with G proteins, therefore 
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AR*G is the only active state. Constitutive activity is represented by receptors 
adopting R* spontaneously. This allows for the description of inverse agonist 
activity, because unlike neutral antagonists, inverse agonists bind to the R 
state preferentially, thus decreasing constitutive activity (Samama et al., 
1993). 
1.6.1.4 G protein structure 
dŚĞ'ɲƐƵďƵŶŝƚŚĂƐĂĐŽŶƐĞƌǀĞĚƉƌŽƚĞŝŶĨŽůĚŽĨĂ'dWĂƐĞĚŽŵĂŝŶ ?ŵĂĚĞƵƉŽĨ
5 helices plus a 6 stranded beta sheet), which is highly conserved throughout 
Ăůů 'dWĂƐĞƐ ? ĂŶĚ Ă ŚĞůŝĐĂů ĚŽŵĂŝŶ ƚŚĂƚ ŝƐ ƐƉĞĐŝĨŝĐ ƚŽ 'ɲ ƉƌŽƚĞŝŶƐ  ? ? ĂůƉŚĂ
helices), with the nucleotide binding site located at the interface between the 
two domains (Noel et al., 1993). 
dŚĞƐƚƌƵĐƚƵƌĞŽĨƚŚĞɴƐƵďƵŶŝƚŝƐŽĨĂƐĞǀĞŶƉƌŽŶŐĞĚɴƉƌŽƉĞůůĞƌƚŚĂƚĐŽŶƚĂŝŶƐ
seven WD-40 motif repeats (Wall et al., 1995). The amino terminal helix of the 
ɴ ƐƵďƵŶŝƚ ŝŶƚĞƌĂĐƚƐ ǁŝƚŚ ƚŚĞ ɶ ƐƵďƵŶŝƚ ? ďǇ ĨŽƌŵŝŶŐ ĂƉĂƌĂůůĞů ĐŽŝůĞĚ-coil 
interface through hydrophobic interactions with the amino terminal helix also 
ƉƌĞƐĞŶƚŽŶ ƚŚĞ ɶ ƐƵďƵŶŝƚ (Sondek et al., 1996) ?'ɶ ƐƵďƚǇƉĞƐ ĐŽŶƚĂŝŶĂ y
motif in the carboxyl terminus that allows for prenylation, a post translational 
modification that causes addition of an unsaturated lipid moiety to the 
subunit. This modification ƚĂƌŐĞƚƐ ƚŚĞ ɴɶ ƐƵďƵnit to the cell membrane 
(Simonds et al., 1991) and stabilises interactions with the GɲƐƵďƵŶŝƚ ?receptor 
and effector molecules (Gautam et al., 1998). dŚŝƐɴɶƐƵďƵŶŝƚŝƐĨƵŶĐƚŝŽŶĂůĂŶĚ
also capable of signalling (Khan et al., 2013); for example, the galanin 1 
receptor signals thoƵŐŚ 'ɲŝ ? ůŝďĞƌĂƚŝŶŐ 'ɴɶ ǁŚŝĐŚ ĐĂƵƐĞƐ ŵŝƚŽŐĞŶ ĂĐƚŝǀĂƚĞĚ
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protein kinase (MAPK) activation (Wang et al., 1998). There is also evidence 
ĨŽƌ'ɴɶĂĐƚŝǀĂƚŝŶŐƐƌĐĂĐƚŝǀŝƚǇ ?ĂůƐŽĨĞĞĚŝŶŐŝŶƚŽƚŚĞDW<ƉĂƚŚǁĂǇ ?ĐĂƵƐŝŶŐĂ
myriad of cellular responses such as the rearrangement of the cytoskeleton, 
vesicular trafficking, proliferation and survival (Luttrell and Luttrell, 2004). 
'ɲĂůƐŽĨŽƌŵƐĂŶŝŶƚĞƌĂĐƚŝŽŶǁŝƚŚ'ɴŝŶƚŚĞƌĞŐŝŽŶŽĨƐǁŝƚĐŚ/ĂŶĚ//ŽĨ'ɲ ?ĂŶĚ
ŝƚ ŝƐ ƌĞĂƌƌĂŶŐĞŵĞŶƚ ŽĨ ƚŚŝƐ ĂƌĞĂ ĨŽůůŽǁŝŶŐ 'dW ďŝŶĚŝŶŐ ƚŚĂƚ ĐĂƵƐĞƐ 'ɴɶ ƚŽ
ĚŝƐƐŽĐŝĂƚĞĨƌŽŵ'ɲ(Lambright et al., 1996; Wall et al., 1995). There is also an 
ŝŶƚĞƌĂĐƚŝŽŶďĞƚǁĞĞŶƚŚĞĂŵŝŶŽƚĞƌŵŝŶƵƐŽĨ'ɲĂŶĚƚŚĞƉƌŽƉĞůůĞƌƌĞŐŝŽŶŽĨ'ɴ ?
ďƵƚƚŚĞƌĞĂƉƉĞĂƌƚŽďĞŶŽĚŝƌĞĐƚŝŶƚĞƌĂĐƚŝŽŶƐďĞƚǁĞĞŶ'ɲĂŶĚ'ɶ (Lambright 
et al., 1996). Interestingly though, more recent studies using FRET (Lohse et 
al., 2012) ŚĂǀĞ ƐŚŽǁŶ ĞǀŝĚĞŶĐĞ ƚŚĂƚ 'ɲ ĂŶĚ ɴɶ ĚŽ ŶŽƚ ĂůǁĂǇƐ ĚŝƐƐŽĐŝĂƚĞ
following activation, as previously thought (Bunemann et al., 2003). This has 
been further backed up with studies on G proteins of the Gi family that 
showed that the constituents of Gi G proteins instead undergo a 
rearrangement, rather than dissociation (Frank et al., 2005). 
G proteins have been shown to form an interaction with the GPCR between 
ďŽƚŚƚŚĞĂŵŝŶŽĂŶĚĐĂƌďŽǆǇůƚĞƌŵŝŶŝŽĨ'ɲ ?ĂŶĚ/> ?ŝŶƚŚĞƌĞĐĞƉƚŽƌ(Cai et al., 
2001; Itoh et al., 2001). There is also evidence for interactions between helix 8 
of the GPCR and the G protein (Qin et al., 2011) ?ĂŶĚƚŚĂƚ'ɲŝŶƚĞƌĂĐƚƐǁŝƚŚĂ
interface found at TM 5 and TM 6 (Hu et al., 2010). There is also now a crystal 
structure oĨ ɴ2AR ŝŶ ĐŽŵƉůĞǆ ǁŝƚŚ Ă 'ɲƐ ƉƌŽƚĞŝŶ ? dŚŝƐ ƐŚŽǁĞĚ ĞǆƚĞŶƐŝǀĞ
contacts between the ICL2, TM 5 and TM 6 of the receptor and the junction of 
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ƚŚĞ ĂŵŝŶŽ ƚĂŝů ĂŶĚ ɴ ƐƚƌĂŶĚ  ? ? ŚĞůŝǆ  ? ? ŚĞůŝǆ  ? ? ĂŶĚ ɴ ƐƚƌĂŶĚ  ? ŽĨ ƚŚĞ 'ɲƐ
protein (Rasmussen et al., 2011b). 
1.6.1.5 G protein coupling selectivity 
It is thought that there are molecular determinants present on receptors that 
account for the differential G protein coupling exhibited. The muscarinic 
receptors lend themselves well to the study of this, because there are 5 
receptor subtypes that fall into two groups in terms of their G protein 
coupling. M1, M3 and M5 couple to Gq, where as M2 and M4 couple to Gi 
(Caulfield and Birdsall, 1998). 
A predominant thought is that hydrophobic residues at the juxtamembrane 
amino and carboxyl ends of ICL3 are important in forming a surface for 
determining the selectivity of G protein coupling (Moro et al., 1994). This 
region was found to be crucial for coupling in M5 (Burstein et al., 1995) and 
the carboxyl end of TM 5 contains the VTIL motif for Gi coupling to M2 and M4 
(Kostenis et al., 1997), which is completely different in the Gq coupled 
muscarinic receptors: AALS (Liu et al., 1995). Later work has suggested that 
ICL3 of M3 is not necessary for precoupling with Gq. Instead, helix 8 of M3 
partially mediates its coupling with Gq (Qin et al., 2011). Mutational analysis 
of the region at the amino terminus of ICL3 found that Tyr254, which is 
present only in the Gq coupled muscarinic receptors and is replaced by serine 
in M2 and M4 subtypes, is at least partially responsible for G protein coupling 
with Gq and the activation of the phosphatidylinositol pathway (Bluml et al., 
1994). This Tyr254 was been implicated in Gq coupling in conjunction with the 
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SRRR motif in ICL2 (Ser168, Arg171, Arg176, Arg183) with Arg176 being of 
particular importance. This residue is replaced with Pro in M2 and M4 and is 
thought to considerably alter protein secondary structure (Blin et al., 1995). 
Further work on ICL2 suggested that whilst ICL2 is generally relevant for G 
protein coupling (Hu et al., 2010), selectivity is governed by other sites (Moro 
et al., 1993a). 
More recent work has further shown the importance of the position of the 
cytoplasmic end of TM 5 and 6 in determining G protein selectivity 
(Rasmussen et al., 2011b). The position of TM 5 appears to be M2-like in all 
known Gi/o coupled receptor structures; they have an increased TM 5 to TM 6 
distance, where as Gq receptors have a decreased TM 5 to 6 distance, 
resulting in a different conformation of ICL3 (Hu et al., 2010; Kruse et al., 
2012). Helix 8 also appears to be a key interface between receptor and G 
protein (Hu et al., 2010; Qin et al., 2011). Additionally, the carboxyl tail of the 
'ɲĂůƐŽŐŽǀĞƌŶƐƐĞůĞĐƚŝǀŝƚǇ (Rasmussen et al., 2011b), for example switching 
the terminal 5 amino acids (Gqi5 chimera) can direct receptor coupling from 
Gq to Gi (Hamm, 1998). 
1.6.1.6 Downstream G protein signalling pathways 
BŽƚŚ'ɲƐĂŶĚ'ɲŝĂĐƚƚŽƌĞŐƵůĂƚĞƚŚĞĂĐƚŝǀŝƚǇŽĨĐDW. 'ɲƐƐƚŝŵƵůĂƚĞƐĂĚĞŶǇůǇů
cyclase (an enzyme that converts ATP to cAMP; of which there are 9 isoforms 
(Simonds, 1999)), thus causing cAMP production and activating protein kinase 
A (PKA) ? ǁŚŝůƐƚ 'ɲŝ ŝŶŚŝďŝƚƐ ĂĚĞŶǇůǇů ĐǇĐůĂƐĞ ĂŶĚ ŝŶŚŝďŝƚƐ ĐDW ƉƌŽĚƵĐƚŝŽŶ
(Table 1.1). This process is under regulation from a negative feedback loop: 
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once activated by an increase in cAMP levels, PKA can activate some 
phosphodiesterases (PDE) isoforms which break down cAMP. Then, once 
cAMP levels decrease, so do activated W< ůĞǀĞůƐ ? /Ŷ ĂĚĚŝƚŝŽŶ ƚŽ ƚŚĞ 'ɲ
ƐƵďƵŶŝƚ ?ƚŚĞ'ɴɶƐƵďƵŶŝƚŚĂƐĂůƐŽďĞĞŶĚĞŵŽŶƐƚƌĂƚĞĚƚŽĂůƐŽƌĞŐƵůĂƚĞ cAMP 
generation, depending on which isoform of adenylyl cyclase is present. For 
example, 'ɴɶĐĂŶŝŶŚŝďŝƚĂĚĞŶǇůǇůĐǇĐůĂƐĞ  ?, stimulate the enzyme activity of 
adenylyl cyclase 2 or have no effect upon adenylyl cyclase 3 (Simonds, 1999). 
DĞĂŶǁŚŝůĞ ? ƚŚĞ ƐƚŝŵƵůĂƚŝŽŶ ŽĨ 'ɲƋ/11 activates phospholipaƐĞ   ?W> ) ɴ ?
which cleaves membrane bound phosphatidylinositol 4,5-bisphosphate (PIP2) 
into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 diffuses 
through the cytosol to bind to IP3 receptors present on the surface of the 
endoplasmic reticulum to elicit calcium release from intracellular stores. 
Meanwhile, DAG remains membrane localised, and in combination with the 
increase in intracellular calcium, activates protein kinase C (PKC). This process 
is also regulated through PKC, which becomes recruited to the cell membrane 
and can negatively regulate PLC activity. Additionally, DAG kinases 
phosphorylate DAG and thus prevent further signalling to PKC (Litosch, 2012). 
The IP3 receptor on the endoplasmic reticulum can also be inactivated by 
phosphorylation with many kinases, including PKC to form another negative 
feedback loop (Vanderheyden et al., 2009). 
 ? ? ? ? ?ɴ-arrestin 
dŚĞŶĞǆƚĞĨĨĞĐƚŽƌƉƌŽƚĞŝŶƚŽďĞĚŝƐĐƵƐƐĞĚǁŝůůďĞɴ-ĂƌƌĞƐƚŝŶ ?ɴ-arrestins were 
ŚŝƐƚŽƌŝĐĂůůǇ ŬŶŽǁŶ ĨŽƌ ƐǁŝƚĐŚŝŶŐ 'WZ ' ƉƌŽƚĞŝŶ ƐŝŐŶĂůůŝŶŐ  “ŽĨĨ ? ? Ă ƉƌŽĐĞƐƐ
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known as desensitisation when it occurs rapidly (minutes). However, they are 
now appreciated to have much more diverse functions, and also mediate their 
own signalling pathways. 
1.6.2.1 Desensitisation 
One mechanism of GPCR desensitisation involves the activated receptor 
becoming phosphorylated by GPCR related kinĂƐĞƐ  ?'Z<Ɛ ) ? ůĞĂĚŝŶŐ ƚŽ ɴ-
arrestin binding (Gurevich and Gurevich, 2006) ?ɴ-arrestin is recruited to the 
ƉůĂƐŵĂ ŵĞŵďƌĂŶĞ ĨƌŽŵ ƚŚĞ ĐǇƚŽƐŽů ? ĂŶĚ ɴ-arrestin binding desensitises the 
receptor (Barak et al., 1997; Krilov et al., 2011; Moro et al., 1993b; Wu et al., 
1997), by physically uncoupling the receptor from its cognate G protein and 
associated signalling pathways (Kong et al., 1994). 
Key to desensitisation are arrestins, of which there are 4 isoforms. Two are 
expressed only in the eye; arrestin-1 in the rods and arrestin-4 in the cones. 
The other two are the widely expressed non-visual arrestŝŶƐ ? ŝƐŽĨŽƌŵƐ ɴ-
ĂƌƌĞƐƚŝŶ ? ĂŶĚ ɴ-arrestin2 (also known as arrestin-2 and arrestin-3 
respectively) (Attramadal et al., 1992; Lohse et al., 1990). /ƚŝƐƚŚŽƵŐŚƚƚŚĂƚɴ-
arrestin contains two molecular sensors: one which detects the activated 
receptor conformation, and the other which can detect whether the receptor 
ŝƐƉŚŽƐƉŚŽƌǇůĂƚĞĚ ?dŚĞƌĞĨŽƌĞ ?ĨŽƌŚŝŐŚĂĨĨŝŶŝƚǇɴ-arrestin binding, the receptor 
must be both activated and phosphorylated (Gurevich and Gurevich, 2006). 
The GRKs carry out rapid (on the time scale of seconds) agonist dependent 
phosphorylation (Kim et al., 1993). GRKs require agonist occupancy of the 
receptor for phosphorylation to occur, and this is an example of homologous 
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desensitisation. This is in contrast to heterologous desensitisation, which 
ŽĐĐƵƌƐŝŶƚŚĞĂďƐĞŶĐĞŽĨɴ-arrestin, and is mediated by protein kinases such as 
PKA and PKC. These protein kinases phosphorylate key motifs in receptor ICLs 
and carboxyl tail, which prevent G protein coupling, and can desensitise 
receptors in the absence of agonist (Montiel et al., 2004). 
There are 7 subtypes of GRKs. There is the visual system based rhodopsin 
kinase family, that is comprised of GRK1 which is expressed in rhodopsin 
(Orban et al., 2012); and GRK7, which is specific for cone opsin (Chen et al., 
2001) ? 'Z< ? ĂŶĚ  ?  ?ĂůƐŽ ĐĂůůĞĚ ɴ ĂĚƌĞŶŽĐĞƉƚŽƌ ŬŝŶĂƐĞ  ? ĂŶĚ  ? ƌĞƐƉĞĐƚŝǀĞůǇ )
were historically ĂƐƐŽĐŝĂƚĞĚǁŝƚŚɴ-arrestin, due to their discovery in relation 
ƚŽ  “ĂƌƌĞƐƚŝŶŐ ? ƚŚĞ ĨƵŶĐƚŝŽŶ ŽĨ ɴ2AR (Ferguson et al., 1995; Freedman et al., 
1995; Richardson et al., 1993). Meanwhile, GRK4, 5 and 6 form the GRK family 
(Penela et al., 2003).  
GRK1, 4, 5, 6 and 7 undergo a lipid post translational modification that targets 
them to the plasma membrane (Pitcher et al., 1998). GRK2 and 3 do not have 
this, and have a widespread cytosolic localisation (Penn et al., 2000). These 
ŝƐŽĨŽƌŵƐ ĂƌĞ ŝŶƐƚĞĂĚ ƌĞĐƌƵŝƚĞĚ ƚŽ ƚŚĞ ƉůĂƐŵĂ ŵĞŵďƌĂŶĞ ďǇ 'ɴɶ ĨŽůůŽǁŝŶŐ
receptor activation (Li et al., 2003). GRKs are thought to predominantly 
phosphorylate serine and threonine residues present on ICL3 and the carboxyl 
tail (Appleyard et al., 1999), ĂŶĚ ĨŽůůŽǁŝŶŐ ƚŚŝƐ ƌĞĐĞƉƚŽƌ ƉŚŽƐƉŚŽƌǇůĂƚŝŽŶ ? ɴ-
arrestin can bind to agonist-activated receptors (Gurevich et al., 2012). 
ɴ-arrestin binding to the receptor is thought to occur through motifs found in 
ICL2, such as the DRYxxV/IxxPL motif. The DRY motif, at the bottom of TM 3, is 
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known for its role in receptor activation (section 1.5.1.2.1). Structures of 
GPCRs have shown the opioid, muscarinic and aminergic receptors to contain 
a salt bridge between ICL2 and the DRY motif, perhaps this holds ICL2 in the 
correct conformation (Venkatakrishnan et al., 2013). Also, mutation of one of 
the salt bridge partners, ICL2 Tyr ? ? ? ?ŝŶɴ2AR also led to inhibition of tyrosine 
phosphorylation, and caused hypersensitivity of this receptor to agonists 
(Valiquette et al., 1995), which could be due to a lack of desensitisation. The 
conserved proline residue within this ICL2 helix motif (Pro 3.57) is also seen as 
ŝŵƉŽƌƚĂŶƚ ĨŽƌ ɴ-ĂƌƌĞƐƚŝŶ ďŝŶĚŝŶŐ ? ďĞĐĂƵƐĞ ŝƚƐ ƌĞŵŽǀĂů ĚĞĐƌĞĂƐĞƐ ɴ-arrestin 
binding and ability to undergo endocytosis (see 1.6.2.2 below), whilst its 
addition to receptors that otherwise lack the proline improves these functions 
(Marion et al., 2006). The central residue of this motif (at position 3.56) is also 
highly conserved as a hydrophobic residue. In this position in the M1 is 
>ĞƵ ? ? ? ? WŚĞ ? ? ? ŝŶ ƚŚĞ ɴ2AR (Moro et al., 1994) and Leu147 in the 
gonadotropin-releasing hormone receptor (Arora et al., 1995). Mutations 
throughout it have been shown to disrupt G protein coupling and arrestin-
mediated internalisation (Moro et al., 1994).  
1.6.2.2 Role of arrestins in receptor internalisation 
KŶĐĞɴ-arrestin is bound to the receptor, it also acts as a scaffold, interacting 
with clathrin (Kang et al., 2009), adaptor protein (AP)-2 (Goodman et al., 
1996) and dynamin to facilitate receptor internalisation, via clathrin coated 
vesicles (Kang et al., 2009; Tsuga et al., 1994) ?ɴ-arrestin is known to interact 
with clathrin through the LIEFE (ŽŶ ɴ-arrestin2) or LIELD (on ɴ-arrestin1) 
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binding domain (Kim and Benovic, 2002; Krupnick et al., 1997) ?ɴ2AR requires 
ɴ-arrestin2 to internalise via clathrin coated pits (Kang et al., 2009) ?ɴ-arrestin 
also interacts with AP-2, a clathrin adaptor protein (Goodman et al., 1996), to 
form a ĐŽŵƉůĞǆǁŝƚŚƚŚĞƌĞĐĞƉƚŽƌĂŶĚɴ-arrestin (Laporte et al., 1999) through 
ĂĚŽŵĂŝŶĨŽƵŶĚŝŶƚŚĞĐĂƌďŽǆǇůƚĂŝůŽĨɴ-arrestin2 (DeFea, 2011; Laporte et al., 
2000) ?ɴ2AR internalisation also requires the phosphorylation of dynamin by 
Src; additionally Src is also activated by arrestin (Ahn et al., 1999) in 
ĐŽŶũƵŶĐƚŝŽŶ ǁŝƚŚ 'ɴɶ (Luttrell et al., 1999). Dynamin isoforms are small 
monomeric G proteins involved in the pinching of endocytic vesicles from the 
plasma membrane (Hinshaw and Schmid, 1995; Takei et al., 1995). Studies 
using a dominant negative form of dynamin, dynamin K44A, have supported a 
crucial role for dynamin in clathrin-mediated endocytosis (Damke et al., 1994; 
Gagnon et al., 1998; Zhang et al., 1996). Conversely, some other GPCRs, such 
as the angiotensin II type 1A receptor (AT1AR) have been found to not require 
ĚǇŶĂŵŝŶŽƌɴ-arrestin to internalise (Zhang et al., 1996). Additionally, removal 
of the carboxyl tail from the A2B adenosine receptor altered its internalisation 
phenotype, to one that still relied upon dynamin, but was also both clathrin 
ĂŶĚɴ-arrestin-independent (Mundell et al., 2010). 
1.6.2.3 Receptor trafficking and sorting pathways 
Once internalised, the receptor traffics into the early endosomes (Iwata et al., 
1999; Moore et al., 1995). Here, the receptor becomes dephosphorylated by 
protein phosphatase 2A (PP2A) (Pitcher et al., 1995) and can be recycled back 
to the plasma membrane, termed receptor resensitisation (Pippig et al., 
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1995). Alternatively, the receptors may be sorted to lysosomal compartments, 
contributing to a longer term decrease in cell surface expression 
 ? “ĚŽǁŶƌĞŐƵůĂƚŝŽŶ ? ) ?ĂŶĚůŽŶŐƚĞƌŵƚŽůĞƌĂŶĐĞƚŽĂŐŽŶŝƐƚƐƚŝŵƵůĂƚŝŽŶ ?dhe rate 
of trafficking and which pathway (recycling or degradation) the receptor 
follows is determined by many factors, some of which will be covered now. 
The entry into a specific intracellular trafficking pathway can be influenced by 
ǁŚĞƚŚĞƌ ŝƚƐ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ŝƐ 'Z< ĂŶĚ ɴ-arrestin dependent or independent 
(e.g. requiring PKC instead), and which types of clathrin-coated pits are 
engaged. For example, P2Y12 purine receptors have been found to internalise 
ŝŶ Ă ɴ-arrestin dependent way and via a CCP-1 class pit. Meanwhile P2Y1 
ƌĞĐĞƉƚŽƌƐ ŝŶƚĞƌŶĂůŝƐĞĚ ŝŶĚĞƉĞŶĚĞŶƚůǇŽĨɴ-arrestin and entered a CCP-2 class 
pit. It is thought that this difference influences trafficking, i.e. CCP-1 class 
receptors such as P2Y12 ĂŶĚɴ2AR rapidly recycle back to the surface, whilst the 
CCP-2 pit receptor, P2Y1 receptors undergo further sorting (Mundell et al., 
2006). Also thought to influence these distinct profiles, is sorting nexin 1 
(SNX1), a protein known for directing receptors towards endosomal retention. 
The fact that P2Y1 receptors undergo slow recycling seems to be mediated by 
SNX1, because once SNX1 function is inhibited, P2Y1 receptors then undergo 
faster recycling (Nisar et al., 2010). 
Different categories of receptor trafficking behaviour can be described 
dependent on the stability and nature of interactions with arrestins. Class A 
'WZƐ ?Ğ ?Ő ?ɴ2AR, endothelin A, dopamine D1 )ƉƌĞĨĞƌĞŶƚŝĂůůǇďŝŶĚɴ-arrestin2, 
ƚŚĞŶ ĚŝƐƐŽĐŝĂƚĞ ƌĂƉŝĚůǇ ĨƌŽŵ ɴ-ĂƌƌĞƐƚŝŶ ?  ?ďĞĐĂƵƐĞ ƌĞĐĞƉƚŽƌ Pɴ-arrestin2 
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interactions are transient) and recycle. In contrast, class B GPCRs (e.g. the 
vasopressin V2 receptor, AT1AZ )ďŝŶĚďŽƚŚɴ-arrestins with similar affinity and 
in a sustained manner, and most have slower rates of recycling, with 
increased targeting to the degradative pathway. The switching of carboxyl 
ƚĂŝůƐ ŽĨ ƚŚĞ ɴ2AR and V2 receptor switched phenotype accordingly, showing 
that carboxyl tail plays a key role for these receptors in controlling 
ŝŶƚĞƌĂĐƚŝŽŶƐ ďĞƚǁĞĞŶ ƚŚĞ ƌĞĐĞƉƚŽƌ ĂŶĚ ɴ-arrestin (Oakley et al., 2000). 
Comparison of the carboxyl tails of these two groups of receptors found that 
the rapid recycling receptors lack multiple clustered phosphorylation sites, 
whilst the slower recycling receptors contain highly conserved clusters of GRK-
phosphorylated Ser or Thr residues. Therefore, the presence of these residues 
ĂƉƉĞĂƌƐ ƚŽ ƐƚƌĞŶŐƚŚĞŶ ɴ-arrestin interactions and affect receptor 
dephosphorylation, which then influenĐĞƐ ƚŚĞ ƌĂƚĞ ŽĨ ƌĞĐǇĐůŝŶŐ ? ɴ-arrestin 
ĚŝƐƐŽĐŝĂƚĞƐĨƌŽŵƚŚĞɴ2ZŶĞĂƌƚŚĞƉůĂƐŵĂŵĞŵďƌĂŶĞ ?ĂŶĚďĞĐĂƵƐĞɴ-arrestin 
is not present on the receptor in the endocytic vesicles, then the receptor can 
be rapidly dephosphorylated and recycle. The same is true of the dopamine D1 
receptor and endothelin type A receptor (Zhang et al., 1999). Conversely, the 
V2ZƌĞŵĂŝŶƐďŽƵŶĚƚŽɴ-arrestin into endocytic vesicles, which is thought to 
prevent receptor dephosphorylation (Oakley et al., 1999). This was also found 
for the neurotensin receptor 1 and AT1AR (Zhang et al., 1999). 
A number of GPCRs contain PDZ (Postsynaptic density 95/Disc large/Zonula 
occludens-1 homology) binding domains at their carboxyl terminus (in the 
ɴ2AR the amino acid sequence is DSLL), a further recycling determinant key 
for the sorting of internalised receptors. The PDZ binding is responsible for 
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interacting with the PDZ domain present on scaffold proteins such as EBP50 
(ezrin-binding protein, also known as NHERF1,Na+-H+ exchange regulatory 
factor 1). This appears to facilitate further interactions with the actin 
ĐǇƚŽƐŬĞůĞƚŽŶĂŶĚĨĂĐŝůŝƚĂƚĞƐɴ2ZƌĞĐǇĐůŝŶŐ ?/ŶƚŚĞɴ2AR, Ser411, found within 
this binding domain, becomes phosphorylated by GRK5, but not by GRK2. 
'Z< ?ĂƉƉĞĂƌƐƚŽƉůĂǇŶŽƌŽůĞŝŶɴ2AR recycling, because even over-expression 
of GKR2 had no effect, suggesting GRK-specific roles in receptor trafficking. 
Phosphorylation of Ser411 by GRK5 on the other hand, recreated in the S411D 
mutant (phospho-ĚŽŵŝŶĂŶƚ ) ? ƉƌĞǀĞŶƚĞĚ W ? ? ĨƌŽŵ ďŝŶĚŝŶŐ ƚŚĞ ɴ2AR, and 
thus inhibited its recycling (Cao et al., 1999). Additionally, the removal of this 
region in the A2B adenosine receptor switched its phenotype, and inhibited 
recycling (Mundell et al., 2010). 
Receptors can also enter the degradation pathway, which targets receptors to 
the lysosomes, causing long term down-ƌĞŐƵůĂƚŝŽŶ ?ĨŽƌĞǆĂŵƉůĞƚŚĞɷŽƉŝŽŝĚ
receptor (Marchese et al., 2003; Tsao and von Zastrow, 2000). For several 
GPCRs, ubiquitination has been found to have a role in targeting the receptor 
protein to the lysosomes for degradation, mediated by E3 ligases, a family of 
enzymes which covalently attach ubiquitin to the receptor (Shenoy et al., 
2001; Shenoy et al., 2009). Interestingly, ubiquitination has also been found to 
play a role in regulating the internalisation and trafficking of GPCRs (Canals et 
al., 2012; Wolfe et al., 2007). Similarly, receptors also contain more motifs in 
their carboxyl terminus which regulate the binding of sorting proteins (Castro-
Fernandez and Conn, 2002), such as the GPCR sorting associated protein 
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(Thompson and Whistler, 2011), and SNX1 (Kurten et al., 1996), both of which 
are implicated in lysosomal targeting (Gullapalli et al., 2006). 
dŚƵƐ ? Ă ĐŽŵďŝŶĂƚŝŽŶ ŽĨ ɴ-arrestin regulation, receptor phosphorylation or 
ubiquitination, and other scaffold proteins such as those discussed above, all 
have the capacity to influence receptor trafficking and the ultimate 
destination to recycling or degradative pathways. 
1.6.3 ɴ-arrestin dependent signalling 
Increasing evidence suggests that GPCRs can undergo ɴ-arrestin mediated 
signalling. This is thought to bĞĚƵĞƚŽƚŚĞĨĂĐƚƚŚĂƚǁŚĞŶɴ-arrestin binds to 
the activated receptor, it can also act as a scaffold for other proteins, for 
example for both clathrin and AP-2, which are required for endocytosis 
(section 1.6.2.2), or for both src and extracellular signal-related protein kinase 
(ERK)1/2, signalling pathways (Shenoy and Lefkowitz, 2003). This gave rise to a 
theory that, as well as the original ternary complex of agonist, receptor and G 
protein, it is also possible to postulate that an alternative ternary complex of 
ĂŐŽŶŝƐƚ ?ƌĞĐĞƉƚŽƌĂŶĚɴ-arrestin may also exist, and can elicit signalling, such 
as ERK activation. 
1.6.3.1 The ERK signalling cascade 
The ERK pathway (classically also known as the MAPK pathway; originally 
associated with tyrosine kinase linked receptors), can be activated by GPCRs 
ŝŶ Ă ɴ-ĂƌƌĞƐƚŝŶ Žƌ ' ƉƌŽƚĞŝŶ ĚĞƉĞŶĚĞŶƚ ŵĂŶŶĞƌ ? ɴ-arrestin mediated ERK 
signalling has been found to be slower, but longer lasting than G protein 
mediated ERK signalling, and was localised to the endosomes in the cytosol 
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(Ahn et al., 2004). This is in contrast to the G protein mediated ERK signalling 
which has been found to be rapid but transient, and resulted in activated ERK 
being translocated to the nucleus (Ahn et al., 2004). In vascular smooth 
ŵƵƐĐůĞ ĐĞůůƐ ? ɴ-ĂƌƌĞƐƚŝŶ ĂĐƚŝǀĂƚŝŽŶ ŽĨ Z< ƌĞƋƵŝƌĞƐ W<ɺ ? ĂŶĚ ďŽƚŚ ƚŚĞ '
ƉƌŽƚĞŝŶĂŶĚɴĂƌƌĞƐƚŝŶƉĂƚŚǁĂǇĂƉƉĞĂƌƚŽƌĞŐƵůĂƚĞƉƌŽůŝĨĞƌĂƚŝŽŶŝŶĚĞƉĞŶĚĞŶƚůǇ
of each other (Kim et al., 2009). 
ɴ-arrestin activation of ERK and related pathways such as c-Jun N-terminal 
kinase (JNK) is via activation of the MAPK cascade of phosphorylation. The 
activation of MAPKKKs (e.g. Raf-1 for ERK), leads to the phosphorylation of 
MAPKKs, which in turn phosphorylate MAP kinases, such as JNK, ERK and p38. 
pJNK and pERK become stabilised in the endosomes, or translocate to the 
nucleus. Here, they mediate the phosphorylation and transcription of genes 
involved in differentiation and proliferation (Morrison and Davis, 2003). An 
example of this is in the mesenchymal stem cells: prostaglandin E2 mediated 
ĂĐƚŝǀĂƚŝŽŶŽĨɴ-arrestin and subsequent activation of JNK leads to both cellular 
migration through the reorganisation of the cytoskeleton (Xiao et al., 2010) 
and proliferation (Yun et al., 2011). Additional examples of receptors that 
ƵŶĚĞƌŐŽɴ-ĂƌƌĞƐƚŝŶŵĞĚŝĂƚĞĚZ<ƐŝŐŶĂůůŝŶŐŝŶĐůƵĚĞɴ2AR (Luttrell et al., 1999), 
protease activated receptor (PAR)2 (DeFea et al., 2000) and CXCR7 (Canals et 
al., 2012). There is also evidence for ERK recruitment and signalling continuing 
ŽŶĐĞ ƚŚĞ  “ĚĞƐĞŶƐŝƚŝƐĞĚ ? ƌĞĐĞƉƚŽƌ Pɴ-arrestin complex has entered the 
endosomes (Zimmerman et al., 2011). 
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1.6.3.2 Src scaffolding 
ɴ-arrestin can also activate ERK, via scaffolding with Src (Charest et al., 2007; 
Luttrell et al., 1999; Luttrell et al., 2001); for example src regulates the Rb-
Raf1 pathway, which causes cell proliferation, thought to be the GPCR 
pathway through which nicotine is mitogenic and carcinogenic (Dasgupta et 
al., 2006) ? dŚŝƐ ƌĞĐĞƉƚŽƌ Pɴ-arrestin:Src interaction can also influence 
internalisation (Miller et al., 2000). Src also activates JNK (Kraus et al., 2003) in 
Ă ɴ-arrestin dependent manner (McDonald et al., 2000) ? ĂŶĚ ĂůƐŽ ŝŶ Ă ɴ-
arrestin dependent manner to mediate ghrelin receptor activation of Akt 
(Lodeiro et al., 2009). 
1.6.3.3 Akt and PP2A 
ɴ-arrestin can also form a signalling scaffold with Akt (also known as protein 
kinase B) and PP2A. Akt plays a role in the P13K > Akt > mammalian target of 
rapamycin (mTOR) signalling pathway that is involved in mediating apoptosis, 
cell proliferation and migration (Morgensztern and McLeod, 2005). 
Meanwhile, the activity of PP2A can inhibit Akt signalling (Pandey et al., 2013). 
Therefore, it was interesting that dopamine receptor activation led to a 
ƌĞĚƵĐƚŝŽŶŝŶŬƚĂĐƚŝǀŝƚǇŝŶĂɴ-arrestin dependent way. This was found to be 
ĚƵĞƚŚĞĨĂĐƚƚŚĂƚɴ-arrestin interacts with both Akt and PP2A, bringing them 
both together in a signalling scaffold. Altogether, the dysregulation of this 
complex, and its consequent effects on synaptic transmission, could be 
involved in dopamine-related disorders such as schizophrenia (Beaulieu et al., 
2005). 
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1.6.3.4 Phosphodiesterases 
The activation of ɴ2AR can also result in the formation of another signalling 
ĐŽŵƉůĞǆ ? ŵĞĚŝĂƚĞĚ ďǇ ɴ-arrestin. In this example, the signalling complex is 
completed by a PDE4D, which causes the degradation of cAMP. The formation 
ŽĨ ƚŚŝƐ ƐŝŐŶĂůůŝŶŐĐŽŵƉůĞǆ ŝƐ ƚŚŽƵŐŚƚ ƚŽƉůĂǇĂ ƌŽůĞ ŝŶ ƚŚĞ ƌĞŐƵůĂƚŝŽŶŽĨɴ2AR 
cAMP dependent signalling. More complex consequences can also arise via 
ĂůƚĞƌĂƚŝŽŶƐ ŝŶ W< ƌĞŐƵůĂƚŝŽŶ ŽĨ ƚŚĞ ɴ2AR, which can modify its G protein 
coupling from Gs to Gi, and also affect downstream ERK signalling in 
cardiomyocytes (Baillie et al., 2003). 
1.6.4 Biased signalling 
The realisation that GPCRs can couple to multiple signalling pathways has 
given rise to the concept of biased signalling, in which receptor may show a 
ƉƌĞĨĞƌĞŶĐĞ ĨŽƌ ƐŝŐŶĂůůŝŶŐ ƚŚƌŽƵŐŚ Ă ƉĂƌƚŝĐƵůĂƌ ĞĨĨĞĐƚŽƌ  ?Ğ ?Ő ? ' ƉƌŽƚĞŝŶ Žƌ ɴ-
arrestin) dependent upon which ligand is bound. This is thought to be due to a 
multi state model of activation, whereby different ligands may stabilise 
different conformations of the receptor which then differentially activate 
different signalling molecules (Azzi et al., 2003). For example, one ligand could 
stabilise the receptor in a conformation that uncovers certain cytoplasmic 
loops that allow for G protein coupling and the subsequent signalling through 
that pathway, whereas another ligand could stabilise the receptor in a 
ĚŝĨĨĞƌĞŶƚĐŽŶĨŽƌŵĂƚŝŽŶƚŚĂƚƵŶĐŽǀĞƌƐɴ-arrestin binding sites, giving the basis 
for ligand bias (Kenakin, 2001) ? dŚĞ ɴ-blocker propranolol was an early 
ĞǆĂŵƉůĞŽĨĂůŝŐĂŶĚǁŝƚŚƐŝŐŶĂůůŝŶŐďŝĂƐ ?ƚɴ2AR it was found to be an inverse 
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agonist on the Gs coupled pathway of adenylyl cyclase, which led to a 
decrease in cAMP production, whilst it was an agonist on the MAPK pathway 
and activated ERK1/2 through a G protein independent pathway (Azzi et al., 
2003; Baker et al., 2003). 
This has also been observed in the M3 receptor, where in response to 
different ligands the receptor was shown to undergo different patterns of 
phosphorylation, which then led to different signalling outcomes. Thus, a 
phosƉŚŽƌǇůĂƚŝŽŶ  “ďĂƌ ĐŽĚĞ ? ? ŝŶ ĂĚĚŝƚŝŽŶ ƚŽ ůŝŐĂŶĚ ƐƉĞĐŝĨŝĐ ƌĞĐĞƉƚŽƌ
conformations, could also offer an explanation for biased signalling (Butcher 
et al., 2011).  
/ŶƚŚĞɷŽƉŝŽŝĚƌĞĐĞƉƚŽƌ ?ŝƚŚĂƐďĞĞŶĨŽƵŶĚƚŚĂƚƚŚĞůŝŐĂŶĚƐWWĂŶĚ^E-80 
elicit different recycling profiles by causing distinct receptor conformations, 
ĂůƚĞƌŝŶŐ ƚŚĞŝƌ ŝŶƚĞƌĂĐƚŝŽŶƐ ǁŝƚŚ ɴ-arrestin. This work also showed that 
ĂůƚŚŽƵŐŚƚŚĞɷŽƉŝoid receptor is characterised as being a typical degradation 
pathway receptor, it can also undergo agonist-specific recycling, giving an 
example of ligand directed receptor regulation (Audet et al., 2012). 
1.6.5 The role of GPCR dimerisation 
Another emerging phenomenon that has been shown to regulate GPCR 
function is the potential formation of receptor oligomers (the simplest case 
being a dimer). The arguments and experimental evidence both for and 
against GPCRs undergoing dimerisation will now be presented. 
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1.6.5.1 Evidence for GPCRs as monomeric receptors 
The question of whether class A GPCRs form dimers is controversial (Chabre 
and le Maire, 2005). Some argue that GPCRs exist as monomers, and that the 
formation of dimers in vitro is an artefact, due to co-operativity between 
over-expressed receptors in an artificial environment (the recombinant 
system), a situation that may not occur in vivo (Chabre et al., 2009). There is 
some evidence for the existence of monomers using artificial systems, and 
that these monomers could be functional at all levels of receptor activation. 
&ŝƌƐƚůǇ ? ƚŚĞʅŽƉŝŽŝĚ ƌĞĐĞƉƚŽƌǁĂƐ ƌĞĐŽŶƐƚŝƚƵƚĞĚ ŝŶƚŽŚŝŐŚĚĞŶƐŝƚǇ ůŝƉŽƉƌotein 
(HDL) discs, and using single-molecular imaging was found to be monomeric 
and capable of binding the agonist dermorphin (Kuszak et al., 2009). FRET was 
ƵƚŝůŝƐĞĚ ŝŶƚŚĞƐƚƵĚǇŽĨɴ2AR (Whorton et al., 2007), and rhodopsin (Ernst et 
al., 2007), which were found to be able to dock with the relevant G proteins, 
Gs and transducin respectively, as monomers. Rhodopsin was also 
reconstituted into HDL discs, determined to be a monomer using a size 
exclusion column, and was shown to efficiently activate transducin (Whorton 
et al., 2008). Rhodopsin monomers in nanodiscs were found to activate the 
signalling proteins transducin (Bayburt et al., 2007), rhodopsin GRK1 and 
arrestin1 (Bayburt et al., 2011). Additionally, the crystal structure of Gs bound 
ƚŽɴ2AR was shown to be in monomeric form (Rasmussen et al., 2011b). 
1.6.5.2 Evidence for GPCR homodimers 
Despite the ability of GPCRs to activate their effectors as monomers, many 
studies, using various techniques have shown evidence for a multitude of 
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class A GPCRs forming dimers (reviewed in (Milligan, 2009)), from which some 
examples are discussed below. 
1.6.5.2.1 Functional  “ŵƵƚĂŶƚƌĞƐĐƵĞ ?studies 
There is evidence for receptor dimers in both recombinant systems and native 
ĐĞůůƐ ?ĂƌůǇǁŽƌŬŽŶĐŚŝŵĞƌŝĐƌĞĐĞƉƚŽƌƐĨŽƵŶĚƚŚĂƚďŽƚŚƚŚĞɲ ?adrenergic and 
ɴ2AR (Kobilka et al., 1988), and the M3 ŵƵƐĐĂƌŝŶŝĐĂŶĚɲĂĚƌĞŶĞƌŐŝĐƌĞĐĞƉƚŽƌƐ
could be split into two halves, i.e. TM 1-4 and TM 5-7, which could then 
interact when co-expressed undergo complementation to restore receptor 
function (Maggio et al., 1993). Also, in another study, mutants of the type 1 
angiotensin receptor were created. One mutant was deficient in binding 
ligand, whilst another could no longer couple to G protein. Co-expression of 
the two restored function, thought to be mediated through 
transcomplementation (Monnot et al., 1996). This gave the first glimpse at the 
existence of GPCR dimers, but did not exclude the possibility that one 
ĨƵŶĐƚŝŽŶĂů ŵŽŶŽŵĞƌ ƵŶŝƚ ǁĂƐ ŐĞŶĞƌĂƚĞĚ ďǇ  “ƐǁĂƉƉŝŶŐ ? ƚŚĞ ƌĞůĞǀĂŶƚ dD
domains, though this possibility is perhaps less likely from the recent crystal 
structures. 
Recently, functional co-operativity between binding and signalling receptor 
mutants has also been demonstrated in vivo. A study on the luteinizing 
hormone (LH) receptor using transgenic mice found that the co-expression of 
a binding mutant with a signalling mutant led to co-operation between the 
mutants. Intermolecular functional complementation between the two was 
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observed to restore the normal action of LH, which the authors postulated 
was due to dimer formation between the mutants (Rivero-Muller et al., 2010). 
Additionally, various types of microscopy have also been utilised to determine 
dimerisation, which will now be covered. 
1.6.5.2.2 Dimers indicated by FRET and BRET 
These approaches use measurement of the energy transfer between a donor 
(fluorescence or luminescence) and acceptor label to indicate close proximity 
(< 10 nm) of the tagged proteins. They have been very widely used to 
demonstrate the presence of GPCR oligomers (for a review see (Milligan and 
Bouvier, 2005)). The principle of FRET is of energy transfer between two 
chromophores fused to the proteins of interest. The donor chromophore, 
typically CFP, is laser excited, and if it is within ~100 Å of its FRET partner, 
typically YFP, it transfers energy to the acceptor (Milligan and Bouvier, 2005). 
This technique was used to determine that the serotonin 5-
hydroxytryptamine2c receptor expressed on HEK293 (human embryonic 
kidney) cells undergoes homodimerisation on the plasma membrane, and this 
was also backed up biochemically using co-immunoprecipitation and Western 
blotting (Herrick-Davis et al., 2004). Moreover, the application of time 
resolved (TR)-FRET in native tissues using fluorescent ligands demonstrated 
the presence of endogenous oxytocin receptor higher order oligomers in the 
mammary gland (Albizu et al., 2010). TR-FRET was also used in the detection 
of GABAB receptor tetramers in the plasma membrane of brain tissue (Comps-
Agrar et al., 2011). One limitation of FRET is that it requires a laser as the 
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input to activate the first FRET partner, which can cause background or 
photobleaching. To counteract this, bioluminescence resonance energy 
transfer (BRET) was developed, which requires no laser input, because it uses 
Renilla luciferase and a chemical substrate to activate the donor luminescent 
partner. 
Use of BRET for example (Gales et al., 2005), demonstrated that CXCR4 
undergoes constitutive oligomerisation, which was again backed up 
biochemically using co-immunoprecipitation (Babcock et al., 2003), and later 
by the presence of a dimer structure in the x-ray crystals of CXCR4 (Wu et al., 
2010). However, there is some controversy to the BRET technique, in whether 
receptor over-expression can produce artefacts (James et al., 2006). 
1.6.5.2.3 Other microscopy 
Atomic force microscopy was used on native rod membranes and discovered 
ƚŚĂƚƌŚŽĚŽƉƐŝŶĞǆŝƐƚĞĚŝŶ “ĂƌƌĂǇƐ ?ŽĨĚŝŵĞƌƐ(Fotiadis et al., 2003). Finally, two 
microscopic techniques were employed to undergo single cell imaging. Firstly, 
total internal reflection fluorescence microscopy was used to image a 
fluorescent M1 antagonist bound to its receptor, which suggested that ~30 % 
of the antagonist-occupied M1 muscarinic receptors were in dimeric form at 
any one time (Hern et al., 2010). Fluorescence recovery after photobleaching 
(FRAP) has also been utilised to determine ƚŚĂƚ ɴ1AR undergoes transient 
ĚŝŵĞƌŝƐĂƚŝŽŶ ? ǁŚŝůƐƚ ɴ2AR was found to form sustained dimeric formation 
(Dorsch et al., 2009). Additionally, the utilisation of other techniques to 
measure dimerisation such as FCS and PCH will be discussed in chapter 5. 
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1.6.5.2.4 Structural information about GPCR dimer interfaces 
The x-ƌĂǇ ƐƚƌƵĐƚƵƌĞ ŽĨ ƚŚĞ ʅ ŽƉŝŽŝĚ ƌĞĐĞƉƚŽƌ ĐƌǇƐƚĂůůŝƐĞĚ ǁŝƚŚ ƚŚĞ ĂŶƚĂŐŽŶŝƐƚ
morphinan, showed evidence of higher order oligomer organisation, with 
interactions between TM 1, TM 2 and helix 8 (Manglik et al., 2012), as did the 
ʃ ŽƉŝŽŝĚ ƌĞĐĞƉƚŽƌ ƐƚƌƵĐƚƵƌĞ ? ďŽƵŶĚ ƚŽ ƐĞůĞĐƚŝǀĞ ĂŶtagonist JDTic (Wu et al., 
2012). This interaction has been seen in other x-ray crystal structures of opsin 
(Park et al., 2008), rhodopsin (Salom et al., 2006) ĂŶĚɴ2AR (Cherezov et al., 
2007) ĂŶĚɴ1AR (Huang et al., 2013). 
The x-ray structure of CXCR4, which is involved in the regulation of leukocyte 
migration, was revealed to be in a dimer formation, interacting on the 
extracellular side through TM 5 and 6 (Wu et al., 2010) ?ĂƐĂůƐŽƐĞĞŶŝŶƚŚĞʅ
opioid receptor, where TM 5 and TM 6 of each protomer interacted through a 
four helix bundle motif (Manglik et al., 2012). Interactions between TM 5 have 
also been seen in the M3 muscarinic receptor (Hu et al., 2012). Meanwhile, on 
the intracellular side CXCR4 interacts through TM 2 and 4 with ICL2 (Wu et al., 
2010). 
ThiƐ ǁĂƐ ƐŝŵŝůĂƌ ƚŽ ƚŚĞ ƐĞĐŽŶĚ ŝŶƚĞƌĨĂĐĞ ƐĞĞŶ ŝŶ ƚŚĞ ɴ1AR dimer, mediated 
through TM 4, TM 5 and ICL2, but that only the other form of dimer (TM 1, 2 
and 8) could interact with the G protein (Huang et al., 2013) ? dŚĞ ɷ ŽƉŝŽŝĚ
dimer has also been suggested to have an interface through TM 4 and 5 
(Johnston et al., 2011), but its x-ray structure showed no clear dimerisation 
(Granier et al., 2012). 
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1.6.5.3 GPCR heterodimers 
The strongest evidence for GPCR dimerisation originates from the class C 
receptor family. Indeed, the GABAB receptor requires hetero-dimerisation 
between 2 subunits for plasma membrane expression and function. Both the 
GABAB1 and GABAB2 subunits must be present in dimer formation for the 
GABAB receptor to be fully functional (White et al., 1998). This is because both 
subunits are required for the trafficking of the dimer to the cell surface, as 
ƚŚĞǇŝŶƚĞƌĂĐƚĚŝƌĞĐƚůǇƚŚƌŽƵŐŚĐŽŝůĞĚĐŽŝůɲŚĞůŝĐĞƐƉƌĞƐĞŶƚŝŶƚŚĞŝƌŝŶƚƌĂĐĞůůƵůĂƌ
tails (Kammerer et al., 1999; Kuner et al., 1999). This causes the GABAB2 
subunit to cover an endoplasmic reticulum retention signal of positively 
charged amino acids, RSRR, present on the carboxyl tail of the GABAB1 subunit, 
which then allows the heterodimer to be cell surface expressed (Margeta-
Mitrovic et al., 2000). 
Studies have also shown that the GABAB1 subunit must be present to allow 
agonist binding, whilst the GABAB2 subunit couples to the G protein (Jones et 
al., 1998; Kaupmann et al., 1998). Further work showed more complexity in 
that allosteric modulation between both subunits also contributes to function. 
GABAB2 increases the affinity of GABA for GABAB1, whilst GABAB1 improves 
coupling efficacy of GABAB2 (Galvez et al., 2001; Mukherjee et al., 2006). 
1.6.5.3.1 FRET and BRET approaches to detect heterodimers 
The venus fly trap motif present in class C receptors also plays a significant 
role in GABAB heterodimerisation and the homodimerisation of metabotropic 
glutamate receptors, involving a disulphide bond between the motifs 
72 
 
(Rondard et al., 2008). In fact, the GABA receptors (but not glutamate 
receptor mGluR1 dimers), were found to form higher order tetramers, using a 
combination of labelled SNAP-tag and FLAG-tagged receptors and measuring 
their interactions using TR-FRET (Comps-Agrar et al., 2011; Maurel et al., 
2008). 
Both FRET and BRET have been used extensively to suggest class A GPCR 
heterodimer pairings (in the absence of the clear structural motifs present in 
class C receptors (Milligan and Bouvier, 2005)). For example, BRET was used 
ƚŽ ƐƚƵĚǇ ƚŚĞ ƉƌŽƉĞŶƐŝƚǇ ŽĨ ƚŚĞ ŽƉŝŽŝĚ ɷ ? ʅ ĂŶĚ ʃ ƌĞĐĞƉƚŽƌ ƐƵďƚǇƉĞƐ ƚŽ ĨŽƌŵ
heterodimers. It was found that all three subtypes were equally as likely to 
form heterodimers with each other, but they did not form dimers with the M2 
muscarinic receptor, suggesting that these dimer interactions are specific to 
opioid receptors (Wang et al., 2005). This complements biochemical studies 
done on this group of receptors ?ŽƚŚɷĂŶĚʃ(Jordan and Devi, 1999) ?ĂŶĚʅ
ĂŶĚ ɷ (George et al., 2000) were found to form heterodimers using co-
immunoprecipitation ? ǁŚŝůƐƚ ʅ ĂŶĚ ʃ ǁĞƌĞ ĨŽƵŶĚ ƚŽ ŚĞƚĞƌŽĚŝŵĞƌŝƐĞ ƵƐŝŶŐ
crosslinking approaches (Chakrabarti et al., 2010). 
1.6.5.3.2 Radioligand binding 
Binding has also been used to examine GPCR heterodimerisation (Birdsall, 
2010). One study used radioligand binding studies on the ʃ ĂŶĚ ɷ ŽƉŝŽŝĚ
receptors. Selective ůŝŐĂŶĚƐ ǁĞƌĞ ƵƐĞĚ Ăƚ ƚŚĞ ʃ Pɷ ŚĞƚĞƌŽĚŝŵĞƌƐ ? ĂŶĚ ǁĞƌĞ
found to have lower affinity than for the single subtype expressed alone 
Interestingly however, these ligands were found to bind co-operatively and 
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have synergistic responses in cells expressing both subtypes (Jordan and Devi, 
1999). 
1.6.5.3.3 The potential of dimers to influence the stoichiometry of 
ligand:receptor:effector interaction 
One of the key unresolved questions about the functional role of GPCR dimers 
is the influence this process has on the stoichiometry between ligand, 
receptor and signalling effector molecules. Differences in receptor 
stoichiometry for different ligand and effector combinations for example, 
might lead to an explanation for biased signalling (section 1.6.4). 
Understanding the way in which dimers interact with effectors is also critical 
ĨŽƌ ĞǆƉůĂŝŶŝŶŐŚŽǁŚĞƚĞƌŽĚŝŵĞƌƐŵŝŐŚƚ ĐŽƵƉůĞ ƚŽ  “ŶĞǁ ? ƐŝŐŶĂůůŝŶŐƉĂƚŚǁĂǇƐ
not shared by the single receptor subtypes. Four models have been 
postulated for how this stoichiometry may form in the context of G proteins 
(Gurevich and Gurevich, 2008) which are detailed as follows: 
A) one active receptor monomer: one G protein. As discussed above, various 
ƐƚƵĚŝĞƐ ŽŶ ƌŚŽĚŽƉƐŝŶ ? ɴ2Z ĂŶĚ ʅ ŽƉŝŽŝĚ ƌĞĐĞƉƚŽƌƐ ŚĂǀĞ ĨŽƵŶĚ ƚŚĞŵ ƚŽ ďĞ
fully functional as a monomer in activating one G protein. In these studies, the 
receptors were reconstituted into lipid discs of a defined diameter to only 
allow the incorporation of a monomer, (Bayburt et al., 2007; Ernst et al., 
2007; Kuszak et al., 2009; Whorton et al., 2007; Whorton et al., 2008). 
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B) one active receptor in a dimer: one G protein  
Some class C receptor studies, for example using mutated protomers of the 
class C mGlu receptors, have suggested that a dimer activates a single G 
protein (Baneres and Parello, 2003; Hlavackova et al., 2005). 
Studies have also been carried out on class A receptors. The CXCR4 receptor 
for example, forms heterodimers with CCR2, and experiments using BRET 
found that these dimers are responsive to the agonists for both receptors, but 
only one receptor undergoing activation is required for a response from both 
protomers (Percherancier et al., 2005). Another class A receptor, rhodopsin, 
was reconstituted as dimers in nanodiscs, and it was found that, due to steric 
hindrance, only one rhodopsin moiety in the dimer was able to couple with 
transducin (Bayburt et al., 2007); this also reflects the inhibitory action of 
NTS1 dimers on G protein activation (White et al., 2007). 
Additionally, work on a fluorescently labelled class A leukotriene B4 receptor 
showed it to be activated when only one protomer was activated by ligand, 
leading to asymmetric activation of the G protein (Damian et al., 2006). 
Similarly, using a luminescence assay, a dopamine D2:D4 heterodimer was 
found to undergo asymmetrical activation of one G protein (Han et al., 2009). 
C) two active receptors in a dimer: two G proteins (i.e. each receptor in the 
dimer activates its respective G protein) 
This setup is thought to be less likely. In the study on purified neurotensin 
NTS1 receptors, it was possible for two receptors to activate two G proteins, 
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but there is negative co-operativity between the two G protein binding sites 
on the two NTS1 protomers, resulting in reduced G protein coupling 
compared to in a monomer (White et al., 2007). 
D) two active receptors in a dimer: one G protein 
Using FRET, it was found that the 5-HT2C heterodimer could bind two 
molecules of ligand, which together only activated one G protein (Herrick-
Davis et al., 2005). 
1.6.5.3.4 ɴ-arrestin as an alternative coupling protein 
A final point to consider ŝƐɴ-arrestin as an alternative effector protein. It has 
been suggested (on the basis of modelling inactive structures) that 2 
rhodopsins might interact with ŽŶĞɴ-arrestin molecule (Fotiadis et al., 2003). 
There is also some evidence for hetero-ĚŝŵĞƌŝƐĂƚŝŽŶ ŵŽĚƵůĂƚŝŶŐ ɴ-arrestin 
dependent internalisation (see section 1.6.5.4.3). Conversely, receptors can 
also internalise as monomers (Gurevich and Gurevich, 2008), and in rods, the 
ratio of rhodopsin:ɴ-arrestin has been reported to be 1:1 (Hanson et al., 
2007). 
1.6.5.4 The potential for GPCR dimerisation to lead to altered signalling 
The formation of a receptor dimer may have different signalling 
characteristics to a monomer, perhaps by modulating the response, changing 
it entirely, or creating a novel response (Rozenfeld and Devi, 2011). 
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1.6.5.4.1 Novel signalling pathways and pharmacology for GPCR 
heterodimers 
An interesting example of this was found by the co-activation of both Gs 
coupled D1 and Gi coupled D2 dopamine receptors, which was found to give a 
novel Gq mediated calcium signalling response. This response was not 
mediated by either receptor alone, giving evidence of dimerisation being 
responsible for a completely novel signal (Lee et al., 2004). 
dŚĞ ʅ Pɷ ŽƉŝŽŝĚ ŚĞƚĞrodimer had novel signalling responses as a dimer, 
because although both subtypes are Gi coupled, these responses were no 
longer sensitive to the Gi inhibitor Pertussis toxin (PTx). Dimers also had 
altered pharmacology in response to the selective agonists ŽĨ D'KĂƚ ʅ ?
ĂŶĚWWĨŽƌɷ(George et al., 2000). 
Equally, heterodimers may generate entirely novel pharmacology for ligands. 
&ŽƌĞǆĂŵƉůĞ ?Ă ůŝŐĂŶĚƚŚĂƚƐƉĞĐŝĨŝĐĂůůǇĂĐƚŝǀĂƚĞƐʃ Pɷ opioid heterodimers, but 
not homodimers has been identified, suggesting that the heterodimers form a 
novel binding site. This demonstrated the relevance of targeting opioid 
heterodimers in vivo, and that these could be a druggable target for analgesia 
(Waldhoer et al., 2005). 
1.6.5.4.2 Modulating the overall level of response 
As discussed in 1.6.5.4, different stoichiometries of ligand:receptor:effector 
interaction have potential to produce different levels of associated coupling. 
While for many dimeric receptors, asymmetric activation of the G protein has 
been proposed (option B, section 1.6.5.4), there are exceptions that suggest 
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dimers could increase coupling. For example a study of the serotonin 5-HT4 
receptor showed that activation of both protomers in the dimer was required 
for full activation of signalling, which is in direct opposition to the findings that 
the NTS1 protomers exerted negative co-operation upon each other in a 
dimer with respect to their ability to elicit G protein coupling (White et al., 
2007). This was thought to result from co-operativity between the two 
promoters which doubled the level of G protein activation, measured using 
'dWɶ^ ŝŶĐŽƌƉŽƌĂƚŝŽn. The authors postulated that this may give rise to 
graduated levels of response depending on the activation of one or both 
protomers (Pellissier et al., 2011). A similar finding was also shown for the 
mGlu1 receptor. When agonist bound to one protomer, the receptor was 
partially activated; but for full activation agonist needed to bind both 
protomers in the dimer (Kniazeff et al., 2004). Another example is how 
heterodimerisation appeared to modulate signalling by the opioid receptor 
family. ƐǁŝƚĐŚĨƌŽŵɴ-ĂƌƌĞƐƚŝŶŵĞĚŝĂƚĞĚZ<ƐŝŐŶĂůůŝŶŐŝŶʅ PɷŽƉŝŽŝĚƌĞĐĞƉƚŽƌ
co-ĞǆƉƌĞƐƐŝŶŐ ĐĞůůƐ ƚŽ ŶŽŶ ɴ-arrestin mediated ERK activation was observed 
when cells were co-ƚƌĞĂƚĞĚ ǁŝƚŚ ďŽƚŚ ʅ ĂŶĚ ɷ ůŝŐĂŶĚƐ (Rozenfeld and Devi, 
2007). 
1.6.5.4.3 Modulating intracellular trafficking 
WĞƌŚĂƉƐ ƌĞůĂƚĞĚ ƚŽ ƚŚĞ ĐŚĂŶŐĞ ŝŶ ĂƌƌĞƐƚŝŶ ƌĞĐƌƵŝƚŵĞŶƚ ƉĂƚƚĞƌŶƐ ? ʅ Pɷ ŽƉŝŽŝĚ
receptor heterodimers also show differential intracellular trafficking 
compared to either subtype expressed alone. The agonist etorphine, which 
ŝŶĚƵĐĞƐŝŶƚĞƌŶĂůŝƐĂƚŝŽŶŽĨƚŚĞɷŽƉŝŽid receptor, did not cause internalisation 
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of the heterodimer (George et al., 2000). Also, tŚĞƉƌĞƐĞŶĐĞ ŽĨ ƚŚĞ ʃŽƉŝŽŝĚ
receptor in a co-expressed population prevented internalisation in response 
ƚŽ ŽƉŝŽŝĚ ĂŐŽŶŝƐƚƐ ǁŚĞŶ ĞǆƉƌĞƐƐĞĚ ǁŝƚŚ ƚŚĞ ɷ ŽƉŝŽŝĚ ƌĞĐĞƉƚŽƌ (Jordan and 
Devi, 1999), or in response to adrenergic agonists when expressed with the 
ɴ2Z ? ŽŶǀĞƌƐĞůǇ ? ǁŚĞŶ ɴ2AR was co-ĞǆƉƌĞƐƐĞĚ ǁŝƚŚ ƚŚĞ ɷ ŽƉŝŽŝĚ receptor, 
the heterodimer readily internalised in response to both types of agonists 
(Jordan et al., 2001). 
1.7 Aims and objectives of the thesis 
This introduction has demonstrated that whilst obesity and type II diabetes 
are growing health concerns in the world, there is an enduring need for new 
pharmacological tools to clinically deal with both morbidities. Of a range of 
novel therapeutic targets, the FFA nutrient sensing GPCRs FFA1 and GPR120 
have been identified as being of particular interest, because of their 
localisation on gut and pancreatic endocrine cells, and their potential to 
stimulate insulin and satiety hormone secretion. The understanding of the 
pharmacology and signalling exhibited by these receptors is still at a relatively 
early stage. The aims and objectives of this thesis could be seen as follows. 
Firstly, following the de-orphanisation of GPR120, no full comparison of its 
signalling and regulatory pathways has been carried out, particularly in the 
context of the two splice variant isoforms. To address this, these pathways 
will be investigated, to ascertain if there are any pharmacologically relevant 
isoform specific differences (chapter 3). This characterisation will be achieved 
using an array of both high content screening and confocal imaging 
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techniques in conjunction with functional assays. Additionally, constrained 
GPR120 and FFA1 dimers will be generated using the technique of bimolecular 
ĨůƵŽƌĞƐĐĞŶĐĞĐŽŵƉůĞŵĞŶƚĂƚŝŽŶƚŽŝŶǀĞƐƚŝŐĂƚĞƚŚĞƉŽƐƐŝďŝůŝƚǇŽĨŶŽǀĞů ?ĚŝŵĞƌ ?
pharmacology. Following on from this, there is published mutagenesis 
information defining the FFA1 binding site but not for GPR120. Therefore, if 
drugs are to be designed to selectively target GPR120 over FFA1 (or vice 
versa), more detailed knowledge of the GPR120 binding site is required, which 
is addressed in chapter 4. Site-directed mutagenesis, led by molecular 
modelling from colleagues at AstraZeneca, will be used to define the way 
different endogenous and synthetic agonists bind GPR120. 
There is also another issue for drug discovery at these receptors. There is a 
lack of high affinity selective radiolabelled ligands for traditional binding 
assays. These types of assay are key for deriving essential data (affinity 
estimates) about potential drug candidates. Therefore, a fluorescent agonist 
will be generated and characterised with the aim of replicating these binding 
assays to determine ligand affinity, for example at FFA1. Fluorescence 
correlation spectroscopy studies will also be undertaken to characterise the 
diffusion and stoichiometry of FFA1 receptors, and to demonstrate the ability 
to measure ligand binding at the single cell level (chapter 5).  
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Chapter Two: Materials and Methods 
 
2.1 Materials 
pcDNA4/TO and pcDNA3.1zeo DNA vectors, HEK293T/TR cells, lipofectamine, 
Optimem, selection antibiotics, Fluo4AM, Pluronic® F-127, LysoTracker® red 
and transferrin conjugated to AlexaFluor(AF)-633 were from Invitrogen, 
Paisley, UK. 
Restriction enzymes, fast shrimp alkaline phosphatase and pJET cloning kit 
were from Fermentas, St. Leon-Rot, Germany. 
All other chemicals and reagents were purchased from Sigma Aldrich, Poole, 
UK unless otherwise stated.  
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2.2 Methods 
2.2.1 Molecular Biology 
All molecular biology procedures that follow were a modified version of those 
ĨŽƵŶĚŝŶ “DŽůĞĐƵůĂƌůŽŶŝŶŐ ?ďǇ^ĂŵďƌŽŽŬĂŶĚZƵƐƐĞůů (Sambrook and Russell, 
2001). 
2.2.1.1 Analysis of DNA products 
To analyse a DNA product, it had to be excised from the vector in which it was 
contained by performing a restriction digest. This digest product was then run 
on an agarose electrophoresis gel to determine its size. If the band was of the 
correct size, this band would be excised to liberate the DNA. This protocol will 
be covered in the next 3 sections. 
2.2.1.1.1 Restriction digestion 
The choice of enzymes for performing a restriction digest was key, because 
they must only cut in the one place required. Also, it was seen as preferential 
to use 2 different enzymes, one at either end of the insert, where the purpose 
ǁĂƐƚŽ ůŝŐĂƚĞĂŶ  “ŝŶƐĞƌƚ ?E  ?Ğ ?Ő ? ĨŽƌƚŚĞƌĞĐĞƉƚŽƌ ) ŝŶƚŽĂĚŝĨĨĞƌĞŶƚƉůĂƐŵŝĚ
vector. This ensured that the insert could only go into the plasmid in the 
correcƚŽƌŝĞŶƚĂƚŝŽŶ ?ĚĚŝƚŝŽŶĂůůǇ ? ƚŚĞĞŶǌǇŵĞƐĐŚŽƐĞŶĂůƐŽƉƌŽĚƵĐĞĚ  “ƐƚŝĐŬǇ ?
ends that overhang, again to ensure the correct orientation of insert in the 
vector (the exception to this is pJET ligation, in which blunt ended PCR 
products were used, covered in section 2.2.1.7.3). 
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dŽ ƉĞƌĨŽƌŵ Ă ƌĞƐƚƌŝĐƚŝŽŶ ĚŝŐĞƐƚ ? Ă ƌĞĂĐƚŝŽŶ ŵŝǆƚƵƌĞ ŽĨ  ? ? ʅů ŝŶ ƚŽƚĂů ǁĂƐ
ƉƌĞƉĂƌĞĚŝŶĂƐƚĞƌŝůĞ ? ? ?ŵůƚƵďĞ ?ĂŶĚĐŽŶƐŝƐƚĞĚŽĨ ?ʅŐŽĨE ? ?ʅů ? ?ƵŶŝƚ ?1 
unit is defined as the amount of enzyme required to incorporate 10 nmoles of 
dNTPs into acid insoluble form in 30 min at 72oC) per restriction enzyme (Fast 
ŝŐĞƐƚ ? ĨƌŽŵ &ĞƌŵĞŶƚĂƐ ) ǁŝƚŚ  ? ʅů ŽĨ  ? ?ǆ &ĂƐƚ ŝŐĞƐƚďƵĨĨĞƌ  ?ƐƵƉƉůŝĞĚ ǁŝƚŚ
enzyme). This underwent a 1 hr incubation at 37oC, then a 20 min incubation 
at 65oC, with an additional enzyme heat inactivation step of 5 min at 80oC. 
2.2.1.1.2 Gel electrophoresis 
Following restriction enzyme digestion, gel electrophoresis was utilised to 
separate the DNA fragments produced (e.g. insert and plasmid vector). The 
principle behind this is that the negatively charged DNA migrates via the gel 
pores towards the positive electrode in a size dependent manner, i.e. the 
smaller DNA products migrate faster than the larger DNA products. 
This was done by preparing an agarose gel that consisted of agarose (1 % w/v) 
dissolved in TBE buffer (89 mM Tris HCl, 89 mM Boric acid, 2 mM EDTA 
(ethylenediaminetetraacetic acid), pH 7.6) using a microwave. After allowing 
ƚŚĞ ŵŝǆƚƵƌĞ ƚŽ ĐŽŽů ƐůŝŐŚƚůǇ ? ĞƚŚŝĚŝƵŵ ďƌŽŵŝĚĞ  ? ? ? ? ʅŐ ŵů-1) was added, 
because this is an agent that intercalates into DNA, which allowed for the 
visualisation of the DNA under ultra violet light. This was then poured into a 
tray and a comb was added. Once set, this was placed into an electrophoresis 
tank and covered completely with TBE buffer. DNA samples were mixed with a 
blue loading buffer (0.25 % w/v bromophenol blue, 50 % v/v glycerol in TBE) 
and loaded into the wells created by the comb. A molecular weight marker 
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was also added to a well (BenchTop 1 kb DNA ladder, Promega). The gel was 
then run at 80 V until sufficient separation has been achieved based on dye 
migration. DNA was visualised on a Syngene GVS-30 transilluminator, which 
allowed the size of the DNA sample to estimated by comparison to the 
molecular weight marker (an example gel is shown in Figure 2.1). 
2.2.1.1.3 Gel extraction 
The DNA was then purified using a Gel Purification Kit (Sigma) to 
ŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ ŝŶƐƚƌƵĐƚŝŽŶƐ ? dŚŝƐ Ŭŝƚ ƵƐĞĚ Ă ƐŝůŝĐĂ ŐĞů-based method of DNA 
purification using column chromatography. Firstly, the gel was weighed in an 
Eppendorf and 3 gel volumes of gel solubilisation solution were added (i.e. for 
 ? ? ?ŵŐŽĨŐĞů ? ? ? ?ʅůŽĨƐŽůƵƚŝŽŶǁĂƐĂĚĚĞĚ )ĂŶĚŝŶĐƵďĂƚĞĚĨŽƌ ? ?ŵŝŶĂƚ ? ?oC, 
with occasional vortexing to help solubilisation. This solution contained a 
chaotropic salt, which removed the water molecules that surrounded the DNA 
phosphate backbone. This resulted in these phosphates being able to bind 
onto the silica in the columns. One gel volume of isopropanol was added to 
the solubilised gel solution (this both enhanced specific binding and reduced 
non-specific binding to the silica), and the binding column was prepared with 
column preparation solution, prior to the addition of the solubilised gel 
solution to the binding column. This addition resulted in the DNA becoming 
bound to the silica filter. An ethanol based wash solution was used to remove 
contaminants, but does not affect the DNA binding. The DNA was then eluted 
ŝŶ ? ?ʅůĚ,20, resulting in rehydration of the DNA which then allows the DNA 
to become unbound from the silica in the column. 
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Figure 2.1 A representative agarose gel. 
Clone 1 (middle lane) and 2 (right lane) have been digested with BamHI and 
XhoI, and for clone 2, this liberated the insert, SNAP-GPR120S-ȴ ? ? ? ŽĨ ƚŚĞ 
correct size (1041 bp) from the pJET cloning vector (2974 bp), with a DNA 
ladder in the left lane.  
85 
 
2.2.1.2 Transformation of DNA into chemically competent cells 
Next to be described is the protocol by which DNA was transferred into 
chemically competent cells, which allowed for further downstream 
applications such as mini prep DNA purification. 
2.2.1.2.1 Preparation of competent cells 
There are a few strains of E.coli suitable for making chemically competent 
cells, including XL-1. These cells contain mutations to make them more 
suitable for DNA transformation. For example, XL-1 cells contain a hsdR17 
mutation which knocks out the EcoK I methylase, preventing the cells from 
cleaving plasmid DNA by the EcoK endonuclease enzymes; they lack both 
endA nuclease, which improves the quality of DNA purified using the miniprep 
protocol and recA recombinase which improves the stability of inserts; and 
they also contain a gene for tetracycline resistance. 
Prior to transformation, agar plates were produced. Luria Bertani (LB) agar 
was made using 35 g of commercially available powder (containing 1 % 
peptone, 0.5 % yeast extract and 1 % NaCl), made up to 1 L using deionised 
water. This was sterilised by autoclaving, and when it had cooled to 55oC, 
tetracycline was ĂĚĚĞĚĂƚ ? ?ʅŐŵů-1. The mixture was then poured into Petri 
dishes, any bubbles were removed and the dishes allowed to set. 
To generate chemically competent cells, XL-1 strain E.coli cells were then 
streaked out onto an LB agar plate. Streaking involves using sterile apparatus 
such as an inoculation loop to introduce progressively fewer bacterial cells to 
the agar, until single colonies are able to grow. This plate was incubated 
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overnight at 37oC. The next day, one colony was picked using a sterile pipette 
tip and grown overnight in 5 ml LB broth at 37oC. On the third day, this 5 ml 
was added to 20 ml 2YT (2x yeast and tryptone; 1.6 % peptone, 1 % yeast 
extract and 0.5 % NaCl) media, and agitated at 250 rpm until the cells had 
grown to a density of OD600 = 0.2  W 0.8 (this corresponds roughly to the mid-
log phase of bacterial growth). When at the correct density, this was then 
ƉŽƵƌĞĚ ŝŶƚŽ  ? > ĨůĂƐŬ ĐŽŶƚĂŝŶŝŶŐ  ? ? ŵů  ?zd ŵĞĚŝƵŵ ƉůƵƐ  ? ? ʅŐml-1 
tetracycline, and was agitated again until OD600 = 0.5  W 0.9. This was then 
further diluted to 250 ml using 2YT medium, and again agitated until OD600 = 
0.6. This was then rapidly cooled in ice water with gentle shaking. The pellet 
was collected by centrifugation for 15 min at 4,000 rpm at 4oC. The pellet was 
resuspended in 50 ml TfB I (30 mM potassium acetate, 50 mM MnCl2, 64 mM 
KCl, 10 mM CaCl2, 15 % glycerol at pH 5.8) with gentle shaking on ice. The 
pellet was again collected by centrifugation for 8 min at 4,000 rpm at 4oC, 
then the supernatant was poured off. The pellet was resuspended in 10 ml 
cold TfB II (10 mM 3-(N-morpholino)propanesulphonic acid [MOPS], 1 mM 
KCl, 75 mM CaCl2, 15 % glycerol, pH 7.0) with ŐĞŶƚůĞ ƐŚĂŬŝŶŐ ŽŶ ŝĐĞ ?  ? ? ? ʅů
were aliquoted into pre-chilled microfuge tubes, snap frozen in liquid nitrogen 
and stored as competent cell aliquots at -80oC until required for use. 
2.2.1.2.2 Transformation 
The appropriate number of aliquots of cells were thawed on ice, and then 
ĂůŝƋƵŽƚĞĚ ŝŶƚŽ ĐŚŝůůĞĚ ƉƉĞŶĚŽƌĨ ƚƵďĞƐ ?  ? ? ? ʅů ƉĞƌ ƚƵďĞ ĨŽƌ ĞĂĐŚ
ƚƌĂŶƐĨŽƌŵĂƚŝŽŶ ƌĞĂĐƚŝŽŶ ?  ? ? ? ʅů ŽĨ ɴ-mercaptoethanol was added (1.4 M in 
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H20), which is a reducing agent used to break disulphide bonds and inactivate 
surface nucleases, increasing efficiency of transformation of DNA across the 
cell wall (Brzobohaty and Kovac, 1986). The cells were swirled to mix and 
incubated for 10 min on ice, swirling every 2 min. 10 ng circular plasmid DNA, 
Žƌ ?ʅůŽĨĂůŝŐĂƚŝŽŶƌĞĂĐƚŝŽŶǁĂƐĂĚĚĞĚĂŶĚƐǁŝƌůĞĚ ?dŚŝƐǁĂƐŝŶĐƵďĂƚĞĚ on ice 
for 30 min. Then, it was heatshocked for 45 s at 42oC (this temperature and 
time period are crucial for maximum efficiency of transformation). The tubes 
ǁĞƌĞƌĞƚƵƌŶĞĚƚŽŝĐĞĨŽƌ ?ŵŝŶ ?ƚŚĞŶ ? ? ?ʅů>ǁĂƐĂĚĚĞ ĂŶĚŝŶĐƵďĂƚĞĚĨŽƌ ?
hr at 37oC, shakinŐ Ăƚ  ? ? ? ƌƉŵ ?  ? ? ? ʅů ǁĂƐ ƉůĂƚĞĚ ŽŶƚŽ > ĂŐĂƌ ƉůĂƚĞƐ
ĐŽŶƚĂŝŶŝŶŐƚŚĞĐŽƌƌĞĐƚƉůĂƐŵŝĚƐĞůĞĐƚŝŽŶĂŶƚŝďŝŽƚŝĐ ?Ğ ?Ő ? ? ?ʅŐ ml-1 ampicillin or 
 ? ?ʅŐ ml-1 kanamycin), and grown overnight at 37oC. The next day, a minimum 
of two colonies were picked and placed in a 20 ml tube containing 5 ml LB 
ďƌŽƚŚ ĂŶĚ  ? ? ʅŐ ŵů-1 ampicillin, and grown overnight at 37oC with shaking 
(250 rpm). 
2.2.1.3 Small scale (miniprep) isolation and purification of cDNA  
The next day, this was screened using the GenElute Plasmid Miniprep Kit 
(Sigma-Aldrich). This procedure purified the DNA using a silica binding-spin 
column format of the alkaline-SDS lysis procedure and was performed 
ĂĐĐŽƌĚŝŶŐ ƚŽ ƚŚĞ ŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ ŝŶƐƚƌƵĐƚŝŽŶƐ ?  ďƌŝĞĨ ŽǀĞƌǀŝew is as follows: 
first, 3 ml of the overnight culture was pelleted by centrifugation for 5 min at 
5,000 rpm. This pellet was resuspended in resuspension buffer, which was a 
hyperosmotic sucrose solution containing RNase that degraded any RNA that 
may be present.  
88 
 
Then, an alkaline-detergent solution (NaOH/SDS) lysed the cells. It does this 
by the SDS degrading the cell walls, whilst the alkaline pH irreversibly 
denatured the chromosomal DNA, but not plasmid DNA. This occurs because 
the alkaline pH disrupts DNA base pairing, but due to the supercoiled 
structure of the plasmid DNA, it is not irreversibly affected. However, the 
chromosomal DNA, along with proteins and lipids, become coated with 
dodecyl sulphate.  
Once this solution was neutralised with potassium acetate, the chromosomal 
DNA, proteins and lipids undergo precipitation into an insoluble cluster, due 
to the replacement of Na+ with K+ (Ish-Horowicz and Burke, 1981), which left 
the plasmid DNA intact in the supernatant. This step also added the 
chaotropic binding salts, which enabled the plasmid DNA to become bound to 
silica. This solution was then pelleted by centrifugation for 10 min at 13,000 
rpm to remove the contaminants and prepare the plasmid DNA-containing 
lysate. 
The binding column was placed into a microcentrifuge tube and column 
preparation solution was added and centrifuged. This maximised the DNA 
binding to the membrane in the column. The lysate was transferred to the 
column, and centrifuged, resulting in binding the DNA to the silica filter.  
Next, the filter was washed with a wash solution containing solvent (80 % 
ethanol) which removes residual salts and other contaminants from the DNA, 
and was then re-spun without additional wash solution to remove excess 
ĞƚŚĂŶŽů ?dŚŝƐƚŚĞŶĂůůŽǁĞĚƚŚĞEƚŽďĞĞůƵƚĞĚŝŶ ? ?ʅůǁĂƚĞƌŽƌdƌŝƐ-EDTA 
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(TE, 10 mM Tris HCl, 0.1 mM EDTA; pH 8.0) (Birnboim and Doly, 1979; 
Vogelstein and Gillespie, 1979). 
2.2.1.4 Generating tagged receptors from pre-existing constructs 
Human GPR120S (GenBank accession number BC101175) and GPR120L 
(NM_181745) cDNAs were supplied by AstraZeneca, Alderley Park, Cheshire, 
UK; and human FFA1 (NM_005303) cDNA was supplied by Prof T Schwartz, 
University of Copenhagen, Denmark. These cDNAs were inserted into three 
different expression vectors (Table 2.1). 
These vectors had the following main features (see also plasmid maps Figure 
2.3, 2.4 and 2.5): a human cytomegalovirus (CMV) promoter, which allows for 
high level expression and provides a binding site for sequencing. In 
pcDNA4T/O, this promoter also includes the tetracycline repressor protein 
site for tetracycline regulated expression in mammalian cells. There is also a 
polyadenylation signal derived from bovine growth hormone mRNA (BGH) 
designed for mRNA stability, which again provides a primer binding site for 
sequencing. The vector also provides other sites for sequencing primers to 
bind. In pcDNA4T/O, these are CMV F and BGH Rev; in p3.1 zeo they are T7 
and BGH Rev; and in pCMV FLAG these are T3 and T7. The vectors also contain 
sites of antibiotic resistance for both selection in transfected mammalian cell 
lines and transformed bacterial cells, see table 2.1 for specific details. All 
vectors also contain a multiple cloning site (MCS) that contains several 
restriction enzyme sites to insert genes of interest into the vector. 
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Figure 2.2 Map of restriction enzymes typically used in generating FFA 
receptor constructs. 
Positions of KpnI, BamHI, XhoI and XbaI restriction sites used to generate 
receptor constructs in a vector, and positions of FLAG epitope, signal-
sequence SNAP-ƚĂŐ ? “ƐƐ ? ) ?ƌĞĐĞƉƚŽƌĐEĂŶĚƐĨ'&WŽƌǀz&WŝĨĂƉƉůŝĐĂď Ğ ? 
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Inserted FFA receptor cDNA sequences (Figure 2.2) lacked the start Met codon 
and included a stop codon unless stated otherwise. Additionally, some 
constructs were also modified to include the insertion of a Kozak site for 
translation initiation (GCCACC) followed by appropriate coding sequences 
ďĞƚǁĞĞŶ <ƉŶ/  ? ? ? ) ĂŶĚ Ăŵ,/  ? ? ? ) ƚŽ ŐĞŶĞƌĂƚĞ ƌĞĐĞƉƚŽƌƐ ƚĂŐŐĞĚ Ăƚ ƚŚĞ E
terminus, with either the FLAG epitope tag (MDYKDDDDK) or a 5HT3 receptor 
derived signal sequence (MRLCIPQVLLALFLSMLTGPGEGSRK) joined to the 
SNAP-tag (181 amino acids), which allowed for fluorescent labelling (Keppler 
et al., 2003). 
^ŽŵĞ ĐE ƐĞƋƵĞŶĐĞƐ ĂůƐŽ ŚĂĚ ƚŚĞ  ? ? ƐƚŽƉ ĐŽĚŽŶ ƌĞŵŽǀĞĚ ƚŽ ĂůůŽǁ ƚŚĞ
ĂĚĚŝƚŝŽŶŽĨĂĨůƵŽƌĞƐĐĞŶƚƉƌŽƚĞŝŶďĞƚǁĞĞŶyŚŽ/ ? ? ? )ĂŶĚyďĂ/  ? ? ? ) ?ƵƐŝŶŐĂn LE 
linker. The fluorescent proteins used were green fluorescent protein (GFP) 
containing superfolder mutations S30R, F99S, N105T, M153T and V163A 
(Pedelacq et al., 2006), venus yellow fluorescent protein (vYFP) (Nagai et al., 
2002), or YFP BiFC fragments 2-172 (vYN) or 155-238 vYC; these residue 
numbers correspond to the native GFP sequence (Kilpatrick et al., 2012) 
A full table of vectors and their receptors follows (Table 2.1).  
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Vectors Receptor insert 
Bacterial 
resistance 
Mammalian 
resistance Tags 
Tetracycline 
inducible? 
Made in 
current project Experimental use Plasmid map 
pcDNA4/TO SNAP-GPR120S-GFP Ampicillin Zeocin SNAP Yes Y Multiple Figure 2.3 
 
SNAP-GPR120L 
    
Y 
  
 
SNAP-GPR120S 
    
Y 
  
 
Includes all mutants: 
       
 
SNAP-GPR120S R99A 
    
Y 
  
 
SNAP-GPR120S R178A 
    
Y 
  
 
SNAP-GPR120S N215A 
    
Y 
  
 
SNAP-GPR120S W277A 
    
Y 
  
 
SNAP-GPR120S W277F 
    
Y 
  
 
SNAP-GPR120S F311A 
    
Y 
  
 
SNAP-'WZ ? ? ?^ȴ ? ? ? 
    
Y 
  
 
SNAP-FFA1-GFP 
    
Y 
  
 
SNAP-FFA1 
    
Y 
  
 
Includes mutant: 
       
 
SNAP-FFA1 R258A 
    
N 
  pCMV FLAG FLAG-GPR120S-vYC Kanamycin Neomycin (G418) FLAG No N ɴ-arrestin association Figure 2.4 
 
FLAG-GPR120L-vYC 
     
Constrained dimers 
 
 
FLAG-FFA1-vYC 
       p3.1 zeo+ SNAP-GPR120S-vYNL Ampicillin Zeocin SNAP No Y Constrained dimers Figure 2.5 
 
Table 2.1 Table of tagged receptor constructs. 
This table shows which receptor cDNAs were inserted into which vector. It also details the major features of these vectors. 
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Figure 2.3 Vector map of pcDNA4T/O. 
SNAP-GPR120S was placed into the pcDNA4T/O vector and contained the 
following features: enzyme that only cut once in the vector (blue); enzymes 
that cut twice in the vector (orange); the tet repressor operon binding site 
(TetO); bacterial origin of replication (ori); the polyadenylation sequence (pA); 
the signal sequence (sig); and the sites of antibiotic resistance (zeocinR; 
ampiR). 
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Figure 2.4 Vector map of pCMV FLAG. 
GPR120S-vYC was placed into the pCMV FLAG vector and contained these 
features (see Figure 2.3 legend for more details on abbreviations). The pCMV 
FLAG vector was from Stratagene, Agilent (Cheshire, UK). 
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Figure 2.5 Vector map of p3.1 zeo. 
SNAP-GPR120S-vYNL was placed into the pcDNA 3.1 zeocin (+) (p3.1) vector 
and contained these features (see Figure 2.3 legend for more details on 
abbreviations); additionally, the + refers to the orientation of the multiple 
cloning sequence.  
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These receptor cDNAs were inserted into pre-existing plasmid vectors 
between restriction sites BamHI  ? ? ? ) and XhoI  ? ? ? ? &ŝŐƵƌĞ  ? ? ? ) ƵƐŝŶŐ ƚŚĞ
following protocol. 
 ? ? ? ? ? ? ? ? ?WƌĞƉĂƌĂƚŝŽŶŽĨ “ŝŶƐĞƌƚ ?ĐE 
dŚĞ  “ŝŶƐĞƌƚ ? ǁĂƐ ĚĞĨŝŶĞĚ ĂƐ ƚŚĞ ƌeceptor cDNA. This was prepared by 
restriction digestion, isolated by electrophoresis on an agarose gel, visualised 
using UV light, cut out and purified (see section 2.2.1.1). 
 ? ? ? ? ? ? ? ? ?WƌĞƉĂƌĂƚŝŽŶŽĨ “ǀĞĐƚŽƌ ?ĐE 
dŚĞ  “ǀĞĐƚŽƌ ? ǁĂƐ ĚĞĨŝŶĞĚ ĂƐ ƚŚĞ ƉůĂƐŵŝĚ ?The vector underwent shrimp 
ĂůŬĂůŝŶĞ ƉŚŽƐƉŚĂƚĂƐĞ  ?^W ) ƚƌĞĂƚŵĞŶƚ  ? ? ʅů  ? ?h ) ^W ďƵĨĨĞƌ  ?ƐƵƉƉůŝĞĚ ǁŝƚŚ
enzyme; 100 mM Tris-HCl, 50 mM MgCl2, 1 M KCl, 0.2 % Triton X-100, 1 mg 
ml-1 ^ ?Ɖ, ? ? ? )ĂŶĚ ?ʅů^W )ĨŽƌ ? ? ?ŚƌĂƚ ? ?oC, followed by 20 min at 75oC 
to ŚĞĂƚŝŶĂĐƚŝǀĂƚĞƚŚĞĞŶǌǇŵĞ ?dŚŝƐƐƚĞƉǁĂƐƚŽĚĞƉŚŽƐƉŚŽƌǇůĂƚĞƚŚĞ ? ?ĞŶĚŽĨ
the DNA, to prevent self re-ligation. The vector was then purified using a PCR 
Clean-Up Kit (Sigma), to remove contaminants using a silica binding format as 
ďĞĨŽƌĞ ?ƚŽŵĂŶƵĨĂĐƚƵƌĞƌ ?s instructions except that the DNA was eluted into 40 
ʅůĚ,2O. 
2.2.1.4.3 Ligations 
The insert and vector were ligated together overnight, in a 3:1 insert:vector 
ratio, where DNA amounts were initially calculated using the equation as 
follows, assuming 80 % yield from the gel purification kit (insert) or PCR clean 
ƵƉŬŝƚ ?ǀĞĐƚŽƌ )ĂŶĚƐƚĂƌƚŝŶŐĨƌŽŵ ?ʅŐE P 
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In the 3:1 molar ratio, 50 ng of vector DNA was optimal for ligation (to 
produce single circular plasmids rather than long concatenated products. To 
determine the correct amount of insert DNA to be used for the molar ratio, 
assuming x moles of vector in 50 ng, the following equation was used, then 
multiplied by 3: 
 
The volume of insert and vector added was then calculated. Positive and 
negative ligations were set up in Eppendorf tubes: 50 ng vector and 3 times 
ƚŚĞŵŽůĂƌƌĂƚŝŽŽĨŝŶƐĞƌƚ ?ĂƐĂďŽǀĞ ?ŽƌŶŽŶĞĨŽƌĂŶĞŐĂƚŝǀĞĐŽŶƚƌŽů ) ? ?ʅůůŝŐĂƐĞ
buffer (provided with enzyme )ĂŶĚ ?ʅů ? ?h )d ?EůŝŐĂƐĞŝŶĂƚŽƚĂůǀŽůƵŵĞŽĨ
 ? ?ʅůǁŝƚŚĚ,2O, and were incubated for 16 hr at 16oC. 
 ? ʅů ŽĨ ƚŚŝƐ ůŝŐĂƚŝŽŶ ƌĞĂĐƚŝŽŶ ǁĂƐ ƚƌĂŶƐĨŽƌŵĞĚ ŝŶƚŽ y>-1 cells, grown into 
miniprep cultures and screened for inserts by the appropriate restriction 
digests (see section 2.2.1.2). 
2.2.1.5 Large scale (maxiprep) isolation and purification of DNA 
If the miniprep screening yielded the correct results, the cDNA required for 
cellular transfection was cultured on a larger scale using the maxiprep kit 
(Sigma-ůĚƌŝĐŚ )ƚŽŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐŝŶƐƚƌƵĐƚŝŽŶƐ ? 
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dŽĚŽƚŚŝƐ ?Ă “ƐƚĂƌƚĞƌ ?ĐƵůƚƵƌĞǁĂƐƐƚĂƌƚĞĚŝŶƚŚĞŵŽƌŶŝŶŐ ?ĐŽŶƐŝƐƚŝŶŐŽĨ ? ?ʅů
of the cells from the respective miniprep placed in a 20 ml tube containing 5 
ŵů>ǁŝƚŚ ? ?ʅŐŵů-1 ampicillin and incubated for 6 hr at 37oC, with 250 rpm. 
ĨƚĞƌ ?Śƌ ?ƚŚŝƐƐƚĂƌƚĞƌĐƵůƚƵƌĞǁĂƐĂĚĚĞĚƚŽ ? ? ?ŵůƐƚĞƌŝůĞ>ĐŽŶƚĂŝŶŝŶŐ ? ?ʅŐ
ml-1 ampicillin, in a 500 ml conical flask, and left to incubate overnight at 37oC, 
250 rpm. 
The next day, the overnight culture was pelleted by centrifugation for 15 min 
at 4,000 rpm. This pellet was resuspended in resuspension buffer, which was a 
hyperosmotic sucrose solution containing RNase that degraded any RNA that 
may be present. 
Then, an alkaline-detergent solution (NaOH/SDS) was added, and underwent 
immediate inversion to lyse the cells. Again, the SDS degraded the cell walls, 
liberating cell contents, allowing the alkaline pH to irreversibly denature the 
chromosomal DNA, whilst leaving the plasmid DNA unaffected. The 
chromosomal DNA, along with proteins and lipids, become coated with 
dodecyl sulphate. This solution was allowed to sit for 3 -5 min, until clear and 
viscous. During this time a filter syringe is prepared, by removing the plunger 
and the barrel placed upright in a rack. 
This solution was then neutralised with chilled neutralisation solution 
containing potassium acetate and gently inverted. The chromosomal DNA, 
proteins and lipids undergo precipitation into a white aggregate, due to the 
replacement of Na+ with K+ (Ish-Horowicz and Burke, 1981), which leaves the 
plasmid DNA intact in the supernatant. 
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A binding solution was then added, which contained the chaotropic binding 
salts that enabled the plasmid DNA to become bound to silica. This solution 
was then immediately poured into the barrel of the filter syringe, and allowed 
to sit for 5 min. During this step, the binding column was placed into a 50 ml 
collection tube, column preparation solution was added and centrifuged at 
4,000 rpm for 2 min, which allows for maximum DNA binding to the 
membrane in the column. 
Half of the cleared lysate was expelled from the syringe into the binding 
column, centrifuged at 4,000 rpm for 2 min and the eluate discarded. The 
remaining lysate was also centrifuged in the same way, resulting in the DNA 
becoming bound to the membrane. 
Next, the filter was washed with two wash solutions, the first at 4,000 rpm for 
2 min; then the second wash solution containing solvent (80 % ethanol) which 
removes residual salts and other contaminants from the DNA by 
centrifugation at 4,000 rpm for 5 min. 
The binding column was then moved to a clean 50 ml collection tube, 3 ml of 
elution solution is added, and centrifuged at 4,000 rpm for 5 min. This eluate 
then underwent a further ethanol precipitation treatment to further 
concentrate and purify the DNA.  
The ethanol precipitation was as follows: 3 M sodium acetate (pH 5.0) was 
ĂĚĚĞĚŝŶĂ ? P ? ?ƌĂƚŝŽ ? ? ? ?ʅů ?ƌĞƐƵůƚŝŶŐŝŶĂĨŝŶĂůĐŽŶĐĞŶƚƌĂƚŝŽŶŽĨ ? ? ?D )ƚŽƚŚĞ
3 ml DNA eluate and 2.2 volumes of chilled 100 % ethanol (7.2 ml) was also 
added. Ethanol displaced the less polar water molecules that surrounded the 
100 
 
DNA phosphates, which then allowed the Na+ ions from the sodium acetate to 
bind to the DNA phosphates instead. This reduced the repulsive charges 
between DNA and caused the DNA to undergo precipitation. This was then 
centrifuged at 4,000 rpm for 30 min, which produced a DNA pellet. 
1 ml of chilled 70 % ethanol was then added, and the sample re-centrifuged 
for 10 min at 4,000 rpm, to remove salt contaminants. The supernatant was 
then poured off and the DNA pellet was left to air-dry for approximately 15 
min. After this, the pellet was resuspended in TE buffer (10 mM Tris-HCl, 1 
mM EDTA; pH 7.5) ? ƚǇƉŝĐĂůůǇ  ? ? ? ʅů ? dŚĞ ƉƵƌŝƚǇ ĂŶĚ ĐŽŶĐĞŶƚƌĂƚŝŽŶ ǁĂƐ ƚŚĞŶ
estimated using a spectrophotometer (BioPhotometer, Eppendorf). The 
concentration was measured at A260, as absorption for double stranded DNA is 
greatest at 260 nm; the conversion factor is based on A260 of 1, representing 
 ? ? ʅŐ ŵů-1 double stranded DNA. Additionally, proteins absorb at 280 nm, 
therefore the ratio A260/280 is used to indicate purity of the sample. An 
absorption ratio between 1.7 and 1.9 indicates relatively pure double 
stranded DNA, because < 1.7 indicated protein contamination, whilst > 1.9 
indicated RNA contamination. 
2.2.1.6 Site-directed PCR mutagenesis of GPR120S point mutants 
Point mutations were introduced into the target GPR120S cDNA sequence 
using site-directed PCR mutagenesis (QuikChange). This method used 
Accuzyme, Ă ? ? W  ? ?EƉŽůǇŵĞƌĂƐĞǁŝƚŚĂ ? ?  W  ? ?ƉƌŽŽĨƌĞĂĚŝŶŐĞǆŽŶƵĐůĞĂƐĞ
activity, that produces blunt ended products. It is advantageous to use it in 
this protocol because it amplifies long DNA fragments, such as the entire 
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plasmid DNA that requires amplification (~7  W 8 kbp), with minimal errors. 
This protocol also requires DpnI. DpnI is a restriction enzyme that cleaves 
ŵĞƚŚǇůĂƚĞĚ E ? ƚŚĞƌĞĨŽƌĞ ŝƚ ĚŝŐĞƐƚƐ ĂŶǇ ƌĞŵĂŝŶŝŶŐ ŵĞƚŚǇůĂƚĞĚ  “ƉĂƌĞŶƚĂů ?
DNA, leaving only the non-methylated amplified DNA which contains the 
mutation. 
2.2.1.6.1 Primer design 
The design of PCR primers for point mutations, involved taking the cDNA 
sequence and identifying the codon for the amino acid required for mutation 
(mutation highlighted in yellow; Figure 2.6). The sequence either side of this 
codon is duplicated, approximately 12-15 bases either side; long enough to 
minimise primer mishybridisation to other parts of the DNA template. For the 
forward primer, the sequence is complementary to the cDNA (except for the 
mutation). When choosing which amino acid codon to mutate to, some amino 
acids have degenerate codes, so it was best to mutate to a codon that is used 
most frequently in man (human embryonic kidney cell hosts) to comply with 
codon usage bias and avoid undue influences on protein expression. The 
reverse primer is the reverse complement of the forward primer sequence. 
Primers were also designed to have at least 40 % GC content, and the primers 
ĞŶĚĞĚ ǁŚĞƌĞƉŽƐƐŝďůĞ ǁŝƚŚ Ă '  “ĐůĂŵƉ ? ? ĂƐ ƚŚĞ  ? ŚǇĚƌŽŐĞŶ ďŽŶĚƐƉƌĞƐĞŶƚ
 “ĐůĂŵƉ ? ƚŚĞĞŶĚƐ ?ǁŚŝĐŚŚĞůƉƐǁŝƚŚĂŶŶĞĂůŝŶŐ ?ůů ƚŚĞ WZƉƌŝŵĞƌƐƵƐĞĚĂƌĞ
indicated in Table 2.2; primers were purchased from Eurogentec 
(Southampton, UK).  
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Figure 2.6 Example of point mutation PCR primer design for GPR120 F311A. 
The top line shows the numbered native GPR120S amino acid sequence, with 
the residue and its corresponding codon in the numbered nucleotide 
sequence to be mutated highlighted. The second line shows the proposed 
mutation highlighted. The third line shows the sequence for the forward 
primer (sense; which is identical to the sequence), whilst the fourth line shows 
the sequence for the reverse primer (antisense; the reverse complement). 
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Mutant Forwards Primer (5'-3') Reverse Primer (5'-3') 
Tm 
(
o
C) % GC Length 
SNAP-GPR120S R99A accacgaccggcaccggacctgactccggacc ggtccggagtcaggtccggtgccggtcgtggt 85 72 32 
SNAP-GPR120S R178A gcctctctgcgtcttcttcgcagtcgtcccgcaacggc gccgttgcgggacgactgcgaagaagacgcagagaggc 87 66 38 
SNAP-GPR120S N215A ggatgtctcttttgttactttggccttcttggtgccagg cctggcaccaagaaggccaaagtaacaaaagagacatcc 78 49 39 
SNAP-GPR120S W277A ccttcttcatcatggctagccccatcatcatcacc ggtgatgatgatggggctagccatgatgaagaagg 77 51 35 
SNAP-GPR120S W277F ccttcttcatcatgttcagccccatcatcatcacc ggtgatgatgatggggctgaacatgatgaagaagg 77 49 35 
SNAP-GPR120S F311A ggtggccttcacagccgctaattcagccc gggctgaattagcggctgtgaaggccacc 77 62 29 
SNAP-'WZ ? ? ?^ȴ ? ? ? gcaaggatcctcccctgaatgcgcgcgg 
 
82 68 28 
  
gcttctcgagctataaaatggctcccttttctgg 73 47 34 
 
Table 2.2 PCR primers used for point mutagenesis and GPR120S truncation. 
This table contains the PCR primers used to generate all the GPR120S mutants. The mutation is indicated in red. Also included are the melting 
temperatures (Tm), % GC and length of primer. 
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2.2.1.6.2 PCR reaction protocol for site-directed mutagenesis 
dŚĞ WZ ƌĞĂĐƚŝŽŶ ǁĂƐ ƐĞƚ ƵƉ ŝŶ Ă  ? ? ʅů ƌĞĂĐƚŝŽŶ ǀŽůƵŵĞǁŝƚŚŝŶ  ? ? ? ʅů WZ
ƚƵďĞƐ ? /ƚǁĂƐĐŽŵƉƌŝƐĞĚŽĨ  ?ʅů  ? ?ǆĐĐƵƵĨĨĞƌƌĞĂĐƚŝŽŶďƵĨĨĞƌ  ? ? ?ŵDdƌŝƐ-
HCl, 6 mM (NH4)2SO4, 10 mM KCl, 2 mM MgSO4, pH 8.3), 25 ng of template 
ƉĐE ? ? ? ?ʅDĚEdWƐ ? ? ? ?ŶŐŽĨĨŽƌǁĂƌĚĂŶĚƌĞǀĞƌƐĞƉƌŝŵĞƌƐĂŶĚ ? ? ?ƵŶŝƚƐŽĨ
Accuzyme (from Bioline, London, UK), in double distilled water (ddH2O). This 
reaction mixture was set up in the PCR tubes, omitting Accuzyme. The PCR 
tubes were then placed in the thermocycler block (Mastercycler gradient, 
Eppendorf, UK), and reactions underwent the initial denaturation step of 30 
sec at 90oC. At this point, the thermocycler block cooled, typically to 60oC for 
mutagenesis (can be varied depending on the annealing temperature of the 
primers; see table 2.2), at which point Accuzyme was added to the PCR tubes. 
This was hot start PCR, which aimed to prevent any non-specific DNA 
amplification by the polymerase that could occur at lower temperatures. At 
this point the thermocycler then went through 18 cycles of denaturation (30 s 
at 90oC), annealing (1 min at 55oC) and extension (10 min at 68oC, which 
corresponds to approximately 1.5 min per kbp). Once these cycles had 
completed, the tubes were cooled to, and held at 4oC. 
Following PCR, the samples underwent DpnI treatment for 2 hr at 37oC to 
digest template DNA. They were then transformed into XL-1 cells (section 
2.2.1.2), DNA was isolated using a miniprep (section 2.2.1.3), and screened 
using restriction digestion enzymes (section 2.2.1.1.1) and sequenced (Section 
2.2.1.8). 
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If the sequence was correct the DNA was ligated into a fresh vector plasmid, 
to ensure that no unwanted mutations are carried over into the DNA used for 
transfections. DNA was again transformed into XL-1 cells (section 2.2.1.2), 
then the cDNA was cultured on a larger scale using the maxiprep protocol 
(section 2.2.1.5). 
2.2.1.7 Generation of the carboxyl tail-truncated GPR120S receptor using 
PCR 
2.2.1.7.1 Primer design 
When SNAP-'WZ ? ? ?^ ȴ ? ? ?  ?ŶƵŵďĞƌĞĚ ďĞĐĂƵƐĞ 'WZ ? ? ?^ ǁĂƐ ƚƌƵŶĐĂƚĞĚ Ăƚ
residue 346) was made, it followed a different protocol. This is because the 
entire receptor cDNA was amplified from residue 2 to residue 346 using a PCR 
approach. After identifying the residue at which to prematurely truncate the 
protein, the reverse primer was designed to introduce a stop codon, plus the 
code for a desired restriction enzyme site (XhoI). The forward primer 
consisted of a restriction enzyme site of choice (BamH1), followed by the 
sequence for the receptor, starting at residue 2 because the start codon has 
been removed (mutation highlighted in yellow; Figure 2.7; Table 2.2). 
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Figure 2.7 Example of a truncation mutation PCR primer design for 
'WZ ? ? ?ȴ ? ? ?ŵƵƚĂŶƚ ? 
The top section shows the primer design for the forwards primer, with the top 
line being the WT sequence, and the second line shows the primer sequence. 
The second section shows the primer design for the reverse primer, with the 
top line again being the numbered amino acid GPR120 sequence; the second 
line shows the site for the introduction of the stop codon, with the nucleotide 
sequence number for GPR120; and the third line shows the sequence for the 
reverse primer (the reverse complement).  
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2.2.1.7.2 PCR reaction protocol 
The carboxyl tail truncated GPR120S receptor was generated using a slightly 
different protocol and a different enzyme, PWO (Roche, Burgess Hill, UK). 
WtK ŝƐ Ă  ? ?  W  ? ? E ƉŽůǇŵĞƌĂƐĞ ? ǁŝƚŚ  ? ?  W  ? ? ĞǆŽŶƵĐůĞĂƐĞ ƉƌŽŽĨƌĞĂĚŝŶŐ
activity, which produces blunt ended products. The reaction mixture 
ĐŽŵƉƌŝƐĞĚ ŽĨ  ? ʅů  ? ?ǆ WtK ďƵĨĨĞƌ  ? ? ? ŵD dƌŝƐ-HCl, 25 mM KCl, 5 mM 
(NH4)2SO4, 2 mM MgSO4, pH  ? ? ? ) ?  ? ? ŶŐ ƚĞŵƉůĂƚĞ E ?  ? ? ? ʅDĚEdWƐ ?  ? ? ?
ŶDŽĨďŽƚŚĨŽƌǁĂƌĚĂŶĚƌĞǀĞƌƐĞƉƌŝŵĞƌƐĂŶĚ ? ? ?ʅů ? ? ? ?h )WǁŽĞŶǌǇŵĞ ?ŵĂĚĞ
ƵƉƚŽĂƚŽƚĂůƌĞĂĐƚŝŽŶǀŽůƵŵĞŽĨ  ? ?ʅů ?dŚĞƉƌŽƚŽĐŽůƚŚĞŶĨŽůůŽǁĞĚƚŚĞƐĂŵĞ
thermocycler protocol as for Accuzyme, with a slight modification to the 
extension step (since the receptor fragment amplified is smaller, 1.2 kbp). The 
first 10 cycles had an extension step of 1 min 15 s, then for the next 15 
extension steps, 5 s was added to this extension period each cycle. Following 
PCR, the DNA was ran on a gel; and if correct, excised and purified (section 
2.2.1.1). 
2.2.1.7.3 Ligation of the mutant into the pJET vector 
The truncated receptor PCR cDNA was then cloned into the pJET vector 
(CloneJET PCR cloning kit, Fermentas). A feature of this vector is that the 
successful blunt end ligation of the receptor DNA insert interrupts the 
expression of a lethal restriction endonuclease enzyme (eco47/R), therefore 
only bacterial clones that contain the DNA insert grow. The ligation reaction 
ǁĂƐ  ? ?ʅů  ?ǆ Ɖ:dƌĞĂĐƚŝŽŶďƵĨĨĞƌ  ?ƉƌŽǀŝĚĞĚǁŝƚŚĞŶǌǇŵĞ ) ?  ?ʅůƉƵƌŝĨŝĞĚWZ
ƉƌŽĚƵĐƚ ? ?ʅů ? ? ?ŶŐ )Ɖ:dǀĞĐƚŽƌ ? ?ʅů ? ?h )d ?EůŝŐĂƐĞ ?ŵĂĚĞƵƉƚŽĂƚŽƚĂů
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ǀŽůƵŵĞŽĨ ? ?ʅůǁŝƚŚŶƵĐůĞĂƐĞĨƌĞĞǁĂƚĞƌ ?dŚŝƐůŝŐĂƚŝŽŶƌĞĂĐƚŝŽŶǁĂƐŝŶĐƵďĂƚĞĚ
for 30 min at 22oC. This was then transformed into XL-1 cells (section 2.2.1.2), 
DNA was isolated using a miniprep (section 2.2.1.3), and screened using 
restriction digestion enzymes (section 2.2.1.1.1) and sequenced (section 
2.2.1.8). If the sequence was correct, then the cDNA was cultured on a larger 
scale using the maxiprep protocol (section 2.2.1.5). 
2.2.1.8 Sequencing 
Receptor cDNA sequences were confirmed by sending the vectors to the 
School of Biomedical Sciences sequencing facility, using appropriate forward 
and reverse primers (primers chosen were dependent upon which vector 
cDNA had been inserted into, see Table 2.1). A sample of a sequence 
chromatogram loaded using Chromas 2 shows the correct codon mutation 
was present for F311A (Figure 2.8).  
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Figure 2.8 A sequence chromatogram showing the position of the SNAP-
GPR120S F311A mutant. 
The chromatogram was generated using Chromas 2. The arrow shows the 
position of the altered nucleotide codon that resulted in the Phe (TTT) to Ala 
(GCC) substitution at position 311.  
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2.2.2 Cell Culture 
In this section the methods of generating and maintaining mammalian cell 
lines, using human embryonic kidney (HEK293) cells expressing the receptor 
of interest will be covered. 
2.2.2.1 Standard cell line maintenance 
2.2.2.1.1 Cell lines and passaging  
The HEK293TR inducible cell lines were used for the majority of the 
experiments. The receptor sequences were placed between BamHI and XhoI 
in the pcDNA4T/O vector, downstream of the signal-SNAPtag sequence or 
FLAG epitope. 
The cell line used for bimolecular fluorescence complementation (BiFC) 
ƐƚƵĚŝĞƐ ŽĨ ƌĞĐĞƉƚŽƌ Pɴ-arrestin association were dual transfects. They were 
dually transfected with -arrestin2 fused to vYFP fragment 2-172 (vYN) and 
FLAG-tagged receptor cDNAs lacking the STOP codon in pCMV FLAG with the 
vYFP fragment 155  W 238 (vYC; these residue numbers correspond to the 
native GFP sequence) inserted between XhoI and XbaI using the LRPLE linker, 
generating FLAG receptor-vYC fusion (Kilpatrick et al., 2012). 
The cell lines used for BiFC studies of constrained dimers were also dual 
transfects. Receptor-vYNL cDNA was also generated as above (section 
2.2.1.4.1-3), but was instead placed within the p3.1 zeo+ vector and 
cotransfected with pCMV FLAG receptor vYC (Kilpatrick et al., 2010). 
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Most transfected cell lines were stable mixed populations, and were kept in 
DulďĞĐĐŽ ?ƐŵŽĚŝĨŝĞĚĂŐůĞ ?ƐŵĞĚŝƵŵ (DMEM) with 10 % foetal bovine serum 
(FBS), the appropriate concentration of the antibiotics needed for that 
particular cell line (see Table 2.3) and grown in a T75 flask at 37oC and 95 % 
O2/5 % CO2 in a humidified incubator. The antibiotics used were blasticidin, 
zeocin and G418. Blasticidin prevents protein synthesis by causing premature 
translation termination by interfering with peptide transfer (Izumi et al., 1991; 
Kimura et al., 1994). G418 (neomycin) also interferes with protein synthesis, 
but by blocking ribosomal functions (Southern and Berg, 1982), whilst zeocin 
intercalates into DNA, causing strand cleavage (Mulsant et al., 1988).  
Cells were passaged by washing with PBS to remove residual FBS that would 
deactivate trypsin, followed by treatment with 1 ml trypsin at 37oC (0.25 % 
w/v in Versene; Lonza Wokingham Ltd (Wokingham, UK) to detach cells from 
the flask. The flask was then washed with 10 ml DMEM to wash the cells off 
the flask surface. This was then transferred into a 20 ml tube and centrifuged 
for 5 min at 1,000 rpm, and resuspended in an appropriate volume of DMEM. 
If cells were being split for experiments, this typically occurred two days prior 
to experimentation for tetracycline inducible lines. The cells were counted 
ƵŶĚĞƌĂ ůŝŐŚƚŵŝĐƌŽƐĐŽƉĞƵƐŝŶŐĂŚĂĞŵŽĐǇƚŽŵĞƚĞƌ ?  ? ? ?ʅůŽĨĐĞůůƐƵƐƉĞŶƐŝŽŶ
was loaded and the number of cells within two 1 mm2 ĂƌĞĂƐ  ?ĞĂĐŚ  ? ? ? ʅů
volume) were counted. This number was divided by 2 and multiplied by 
10,000 to get an average number of cells per ml. The cells were then 
resuspended in DMEM to give the required cell density, and were seeded into 
an appropriate plate that had been poly-D-lysine coated ( ? ?ʅŐŵů-1 made up 
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Antibiotic resistance 
 
Parent cell line Cell line Concentration Receptor plasmid Concentration Experiments 
HEK293TR 
Blasticidin 
 ?ʅŐŵů-1  Zeocin  ? ?ʅŐŵů-1  Most (tetracycline repressor protein) 
HEK293T 
Zeocin 
 ?ʅŐŵů-1  Neomycin (G418) 0.2 mg ml-1  ŝ&ɴ-arrestin association ( arrestin2-vYNL) 
HEK293T 
Zeocin 
 ?ʅŐŵů-1  Neomycin (G418)  ?ʅŐŵů-1  BiFC constrained dimers (SNAP-GPR120S vYNL) 
 
Table 2.3 A summary of the use of antibiotics in routine cell culture. 
A table showing the antibiotics used in routine cell culture, and what they select for (parent cell line plasmids for tetracycline repressor protein, 
arrestin and receptor BiFC partners; versus introduced receptor vector) and at what concentration they were used at. 
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ŝŶ ,^^ ?  ? ? ? ʅů ǁĂƐ ƉŝƉĞƚƚĞĚ ŝŶƚŽ ĞĂĐŚ ǁĞůů ĂŶĚ ŝŶĐƵďĂƚĞĚ Ăƚ ƌŽŽŵ
temperature for 30 min; then aspirated and the wells washed with media). 
The next day, 18 hr prior to experiment, the medium was replaced with 
DDĐŽŶƚĂŝŶŝŶŐ ?ʅŐ ml-1 tetracycline. 
2.2.2.1.2 Tetracycline induction of receptor expression 
The promoter of pcDNA4T/O allowed for tetracycline regulation of receptor 
expression because it contained two tetracycline operon sites (TetO2), that 
the repressor protein co-expressed in HEK293TR cells bind to (Figure 2.3). 
&ŽůůŽǁŝŶŐ ƚĞƚƌĂĐǇĐůŝŶĞ ƚƌĞĂƚŵĞŶƚ  ? ? ʅŐ ml-1, 18-21 hr), a de-repression 
mechanism occurs, by which the tetracycline binds to the repressor protein, 
dissociating it from the TetO2 sites, and allowing receptor expression (Yao et 
al., 1998). 
2.2.2.1.3 Freezing 
Routinely, cells were frozen down for long term storage. This followed the 
above protocol (section 2.2.2.1.1), but instead of resuspension in DMEM, cells 
from a T75 flask were instead resuspended in 3 ml freezing solution (10 % v/v 
DMSO in FBS) and placed into cryovials in 1 ml aliquots. These aliquots were 
initially placed in a freezing container at -80oC (the container was filled with 
isopropanol to allow a gradual temperature decrease), and at least 24 hr later 
moved to liquid nitrogen for long term storage at -190oC.  
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2.2.2.1.4 Defrosting 
Aliquots were allowed to defrost naturally at room temperature. They were 
then transferred to a 20 ml universal tube with 9 ml DMEM and centrifuged 
for 5 min at 1,000 rpm. They were then resuspended in an appropriate 
volume of DMEM and allowed to grow overnight in a T75 flask at 37oC and 95 
% O2/5 % CO2 in a humidified incubator. The next day, the cells were passaged 
again (section 2.2.2.1.1), but this time were grown in a T75 in the presence of 
the appropriate antibiotics. 
2.2.2.2 Transfections 
Stable transfections to generate mixed populations were performed using the 
appropriate cell line (typically HEK293TR cells) using lipofectamine in 
Optimem (Invitrogen). Per flask (T25) of 90 % confluent cells, a reaction 
ŵŝǆƚƵƌĞ ŽĨ  ? ʅŐ E  ?ŝŶ  ? ? ? ʅůOƉƚŝŵĞŵ ) ƚŽ  ? ? ʅů ůŝƉŽĨĞĐƚĂŵŝŶĞ  ? ? P ? ƌĂƚŝŽ ?
ĂůƐŽŝŶ ? ? ?ʅůOptimem) was prepared, then combined to make a total volume 
ŽĨ ? ? ?ʅůŝŶĂ ? ?ŵůƚƵďĞ ?dŚŝƐǁĂƐůĞĨƚĂƚƌŽŽŵƚĞŵƉĞƌĂƚƵƌĞĨŽƌ ? ?ŵŝŶ ?ǁŚŝůƐƚ
1.2 ml optimem was added to replace the medium in the flask of HEK293 cells 
and also left for 45 min at 37o ?ĨƵƌƚŚĞƌ ? ? ?ʅůKptimem was added to the 
DNA-lipofectamine reaction mix, which was added to the cells and left for 24 
hr at 37oC. The next day, the cells were passaged as per standard protocol 
(section 2.2.2.1.1), with the addition of antibiotics for selection (Table 2.3). 
2.2.2.3 Dilution cloning 
Dilution cloning was used to generate a clonal SNAP-GPR120S-vYNL modified 
cell line for creating a dual transfect cell line for BiFC dimer experiments 
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(Chapter 3). Following the establishment of a mixed population by stable 
transfection (section 2.2.2.2), cell density in a 5 ml resuspension (after 
trypsinisation; in section 2.2.2.1.1) was calculated using a haemocytometer. 
This suspension was turned into serial dilutions that resulted in ~100 cells per 
10 ml, and this solution was půĂƚĞĚŽƵƚ ? ? ? ?ʅůƉĞƌǁĞůůŽŶƚŽĂ ? ?ǁĞůůƉůĂƚĞ ?
resulting in 1 to 2 cells per well. Seven days later, this plate was screened, and 
wells with no colonies or multiple colonies were discarded. During this 
dilution phase, cells were selected for using the appropriate antibiotics (Table 
2.3). The SNAP-GPR120S-vYNL clonal cell lines were then screened for 
expression using SNAP-tag fluorophore labelling and imaging on the IX Ultra 
plate-reader, prior to expansion. The vYC (Table 2.3) constructs were then co-
transfected into this cell line as a mixed population. 
2.2.3 Cell signalling assays 
2.2.3.1 Ligand preparation 
FFAs were stored at 100 mM in DMSO, whilst 10 mM stocks were made of 
GW9508 (from Tocris Bioscience, Bristol, UK), thiazolidinediones (from 
Cayman Chemical, Tallinn, Estonia), and GW1100 and Metabolex compound 
36 (Met36; from AstraZeneca, Alderley Park, UK). These were stored as 
aliquots at -20oC until required, when they were defrosted on the day of the 
experiment. From this, FFAs were made into 1.8 mM DMSO stock solutions; 
whilst synthetic ligands were simply defrosted, and both underwent serial 
dilution, typically to 6x or 10x the required final assay concentration in HBSS, 
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containing 0.02 % bovine serum albumin (BSA, unless otherwise stated) to aid 
in solubilisation. 
2.2.3.2 Calcium mobilisation assay 
FFA1 or GPR120 receptor cell lines were seeded at 20,000 cells per well in 
poly-D-lysine coated 96 well clear-bottomed black-sided plates (Costar 3904, 
from Corning Life Sciences (Corning, NY)). The next day, tetracycline was 
added (section 2.2.2.1.2). In the inhibitor studies 100 nM PTx (from 
Calbiochem, La Jolla, CA) was also added at this stage, for 18 hr at 37oC. The 
next day, plates were incubated with DMEM/10 % FBS, 2.5 mM probenecid, 
 ? ? ? ʅDFluo4AM and 0.023 % pluronic acid for 45 min at 37oC. Fluo4 is a 
calcium sensor, which undergoes increased fluorescence in the presence of 
calcium ions. Its excitation and emission spectral peaks are 494 nm and 506 
nm respectively. A cleavable ester (AM) form of Fluo4 was used, as this 
provided initial cell permeability. Probenecid was used to prevent the export 
of cleaved, negatively charged Fluo4, by its blocking action upon organic anion 
transporters. Pluronic acid was also used, because it is a non-ionic surfactant 
that facilitated the solubility of Fluo4 in aqueous solution. Cells were washed 
once and then incubated in HEPES buffered saline solution (HBSS; 25 mM 
HEPES, 140 mM NaCl, 5 mM KCl, 1 mM MgSO4, 2 mM sodium pyruvate and 
1.3 mM CaCl2) with 2.5 mM probenecid and 0.02 % fatty acid free BSA (unless 
otherwise stated) for 20 min at 37oC. In antagonist assays, antagonist, or in 
ŝŶŚŝďŝƚŽƌ ƐƚƵĚŝĞƐ ?  ? ?ʅD2-aminoethoxydiphenyl borate (2-APB) (from Tocris 
Bioscience, Bristol, UK), was present in the HBSS added at this step. Plates 
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were then loaded onto the FlexStation I or FlexStation III (Molecular Devices, 
Sunnyvale, CA, USA) and fluorescence (settings for excitation 485 nm, 
emission 520 nm; cut-off 515 nm) was measured every 1.52 s for 165 s after 
agonist (in HBSS/BSA) addition from a compound plate at 15 s (May et al., 
2010). 
2.2.3.3 Dynamic mass redistribution 
SNAP-GPR120S, SNAP-GPR120L or HEK293TRs were seeded at 15,000 cells per 
well on fibronectin coated 384 well clear-bottomed black-sided plates 
(Corning 5042, from Corning Life Sciences (Corning, NY), one day prior to 
experiments in medium containing tetracycline (section 2.2.2.1.2); this 
medium also contained 100 nM PTx in the inhibitor studies. 2 hr prior to 
experiment, plates underwent a 5 wash buffer exchange (HBSS/0.02 % BSA) 
and were left to equilibrate (2 hr at 26oC) in the Corning Epic Biosensor 
(Corning Life Sciences, Corning, NY), which is a label free system that 
measures dynamic mass redistribution (DMR); a measure of whole cell 
response in real time (Schroder et al., 2010). DMR has been postulated to be a 
mechanism for identifying which G protein is coupled to the receptor because 
each G protein gives a unique response signature. Responses due to Gi 
showed a steep positive increase, followed by a gradual decrease, in contrast 
to Gq which gave a gradual positive increase. G12/13 gave a sharp increase, 
followed by a slight dip, and then another gradual increase, but G12/13 was 
measured in HEK cells, whereas the others were in CHO cells (Figure 2.9). A 
difficulty in this assay is that the signature response for Gs varies depending 
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on the cell background. In CHO cells, Gs responses were a steep negative 
decrease followed by a plateau, whilst in HEK cells Gs gave a positive 
inflection (Schroder et al., 2010). 
If 2-APB was used, this was added 1 hr post buffer exchange, and plates were 
left to equilibrate for 1 hr. Agonists were made on a DMSO stock plate at 
[1000x], which were then transferred into a [5x] compound plate. Agonists 
were added in quadruplicate (0.1 % final DMSO concentration) and readings 
were taken every 40 s for 50 min.  ? ? ?ʅDdWǁĂƐƵƐĞĚĂƐĂƉŽƐŝtive control 
to stimulate endogenous P2Y receptors, and data were normalised to this 
response.  
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Figure 2.9 Diagram showing the principle of DMR. 
The GPCR is activated, coupling to a G protein and eliciting cellular effects, causing the movement of cellular constituents. This movement is 
measured by a wavelength shift in the broadband light that is shone into the layer of adherent cells on the plate. Image adapted from Schroder 
et al., 2010. 
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2.2.4 Automated imaging of receptor internalisation 
2.2.4.1 FFA receptor visualisation 
FFA1 or GPR120 receptors were visualised directly through fluorescent 
protein carboxyl terminal fusions, or more commonly using the SNAP-tag 
system (SNAP-surface reagents were from New England Biolabs, Hitchin, UK; 
Figure 2.10). As described above, the receptor cDNA was cloned directly 
downstream of the SNAP-tag and fusion proteins expressed in tetracycline 
inducible HEK293 cells. The SNAP-tag is a 20 kDa mutant of a DNA repair 
protein, an alkyl guanine-DNA transferase. This reacts covalently with 
fluorescent benzyl-guanine (BG), leading to irreversible labelling of the SNAP-
tag with a fluorescent probe and enabling receptor visualization. The 
advantages of this system are that one cell line can be labelled with a variety 
of different wavelength fluorophores, and also that SNAP-surface label 
variants are membrane impermeant, so that only receptors that have reached 
the cell surface are labelled, and not nascent polypeptides in the endoplasmic 
reticulum or Golgi apparatus.  
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Figure 2.10 A schematic of the SNAP-tag receptor system. 
The first panel shows the modified receptor containing the SNAP-tag protein 
fused to the amino terminus. The second and third panels depict the reaction 
of the benzyl-guanine label (SNAP-surface fluorophore) undergoing the 
specific reaction which results in the receptor becoming fluorescently 
labelled. 
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2.2.4.2 Internalisation assay using an automated confocal platereader 
SNAP-FFA1 or GPR120 receptors were seeded at 20,000 cells per well in poly-
D-lysine coated 96 well clear-bottomed black-sided plates (Greiner 655090; 
from Greiner Bio-One, Stonehouse, UK). The next day, tetracycline was added 
(section 2.2.2.1.2). Then, the next day, the day of the experiment, plates were 
incubated with DMEM/10 % &^ ĐŽŶƚĂŝŶŝŶŐ  ? ? ? ʅDSNAP-surface 
AlexaFluor(AF)-488 (unless otherwise stated) for 30 min at 37oC. Cells were 
washed once with and then incubated in HBSS. Vehicle or agonist (in 
HBSS/0.02 % fatty acid free BSA unless otherwise stated) were added in 
triplicate wells and incubated for the indicated times at 37oC. Following this, 
cells were rinsed twice with PBS, then fixed in 3 % paraformaldehyde (PFA) in 
PBS for 10 min at room temperature, followed by another two 5 min washes 
with PBS, then treatment with ŶƵĐůĞĂƌ ƐƚĂŝŶ , ? ? ? ? ?  ? ? ʅŐ ml-1 in PBS), 
followed by two more washes in PBS, all at room temperature. Plates were 
then imaged on the IX Ultra confocal plate reader (Molecular Devices), with 
four central sites being imaged per well, using a Plan Fluor 40x NA0.6 
 ?ŶƵŵĞƌŝĐĂů ĂƉĞƌƚƵƌĞ ? ƐŝŐŶŝĨŝĞƐ ƚŚĞ ŽďũĞĐƚŝǀĞ ?Ɛ ĂĐĐĞƉƚĂŶĐĞ ĐŽŶĞ ? ƚŚĞ ƌĂŶŐĞ ŽĨ
angles over which light can be accepted into the lens i.e. its light gathering 
power) extra long working distance air objective and 405 nm (H33342; cell 
nuclei) or 488 nm (SNAP-surface AF-488; receptor) laser excitation. The laser 
power, gain and offset settings were set relative to positive and negative 
controls on the plate. Initially, cells were also imaged live on the widefield IX 
Micro plate reader (Molecular Devices) using the same protocol, to optimise 
the concentrations of SNAP-surface fluorophore used. 
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2.2.4.3 Receptor Recycling 
The same protocol as for internalisation (section 2.2.3.3.2) was followed, 
except that additional wash steps were included. SNAP-GPR120 expressing 
cells were treated as before for 30 min at 37oC with agonist, then cells were 
washed with HBSS/0.1 % BSA (the higher BSA concentration used to more 
effectively remove receptor bound FFA) and incubated for 5 W60 min at 37oC. 
The cells were then washed and fixed as above (section 2.2.4.2). 
2.2.5 Bimolecular fluorescence complementation 
BiFC is a technique based around the formation of a functional, fluorescent 
protein, which in this study was venus yellow fluorescent protein (vYFP). This 
variant of YFP contains mutations F64L, M153T, V163A and S175G (Nagai et 
al., 2002). F64L accelerates oxidation of the chromophore, which is the rate-
limiting step of fluorophore maturation, whilst the other mutations facilitate 
the vYFP to fold correctly into its beta-barrel structure (Nagai et al., 2002). 
This vYFP is split into 2 non-fluorescent fragments, which are fused to the 
proteins of interest, e.g. receptor-vYC (155-238) and ɴ-arrestin2-vYNL (2-172) 
(Kilpatrick et al., 2010; MacDonald et al., 2006). During the course of the 
assay, the tagged proteins interact, allowing the fragments to associate and 
refold. Then, the chromophore matures, giving out YFP fluorescence and 
allowing visualisation of protein complex (Figure 2.11 (Hu et al., 2002; 
Kerppola, 2008)).  
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Figure 2.11 Diagram showing principle of BiFC. 
Two proteins of interest are genetically engineered with two fragments of 
vYFP. Following protein interaction, these fragments undergo association and 
refold, generating fluorescence.  
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2.2. ? ? ?DĞĂƐƵƌŝŶŐƌĞĐĞƉƚŽƌĂƐƐŽĐŝĂƚŝŽŶǁŝƚŚɴ-arrestin using BiFC 
Figure 2.12 shows the theory behind using BiFC to measure the receptor 
ĂƐƐŽĐŝĂƚŝŶŐǁŝƚŚɴ-arrestin2. Cells dually expressing FLAG-GPR120-vYc ĂŶĚɴ-
arrestin2-vYN were seeded at 20,000 cells per well on poly-D-lysine coated 96 
well clear-bottomed black-sided plates (Greiner 655090) one day prior to 
experiment. Cells were washed once with and incubated in HBSS/0.02 % BSA 
for 30 min at 37oC. Agonist in HBSS/0.02 % BSA was added in triplicate and 
incubated, 30 min at 37oC (unless otherwise stated). Cells were washed, fixed 
and imaged as for internalisation (Kilpatrick et al., 2010). 
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Figure 2.12 Diagram showing principle of BiFC used to study the interaction 
ďĞƚǁĞĞŶƌĞĐĞƉƚŽƌĂŶĚɴ-arrestin2. 
In this application of BiFC, split vYFP fragments are attached to the receptor 
carboxyl tail ĂŶĚɴ-arrestin2 to measure their interaction.  
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2.2.5.2 Constraining receptor dimers using BiFC 
BiFC between two different receptor constructs allows a unique measurement 
of BiFC dimer internalisation, because it allows two series of images to be 
taken concurrently. These two sets are of the SNAP-surface BG-647 
fluorophore labelling the SNAP-GPR120S-vYNL population, whilst the 
recombined vYFP fluorescence (measuring the BiFC dimer with the second 
expressed receptor-vYC construct) can also be simultaneously imaged using 
the 488 nm channel (Figure 2.13). 
Cells dually expressing SNAP-GPR120S-vYNL and FLAG-tagged FFA1-vYC, 
GPR120S-vYC or GPR120L-vYC were seeded at 20,000 cells per well on poly-D-
lysine coated 96 well clear-bottomed black-sided plates (Greiner 655090) one 
day prior to experiment (because these receptor cDNAs were not in a plasmid 
containing the tetracycline promoter). Cells were washed once with and 
incubated in HBSS/0.02 % BSA, 30 min at 37oC. Agonist in HBSS / 0.02 % BSA 
was added in triplicate wells and incubated, 30 min at 37oC (unless otherwise 
stated). Cells were washed, fixed and imaged as for internalisation (Kilpatrick 
et al., 2010). 
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Figure 2.13 Diagram showing principle of BiFC used to study the interaction 
between two fatty acid receptor protomers. 
In this application of BiFC, vYFP is split between the two fatty acid receptor 
constructs in question to measure the behaviour of the A-B receptor dimer in 
internalisation assays. This also allowed SNAP-surface measurements (of 
population A) in conjunction with vYFP (A-B) measurements.  
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2.2.6 Fluorescent ligand binding assay 
HEK293TR FLAG-FFA1 cells were seeded at 10,000 cells per well on poly-D-
lysine coated 96 well clear-bottomed black-sided plates (Greiner 655090). On 
the day of the experiment, medium was replaced with HBSS (in the absence of 
BSA) and left to incubate at 37oC for 30 min. Competing ligands in the range of 
 ? ? ? ?ŶDƚŽ ? ? ?ʅDǁĞƌĞĂĚĚĞĚĂŶĚůĞĨƚƚŽŝŶĐƵďĂƚĞĨŽƌ ?ŵŝŶĂƚ ? ?oC (unless 
otherwise stated), followed by treatment with 100 nM 40Ag-Cy5 (synthesised 
by CellAura Technologies, Nottingham, UK) for 30 min at 37oC (unless 
otherwise stated). The plate was then imaged live immediately on the IX 
Ultra, 2 sites per well, using 633 nm laser excitation (Stoddart et al., 2012).  
2.2.7 Confocal imaging 
2.2.7.1 Colocalisation of internalised receptors with intracellular markers 
HEK293TR SNAP-GPR120S or SNAP-GPR120L cells were seeded on poly-D-
lysine coated 8-well clear plates (Nunc Lab-Tek, from Thermo Fisher Scientific, 
UK) at 20,000 cells per well. The next day, 1 g ml-1 tetracycline was added 
(section 2.2.2.1.2). Then the next day, live celůƐ ǁĞƌĞ ůĂďĞůůĞĚ ǁŝƚŚ  ? ? ? ʅD
SNAP-surface AF-488 as previously described (section 2.2.4.1), followed by 
ƚƌĞĂƚŵĞŶƚǁŝƚŚǀĞŚŝĐůĞŽƌ  ? ? ?ʅDŽůĞŝĐĂĐŝĚ ŝŶ,^^ ? ? ? ? % FFA free BSA (60 
min at 37oC), with the HBSS also containing either 10 nM lysotracker red 
(Invitrogen; 60 min at 37o ) ?Žƌ ?ʅŐ ml-1 transferrin AF-633 (Invitrogen) added 
15 min prior to imaging. Live cell images were taken, following 60 min 
treatment at 37oǁŝƚŚǀĞŚŝĐůĞŽƌ ? ? ?ʅDŽůĞŝĐĂĐŝĚ ? using a Zeiss LSM (laser 
scanning microscope) 510 (Carl Zeiss, Ltd., Welwyn, UK) using a 63x Plan-
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Apochromat NA 1.4 oil objective with Ar 488 nm (SNAP-surface AF-488), HeNe 
543 nm (lysotracker red) and HeNe 633 nm (transferrin) laser lines for 
excitation. Images were taken sequentially with band passes of 505-530 nm 
(BG-AF488), 560-615 nm (lysotracker red) and a long bandpass of 650 nm 
(transferrin). Pinhole diameter was set to 1 Airy unit for the longest 
wavelength, and microscope detector gain and amplifier offset were adjusted 
(consistently within data groups) to ensure images were not saturated. 
2.2.8 Fluorescence correlation spectroscopy 
Fluorescence correlation spectroscopy (FCS) is a technique that measures the 
diffusion of fluorescent molecules through a fixed confocal detection volume 
 ?ĂƉƉƌŽǆŝŵĂƚĞůǇ  ? ? ? ?ʅŵ3, approximately corresponding to approximately 0.1 
ʅŵ2 of the illuminated plasma membrane), by recording the time dependent 
fluctuations in intensity that result from this mobility (see analysis section 
2.2.9.5 and Chapter 5 for more background). This technique has been 
estimated to be sensitive enough to measure the behaviour of approximately 
1  W 100 particles within the volume (Briddon et al., 2011).  
2.2.8.1 Calibration 
FCS was carried out on a Zeiss Confocor 2 fluorescence microscope with a c-
Apochromat 40x NA1.2 water immersion objective lens. The system was first 
calibrated using Cy5 (used to calibrate the 633 nm beampath; diffusion 
coefficient, D = 3.16 x10-10 m2/s; Amersham Pharmacia Bioscience) to 
determine the size of the confocal volume. Cy5 was diluted from a 5 mM 
ƐƚŽĐŬƐŽůƵƚŝŽŶƌĞƐƉĞĐƚŝǀĞůǇ ?ƚŽ ?ʅDĂŶĚ ? ?ŶDƐŽůƵƚŝŽŶƐŝŶĨůƵŽƌĞƐĐĞŶĐĞĨƌĞĞ
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ǁĂƚĞƌ ?ĂŶĚ ? ? ?ʅůŽĨĞĂĐŚƐŽůƵƚŝŽŶǁĂƐƉůĂĐĞĚŝŶƚŽƐĞƉĂƌĂƚĞǁĞůůƐŽĨĂŶ ?ǁĞůů
plate. Immersion water was placed on the objective lens, then the 8 well plate 
was placed ŽǀĞƌƚŚĞŽďũĞĐƚŝǀĞ ?ĐĞŶƚƌĞĚŽŶƚŚĞǁĞůůĐŽŶƚĂŝŶŝŶŐƚŚĞ  ?ʅDǇ ?
solution. Next, the reflection beampath was used to first find the lower, then 
the upper surface of the 8 well plate, and once this was found, the focal 
ǀŽůƵŵĞǁĂƐƉůĂĐĞĚ ? ? ?ʅŵĂďŽǀĞŝŶƚŽƚŚĞ solution containing the Cy5. 
Next the beampath was selected, for the correct combination of laser 
excitation, dichroic mirror and emission filter. The excitation light was then 
turned on and laser power adjusted until the count rate was 250-500 kHz at 
the detector. The correction collar on the objective was adjusted to achieve 
the maximal count rate, and the pinhole was set to 1 Airy unit. Following this, 
the position of the pinhole in both x and y axes were scanned and adjusted 
automatically by the machine to obtain the maximum count rate, and similar 
optimisation of the collimator position (z) was carried out Following this, the 
objective was moved to the 20 nM well and the laser power was adjusted to 
achieve a count rate 20 -100 kHz.  
Cy5 calibration reads were then carried out, 3 x 15 s at 5, 4, 3, 2, and 1 % laser 
power. These autocorrelation curve data were then fitted to one component 
3D diffusion model using the analysis software (Zeiss AIM, Jena, Germany), 
ensuring the fitted structural parameter (the ratio of the confocal volume 
height to waist radius) was between 5 and 8. The dwell time measured by 
these calibration reads, in conjunction with the known value for the Cy5 
diffusion coefficient, allowed for the detection volume to be calculated. This 
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in turn allowed the calculation of diffusion co-efficients and concentrations 
from dwell times and particle measurements from fluorescent ligands and 
receptors in cell data (section 2.2.9.5) (Briddon et al., 2011). 
2.2.8.2 Experiments 
HEK293TR cells expressing SNAP-FFA1 receptors were seeded at 20,000 cells 
per well on poly-D-lysine coated 8 well clear plates (Nunc Lab-Tek,Thermo 
Fisher Scientific, UK). The next day, tetracycline was added (section 2.2.2.1.2). 
Then, the next day the cells were ready for FCS studies. 
2.2.8.2.1 Receptor diffusion 
To measure receptor diffusion, HEK293TR cells expressing SNAP-FFA1 
receptors were labelled with SNAP-surface BG-647 (section 2.2.4.1) and left to 
equilibrate at 22oC. The nucleus of the cell was found using live imaging from 
the Zeiss Axiocam HR camera. This allowed positioning in xy, followed by a 
confocal z scan (at low laser power to prevent bleaching), to be performed to 
determine the position of the upper membrane above the nucleus 
(corresponding to peak fluorescence intensity). The confocal volume was then 
placed at the z position defined by this peak. Data were routinely collected 
following a 15 s prebleach at 0.5 % laser power at 633 nm, and then 3 x 15 s 
reads at 0.7 % laser power at 633 nm, with emission collected by avalanche 
photodiodes using a 650 nm long pass filter.  
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2.2.8.2.2 Ligand binding 
To measure ligand binding to FLAG-FFA1 receptors, HEK293TR cells expressing 
SNAP-FFA1 were labelled with SNAP-surface AF-488 and left to equilibrate at 
22oC. The nucleus of the cell was found using the SNAP-labelled receptors 
imaged from the Zeiss Axiocam HR camera, and the confocal volume was 
positioned using a z scan as before. However, in this case the confocal volume 
ǁĂƐƉůĂĐĞĚĂƚŽŶĞ ? ? ?ʅŵƐƚep above the upper membrane peak intensity. 
Data were then collected using SNAP-FFA1 receptor expressing cells treated 
with fluorescent 40Ag-Cy5 (25 W100 nM). Some experiments examined the 
ĞĨĨĞĐƚŽĨ ?ʅD't ? ? ? ? ?ǁŚŝĐŚǁĂƐĂĚĚĞĚ ? ?ŵŝŶƉƌŝŽƌƚŽƚŚĞĂĚĚŝƚŝŽŶof 100 
nM 40Ag-Cy5 (5 min at 22oC). Data were routinely collected following a 15 s 
prebleach at 0.5 % laser power at 633 nm, and then 3 x 15 s reads at 0.7 % 
laser power at 633 nm, with emitted photons collected by sensitive avalanche 
photodiodes through a 650 nm long pass filter. 
2.2.9 Data analysis 
2.2.9.1 Calcium mobilisation 
Calcium signalling data were analysed by the peak agonist response 
(maximum Wminimum) using an average of triplicate wells. Data were 
generally normalised as a percentage response to a positive agonist control 
 ?ƚǇƉŝĐĂůůǇ ? ? ?ʅDŽleic acid, unless stated otherwise). In some cases, to allow 
for comparison between cell lines, peak calcium data were analysed as fold 
over basal levels instead. In either case, experiments were pooled, and data 
expressed as mean ± S.E.M. to generate concentration response curves fitted 
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using nonlinear least-squares regression (Prism v5.02; GraphPad Software, 
Inc., San Diego, CA, USA). EC50 values were quoted (as  Wlog EC50; pEC50) if a 
maximum agonist response could be defined. 
The effects of antagonist in calcium signalling studies were further analysed, 
using the Gaddum equation: 
 
The Gaddum equation links concentration ratio, CR, to antagonist 
concentration, [B] and allows KB, the antagonist equilibrium dissociation 
constant to be calculated. A derivation results in the Schild analysis, giving the 
equation: 
 
Log [CR-1] was plotted against log antagonist concentration (log [B]) on a 
Schild plot. This theoretically gives a straight line of slope 1 provided the 
experiment was under equilibrium conditions and the antagonist is both 
competitive and reversible, and the intercept gives  Wlog KB, called pA2 when 
estimated by this method (Arunlakshana and Schild, 1959). 
2.2.9.2 DMR 
DMR data were analysed by the peak agonist response (maximum Wminimum) 
using an average of quadruplicate wells. Data were normalised as a 
ƉĞƌĐĞŶƚĂŐĞ ƌĞƐƉŽŶƐĞ ƚŽ Ă ƉŽƐŝƚŝǀĞ ĐŽŶƚƌŽů  ? ? ? ? ʅD dW ) ? xperiments were 
pooled, and data expressed as mean ± S.E.M. to generate concentration 
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response curves fitted using nonlinear least-squares regression (Prism v5.02; 
GraphPad Software, Inc., San Diego, CA, USA). pEC50 values were quoted if a 
maximum agonist response could be defined.  
2.2.9.3 Internalisation 
2.2.9.3.1 Internalisation and BiFC 
For quantitative analysis of internalisation and BiFC images (see Figures 3.15 
and 3.13 respectively for examples), a granularity algorithm (MetaXpress 2.0, 
Molecular Devices) ĚĞƚĞĐƚĞĚ ŝŶƚƌĂĐĞůůƵůĂƌ ĐŽŵƉĂƌƚŵĞŶƚƐ ĂƐ  “ŐƌĂŶƵůĞƐ ? ŽĨ
specified diameter (typically 2- ?ʅŵ ?ƵŶůĞƐƐƐƚĂƚĞĚŽƚŚĞƌǁŝƐĞ )ĂŶĚƐĞƚĂďŽǀĞĂ
specified intensity threshold, which were set relative to negative (vehicle) and 
ƉŽƐŝƚŝǀĞ ? ? ? ?ʅDŽůĞŝĐĂĐŝĚ )ĐŽŶƚƌŽůƐƉƌĞƐĞŶƚŽŶƚŚĞƉůĂƚĞ ?^ĞǀĞƌĂůƉĂƌĂŵĞƚĞƌƐ
were given by this analysis, which were normalised to cell count (defined as 
cell nuclei stained by H33342), such as granule count, area and intensity per 
cell, all of which were averaged from triplicate wells (i.e. 12 sites per data 
point). All parameters produced similar results, and all figures presented were 
derived from measurements of average granule intensity per cell. 
Experiments were pooled, and data expressed as mean ± S.E.M. to generate 
concentration response curves fitted using nonlinear least-squares regression 
(Prism v5.02; GraphPad Software, Inc., San Diego, CA, USA). pEC50 values were 
quoted if a maximum agonist response could be defined.  
Time course data were analysed using single phase association kinetics, and a 
latency period where appropriate. This latency was to take into account that 
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&& ŝŶĚƵĐĞĚ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶĂŶĚɴ-arrestin recruitment showed a short delay 
(usually 2-5 min) between agonist addition and response. 
2.2.9.3.2 Receptor expression 
Comparisons of receptor expression were estimated by further analysis of 
control images acquired using identical settings, with reference cells 
expressing SNAP-GPR120S wild type on the same plate. SNAP-surface labelled 
receptors under vehicle conditions were analysed using the multiwavelength 
cell scoring algorithm (MetaXpress 2.0). This defined regions of the image 
covered by individual cells, on the basis of both the location of H33342 
stained nuclei and the boundary of SNAP-surface labelled receptor staining. 
The mean pixel intensities within these regions (covering both plasma 
membrane and cytoplasm) were then averaged for all cells in each image. This 
measure of cellular fluorescence intensity was pooled between experiments 
(mean ± S.E.M.) and was used to indicate receptor expression levels. 
2.2.9.4 Fluorescent ligand binding 
Following acquisition of 40Ag-Cy5 binding images, a modified version of the 
granularity analysis was applied. The parameters of the granules were set to 
selectively record the fluorescent ligand bound to the cell expressed receptors 
 ? “ǁŚŝƚĞĚŽƚƐ ? ?ŐƌĂŶƵůĞƐ ?- ?ʅŵŝŶĚŝĂŵĞƚĞƌ ) ?ǁŝƚŚĂŶŽƚŚĞƌƐĞƚƚŽĞǆĐůƵĚĞƚŚĞ
larger, non-ďŽƵŶĚĂŐŐƌĞŐĂƚĞƐŽĨůŝŐĂŶĚ ? “ƌĞĚĚŽƚƐ ? ?AN ?ʅŵŝŶĚŝĂŵĞƚĞƌ ) ?ĂƚĂ
were normalised, with no tet set as the negative control (0 %), and the totals 
were set as the positive control (100 %; Figure 2.14). Experiments were 
pooled, and data expressed as mean ± S.E.M. to generate inhibition curves  
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Figure 2.14 Representative images and quantitative analysis of 40Ag-Cy5 
binding to FLAG-FFA1 receptors. 
The top row shows representative images from the binding assay using 100 
nM 40Ag-Cy5 throughout, whilst the bottom row shows the resulting analysis. 
The top (L-R) shows images of HEK293TR cells that did not undergo 
tetracycline induction of FLAG-FFA1 expression; cells that did not undergo 
ĐŽŵƉĞƚŝŶŐ ůŝŐĂŶĚ ƚƌĞĂƚŵĞŶƚ  ?ƚŽƚĂůƐ ) ? ƚŚĞŶ ĐĞůůƐ ƚŚĂƚǁĞƌĞ ƉƌĞƚƌĞĂƚĞĚ  ? ? ʅD
GW1100; all underwent treatment with 40Ag-Cy5 for 30 min at 37oC. The 
bottom row shows the granularity analysis, which measured the pit count on 
ĐĞůůƐƵƌĨĂĐĞ  ? “ǁŚŝƚĞĚŽƚƐ ? ?ŐƌĂŶƵůĞƐ  ?- ?ʅŵŝŶĚŝĂŵĞƚĞƌ )ǁŚŝůƐƚĞǆĐůƵĚŝŶŐƚŚĞ
ůĂƌŐĞƌĂŐŐƌĞŐĂƚĞƐ ? “ƌĞĚĚŽƚƐ ? ?AN ?ʅŵŝŶĚŝĂŵĞƚĞƌ ) ?  
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fitted using nonlinear least-squares regression (Prism v5.02; GraphPad 
Software, Inc., San Diego, CA, USA), and IC50 values were calculated as 
appropriate. 
Next, paired competition curves were carried out using the antagonist 
GW1100. This allowed for the estimation of the dissociation constant of 40Ag-
Ǉ ? ? dǁŽ ƐĞƚƐ ŽĨ ĚŝƐƉůĂĐĞŵĞŶƚƐ ǁĞƌĞ ĐĂƌƌŝĞĚ ŽƵƚ ƵƐŝŶŐ  ? ʅD ĂŶĚ  ? ? ? ŶD
40Ag-Cy5. This gave two pIC50 estimates, A and B, for GW1100, which allowed 
for the simultaneous solution of the Cheng-Prusoff equation (below) (Cheng 
and Prusoff, 1973). This resulted in an estimation of both the 40Ag-Cy5 (KFL) 
dissociation constant and the GW1100 Ki. 
 
 
 
 
pIC50 values from competition binding studies using other ligands were further 
analysed to derive affinity values (Ki) using the Cheng-Prusoff equation and 
the 40Ag-Cy5 concentration [FL] and  dissociation constant (KFL): 
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2.2.9.5 FCS 
2.2.9.5.1 Autocorrelation analysis 
In FCS, the confocal spot focuses on a small area of interest, such the plasma 
membrane (area 0.1 W ? ? ?ʅŵ2), defining a detection volume (~0.25fl), which is 
Gaussian in shape. Within this volume, fluctuations in fluorescent intensity are 
measured as fluorescently labelled receptors or ligand diffuse through (Figure 
2.15). Autocorrelation analysis of these fluctuations gives quantitative data on 
the fluorescent particles present. This includes the average number of 
ƉĂƌƚŝĐůĞƐ ĂŶĚ ƚŚĞŝƌ ĂǀĞƌĂŐĞ ĚǁĞůů ƚŝŵĞ ? ʏ ? ǁŚŝĐŚ ŝŶĐŽŶũƵŶĐƚŝŽŶ ǁŝƚŚ
knowledge of the size of the confocal volume can then be used to calculate 
the particle concentration and diffusion co-efficients (D) of the fluorescent 
species respectively (Briddon and Hill, 2007). 
ƵƚŽĐŽƌƌĞůĂƚŝŽŶĂŶĂůǇƐŝƐĚŽĞƐƚŚŝƐďǇƚĂŬŝŶŐƚŚĞƐŝǌĞŽĨĂĨůƵĐƚƵĂƚŝŽŶ ?ɷ/ )ĨƌŽŵ
the average intensity at time T and comparing it with a subsequent fluctuation 
at time TA?ʏ ?hƐŝŶŐƚŚĞǁŚŽůĞƌĂŶŐĞŽĨʏǀĂůƵĞƐŐŝǀĞƐ' ?ʏ ) ?ƚŚĞĂƵƚŽĐŽƌƌĞůĂƚŝŽŶ
function, which is normalised to the square of the mean intensity, <I>, 
resulting in an autocorrelation decay curve (see equation in Figure 2.16 C). 
The dwell ƚŝŵĞ ?ʏ ?ŝƐĚĞƌŝǀĞĚĨƌŽŵƚŚĞŚĂůĨǁĂǇƉŽŝŶƚŽĨƚŚĞ' ?ʏ )ĚĞĐĂǇŽĨƚŚĞ
autocorrelation function, whilst the particle number, N, is derived from its 
inverse relationship to the amplitude of G0 (Briddon and Hill, 2007). 
In an actual experiment, calibration using a fluorophore with a known 
diffusion co-efficient, such as Cy5 (D 3.16 x10-10 m2 s-1), allows the confocal 
ǀŽůƵŵĞĂŶĚƌĂĚŝƵƐ ?ʘ0 = (4DCy5ʏD)1/2)to be calculated. In turn this allows the  
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Figure 2.15 The principle of FCS. 
As fluorescent molecules diffuse in and out of the confocal volume placed on 
the upper membrane of the cell (A), these fluorescent fluctuations are 
measured (B). These data are then fit to an autocorrelation analysis model (C). 
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diffusion co-efficient (D) of the labelled receptor or ligand to be calculated 
from indŝǀŝĚƵĂůʏD values using A?ʘ20 ? ?ʏD; and the particle concentration (for 
the circular area on a 2D membrane) can be calculated using N ? ?ʋʘ20). These 
 “ŶŽƌŵĂůŝƐĞĚ ?ǀĂůƵĞƐĂůůŽǁĐŽŵƉĂƌŝƐŽŶďĞƚǁĞĞŶĚĂƚĂƐĞƚƐ ? 
Autocorrelation analysis can be fitted to different models (as follows 
ŽǀĞƌůĞĂĨ ) ?dŚĞƐĞŵŽĚĞůƐĂůůŝŶĐŽƌƉŽƌĂƚĞĂĨĂƐƚ “ďůŝŶŬŝŶŐ ?ĐŽŵƉŽŶĞŶƚ ?AM ? ?s) 
to account for the photophysics of the fluorescent molecule, a pre-
exponential term which is not indicated in the following equations (Briddon 
and Hill, 2007; Briddon et al., 2011). The 1x3D model was used for the 
diffusion of the free ligand, because this incorporates movement in x, y and z 
dimensions. It was used to fit the data for the calibrations and free 40Ag-Cy5 
in solution (other than definitions already given: m is the total number of 
components (here m=1), fi is the fractional contribution that component i 
makes to the curve while S is the structure parameter related to the shape of 
the confocal volume): 
 
The 2D model was used for receptor-bound ligand or SNAP-labelled receptors, 
because this model only incorporates movement in x and y, and so was used 
to measure the diffusion of SNAP-FFA1 within the plasma membrane (here 
m=1 or 2 for 1/2 components): 
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For example, the  ?ǆ ? ŵŽĚĞů ŐĂǀĞ ƚǁŽ ĚǁĞůů ƚŝŵĞƐ ʏD1 and ʏD2, and their 
percentage contribution to the overall amplitude of the autocorrelation, G(0), 
ǁŚŝĐŚŝƐĞǆƉƌĞƐƐĞĚĂƐʏD1 A?ĂŶĚʏD2 % (related to fi). (Briddon et al., 2004). In 
the actual experimental data using fluorescent ligands, a combination of these 
models was required (1x3D + 1 or 2 2D components), with the 1x3D 
component used to account for ligand that was free in solution; whilst one or 
more 2D components were used to model ligand bound to FFA1. 
2.2.9.5.2 PCH analysis 
These raw measurements can also undergo an alternative statistical analysis 
(using Zeiss Zen 2000 software), known as the photon counting histogram 
(PCH) analysis (Chen et al., 1999). This analysis can provide a different 
calculation of the particle concentration, and also gives information on 
molecular brightness ( ), the brightness of each species. PCH is an amplitude 
rather than time dependent analysis. The fluorescence record is divided into 
bins of appropriate time, which should be lower than the FCS dwell times of 
the species of interest, but higher than those to be eliminated from the 
analysis. For example, the bin time in this study was 1 ms (to avoid 
contributions from the free diffusing ligand, and photophysics effects from 
the fluorophore). Throughout the record, the photon counts in each bin are 
calculated, and this generates a frequency histogram, with the number of 
photon counts k represented on the x axis, and the number of bins containing 
those counts k on the y axis. While this histogram might be expected to follow 
a Poisson distribution, the uneven illumination of the confocal volume (with 
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greatest excitation in the centre of the volume) generates deviations from the 
Poisson fit. PCH analysis measures this deviation from the ideal Poisson fit, 
and models it based on the number (N) and molecular brightness ( ) of one or 
more fluorescent species components. 
The PCH calibration was fitted to the 1 component model. This gave a first 
order correction, which takes into account deviations from a Gaussian 
observation volume when using single photon (rather than multi-photon) 
excitation (Huang et al., 2004). This first order correction was then used in the 
analysis of the cell data, which was analysed using the 2 component PCH 
model, with the bin time of 1 ms. 
2.2.9.6 Statistical significance 
Statistical significance was determined as specified in figure legends, using 
GraphPad Prism. Typically, 2 way ANOVA (analysis of variance) with 
Bonferroni post-tests were used when comparing GPR120 isoform responses 
(Chapter 3); 1 way ANOVA was used when comparing the GPR120S mutants 
when studying the binding site (Chapter 4); and Kruskal-Wallis or Mann-
tŚŝƚŶĞǇ ƚĞƐƚ ǁŝƚŚ ƵŶŶ ?Ɛ ŵƵůƚŝƉůĞ ĐŽŵƉĂƌŝƐŽŶ ƉŽƐƚ-tests were used when 
analysing FCS data (Chapter 5). A ^ƚƵĚĞŶƚ ?ƐƵŶƉĂŝƌĞĚ ƚ ƚĞƐƚǁĂƐƵƐĞĚƚŽ ƚĞƐƚ
significance in all other situations, as stated.  
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Chapter Three: Signalling and trafficking characterisation 
of FFA1 and GPR120 isoforms 
3.1 Introduction 
3.1.1 Fatty acid receptor signalling pathways 
Fatty acid receptors are G protein-coupled receptors, and therefore some of 
their effects are mediated through G proteins. FFA1 couples predominantly 
through the Gq/11 class of G proteins to elicit ERK activation (Seljeset and 
Siehler, 2012) and calcium signalling, leading to the potentiation of insulin 
secretion (Briscoe et al., 2003; Itoh et al., 2003), but it has also been found to 
couple partially through Gi to inhibit cAMP production (Schroder et al., 2010). 
Less is known about the specific coupling of GPR120, but it can stimulate 
calcium signalling, via Gq/11 (Oh da et al., 2010), and ERK activation which 
leads to GLP-1 secretion. GPR120 activation had no effect upon cAMP 
signalling (Hirasawa et al., 2005). Furthermore, there is evidence for FFA1 and 
GPR120 expression in the breast cancer cell line MCF-7, and treatment with 
oleic acid promoted ERK phosphorylation through Gi, leading to cell 
proliferation (Soto-Guzman et al., 2008). 
In terms of non G protein mediated signalling, not much is known for GPR120. 
GPR120 has been shown to undergo internalisation (Fukunaga et al., 2006; 
Hirasawa et al., 2005), whereas there is no mention in the literature of this for 
FFA1. A recent investigation has suggested that GPR120 is capable of ɴ-
arrestin association using a DiscoverX complementation assay (Shimpukade et 
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al., 2012). Additionally, very little data exists directly comparing GPR120 
isoforms, though it has previously been suggested that the longer form may 
be functionally impaired in initiating signalling cascades (Moore et al., 2009). 
It has also been found that the shorter form of the receptor is constitutively 
phosphorylated to a greater extent than the longer form (Burns and Moniri, 
2010). Interestingly, one study found that GPR120 had cell specific signalling. 
It was found that in adipocytes the receptor signals through Gq for glucose 
uptake, whilst in macrophages, GPR120 was found to prevent insulin 
resistance through an inhibitory mechaŶŝƐŵŵĞĚŝĂƚĞĚďǇɴ-arrestin2 (Oh da 
et al., 2010). Perhaps this gives a hint to possible isoform specific functions, 
but there has been no published identification of corresponding isoform 
specific localisation in different cell types. 
3.1.2 Potential fatty acid receptor dimerisation 
&& ? ŝƐŬŶŽǁŶƚŽďĞĞǆƉƌĞƐƐĞĚ ŝŶƚŚĞɴ-cell (Briscoe et al., 2003), whilst the 
expression of GPR120 within this cell type is still up for debate (Morgan and 
Dhayal, 2009). Both receptors are also expressed in the colonic L cells 
(Katsuma et al., 2005). Interestingly, a link between the two systems has been 
show by an increase in incretin levels enhancing GSIS and increasing 
ƉĂŶĐƌĞĂƚŝĐ ɴ-cell proliferation (Tanaka et al., 2008b). As discussed in the 
introduction, GPR120 and FFA1 also have a similar range of endogenous 
ligands, in terms of size (medium to long chain) and both saturated and 
unsaturated fatty acids (Briscoe et al., 2003; Hirasawa et al., 2005). This 
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redundancy is intriguing, and perhaps it indicates the potential of these 
receptors to undergo homo- or heterodimerisation (section 3.2.6). 
3.1.3 Novel techniques used in this study of fatty acid receptor signalling 
3.1.3.1 DMR 
This study utilised two novel methods: dynamic mass redistribution (DMR) 
and bimolecular complementation (BiFC). DMR was measured on the Corning 
Epic Biosensor and gave a measurement of the whole cell response in a label 
free system, by measuring the movement of cell constituents in the cell 
following receptor activation (the experimental technique can be found in 
section 2.2.3.2, whilst more detail on the theory can be found in section 
2.2.3.3). One advantage of DMR was that it used label free technology, 
therefore cell lines do not have to be genetically modified either with a 
fluorescent moiety (e.g. GFP) or a genetic sequence that allows exogenous 
fluorescent labelling (e.g. SNAP-tag technology) (Schroder et al., 2010). 
Another advantage to DMR was the two types of high sensitivity; for example 
to determine endogenous receptor coupling at low receptor expression levels 
in native cells. It can also reveal subtleties in signalling pathways, for example 
how it uncovered novel pharmacology of FFA1. FFA1 was classified as coupling 
to Gq/11, but DMR found that FFA1 signals were only partially blocked using a 
Gq inhibitor (YM254890). The use of PTx demonstrated that FFA1 could also 
couple through Gi. In fact, only the use of both YM254890 and PTx inhibitors 
completely blocked FFA1 signalling. Also, when treated with either inhibitor, 
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the trace left was characteristic for the uninhibited G protein subtype in 
question (Schroder et al., 2010). 
3.1.3.2 BiFC 
BiFC is a technique based around the formation of a functional, fluorescent 
protein from non-fluorescent complementary fragment tags, allowing 
visualisation of the labelled protein-protein complex (covered in more detail 
in section 2.2.4). Here, BiFC was used in two ways. First the ƌĞĐĞƉƚŽƌ Pɴ-
arrestin association assay (described in Kilpatrick et al., 2010) was adapted to 
study GPR120 arrestin recruitment. Secondly, BiFC was used to constrain FFA 
receptor homo- and hetero-dimers. The purpose of using BiFC to study the 
dimerisation of the fatty acid receptors is that it constrains the receptors in a 
known stoichiometry (Kilpatrick et al., 2012). Another advantage to the 
system is that it allows two simultaneous measurements to be made in 
receptor internalisation assays. The red channel allowed measurements of the 
overall SNAP-tagged GPR120 receptor-vYNL population, whilst the green 
channel measured recomplemented vYFP, and so the behaviour of the specific 
homo- or hetero-dimer held together by complementation. 
3.1.4 Aims of this study 
The primary aim of this study was the characterisation of the GPR120 
isoforms to investigate the possibility of isoform specific signalling, because 
previously only their phosphorylation status had been determined (Burns and 
Moniri, 2010). This included using the novel DMR assay to compare results 
with the more traditional calcium signalling assay. Another non-standard 
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assay, BiFC was also employed to identify any novel interactions between the 
'WZ ? ? ? ŝƐŽĨŽƌŵƐ ĂŶĚ ɴ-arrestin2, and if there were any isoform specific 
interactions, in conjunction with the receptor internalisation assay. 
Downstream intracellular trafficking of these receptors was then determined, 
and was important to study because the internalisation of these receptors had 
also not been studied before. Furthermore, BiFC was also used to identify 
GPR120 homo- and hetero-dimers and to investigate whether this altered 
their pharmacology.  
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3.2 Results 
3.2.1 Cell surface expression & fluorescent labelling of receptors 
Firstly, FFA1 or GPR120 receptor cDNAs were inserted into the expression 
vector, typically pcDNA 4T/O, between endonuclease enzyme restriction sites 
(section 2.2.1.4). The receptor was placed downstream of the SNAP-tag 
sequence which allowed for fluorescent labelling, and upstream of the GFP 
tag where applicable. These vectors were then transfected into HEK293TR 
cells (section 2.2.2.2), and receptor expression was under the control of a 
tetracycline inducible system (section 2.2.2.1.2). 
These receptor cell lines were initially imaged on the IX Micro epifluorescence 
platereader to determine that the addition of the SNAP-tag did not affect 
receptor expression and that the receptor could be successfully labelled. 
Comparison of images from receptors that had been treated with vehicle 
 ?ĐŽŶƚƌŽů ĐŽŶĚŝƚŝŽŶƐ ) ĂŶĚ  ? ? ? ʅD ŽůĞŝĐ ĂĐŝĚ ƐŚŽǁĞĚ ƚŚĂƚ ƚŚĞ ŵĞŵďƌĂŶĞ
impermeant SNAP-surface fluorophore only labelled plasma membrane 
expressed receptors, and that only once treated with oleic acid was the 
labelled receptor internalised, for example SNAP-GPR120S labelled with 
SNAP-surface AF-488 (Figure 3.1 B). Additionally, vehicle treated SNAP-FFA1-
GFP was observed to be both present at the plasma membrane and in 
intracellular vesicles (Figure 3.2 A). However, the SNAP-labelled SNAP-FFA1-
GFP population was predominantly plasma membrane localised (Figure 3.2 B). 
As the cell lines utilise a tetracycline inducible system to initiate receptor 
expression, it follows that in the absence of tetracycline pre-treatment, there 
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was no receptor expression. The no tetracycline controls thus show that the 
SNAP-surface label was specific for the receptor, as there was no labelling in 
the absence of receptor. This label specificity was also observed through 
comparison of images with GFP fluorescence, because the SNAP-surface 
labelled receptor images showed colocalisation with the images of receptor 
GFP fluorescence, for example when SNAP-GPR120S-GFP was labelled with 
SNAP-surface BG-546 (Figure 3.1 A).  
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Figure 3.1 SNAP-surface BG-546 and SNAP-surface AF488 specifically label SNAP-
GPR120S-GFP (A) and SNAP-GPR120S (B) respectively. 
HEK293TR cells were stably transfected with SNAP-GPR120S-GFP (A) or SNAP-
GPR120S (B). Receptor expression was induced by 18 hour treatment with 
tetracycline. Cells were then pre-ƚƌĞĂƚĞĚ ǁŝƚŚ  ? ? ? ʅDŽƌ  ? ? ? ʅD ^EW-surface BG-
546 (A) or SNAP-surface AF- ? ? ?  ? ) ? ĨŽůůŽǁĞĚďǇ ƚƌĞĂƚŵĞŶƚǁŝƚŚǀĞŚŝĐůĞŽƌ  ? ? ?ʅD
oleic acid (30 min at 37oC) and were imaged live on the IX Micro, using 546 nm 
(SNAP-surface BG-546) or 488 nm (GFP/SNAP-surface AF-488) excitation. Scale bar = 
 ? ?ʅŵ ? 
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Figure 3.2 SNAP-surface BG-546 and SNAP-surface AF-488 specifically label SNAP-
FFA1-GFP (A) and SNAP-FFA1 (B) respectively. 
HEK293TR cells were stably transfected with SNAP-FFA1-GFP (A) or SNAP-FFA1 (B). 
Receptor expression was induced by 18 hour treatment with tetracycline. Cells were 
then pre-ƚƌĞĂƚĞĚǁŝƚŚ  ? ? ? ʅDŽƌ  ? ? ?ʅD^EW-surface BG-546 (A) or SNAP-surface 
AF- ? ? ? ? ) ?ĨŽůůŽǁĞĚďǇƚƌĞĂƚŵĞŶƚǁŝƚŚǀĞŚŝĐůĞŽƌ ? ? ?ʅDŽůĞŝĐĂĐŝĚ ? ? ?ŵŝŶĂƚ ? ?oC) 
and were imaged live on the IX Micro, using 546 nm (SNAP-surface BG-546) or 488 
nm (GFP/SNAP-surface AF-488 )ĞǆĐŝƚĂƚŝŽŶ ?^ĐĂůĞďĂƌA? ? ?ʅŵ ? 
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3.2.2 G protein mediated calcium mobilisation 
Firstly, expression levels of the two SNAP tagged GPR120 isoforms, expressed 
in separate stably transfected HEK293TR cell lines, were measured using 
quantitative imaging. Receptors were labelled with SNAP-surface AF-488 and 
treated with vehicle, then fixed, labelled with H33342 (a nuclear DNA stain) 
and imaged (section 2.2.3.4). Both SNAP-GPR120 isoforms showed similar 
plasma membrane localisation under unstimulated conditions (see Figure 3.15 
for images). To these control images, a multiwavelength cell scoring algorithm 
(MetaXpress2) was applied. This defined regions of the image covered by 
individual cells, on the basis of both the location of H33342 stained nuclei and 
the boundary of SNAP-surface AF-488 labelled receptor staining. The mean 
pixel intensity within these regions (covering both plasma membrane and 
cytoplasm) was then averaged for all cells in each image. This measure of 
cellular fluorescence intensity was pooled between experiments (mean ± 
S.E.M.). Using this measure, expression of SNAP-GPR120L was quantified to 
be approximately 58 A?ŽĨ'WZ ? ? ?^ ?^ƚƵĚĞŶƚ ?ƐƚƚĞƐƚ ?* P < 0.05; Figure 3.3). 
Next, the effect of BSA concentration upon FFA1 and GPR120 stimulated 
calcium mobilisation (measured by Fluo4 fluorescence) was optimised for 
future experiments (section 2.2.3.2). There are multiple FFA binding sites 
found on albumin (Krenzel et al., 2013), which could be responsible for 
sequestering FFA (free fatty acids), and effectively causing a lower free 
concentration to be available to bind the receptor. A comparison of 
representative calcium time course traces show that ligands gave greater 
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absolute responses at SNAP-FFA1 compared to SNAP-GPR120S (Figure 3.4). 
The GW9508 peak response at SNAP-FFA1 was over twice the magnitude of 
that of SNAP-GPR120S, 23,621 ± 938 RFU for SNAP-FFA1, whilst at SNAP-
GPR120S it was 11,090 ± 624 RFU (n= 3  W 5). These peak responses at 23 s 
were found to be significantly different, P AM  ? ? ? ? ? ƵƐŝŶŐ Ă ^ƚƵĚĞŶƚ ?Ɛ ƚ ƚĞƐƚ
(Figure 3.4). For comparison between receptor cell lines, peak responses were 
ŶŽƌŵĂůŝƐĞĚ ƚŽ Ă ƌĞĨĞƌĞŶĐĞ ĂŐŽŶŝƐƚ ?  ? ? ? ʅD ŽůĞŝĐ ĂĐŝĚ ?ĂŶĚ ĐŽŶĐĞŶƚƌĂƚŝŽŶ
response curves constructed to give potency values where a clear maximum 
response could be defined. This showed that ligands were also more potent at 
SNAP-FFA1 (Figure 3.6; Table 3.2) than at SNAP-GPR120S (Figure 3.5; Table 
3.1). The difference in GW9508 pEC50 values for SNAP-GPR120S and SNAP-
FFA1 were significantly different, P AM ? ? ? ? ?ƵƐŝŶŐĂ^ƚƵĚĞŶƚ ?ƐƚƚĞƐƚ ?dĂďůĞ ? ? ? ) ? 
Altering BSA concentration from 0.02 % BSA (Figure 3.5 A; n = 5) to 0.1 % BSA 
(Figure 3.5 B; n = 3) did not affect the pEC50 of GW9508 at SNAP-GPR120S, but 
ŝƚĚŝĚĚĞĐƌĞĂƐĞ ƚŚĞ ŵĂǆŝŵƵŵ ƌĞƐƉŽŶƐĞ ƚŽ  ? ? ?ʅD't ? ? ?   ?dĂďůĞ  ? ? ? ); this 
ǁĂƐ ŶŽƚ ƐƚĂƚŝƐƚŝĐĂůůǇ ƐŝŐŶŝĨŝĐĂŶƚ ǁŚĞŶ ƚĞƐƚĞĚ ƵƐŝŶŐ Ă ^ƚƵĚĞŶƚ ?Ɛ ƚ ƚĞƐƚ ? dŚĞ
potencies of oleic acid at SNAP-GPR120S and GW9508 at SNAP-FFA1 were 
significantly right-shifted by the increased BSA concentration (Table 3.1, Table 
3.2); although clear pEC50s could not be obtained, this was also evident for 
FFA1 responses to oleic acid and myristic acid. 
From these results, 0.02 % BSA was chosen as the optimal assay 
concentration.  
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Figure 3.3 Relative expression levels of SNAP-GPR120S and SNAP-GPR120L. 
Using images acquired on the IX Ultra of HEK293TRs stably transfected with 
SNAP-GPR120S and SNAP-'WZ ? ? ?> ?ƐĞĞ&ŝŐƵƌĞ ? ? ? ? )ĂŶĚůĂďĞůůĞĚǁŝƚŚ ? ? ?ʅD
SNAP-surface AF-488, relative expression levels of each isoform could be 
ĚĞƚĞƌŵŝŶĞĚ ?^ƚĂƚŝƐƚŝĐĂůƐŝŐŶŝĨŝĐĂŶĐĞǁĂƐĚĞƚĞƌŵŝŶĞĚƵƐŝŶŐĂ^ƚƵĚĞŶƚ ?ƐƚƚĞƐƚ ? ?
P < 0.05.  
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Figure 3.4 Time courses of calcium mobilisation following SNAP-FFA1 and 
SNAP-GPR120S activation by agonists. 
The time courses of intracellular calcium mobilisation responses were 
measured by Fluo4 fluorescence in HEK293TR cells expressing SNAP-FFA1 (A) 
or SNAP-'WZ ? ? ?^  ? ) ƚŽ  ? ? ? ʅD ŽůĞŝĐ ĂĐŝĚ ĂŶĚ ŵǇƌŝƐƚŝĐ ĂĐŝĚ ? ĂŶĚ  ? ? ? ʅD
GW9508 at 0.02 % BSA. Dotted line represents time of agonist addition. Time 
courses shown are a representative trace of 5 individual experiments. 
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Figure 3.5 The effect of BSA concentration upon SNAP-GPR120S mediated 
calcium mobilisation in response to agonists. 
The effect of 0.02 % (A) versus 0.1 % BSA (B) concentration upon oleic acid 
(with and without tetracycline (tet) induction of receptor expression), myristic 
acid and GW9508 in eliciting intracellular calcium mobilisation was measured 
in HEK293TR cells expressing SNAP-GPR120S. Data were normalised (%) to the 
 ? ? ? ʅD ŽůĞŝĐ ĂĐŝĚ ƌĞƐƉŽŶƐĞ ĂŶĚ ƉŽŽůĞĚ ĨƌŽŵ  ?- 5 individual experiments, 
mean ± S.E.M.  
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0.02% BSA 
 
0.1% BSA 
 
Agonist pEC50 Rmax (%) pEC50 Rmax (%) 
Oleic Acid 4.3 ± 0.1 100 3.9 ± 0.2 * 100 
Myristic Acid N.D. 100 ± 8 4.2 ± 0.1 97 ± 15 
GW9508 5.3 ± 0.2 162 ± 25 5.2 ± 0.2 91 ± 19 
 
Table 3.1 The effect of BSA concentration upon potency and maximal 
responses of agonists at SNAP-GPR120S as measured in the calcium 
mobilisation assay. 
pEC50 and maximal responses of SNAP-GPR120S in response to OA, Myr and 
GW9508 at 0.02 % and 0.1 % BSA, were measured in HEK293TR cells 
expressing SNAP-GPR120S (see Figure 3.5). Myristic acid Rmax values were 
determined from the maximal ƌĞƐƉŽŶƐĞ Ăƚ  ? ? ? ʅD ?Oleic acid pEC50 values 
were found to be significantly different * P AM ? ? ? ?ƵƐŝŶŐ^ƚƵĚĞŶƚ ?ƐƚƚĞƐƚ ?ǁŚŝůƐƚ
GW9508 maximal responses were not. Data were normalised (%) to the 300 
ʅD ŽůĞŝĐ ĂĐŝĚ ƌĞƐƉŽŶƐĞ ĂŶĚ ƉŽŽůĞĚ ĨƌŽŵ ƚŚĞ ŵŝŶŝŵƵŵ ŽĨ  ? ŝŶĚŝǀŝĚƵĂů
experiments, mean ± S.E.M. N.D. not determined.  
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Figure 3.6 The effect of BSA concentration upon SNAP-FFA1 mediated 
calcium mobilisation.  
The effect of 0.02 % (A) versus 0.1 % BSA (B) concentration upon oleic acid, 
myristic acid and GW9508 eliciting intracellular calcium mobilisation was 
measured in HEK293TR cells expressing SNAP-FFA1. The data were normalised 
 ?A? )ƚŽƚŚĞ ? ? ?ʅDŽůĞŝĐĂĐŝĚƌĞƐƉŽŶƐĞĂŶĚǁĞƌĞ pooled from a minimum of 5 
individual experiments, mean ± S.E.M.  
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0.02% BSA 
 
0.1% BSA 
 
Agonist pEC50 Rmax (%) pEC50 Rmax (%) 
Oleic Acid N.D. 100 N.D. 100 
Myristic Acid N.D. 100 ± 7 N.D. 75 ± 3 
GW9508 7.1 ± 0.1 110 ± 8 6.4 ± 0.1** 101 ± 6 
Table 3.2 The effect of BSA concentration upon potency and maximal 
responses of agonists at SNAP-FFA1 as measured in the calcium mobilisation 
assay. 
pEC50 and maximal responses of SNAP-FFA1 in response to oleic acid, myristic 
and GW9508 were measured in HEK293TR cells expressing SNAP-FFA1. Oleic 
acid and myristic acid Rmax values were determined from the maximal 
ƌĞƐƉŽŶƐĞ Ăƚ  ? ? ? ʅD ?GW9508 pEC50 values were found to be significantly 
different ** P < 0.01 using Ă^ƚƵĚĞŶƚ ?ƐƵŶƉĂŝƌĞĚƚƚĞƐƚ. Data were normalised 
 ?A? )ƚŽƚŚĞ ? ? ?ʅDŽůĞŝĐĂĐŝĚƌĞƐƉŽŶƐĞĂŶĚǁĞƌĞƉŽŽůĞĚĨƌŽŵĂ minimum of 5 
individual experiments, mean ± S.E.M. N.D. not determined.  
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The SNAP-GPR120 cell lines were then tested in comparison to equivalent 
FLAG-tagged GPR120 (tagged at the amino terminus with the 8 residue 
epitope of DYKDDDDK) cell lines, to determine that the addition of the signal 
sequence SNAP-tag (209 residues) domain had not affected receptor function 
in eliciting calcium mobilisation responses to agonists. 
Calcium mobilisation responses at FLAG-GPR120S (Figure 3.7 A; n = 4) and 
SNAP-GPR120S (Figure 3.7 C; n = 9) were measured in response to oleic acid, 
myristic acid and GW9508 (section 2.2.3.2). These responses were receptor 
specific because there were no responses in cells that had not undergone 
tetracycline induction of receptor expression. Agonist pEC50 values and 
maximal responses were similar in each cell line, indicating that the addition 
of the amino terminal SNAP-tag did not have a functional impact in this assay 
(Figure 3.7; Table 3.3). Interestingly, neither FLAG-GPR120L (Figure 3.7 B; n = 
4) or SNAP-GPR120L (Figure 3.7 D; n = 3) gave calcium mobilisation responses 
following tetracycline induction of receptor expression. 
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Figure 3.7 The effect of the SNAP-tag addition upon GPR120 mediated 
calcium mobilisation in response to agonist. 
The effect of the SNAP-tag fusion upon oleic acid, myristic acid and GW9508 
eliciting intracellular calcium mobilisation were measured in HEK293TR cells 
expressing the SNAP-GPR120S (C) or SNAP-GPR120L (D), compared to FLAG-
GPR120S (A) or FLAG-GPR120L receptors (B). The dotted line shown in B and D 
denotes the oleic acid response at GPR120S for comparison. Data points for 
each experiment are the mean of triplicate readings; the data shown are 
pooled from the minimum of 4 individual experiments, mean ± S.E.M. RFU = 
relative fluorescent units.  
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FLAG-GPR120S   SNAP-GPR120S   
Agonist pEC50 Rmax (RFU) pEC50 Rmax (RFU) 
Oleic Acid 4.7 ± 0.3 13,768 ± 3,675 4.6 ± 0.2 10,493 ± 1,541 
Myristic Acid 4.5 ± 0.2 12,338 ± 3,102 4.2 ± 0.3 8,901 ± 1,690 
GW9508 5.5 ± 0.3 13,685 ± 3,387 5.5 ± 0.2 13,163 ± 1,949 
 
Table 3.3 Potency and maximal responses of agonists at FLAG-GPR120S and 
SNAP-GPR120S as measured in the calcium mobilisation assay. 
Potency and maximal responses of FLAG-GPR120S and SNAP-GPR120S in 
response to oleic acid, myristic acid and GW9508. Data were pooled from a 
minimum of 4 individual experiments, mean ± S.E.M. RFU = relative 
fluorescent units, peak change to agonist.  
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3.2.2.1 Pharmacological inhibition of calcium signalling 
Next, inhibition of the calcium responses through SNAP-GPR120S activation 
was attempted using two compounds, PTx and 2-aminoethoxydiphenyl borate 
(2-APB). PTx catalyses the ADP ribosylation from nicotinamide adenine 
ĚŝŶƵĐůĞŽƚŝĚĞ ƚŽ ƚŚĞ ɲ ƐƵďƵŶŝƚ ŽĨ ƚŚĞ 'ŝ ƉƌŽƚĞŝŶ ? ĐĂƵƐŝŶŐ ƚŚĞ ďůŽĐŬĂĚĞ ŽĨ 'ŝ-
dependent calcium responses (Katada and Ui, 1982). Whilst 2-APB, originally 
thought to block calcium signalling through blockade of IP3 receptors 
(Maruyama et al., 1997), has later been found to also prevent store operated 
calcium entry (DeHaven et al., 2008). 
Pooled time courses shown in Figure 3.8 represent calcium responses 
ĨŽůůŽǁŝŶŐ ƚŚĞ ĂĚĚŝƚŝŽŶ ŽĨ  ? ? ? ʅD ŽůĞŝĐ ĂĐŝĚ Žƌ  ? ? ? ʅD 't ? ? ? ?  ?Ăƚ  ? ?
ƐĞĐŽŶĚƐ ?ĚŽƚƚĞĚůŝŶĞ )ǁŝƚŚĞŝƚŚĞƌ ? ? ?ŶDWdǆ ?&ŝŐƵƌĞ ? ? ? ? )Žƌ ? ?ʅD ?-APB 
pre-treatment (Figure 3.8 B, D). Responses in the presence of 2-APB were 
significantly shortened compared to controls, for example at 60 seconds the 
responses were statistically different P < 0.01 for both oleic acid and GW9508, 
as tested using 2 way ANOVA with Bonferroni post tests. 
100 nM PTx (Figure 3.8 E; Table 3.4; n = 4) had no significant effect upon 
concentration response curves, but  ? ?ʅD2-APB (Figure 3.8 F; n = 4) inhibited 
ƉĞĂŬ ƌĞƐƉŽŶƐĞƐ ƚŽ ďŽƚŚ  ? ? ? ʅD 't ? ? ? ? ĂŶĚ  ? ? ? ʅD ŽůĞŝĐ ĂĐŝĚ  ?P < 0.001 
using 2 way ANOVA + Bonferroni post-tests). However although 2-APB had a 
significant effect upon SNAP-GPR120S mediated calcium mobilisation, it did 
not completely abolish it. 
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The FFA1 selective antagonist GW1100 was also investigated to determine its 
inhibition of calcium responses mediated by SNAP-FFA1. Increasing 
concentrations of GW1100 right shifted GW9508 concentration response 
curves and eventually abolished calcium signalling at SNAP-FFA1 (Figure 3.9 B; 
n = 4). Following Schild analysis, a slope of 2.7 ± 0.1 was obtained. A pA2 of 6.0 
± 0.8 was also obtained, which corresponds to both the pKB of 6.6 calculated 
using the Gaddum equation, and the GW1100 equilibrium dissociation 
constant previously ĞƐƚŝŵĂƚĞĚĂƚ ?ʅD (Briscoe et al., 2006). 
3.2.2.2 FFA1 non-signalling mutant, R258A 
To inhibit the calcium response at SNAP-FFA1, a non-signalling receptor 
mutant was created, SNAP-FFA1 R258A (Smith et al., 2009; Tikhonova et al., 
2007). Compared to WT, the SNAP-FFA1 R258A mutant had a decreased 
ability to elicit calcium responses to all agonists. (for all, P < 0.001 by 2 way 
ANOVA with Bonferroni post tests; Figure 3.9 A; Table 3.5; n = 4). 
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Figure 3.8 The effects of PTx and 2-APB upon potency and maximal 
responses of agonists at SNAP-GPR120S as measured in the calcium 
mobilisation assay. 
The intracellular calcium mobilisation responses of SNAP-GPR120S in 
response to oleic acid and GW9508 following 18 hr 100 nM PTx (A, C, E) or 20 
ŵŝŶ ? ?ʅD ? WAPB (B, D, F) pre-treatment, were measured in HEK293TR cells 
expressing SNAP-GPR120S. A WD show the time course of response normalised 
to maximal response, whilst E and F show data normalised to  ? ? ? ʅDŽůĞic 
acid response and pooled from 4 individual experiments, mean ± S.E.M. 
Statistical significance was measured using 2 way ANOVA plus Bonferroni post 
tests; *** P < 0.001; * p<0.05.  
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  PTx   2-APB   
Agonist pEC50 Rmax (%) pEC50 Rmax (%) 
Oleic Acid (-) 4.7 ± 0.2 100 4.5 ± 0.1 100 
Oleic Acid (+) 4.9 ± 0.2 115 ± 3 4.4 ± 0.2 64 ± 7 *** 
GW9508 (-) 5.6 ± 0.1 122 ± 14 5.3 ± 0.2 162 ± 25 
GW9508 (+) 5.9 ± 0.1 128 ± 19 5.3 ± 0.2 71 ± 10 *** 
Table 3.4 The effects of PTx and 2-APB upon potency and maximal responses 
of agonists at SNAP-GPR120S as measured in the calcium mobilisation assay. 
pEC50 and maximal responses of SNAP-GPR120S in response to oleic acid, 
myristic and GW9508 ĨŽůůŽǁŝŶŐ  ? ? ?ŶDWdǆŽƌ  ? ?ʅD  ? WAPB pre-treatment 
were measured in HEK293TR cells expressing SNAP-GPR120S ( “+ ? denotes in 
the presence of inhibitor, whilst  “- “ denotes the controls in the absence of 
ŝŶŚŝďŝƚŽƌ ) ? ĂƚĂ ǁĞƌĞ ŶŽƌŵĂůŝƐĞĚ ƚŽ ƚŚĞ  ? ? ? ʅD ŽůĞŝĐ ĂĐŝĚ ƌĞƐƉŽŶƐĞ ĂŶĚ
pooled from 4 individual experiments, mean ± S.E.M. Statistical significance 
was measured using 2 way ANOVA plus Bonferroni post tests *** P < 0.001; 
** P < 0.01, * P <0.05.  
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Figure 3.9 The effect of R258A mutation and GW1100 upon potency and 
maximal responses of agonists at SNAP-FFA1 as measured in the calcium 
mobilisation assay. 
The intracellular calcium mobilisation responses of SNAP-FFA1 in response to 
oleic acid, myristic and GW9508 following R258A mutation were measured in 
HEK293TR cells expressing SNAP-FFA1 (A; see Figure 3.6 for full WT curves). 
Also measured were calcium mobilisation responses to GW9508 following 
pre-treatment with increasing concentrations of GW1100 (B), with data 
ĨƵƌƚŚĞƌĂŶĂůǇƐĞĚŝŶĂ^ĐŚŝůĚƉůŽƚ  ? ? ? ?ʅDĚĂƚĂƉŽŝŶƚǁĂƐĞǆĐůƵĚĞĚ ) ?ĂƚĂŝƐ
pooled frŽŵ  ? ŝŶĚŝǀŝĚƵĂů ĞǆƉĞƌŝŵĞŶƚƐ ? ŶŽƌŵĂůŝƐĞĚ  ?A? ) ƚŽ ƚŚĞ ? ? ? ʅD ŽůĞŝĐ
ĂĐŝĚƌĞƐƉŽŶƐĞ ? )ŽƌƚŚĞ ? ?ʅD't ? ? ? ? ? ) ?ŵĞĂŶA?^ ? ?D ?  
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  SNAP-FFA1   R258A   
Agonist pEC50 Rmax (%) pEC50 Rmax (%) 
Oleic Acid 4.9 ± 0.1 100 N.D. 35 ± 6*** 
Myristic Acid 4.8 ± 0.1 94 ± 2 N.D. 34 ± 3*** 
GW9508 7.2 ± 0.1 96 ± 9 N.D. 2 ± 1*** 
Table 3.5 The effect of R258A mutation upon potency and maximal response 
values of agonists at SNAP-FFA1 as measured in the calcium mobilisation 
assay. 
pEC50 values and responses of SNAP-&& ?ƚŽ ? ? ?ʅDŽůĞŝĐĂĐŝĚ, myristic acid 
and  ? ? ? ʅDGW9508 following both R258A mutation or following pre-
treatment with increasing concentrations of GW1100 were measured in 
HEK293TR cells expressing SNAP-FFA1. R258A Rmax values were determined 
ĨƌŽŵƚŚĞŵĂǆŝŵĂůƌĞƐƉŽŶƐĞĂƚ ? ? ?ʅD ?ŽůĞŝĐ ?ŵǇƌŝƐƚŝĐ )Žƌ ? ? ?ʅD ?'t ? ? ? ? ) ?
The concentration responses of SNAP-FFA1 and SNAP-FFA1 R258A to agonists 
were found to be significantly different from WT *** P < 0.001 using 2 way 
ANOVA and Bonferroni ƉŽƐƚƚĞƐƚƐ ?ĂƚĂǁĞƌĞŶŽƌŵĂůŝƐĞĚ ?A? )ƚŽ ? ? ?ʅDŽůĞŝĐ
ĂĐŝĚƌĞƐƉŽŶƐĞ ? )ŽƌƚŽ ? ?ʅD't ? ? ? ?ƌĞƐƉŽŶƐĞ ? ) ?ƉŽŽůĞĚĨƌŽŵ ?ŝŶĚŝǀŝĚƵĂů
experiments, mean ± S.E.M.  
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3.2.3 Integrated whole cell responses measured by DMR 
Following on from the calcium mobilisation studies, the HEK293TR SNAP-
GPR120 cell lines were then tested on a Corning Epic Biosensor. This is a label 
free system that, following automated ligand additions, measured the whole 
cell response by monitoring the DMR of the cellular contents (Schroder et al., 
2010). After addition of ligand, large positive monophasic responses were 
observed at SNAP-GPR120S (Figure 3.10 A), whilst much smaller responses 
were observed at SNAP-GPR120L (Figure 3.10 B), with ATP used as a control 
compound across all cell lines. 
These DMR responses were also analysed to generate concentration response 
curves, giving pEC50 values (Table 3.6). The results from this assay gave similar 
results to the calcium assay, of SNAP-GPR120S mediating agonist responses 
(Figure 3.11 A; n = 12), whilst SNAP-GPR120L did not (Figure 3.11 B; n = 10). 
Stimulation of cells expressing SNAP-GPR120L did give small responses, but 
these were no larger than those observed for the parent cell line, the 
HEK293TRs (Figure 3.11 C; n = 2). 
Once again, the inhibitors PTx (Figure 3.12 A, B) and 2-APB (Figure 3.12 C, D) 
were utilised to see what effect they had upon the holistic response, as 
measured using DMR. Both inhibitors had a significant effect upon GW9508 
potency in SNAP-GPR120S cells (Table 3.6).  
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Figure 3.10 DMR time courses of SNAP-GPR120S and SNAP-GPR120L in 
response to agonist. 
DMR measurements in HEK293TR cells expressing SNAP-GPR120S (A) or 
SNAP-'WZ ? ? ?>  ? ) ? ŝŶ ƌĞƐƉŽŶƐĞ ƚŽ  ? ? ? ʅD ŽůĞŝĐ ĂĐŝĚ  ?K ) ĂŶĚ ŵǇƌŝƐƚŝĐ ĂĐŝĚ
 ?DǇƌ ) ? ? ? ?ʅDdWĂŶĚ't ? ? ? ? ?ĂŶĚǀĞŚŝĐůĞ ?ĂƚĂƐŚŽǁŶǁĞƌĞƉŽŽůĞĚĨƌŽŵ
the minimum of 4 individual experiments, mean + S.E.M.  
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Figure 3.11 DMR concentration-dependent responses of SNAP-GPR120S and 
SNAP-GPR120L cells in response to agonists. 
Dynamic mass redistribution concentration response curves to ATP, oleic acid, 
myristic and GW9508 in HEK293TR cells expressing SNAP-GPR120S (A), SNAP-
GPR120L receptors (B) or non-transfected cells (C). Data shown were 
ŶŽƌŵĂůŝƐĞĚ ?A? )ƚŽ ? ? ?ʅDdWĂŶĚƉŽŽůĞĚĨƌŽŵƚŚĞŵŝŶŝ ƵŵŽĨ ?ŝŶĚŝǀŝĚƵĂů
experiments, mean ± S.E.M.  
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Figure 3.12 The effects of PTx and 2-APB upon potency and maximal 
responses of agonists at SNAP-GPR120S as measured in the DMR assay. 
The DMR responses mediated by SNAP-GPR120S receptors in response to 
ATP, oleic acid, myristic acid and GW9508 following 100 nM PTX (A, B) or 50 
ʅD ? WAPB (C, D) pre-treatment were measured in HEK293TR cells expressing 
SNAP-GPR120S (A, C) or SNAP-GPR120L (B, D). Data were normalised (%) to 
 ? ? ?ʅDdWĂŶĚƉŽŽůĞĚĨƌŽŵ ? W 5 individual experiments, mean ± S.E.M. 
176 
 
i 
SNAP-GPR120S 
SNAP-GPR120S SNAP-GPR120S 
Agonist 100 nM PTx  ? ?ʅD ?-APB 
  pEC50 Rmax pEC50 Rmax (%) pEC50 Rmax (%) 
ATP 5.0 ± 0.1 100 5.2 ± 0.1 92 ± 2 5.3 ± 0.2 89 ± 5 
Oleic Acid 4.6 ± 0.2 58 ± 6 4.6 ± 0.2 49 ± 3 4.5 ± 0.2 50 ± 13 
Myristic Acid 4.9 ± 0.2 65 ± 5 5.0 ± 0.3 53 ± 9 5.0 ± 0.2 57 ± 9 
GW9508 5.7 ± 0.1 104 ± 6 5.2 ± 0.1* 107 ± 5 5.2 ± 0.2** 107 ± 11 
       ii 
  
SNAP-GPR120L SNAP-GPR120L 
Agonist SNAP-GPR120L 100 nM PTx  ? ?ʅD ?-APB 
  pEC50 Rmax pEC50 Rmax (%) pEC50 Rmax (%) 
ATP 5.2 ± 0.1 100 5.4 ± 0.1 94 ± 8 5.2 ± 0.1 81 ± 10 
Oleic Acid N.D. 21 ± 5 4.5 ± 0.4 10 ± 2 3.9 ± 0.4 20 ± 4 
Myristic Acid N.D. 16 ± 4 3.8 ± 0.8 7 ± 2 4.2 ± 0.6 9 ± 5 
GW9508 N.D. 27 ± 12 3.7 ± 1.3 30 ± 14 4.2 ± 0.5 37 ± 17 
 
Table 3.6 DMR potency and maximal responses of SNAP-GPR120S (i) and SNAP-GPR120L (ii) cells in response to agonists in the presence or 
absence of inhibitors PTx or 2-APB. 
pEC50 and maximal responses in cells expressing SNAP-GPR120S and SNAP-GPR120L in response to oleic acid, myristic acid and GW9508 with or 
without 100 nM PTx Žƌ ? ?ʅD ? WAPB pre-treatment. SNAP-GPR120L Rmax ǀĂůƵĞƐǁĞƌĞĚĞƚĞƌŵŝŶĞĚĨƌŽŵƚŚĞŵĂǆŝŵĂůƌĞƐƉŽŶƐĞĂƚ ? ? ?ʅD ?ŽůĞŝĐ ?
ŵǇƌŝƐƚŝĐ )Žƌ  ? ? ?ʅD ?'t ? ? ? ? ) ?Data ǁĞƌĞŶŽƌŵĂůŝƐĞĚ  ?A? )ƚŽ  ? ? ?ʅDdWĂŶĚƉŽŽůĞĚ from a minimum of 4 individual experiments, mean ± 
S.E.M; N.D. not determined. 
* P < 0.05, ** P < 0.01  compared with control GW9508 pEC50 values in SNAP-'WZ ? ? ?^ĐĞůůƐ ?^ƚƵĚĞŶƚ ?Ɛt test). 
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3.2.4 Arrestin interactions measured using BiFC 
After measuring the holistic, whole cell responses and calcium signalling as a 
measure of G protein signalling, GPR120 receptor isoforms were then 
ŝŶǀĞƐƚŝŐĂƚĞĚĨŽƌƚŚĞŝƌĂďŝůŝƚǇƚŽŝŶƚĞƌĂĐƚǁŝƚŚɴ-arrestin2 using BiFC, and time 
course and concentration response curves were measured (Section 2.2.4). 
This assay required a different modification of the receptors; a FLAG-tagged 
version, with a carboxyl terminal  WvYC tag to initiate the complementation. 
Representative images and the associated analysis are illustrated in Figure 
3.13 (Kilpatrick et al., 2010). 
The time course assay gave half times of interaction of 9 ± 1 min for FLAG-
GPR120S-ǀzĐǁŝƚŚɴ-arrestin2-vYNL (Figure 3.14 A; n = 6) and 14 ± 1 min for 
FLAG-GPR120L-ǀzĐ ǁŝƚŚ ɴ-arrestin2-ǀzE> ŝŶ ƌĞƐƉŽŶƐĞ ƚŽ  ? ? ? ʅD ŽůĞŝĐ ĂĐŝĚ
(Figure 3.14 A; n = 5). Half timeƐ ŽĨ ŝŶƚĞƌĂĐƚŝŽŶ ŝŶ ƌĞƐƉŽŶƐĞ ƚŽ  ? ? ? ʅD
GW9508 for FLAG-GPR120S-ǀzĐǁŝƚŚɴ-arrestin2-vYNL were 7 ± 1 min (Figure 
3.14 B; n = 6) and 8 ± 1 min for FLAG-GPR120L-ǀzĐ ǁŝƚŚ ɴ-arrestin2-vYNL 
(Figure 3.14 B; n = 5). In terms of concentration responses, again, both FLAG-
GPR120S-ǀzĐǁŝƚŚɴ-arrestin2-vYNL (Figure 3.14 C; n = 4) and FLAG-GPR120L-
ǀzĐǁŝƚŚɴ-arrestin2-vYNL (Figure 3.14 D; n = 4) had similar pEC50 values for 
oleic acid and GW9508 (Table 3.7). Therefore it was found that both GPR120 
isoforms interacted witŚ ɴ-arrestin2, both in terms of time course and 
concentration response curves, equivalently (Table 3.7). In comparison, no 
agonist-stimulated association between FLAG-FFA1-vYC and ɴ-arrestin2-vYNL 
was detected by BiFC in equivalent cell lines (data not shown).  
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Figure 3.13 Representative images and quantitative analysis of agonist 
induced FLAG-GPR120S-vYC or FLAG-GPR120L-vYC ŝŶƚĞƌĂĐƚŝŽŶ ǁŝƚŚ ɴ-
arrestin2-vYNL.  
Representative images acquired on the IX Ultra of HEK293TRs stably 
transfected with FLAG-GPR120S-vYC (A) or FLAG-GPR120L-ǀz  ? ) ? ĂŶĚ ɴ-
arrestin2-ǀzE> ĨŽůůŽǁŝŶŐ  ? ? ŵŝŶƵƚĞ ƚƌĞĂƚŵĞŶƚ ǁŝƚŚ ǀĞŚŝĐůĞ Žƌ  ? ? ʅD ŽůĞŝĐ
acid at 37oC. Images shown are BiFC (left panels) and the result of the 
granularity algorithm (right panels). Analysis identified nuclei and 
recomplemented YFP (white dots), with intensity thresholds set relative to 
positive controls present on the plate. Scale bar =  ? ?ʅŵ.  
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Figure 3.14 Time course and concentration response curves of FLAG-
GPR120S-vYC and FLAG-GPR120L-vYC with ɴ-arrestin2-vYNL, in response to 
oleic acid and GW9508 using BiFC. 
120 minute time course BiFC responses of FLAG-GPR120S-vYC and FLAG-
GPR120L-ǀz ǁŝƚŚ ɴ-arrestin2-ǀzE> ƚŽ  ? ? ? ʅD ŽůĞŝĐ ĂĐŝĚ  ? ) ĂŶĚ  ? ? ? ʅD
GW9508 (B), and concentration responses of FLAG-GPR120S-vYC (C) and 
FLAG-GPR120L-ǀz ? )ǁŝƚŚɴ-arrestin2-vYNL to oleic acid and GW9508. Data 
ǁĞƌĞŶŽƌŵĂůŝƐĞĚ ?A? )ƚŽƚŚĞ ? ? ?ʅDŽůĞŝĐĂĐŝĚƌĞƐƉŽŶƐĞĂŶĚƉŽŽůĞĚĨƌŽŵ ? W 6 
individual experiments, mean ± S.E.M.  
181 
 
 
FLAG-GPR120S-ǀz Pɴ-arrestin2-
vYNL 
  
FLAG-GPR120L-ǀz Pɴ-arrestin2-
vYNL 
  
Agonist pEC50 Rmax (%) pEC50 Rmax (%) 
Oleic Acid 4.4 ± 0.1 100 4.6 ± 0.2 100 
GW9508 5.2 ± 0.1 118 ± 9 5.1 ± 0.2 89 ± 21 
Table 3.7 Agonist potency and maximal responses for FLAG-GPR120S-vYC 
and FLAG-GPR120L-ǀzĂƐƐŽĐŝĂƚŝŽŶǁŝƚŚɴ-arrestin2-vYNL. 
pEC50 ǀĂůƵĞƐĂŶĚƌĞƐƉŽŶƐĞƐƚŽ ? ? ?ʅDŽůĞŝĐĂĐŝĚŽƌ ? ? ?ʅD't ? ? ? ?ŽĨ&>'-
GPR120S-vYC and FLAG-GPR120L-ǀz ǁŝƚŚ ɴ-arrestin2-vYNL as measured 
using bimolecular fluorescence complementation. Data were normalised (%) 
ƚŽ ƚŚĞ  ? ? ? ʅD ŽůĞŝĐ ĂĐŝĚ ƌĞƐƉŽŶƐĞ ĂŶĚ ƉŽŽůĞĚ ĨƌŽŵ  ?  W 6 individual 
experiments, mean ± S.E.M.  
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3.2.5 Agonist mediated endocytosis of GPR120 receptor isoforms 
Next, agonist mediated endocytosis of the SNAP-GPR120 receptor was 
quantified using an automated imaging plate reader to image receptors 
labelled with SNAP-surface AF-488 (Section 2.2.4.1). Cells were then treated 
with agonist, and fixed prior to imaging. Firstly, the time course of agonist 
mediated endocytosis was measured (representative images Figure 3.15). 
Interestingly, time courses of agonist mediated endocytosis showed that both 
SNAP-GPR120 isoforms underwent internalisation, with half times in response 
to oleic acid of 20 ± 6 min at SNAP-GPR120S and 17 ± 2 min at SNAP-GPR120L 
(Figure 3.16 A; n = 4); and half times in response to GW9508 of 13 ± 1 min at 
SNAP-GPR120S and 21 ± 3 min at SNAP-GPR120L (Figure 3.16 B; n = 4). Half 
times of agonist mediated endocytosis of the isoforms to GW9508 were 
significantly different * P AM ? ? ? ? ?^ƚƵĚĞŶƚ ?Ɛ ?ƚĂŝůĞĚƚƚĞƐƚ ) ? 
This in conjunction with the BiFC data, suggests that both GPR120 isoforms 
ĐĂŶ ŝŶƚĞƌĂĐƚ ǁŝƚŚ ɴ-arrestin proteins and subsequently undergo agonist 
induced endocytosis.  
Next, the internalisation assay was used to test concentration responses of 
the isoforms. Both isoforms underwent agonist induced endocytosis to an 
equivalent extent in response to maximum agonist concentrations (e.g. Figure 
3.15). There was a slight variance in agonist potencies and maximum 
responses when measured at 30 (Figure 3.17 A, B; n = 6) versus 60 min (Figure 
 ? ? ? ? ? ?ŶA?  ? )ĞƐƉĞĐŝĂůůǇ ŝŶƚŚĞ ƌĞƐƉŽŶƐĞƐ ƚŽ  ? ? ?ʅD't ? ? ? ?  ?ƌĞůĂƚŝǀĞ ƚŽ
fatty acids) at SNAP-GPR120S for 30 min versus 60 min (Table 3.8). 
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Figure 3.15 Quantitative analysis of agonist induced SNAP-GPR120S and SNAP-GPR120L endocytosis. 
Representative images acquired on the IX Ultra of HEK293TRs stably transfected with SNAP-GPR120S (A) or SNAP-GPR120L (B) following 60 
ŵŝŶƵƚĞ ƚƌĞĂƚŵĞŶƚ ǁŝƚŚǀĞŚŝĐůĞ Žƌ  ? ? ? ʅD K Ăƚ  ? ?oC. Images shown are H33342 stained cell nuclei (left panels); SNAP-GPR120S or SNAP-
GPR120L prelabelled with SNAP-surface AF-488 (middle panels; A, B respectively) and the result of the granularity algorithm (right panels). 
Analysis identified nuclei (grey) and internalised receptors 2- ?ʅŵŝŶĚŝĂŵĞƚĞƌ ?ǁŚŝƚĞĚŽƚƐ ) ?ǁŝƚŚŝŶƚĞŶƐŝƚǇƚŚƌĞƐŚŽůĚƐƐĞƚƌĞůĂƚŝǀĞƚŽƉŽƐŝƚŝǀĞĂŶĚ
negative controls present on the plate. ^ĐĂůĞďĂƌA? ? ?ʅŵ ? 
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Figure 3.16 Time course of SNAP-GPR120S and SNAP-GPR120L endocytosis 
ŝŶƌĞƐƉŽŶƐĞƚŽ ? ? ?ʅDŽůĞŝĐĂĐŝĚĂŶĚ ? ? ?ʅD't ? ? ? ? ? 
Endocytosis time course responses of SNAP-GPR120S and SNAP-GPR120L to 
 ? ? ?ʅDŽůĞŝĐĂĐŝĚ  ? )ĂŶĚ ? ? ?ʅD't ? ? ? ?  ? )ĂƐŵĞĂƐƵƌĞĚŽŶƚŚĞ confocal 
plate reader. Data were normalised (%) to the 90 min response and were 
pooled from 4 individual experiments, mean ± S.E.M.  
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Figure 3.17 Endocytosis of SNAP-GPR120S and SNAP-GPR120L in response to 
agonists measured at 30 and 60 min. 
Concentration response relationships of SNAP-GPR120S (A, C) and SNAP-
GPR120L (B, D) internalisation to agonists at 30 (A, B) and 60 (C, D) min post 
addition, as measured on the confocal plate reader. Data were normalised (%) 
ƚŽ ƚŚĞ  ? ? ? ʅD ŽůĞŝĐ ĂĐŝĚ ƌĞƐƉŽŶƐĞ ĂŶĚ ǁĞƌĞpooled from 4 - 7 individual 
experiments, mean ± S.E.M.  
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i 30 min 
   
 
SNAP-GPR120S 
 
SNAP-GPR120L 
 
Agonist pEC50 Rmax (%) pEC50 Rmax (%) 
Oleic Acid 3.8 ± 0.2 100 3.8 ± 0.3 100 
Myristic Acid 3.8 ± 0.4 116 ± 26 3.4 ± 0.8 82 ± 26 
GW9508 4.5 ± 0.2 244 ± 40 4.6 ± 0.3 103 ± 14 
     ii 60 min 
   
 
SNAP-GPR120S 
 
SNAP-GPR120L 
 
Agonist pEC50 Rmax (%) pEC50 Rmax (%) 
Oleic Acid 4.0 ± 0.1 100 3.1 ± 0.4 100 
Myristic Acid 4.2 ± 0.2 109 ± 19 4.3 ± 0.3 93 ± 3 
GW9508 5.0 ± 0.2 104 ± 14 4.7 ± 0.3 86 ± 16 
Table 3.8 Potency and maximal responses of SNAP-GPR120S and SNAP-
GPR120L agonist induced endocytosis at 30 and 60 min. 
Concentration responses of SNAP-GPR120S and SNAP-GPR120L to agonists at 
30 min (i) and 60 min (ii) post addition, as measured on the confocal plate 
reader. Data were ŶŽƌŵĂůŝƐĞĚ  ?A? ) ƚŽ ƚŚĞ  ? ? ? ʅD ŽůĞŝĐ ĂĐŝĚ ƌĞƐƉŽŶƐĞ ĂŶĚ
pooled from 4  W 7 individual experiments, mean ± S.E.M.  
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TZDs are synthetic ligands used as a treatment in type II diabetes (Section 
1.4.4.1.1.4). A number of these compounds were also found to elicit 
responses from GPR120S, measured as calcium mobilisation (Figure 3.18 A, B; 
Table 3.10). SNAP-GPR120S also underwent endocytosis in response to 100 
ʅD ƌŽƐŝŐůŝƚĂǌŽŶĞ ĂŶĚ ĐŝŐůŝƚĂǌŽŶĞ ? ǁŚŝůƐƚ ŶŽ ^EW-GPR120S endocytosis was 
ŝŶĚƵĐĞĚ ďǇ ƉŝŽŐůŝƚĂǌŽŶĞ Ăƚ ƵƉ ƚŽ  ? ? ʅD ?However, troglitazone and 
pioglitazone both also induced visible changes in cell morphology at 
concentrations above  ? ?ʅD ?&ŝŐƵƌĞ  ? ? ? ? ?dĂďůĞ  ? ? ?; n = 4), and also TZDs 
were not tested on cells that had not been tet treated, therefore these may 
be non specific responses.   
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Figure 3.18 Thiazolidinediones are  GPR120S agonists at high concentration. 
Calcium mobilisation time courses (A) and concentration response curves (B); 
and internalisation concentration responses (C) of SNAP-GPR120S to 
thiazolidinediones. Experiments were conducted as in Figures 3.6 (calcium 
ŵŽďŝůŝƐĂƚŝŽŶ )ĂŶĚ ? ? ? ? ?ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ) ?ĂƚĂǁĞƌĞŶŽƌŵĂůŝƐĞĚ ?A? )ƚŽ ? ? ?ʅD
oleic acid and is pooled from 4  W 5 individual experiments, mean ± S.E.M. 
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Calcium   Internalisation   
Agonist  pEC50 Rmax (%) pEC50 Rmax (%) 
Oleic Acid 4.9 ± 0.1 100 4.1 ± 0.1 100 
Rosiglitazone N.D. 47 ± 8 N.D. 42 ± 15 
Troglitazone N.D. 148 ± 17 N.D. 77 ± 15 
Ciglitazone N.D. 21 ± 7 N.D. 87 ± 20 
Pioglitazone N.D. 12 ± 2 N.D. N.D. 
Table 3.9 Potency and maximal responses of SNAP-GPR120S in response to 
thiazolidinediones. 
Calcium and internalisation potency and maximal responses of SNAP-GPR120S 
to different thiazolidinediones. Rmax values were determined from the 
maximal response at the highest ligand concentration tested. Data were 
ŶŽƌŵĂůŝƐĞĚ  ?A? ) ƚŽ ƚŚĞ  ? ? ? ʅD ŽůĞŝĐ ĂĐŝĚ ƌĞƐƉŽŶƐĞ ĂŶĚƉŽŽůĞĚ ĨƌŽŵ  ?- 5 
individual experiments, mean ± S.E.M.  
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3.2.6 The subcellular trafficking of the internalised GPR120 isoforms 
To determine which pathway GPR120 isoforms follow once they had 
undergone agonist mediated endocytosis, confocal images were taken in the 
presence of different pathway markers. Lysotracker red is a compound which 
localises to acidic organelles, such as lysosomes, and was used to mark the 
degradation pathway (Figure 3.19 A, B). Meanwhile, transferrin was used to 
label the recycling pathway, because it localises to the recycling endosomes as 
well as other parts of the clathrin-mediated endocytosis pathway (Figure 3.19 
C, D). The extent of colocalisation of the receptors with these compounds was 
used as an indication of which trafficking pathway the receptors followed. 
From the confocal images, it appears that after stimulation oleic acid, 
internalised SNAP-GPR120S (Figure 3.19 A, C) and SNAP-GPR120L (Figure 3.19 
B, D) predominantly colocalised with lysotracker red, to a greater extent than 
transferrin Figure 3.19). 
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Figure 3.19 Representative confocal colocalisation images of SNAP-GPR120S and SNAP-GPR120L in cells additionally labelled with transferrin 
or lysotracker red. 
HEK293TRs stably transfected with SNAP-GPR120S (A, C) or SNAP-GPR120L (B, D) were treated with vehicle (top panels) or 300 ʅD oleic acid 
(OA, bottom panels) for 60 min at 37oC. Images are of SNAP-surface AF-488 labelled receptor (left panels), lysotracker red (middle panels; A, B) 
or transferrin (middle panels; C, D) and the overlay (right panels). Images were acquired using a Zeiss LSM510 confocal microscope with laser 
excitation at 488 nm (SNAP-surface AF-488 labelled receptors), 543 nm (lysotracker red), or 633 nm (transferrin). Arrows denote example 
regions of colocalisation. Scale bar = 2 ?ʅŵ ?/ŵĂŐĞƐĂƌĞƌĞƉƌĞƐĞŶƚĂƚŝǀĞŽĨ those acquired from 4 independent experiments. 
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Following on from the confocal imaging studies, a quantitative strategy for 
measuring whether the internalised GPR120 receptors recycled back to the 
plasma membrane was adopted. For this, agonist was added for 30 min, the 
cells were washed with HBSS/0.1 % BSA (higher BSA concentration to aid in 
agonist removal) and then left for 5 -  ? ?ŵŝŶ ?ƚŚĞ “ƌĞĐǇĐůŝŶŐ ?ƉĞƌŝŽĚ )ǁŝƚŚŽƵƚ
ligand. 
&Žƌ  ? ? ? ʅD ŽůĞŝĐ ĂĐŝĚ ƚƌĞĂƚĞĚ ĐĞůůƐ ?  ? ? ŵŝŶ ĂĨƚĞƌ ƚŚĞwash step, at SNAP-
GPR120S 74 ± 8 %, and at SNAP-GPR120L 67 ± 6 % receptors remained in 
internalised vesicles, i.e. they had not returned back to the cell surface (Figure 
3.20 A, B respectively; n = 5). Following GW9508 addition, there was also little 
decrease in the percentage of receptors remaining internalised 60 min post 
ǁĂƐŚ ?ďƵƚƚŚŝƐŵĂǇďĞĚƵĞƚŽƚŚĞ ? ?ʅD't ? ? ? ?ĐŽŶĐĞŶƚƌĂƚŝŽŶƵƐĞĚŝŶƚŚŝƐ
assay, which induced less receptor internalisation in 
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Figure 3.20 Recycling of SNAP-GPR120S and SNAP-GPR120L following 30 min 
stimulation with agonist. 
Cells expressing SNAP-GPR120S (A) or SNAP-GPR120L (B) were treated with 
agonist, then underwent washes (HBSS / 0.1 % BSA) and were left 5  W 60 min, 
at which point they were fixed, then imaged on the confocal plate reader. 
ĂƚĂǁĞƌĞŶŽƌŵĂůŝƐĞĚ ?A? )ƚŽƚŚĞ ? ? ?ʅDŽůĞŝĐĂĐŝĚƌĞƐƉŽŶ ĞĂŶĚƉŽŽůĞĚĨƌŽŵ
5 individual experiments, mean ± S.E.M.  
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3.2.6.1 Role of carboxyl tail in the calcium signalling and agonist mediated 
endocytosis of GPR120 
As discussed earlier (section 1.6.2.1), the carboxyl tail of many GPCRs is key 
for receptor phosphorylation, which in turn supports ɴ-arrestin recruitment, 
desensitisation and internalisation. To investigate this for GPR120S, SNAP-
GPR120S was modified to truncate the carboxyl tail following the leucine-346 
residue (SNAP-GPR120S ȴ346) and stably expressed in tet-inducible HEK293TR 
cells as before. The function of this mutant was then examined in calcium and 
internalisation assays in comparison to SNAP-120S cells. To enable 
comparison between the different cell lines, data for these assays were 
expressed as fold over basal, instead of being normalised to a reference 
compound.  
Interestingly, the 346 truncation led to a significant increase in peak 
response amplitude of GPR120 calcium responses to agonists, and prolonged 
ĐĂůĐŝƵŵƌĞƐƉŽŶƐĞƐ ?&ŝŐƵƌĞ ? ? ? ? ) ?dŚĞƌĞƐƉŽŶƐĞƚŽ ? ? ?ʅDŽůĞŝĐĂĐŝĚĂƚ ? ?Ɛ
(measured using time course data) was significantly different P < 0.01 using a 
^ƚƵĚĞŶƚ ?Ɛ ƚ test (Figure 3.21 A; Table 3.10). The mutation also caused 
increases in agonist potency and maximum response from concentration 
response curves, but only the difference in myristic acid responses was 
significantly different, P AM  ? ? ? ? ƵƐŝŶŐĂ ^ƚƵĚĞŶƚ ?Ɛ ƚ test (Figure 3.21 B; Table 
3.10; n = 5). 
Conversely, in the internalisation assay, the same mutation led to a decrease 
in maximal internalisation for both time course and concentration response 
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curves, but surprisingly the mutation did not completely abolish agonist 
mediated endocytosis (representative images Figure 3.22). The SNAP-
GPR120S ȴ346 90 min time course maximum responses for both oleic acid 
and GW9508 were approximately 50 % of that for WT. This was not due to a 
difference in expression levels, which were not significantly different, as 
ĚĞƚĞƌŵŝŶĞĚ ƵƐŝŶŐ Ă  ? ƚĂŝůĞĚ ^ƚƵĚĞŶƚ ?Ɛ ƚ ƚĞƐƚ  ?&ŝŐƵƌĞ  ? ? ? ?  ? Ŷ A?  ? ) ? dŚĞ ŚĂůĨ
ƚŝŵĞŽĨĂŐŽŶŝƐƚŝŶĚƵĐĞĚĞŶĚŽĐǇƚŽƐŝƐŝŶƌĞƐƉŽŶƐĞƚŽ ? ? ?ʅDŽůĞŝĐĂĐŝĚǁĂƐ ? ?A?
 ?ŵŝŶ ?ĐŽŵƉĂƌĞĚƚŽ ? ?A? ?ŵŝŶĨŽƌtd ?&ŝŐƵƌĞ ? ? ? ? ?ŶA? ? )ĂŶĚƚŽ ? ? ?ʅD
GW9508 was 18 ± 3 min (in comparison to 12 ± 2 min for WT; Figure 3.23 B; n 
A? ? ) ?ŝŶĞĂĐŚĐĂƐĞŶŽƚƐŝŐŶŝĨŝĐĂŶƚůǇĚŝĨĨĞƌĞŶƚĨƌŽŵtd  ?^ƚƵĚĞŶƚ ?Ɛt test). On the 
other hand, the response to GW9508 at 60 min was found to be significantly 
different between WT ĂŶĚ 'WZ ? ? ?^ ȴ ? ? ?P < 0.05 ƵƐŝŶŐ Ă ^ƚƵĚĞŶƚ ?Ɛ ƚ ƚĞƐƚ ?
There was no significant difference in agonist pEC50 values between WT and 
SNAP-GPR120S ȴ346 endocytosis responses (Table 3.10).  
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Figure 3.21 Calcium time courses and concentration responses of a mutant, 
SNAP-GPR120S ȴ346. 
Calcium time courses (A) and concentration responses (B) of SNAP-GPR120S 
ȴ346. Data is normalised as fold over basal and is pooled from 5 individual 
experiments, mean ± S.E.M.  
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Figure 3.22 Representative images of SNAP-GPR120S ȴ346 internalisation. 
Images were acquired on the IX Ultra of HEK293TRs stably transfected with 
SNAP-GPR120S ȴ346, following 30 min treĂƚŵĞŶƚǁŝƚŚǀĞŚŝĐůĞŽƌ ? ? ?ʅDŽůĞŝĐ
acid. ^ĐĂůĞ ďĂƌ A?  ? ? ʅŵ ? Refer back to Figure 3.15 for WT representative 
images.  
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Figure 3.23 Agonist mediated endocytosis time courses and concentration 
responses of a truncation mutant, SNAP-GPR120S ȴ346. 
/ŶƚĞƌŶĂůŝƐĂƚŝŽŶƚŝŵĞĐŽƵƌƐĞƐŝŶƌĞƐƉŽŶƐĞƚŽ ? ? ?ʅDŽůĞŝĐĂĐŝĚ ? )ĂŶĚ ? ? ?ʅD
GW9508 (B), and concentration responses (C, measured at 60 min; dotted line 
representing WT response to oleic acid) of SNAP-GPR120S ȴ346 in 
comparison to WT, with relative expression levels quantified (D). Data were 
ŶŽƌŵĂůŝƐĞĚ  ?A?ƚŽ  ? ? ?ʅDŽůĞŝĐĂĐŝĚ ŝŶ ? ?ĨŽůĚŽǀĞƌďĂƐĂů ŝŶ )ĂŶĚƉŽŽůĞĚ
from 4 individual experiments, mean ± S.E.M. 
205 
 
 
Calcium 
   
Internalisation 
   
 
SNAP-GPR120S   
SNAP-GPR120S 
ȴ ? ? ?   SNAP-GPR120S   
SNAP-GPR120S 
ȴ ? ? ?   
Agonist pEC50 
Rmax (fold over 
basal) pEC50 
Rmax (fold over 
basal) pEC50 
Rmax (fold over 
basal) pEC50 
Rmax (fold over 
basal) 
Oleic Acid 4.6 ± 0.3 1.5 ± 0.2 4.9 ± 0.1 2.7 ± 0.1 4.0 ± 0.2 1.6 ± 0.1 3.7 ± 0.5 1.4 ± 0.1 
Myristic Acid 4.3 ± 0.4 1.6 ± 0.2 4.9 ± 0.1* 2.7 ± 0.2* 4.3 ± 0.1 1.6 ± 0.1 4.0 ± 0.4 1.4 ± 0.1 
GW9508 5.3 ± 0.3 1.9 ± 0.2 5.9 ± 0.2 2.7 ± 0.2 5.0 ± 0.1 1.6 ± 0.1 5.0 ± 0.3 1.3 ± 0.1 
Table 3.10 Potency and maximal responses of SNAP-GPR120S ȴ346. 
pEC50 values and maximal responses of SNAP-GPR120S ȴ346 in comparison to WT, for agonists as measured in the calcium mobilisation assay 
and the internalisation assay. Data were normalised as fold over basal and pooled from 4  W 5 individual experiments, mean ± S.E.M. Statistical 
significance determined using Ă^ƚƵĚĞŶƚ ?ƐƚƚĞƐƚ ? ?P < 0.05. 
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3.2.7 Potential effects of GPR120 receptor homo- and hetero-dimerisation 
To investigate the potential altered pharmacology of GPR120 homo- and 
hetero-ĚŝŵĞƌƐ ?ĐŽŶƐƚƌĂŝŶĞĚ “ŝ&ĚŝŵĞƌ ?ƌĞĐĞƉƚŽƌcell lines were created. To 
enable this, firstly a SNAP-GPR120S-vYNL cell line was dilution cloned, and 
characterised in its ability to elicit calcium and internalisation responses. 
SNAP-GPR120S-vYNL elicited responses similar to those exhibited by SNAP-
GPR120S (Figure 3.25; Table 3.11, 3.12). 
The SNAP-GPR120S-vYNL cell line was then stably cotransfected with FLAG 
tagged GPR120S-vYC, GPR120L-vYC or FFA1-vYC. By additionally labelling the 
SNAP-tag with SNAP-surface BG-647 this enabled two populations to be 
measured at the same time in the internalisation assay: all SNAP-labelled 
GPR120SvYNL receptors, and the specific dimer (120S:120S, 120S: 120L or 
120S:FFA1) identified by recomplemented vYFP (representative images in 
Figure 3.24; Table 3.12, 3.13). The calcium responses were also measured to 
assess whether there were any changes resulting from co-expression of the 
ƚǁŽƌĞĐĞƉƚŽƌƐĂƚĂ “ƉŽƉƵůĂƚŝŽŶ ?ůĞǀĞů ? 
The 120S:120S cell line showed no significant difference between 
internalisation of the overall SNAP-labelled SNAP-GPR120S-vYNL population 
and the SNAP-GPR120S-vYNL:GPR120S-vYC BiFC dimer, either when 
measuring the time course of internalisation (Figure 3.26 A, B); or comparing 
concentration response curves to oleic acid or GW9508 (Representative 
images Figure 3.24; Figure 3.26; Table 3.12, 3.13). 
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Next the 120S:120L dimer was characterised (representative images Figure 
3.24 B). Even though GPR120L by itself did not elicit calcium mobilisation, the 
co-expression of GPR120L-vYC and GPR120-SvYNL in the 120S:120L cell line 
did not alter agonist-stimulated calcium mobilisation significantly (Figure 3.27 
A; Table 3.11). 
Once again, there was no difference in internalisation between the SNAP-
labelled SNAP-GPR120S-ǀzE>ƉŽƉƵůĂƚŝŽŶĂŶĚ ƌĞĐŽŵƉůĞŵĞŶƚĞĚǀz&W  “ĚŝŵĞƌ ?
population (SNAP-GPR120S-vYNL:GPR120L-vYC) (Figure 3.27; (Figure 3.28; 
Table 3.12, 3.13; n = 4 - 5). 
Finally, the 120S:FFA1 dimer was characterised (representative images Figure 
3.24 C; Figure 3.28; Figure 3.29; Table 3.11, 3.12, 3.13). As might be expected 
from earlier calcium data (Figure 3.6), the additional expression of FFA1 in the 
cell line affected calcium signalling. The calcium data set for GW9508 fitted to 
a 2 site model better than a 1 site model, perhaps indicating separate FFA1 
component and GPR120S components to the response. This 2 site model gave 
two pEC50 values, with 70 % of the population fitting to an pEC50 value of 5.5 ± 
0.7, whilst the other 30 % gave an pEC50 value of 7.1 ± 0.7 (Figure 3.28 B), of 
which these responses were notably more potent than in either the FFA1 or 
GPR120S single population cells. 
Interestingly, there was a left shift of the GW9508 internalisation response 
curve for the BiFC dimer SNAP-GPR120S-vYNL:FLAG-FFA1-vYC compared to 
SNAP labelled SNAP-GPR120S-vYNL, but this was not deemed significantly 
different by 2 way ANOVA (Figure 3.29 F; Table 3.12; n = 4 - 6).  
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Figure 3.24 Representative images of bimolecular fluorescence 
complementation between SNAP-GPR120S-vYNL:FLAG-GPR120S-vYC, SNAP-
GPR120S-vYNL:FLAG-GPR120L-vYC and SNAP-GPR120S-vYNL:FLAG-FFA1-vYC. 
Images were acquired on the IX Ultra of HEK293TRs stably transfected with 
SNAP-GPR120S-vYNL:FLAG-GPR120S-vYC (A), SNAP-GPR120S-vYNL:FLAG-
GPR120L-vYC (B) and SNAP-GPR120S-vYNL:FLAG-FFA1-vYC (C) following 30 
minute treĂƚŵĞŶƚǁŝƚŚǀĞŚŝĐůĞ ?ůĞĨƚƉĂŶĞůƐ )Žƌ ? ? ?ʅDŽůĞŝĐĂĐŝĚ ?ƌŝŐŚƚƉĂŶĞůƐ ). 
Images show recomplemented vYFP identifying the BiFC dimer (top panels), 
SNAP-surface BG-647 labelled SNAP-GPR120S-vYNL receptors (middle panels) 
ĂŶĚƚŚĞŽǀĞƌůĂǇŽĨďŽƚŚŝŵĂŐĞƐ ?ďŽƚƚŽŵƉĂŶĞůƐ )^ĐĂůĞďĂƌA? ? ?ʅŵ ? 
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Figure 3.25 Characterisation of SNAP-GPR120S-vYNL receptors expressed in 
HEK293T cells. 
The clonal HEK293T SNAP-GPR120S-vYNL cell line was tested for its ability to 
elicit calcium mobilisation, shown as time courses (A; dotted line showing 
time of agonist addition), and concentration response curves (B), and 
internalisation (B) in response to agonist. Data were normalised (%) to 300 
ʅDoleic acid responses and pooled from 3 - 5 individual experiments, mean ± 
S.E.M.  
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Figure 3.26 Internalisation of SNAP-GPR120S-vYNL:FLAG-GPR120S-vYC BiFC 
dimers in response to agonists, compared to the SNAP-GPR120SvYNL 
population. 
The dual-transfected cell line SNAP-GPR120S-vYNL:FLAG-GPR120S-vYC was 
tested for its agonist-stimulated internalisation responses. Time courses of 
the SNAP-GPR120S-vYNL:FLAG-GPR120S-vYC population (measured by 
granularity analysis of the BiFC receptor images) (A) and the SNAP-surface BG-
647 labelled SNAP-GPR120S-ǀzE> ƉŽƉƵůĂƚŝŽŶ  ? ) ƌĞƐƉŽŶƐĞƐ ƚŽ  ? ? ? ʅD ŽůĞŝĐ
ĂĐŝĚ ĂŶĚ  ? ? ? ʅD 't ? ? ? ? ? ĂŶĚ ĐŽŶĐĞŶƚƌĂƚŝŽŶ ƌĞƐƉŽŶƐĞƐ ŽĨ ƚŚĞ ^EW-
GPR120S-vYNL:FLAG-GPR120S-vYC population and SNAP-surface BG-647 
labelled SNAP-GPR120S-vYNL population to oleic acid (C) and GW9508 (D), 
were measured using the bimolecular fluorescence complementation assay. 
ĂƚĂǁĞƌĞŶŽƌŵĂůŝƐĞĚ ?A? )ƚŽƚŚĞ ? ? ?ʅDŽůĞŝĐĂĐŝĚƌĞƐƉŽŶ ĞĂŶĚƉŽŽůĞĚĨƌŽŵ
3  W 5 individual experiments, mean ± S.E.M.  
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Figure 3.27 Calcium, and internalisation responses in the SNAP-GPR120S-
vYNL:FLAG-GPR120L-vYC cell line in response to agonists. 
The dual transfected cell line SNAP-GPR120S-vYNL:FLAG-GPR120L-vYC was 
tested for its calcium and internalisation responses. The calcium mobilisation 
time course (A) and concentration response curves (B) to oleic acid, myristic 
acid and GW9508 were measured using the calcium mobilisation assay. 
Internalisation time courses of the SNAP-GPR120S-vYNL:FLAG-GPR120L-vYC 
population (C) and the SNAP-surface BG-647 labelled SNAP-GPR120S-vYNL 
sub-ƉŽƉƵůĂƚŝŽŶ ? )ƌĞƐƉŽŶƐĞƐƚŽ ? ? ?ʅDŽůĞŝĐĂĐŝĚĂŶĚ ? ? ?ʅD't ? ? ? ? ?ĂŶĚ
concentration responses of the SNAP-GPR120S-vYNL:FLAG-GPR120L-vYC 
population and SNAP-surface BG-647 labelled SNAP-GPR120S-vYNL sub-
population to oleic acid (E) and GW9508 (F), were measured using the 
ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ĂƐƐĂǇ ? ĂƚĂ ǁĞƌĞ ŶŽƌŵĂůŝƐĞĚ  ?A? ) ƚŽ ƚŚĞ  ? ? ? ʅD ŽůĞŝĐ ĂĐŝĚ
response and pooled from 4  W 5 individual experiments, mean ± S.E.M. 
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Figure 3.28 Calcium, and internalisation measurements of SNAP-GPR120S-
vYNL:FLAG-FFA1-vYC in response to agonists. 
The dual transfected cell line SNAP-GPR120S-vYnL:FLAG-FFA1-vYC was tested 
for its calcium and internalisation responses. The calcium mobilisation time 
course (A) and concentration responses (B) to oleic acid, myristic acid and 
GW9508 were measured using the calcium mobilisation assay. Internalisation 
time courses of the SNAP-GPR120S-vYNL:FLAG-FFA1-vYC BiFC dimer 
population (C) and the SNAP-surface BG-647 labelled SNAP-GPR120S-vYNL 
sub-population (D) responses to 30 ?ʅDŽůĞŝĐĂĐŝĚĂŶĚ ? ? ?ʅD't ? ? ? ? ?ĂŶĚ
concentration responses of the SNAP-GPR120S-vYNL:FLAG-FFA1-vYC 
population and SNAP-surface BG-647 labelled SNAP-GPR120S-vYNL sub-
population to oleic acid (E) and GW9508 (F), were measured using the 
internalisation  asƐĂǇ ? ĂƚĂ ǁĞƌĞ ŶŽƌŵĂůŝƐĞĚ  ?A? ) ƚŽ ƚŚĞ  ? ? ? ʅD ŽůĞŝĐ ĂĐŝĚ
response and pooled from 4  W 6 individual experiments, mean ± S.E.M. 
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Calcium 
     
 
GPR120S-vYNL   120S:120L   120S:FFA1   
Agonist pEC50 Rmax (%) pEC50 Rmax (%) pEC50 Rmax (%) 
Oleic Acid 4.5 ± 0.1 100 4.1 ± 0.2 100 4.9 ± 0.2 100 
Myristic Acid 4.5 ± 0.2 92 ± 21 4.3 ± 0.1 133 ± 16 4.9 ± 0.2 112 ± 8 
GW9508 5.6 ± 0.2 98 ± 16 5.3 ± 0.1 204 ± 12 
HI 7.1 ± 0.7 
(30%) 120 ± 13 
     
LO 5.5 ± 0.7 
(70%) 
 
Table 3.11 Potency and maximal calcium responses in SNAP-GPR120S-vYNL, SNAP-GPR120S-vYNL:GPR120L-vYC and SNAP-GPR120S-
vYNL:FFA1-vYC cell lines. 
pEC50 values and maximal responses in SNAP-GPR120S-vYNL cells and the dually transfected cell lines SNAP-GPR120S-vYNL:GPR120L-vYC 
(120S:120L) and SNAP-GPR120S-vYNL:FFA1-vYC (120S:FFA1) to agonist in the calcium mobilisation assay. Data were normalised (%) to the 300 
ʅDŽůĞŝĐĂĐŝĚƌĞƐƉŽŶƐĞĂŶĚƉŽŽůĞĚĨƌŽŵ ? W 6 individual experiments, mean ± S.E.M.  
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i Internalisation 
     
 
GPR120S-vYNL 
     
Agonist pEC50 Rmax (%) 
    
Oleic Acid N.D. 100 
    Myristic Acid 4.5±0.3 73±15 
    GW9508 5.0±0.3 85±24 
    
       
ii 
SNAP-labelled 
population 
     
 
120S:120S 
 
120S:120L 
 
120S:FFA1 
 
Agonist pEC50 Rmax (%) pEC50 Rmax (%) pEC50 Rmax (%) 
Oleic Acid N.D. 100 N.D. 100 N.D. 100 
GW9508 4.8 ± 0.1 140 ± 9 4.7 ± 0.2 112 ± 31 4.5 ± 0.2 179 ± 41 
       
iii 
Recomplemented 
YFP population 
     
 
120S:120S 
 
120S:120L 
 
120S:FFA1 
 
Agonist pEC50 Rmax (%) pEC50 Rmax (%) pEC50 Rmax (%) 
Oleic Acid N.D. 100 N.D. 100 N.D. 100 
GW9508 4.7 ± 0.1 147 ± 5 4.6 ± 0.2 142 ± 20 4.9 ± 0.3 214 ± 78 
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Table 3.12 Potency and maximal responses of SNAP-GPR120S-vYNL, SNAP-GPR120S-vYNL:GPR120S-vYC , SNAP-GPR120S-vYNL:GPR120L-vYC 
and SNAP-GPR120S-vYNL:FFA1-vYC in response to agonists. 
pEC50 values and maximal responses of SNAP-GPR120S-vYNL (i) and the dual transfected cell lines SNAP-GPR120S-vYNL:GPR120S-vYC 
(120S:120S), SNAP-GPR120S-vYNL:GPR120L-vYC (120S:120L) and SNAP-GPR120S-vYNL:FFA1-vYC (120S:FFA1) in response to agonists in the 
internalisation assay, with measurements taken of the SNAP-labelled population (ii) and the recomplemented YFP dimer population (iii). Oleic 
acid Rmax ǀĂůƵĞƐǁĞƌĞĚĞƚĞƌŵŝŶĞĚĨƌŽŵƚŚĞŵĂǆŝŵĂůƌĞƐƉŽŶƐĞĂƚ ? ? ?ʅD ?ĂƚĂǁĞƌĞŶŽƌŵĂůŝƐĞĚ ?A? )ƚŽ ? ? ?ʅDŽůĞŝĐĂĐŝĚĂŶĚƉŽŽůĞĚĨƌŽŵ ? W 6 
individual experiments, mean ± S.E.M; N.D. not determined.  
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SNAP-labelled 
population 
  
Recomplemented 
YFP population 
  
 
120S:120S 120S:120L 120S:FFA1 120S:120S 120S:120L 120S:FFA1 
Agonist T1/2 (min) T1/2 (min) T1/2 (min) T1/2 (min) T1/2 (min) T1/2 (min) 
Oleic Acid 4 ± 1 5 ± 1 4 ± 1 6 ± 1 5 ± 1 8 ± 2 
GW9508 8 ± 1 8 ± 1 7 ± 2 7 ± 1 8 ± 1 11 ± 4 
Table 3.13 Time courses for internalisation responses in SNAP-GPR120S-vYNL:GPR120S-vYC, SNAP-GPR120S-vYNL:GPR120L-vYC and SNAP-
GPR120S-vYNL:FFA1-vYC cell lines. 
Internalisation time course responses of the SNAP-labelled population and the recomplemented YFP population of the dually transfected cell 
lines SNAP-GPR120S-vYNL:GPR120S-vYC (120S:120S), SNAP-GPR120S-vYNL:GPR120L-vYC (120S:120L) and SNAP-GPR120S-vYNL:FFA1-vYC 
(120S:FFA1) to agonists in the internalisation assay. Time courses appeared biphasic in nature, therefore to better fit the data to obtain half 
times of internalisation, curves were fitted to the first 60 minutes of the time course only. Data were pooled from 3  W 6 individual experiments, 
mean ± S.E.M. 
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3.3 Discussion 
3.3.1 Summary of main findings 
This study was undertaken to compare the GPR120 isoforms in terms of their 
signalling and trafficking, and to also investigate whether GPR120S receptor 
homo- and hetero-dimers had altered pharmacology. 
Firstly, it was found in the calcium signalling assay that GPR120S signals in 
response to agonist, whilst GPR120L does not. Also, it was found that FFA1 
gave absolute calcium responses that were twice the magnitude of those at 
GPR120S. These responses at FFA1 were inhibited by the antagonist GW1100, 
and by the binding site mutation R258A. The picture of GPR120S signalling 
and GPR120L not signalling via G proteins was reiterated in the results from 
the DMR assay, in which GPR120S gave monophasic responses to ligands 
(which could be partially inhibited using 2-APB but not PTx), whilst GPR120L 
did not give responses. These differences were not down to a difference in 
cell surface expression. 
ŽŶǀĞƌƐĞůǇ ?ďŽƚŚ'WZ ? ? ?ŝƐŽĨŽƌŵƐǁĞƌĞĨŽƵŶĚƚŽŝŶƚĞƌĂĐƚǁŝƚŚɴ-arrestin2 in 
the BiFC assay, and also gave responses in the internalisation assay. Further to 
this, when the fate of the internalised receptors was determined both 
qualitatively and quantitatively, both receptor isoforms were found to 
colocalise with the marker for the degradation pathway, lysotracker red; and 
the receptors did not undergo recycling back to the cell surface. 
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These results demonstrated that, in the cell systems studied, only GPR120S is 
capable of G protein mediated signalling, whilst both isoforms are capable of 
ɴ-arrestin2 mediated endocytosis. The carboxyl tail of GPR120S was also 
identified to mediate GPR120S desensitisation. Additionally, it was found by 
cƌĞĂƚŝŶŐ ĐŽŶƐƚƌĂŝŶĞĚ  “ŝ& ? ŚŽŵŽ- and hetero-dimers that dimerisation did 
not alter pharmacology. 
3.3.2 Conclusions of studies into G protein dependent signalling 
In the same host cell system (tetracycline inducible HEK293 cells), FFA1 gave 
absolute calcium responses that were twice the magnitude of those observed 
at GPR120S, whilst GPR120L did elicit calcium responses. FFA1 is known to 
couple predominantly to Gq/11 (Itoh et al., 2003) and weakly to Gi (Schroder 
et al., 2010). 
These results back up previous findings in the literature of GPR120 coupling to 
calcium mobilisation (Hirasawa et al., 2005). Also, GPR120L was only capable 
ŽĨĐĂůĐŝƵŵƐŝŐŶĂůůŝŶŐǁŚĞŶĞǆƉƌĞƐƐĞĚĂƐĂĨƵƐŝŽŶƉƌŽƚĞŝŶǁŝƚŚ'ɲ ? ?(Hirasawa 
et al., 2005). This suggests that co-expression with an over-expressed G 
protein is required for GPR120L to elicit calcium responses. The only 
difference between the isoforms is the insertion in ICL3 (Figure 1.2), which 
might be the cause of steric hindrance for G protein coupling, as discussed 
later. 
3.3.2.1 The effect of 2-APB in the calcium assay 
2-APB inhibited, but did not completely abolish GPR120S calcium signalling. 
Calcium signalling by GPCRs is usually mediated as follows: receptor activation 
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leads to activation of the cognate G protein, which for calcium signalling is the 
Gq alpha subunit or G  subunits released from Gi. The G protein activates 
PLC, which generates soluble IP3 that in turn then binds to IP3 receptors 
present on the endoplasmic reticulum leading to release of calcium from the 
intracellular stores (Charlton and Vauquelin, 2010). 2-APB, an inhibitor of 
calcium signalling, was originally thought to prevent calcium mobilisation 
through the blockade of the IP3 receptors present on the endoplasmic 
reticulum (Maruyama et al., 1997); but a later study suggests it is not a 
consistent blocker of IP3 receptors (Bootman et al., 2002; Gregory et al., 
2001).  
In fact, later research has suggested that 2-APB prevents store operated 
calcium entry (SOCE). SOCE occurs when a protein, ORAI1 which is part of the 
plasma membrane calcium channel complex, associates with STIM1 (stromal 
interacting molecule; acting as an endoplasmic reticulum sensor for calcium 
depletion from this store), resulting in calcium entry from the extracellular 
medium to restore intracellular calcium store levels (DeHaven et al., 2008). 2-
APB blocks SOCE by preventing the migration and formation of STIM1 puncta 
at the plasma membrane. It was found that 2-APB did not fully block this 
process, which is perhaps why this compound did not completely abolish 
calcium signalling when tested on GPR120S responses (DeHaven et al., 2008). 
The concentration of 2-APB used could be increased, but only up to  ? ? ?ʅD ?
because above this 2-APB has been found to actually cause an increase in 
calcium concentration (Maruyama et al., 1997). 
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3.3.2.2 The effects of PTx in the calcium assay 
The calcium responses at GPR120S were largely PTx insensitive, indicating that 
GPR120S coupled to the Gq/11 class of calcium signalling G proteins, as PTx 
only inhibits the Gi class of G proteins. The results do not exclude the 
possibility that GPR120 can couple to multiple G proteins, with Gq activation 
compensating for the inhibited Gi, therefore allowing calcium signalling to still 
occur. This occurs with FFA1, which has been shown to couple to Gq (Briscoe 
et al., 2003), and Gi (Schroder et al., 2010). The absence of G protein response 
with GPR120L suggests it does not couple to the G protein complement 
present in HEK cells, but it is also possible that GPR120S and GPR120L couple 
to other G proteins that exist in the sites of endogenous GPR120 expression, 
for example gustducin which is present in the taste cells, which will be 
discussed later (Section 3.4). In the same family of fatty acid receptors, PTx 
was also used in calcium, cAMP and ERK1/2 accumulation assays to determine 
that both FFA2 and FFA3 also coupled to the PTx sensitive Gi, with FFA2 
additionally coupling to Gq (Le Poul et al., 2003). 
3.3.2.3 Results of the DMR assay 
Another assay was also used to monitor G protein mediated signalling. DMR 
ŵĞĂƐƵƌĞƐ ƚŚĞ  “ŚŽůŝƐƚŝĐ ?whole cell response, which is more indicative of the 
ƌĞĐĞƉƚŽƌ ?Ɛ ǁŚŽůĞrepertoire of G protein dependent signalling, rather than 
measuring one end point, which can be very close to the G protein (such as a 
'dWɶ^ ĂƐƐĂǇ ) ? ŶŽƚŚĞƌ ĂĚǀĂŶƚĂŐĞ ƚŽ DZ ? ŝƐ ƚŚĂƚ ŝƚhas been previously 
reported to show a signature response depending on which G protein is 
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involved (Schroder et al 2010). GPR120S gave large positive monophasic 
responses, which did not match exactly to one profile (could be consistent 
with Gq/11, Gi or G12/13 responses previously reported; Figure 2.9), which 
lead to the thought that perhaps there is multiple G protein involvement. This 
was the rationale for then using the inhibitors 2-APB and PTx to dissect the 
responses, but these inhibitors had no significant effect. This may be due to 
the assay being highly sensitive, detecting low levels of receptor activation 
due to signal amplification. Additionally, this high sensitivity means perhaps 
the partial inhibition may have subtly changed the functional outcome. It is 
also possible that GPR120S couples to more than one G protein subtype, 
giving rise to a unique profile; when one pathway is inhibited (e.g. Gi by PTx), 
the other one (e.g. Gq/11 dependent) can compensate without significantly 
altering the signature.  
Most importantly though, the DMR assay confirmed the calcium results, in 
that the GPR120L isoform does not appear to elicit G protein mediated 
signalling in HEK293 host cells. 
3.3.3 Pharmacology 
The potency of agonist GW9508 was equivalent to previously published data 
for equivalent calcium mobilisation assays, at both FFA1 (pEC50 7.1 compared 
to 7.3 in Briscoe et al., 2006)) and GPR120S (5.3 ± compared to 5.5 (Briscoe et 
al., 2006)). Similarly the pA2 for the antagonist GW1100 at FFA1 receptors 
(6.0) was also similar to both its pKB calculated using the Gaddum equation 
(6.6), and its published equilibrium dissociation constant 1 µM (Briscoe et al., 
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2006). However Schild analysis gave a steep slope value of 2.7 ± 0.1, 
compared to a slope of 1 expected for a competitive reversible antagonist. 
This may indicate a lack of equilibrium between agonist and antagonist 
binding. The kinetic nature of the assay, in which peak calcium responses are 
measured rapidly after the agonist is added, allows very little time for 
equilibrium between agonist and antagonist binding to occur (Charlton and 
Vauquelin, 2010). In agreement with the previous study, GW1100 had no 
effect at GPR120 (data not shown). 
FFA1 has previously been shown to respond to thiazolidinediones with an 
order of potency of rosiglitazone > ciglitazone = troglitazone > pioglitazone 
(Smith et al., 2009). The fact that GPR120S also responds to thiazolidinediones 
was a novel finding. The order of potency at GPR120S (as far as it could be 
determined) was troglitazone > ciglitazone = rosiglitazone. Pioglitazone was 
inactive, providing supporting evidence that these responses are indeed 
ĞůŝĐŝƚĞĚ ďǇ 'WZ ? ? ?^ ƌĂƚŚĞƌ ƚŚĂŶ WWZɶ ? dŚĞ ŽƌĚĞƌ ŽĨ ƉŽƚĞŶĐǇ Ăƚ WWZɶ ŝƐ
rosiglitazone > troglitazone = pioglitazone, completely different to the results 
found at GPR120S (Sakamoto et al., 2000). As with FFA esters, such as methyl 
linoleate, previously found to be inactive at GPR120 (data not shown; 
Hirasawa et al., 2005), thiazolidinediones also lack free carboxylate groups. 
However a study on their mode of action at FFA1 suggested that the 2,4-dione 
group on thiazolidinediones acts in a similar way to the carboxyl group (Smith 
et al., 2009). Additionally, pioglitazone did not elicit responses at GPR120, and 
a reason for this can be seen in their structures because pioglitazone, in 
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comparison to the active rosiglitazone contains an extra ethyl group which 
may occlude binding (Figure 3.29). It should be noted that the potency of all  
 
Figure 3.29 The structures of TZDs. 
The TZD pharmacophore is shown in red, with structural differences shown in 
black.  
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thiazolidinediones in activating GPR120 was relatively low (10 µM and above), 
compared to their known mechanisms of action as PPAR  
The use of BSA in the fatty acid preparations aided their solubility in HBSS, but 
ĂůƐŽƌĞĚƵĐĞĚ “ĨƌĞĞ ?ĨĂƚƚǇĂĐŝĚĐŽŶĐĞŶƚƌĂƚŝŽŶ ?ĂƐĂůďƵŵŝŶĐŽŶƚĂŝŶƐƐĞǀĞƌĂůĨĂƚƚǇ
acid binding sites (Krenzel et al., 2013). This effect was previously shown in 
the Hirasawa et al (2005) study, where the inclusion of 0.1 % BSA was clearly 
ĚĞŵŽŶƐƚƌĂƚĞĚ ƚŽ ƌĞƐƚƌŝĐƚ ɲ-linolenic acid mediated endocytosis of GPR120 
(Hirasawa et al., 2005). This effect was also seen when treating FFA1 with 
lauric acid in the presence of increasing concentrations of BSA and monitoring 
calcium responses (Stoddart et al., 2007). Also, in one study on the creation of 
novel FFA1 agonists and their optimisation, it was found that some 
substituents were favourable for FFA1 receptor binding, i.e. they increased 
agonist activity, but not for binding BSA, i.e. they reduced the inhibitory shift 
in potency in the presence of serum (Sasaki et al., 2011). This knowledge led 
to the optimisation of BSA concentrations (0.1 vs. 0.02 % BSA) and 0.02 % BSA 
 ? ? ?ʅD )ǁĂƐƐĞůĞĐƚĞĚĂƐŽƉƚŝŵĂů ?dŚŝƐĐŽŶĐĞŶƚƌĂƚŝŽŶůĞĚƚŽƚŚĞŽďƐĞƌǀĂƚŝŽŶŽĨ
3-10 fold reductions in FFA potency compared to previous work (Briscoe et al., 
2006; Hirasawa et al., 2005), but also minimised the amount of vehicle (e.g. 
DMSO) required to solubilise the FFAs at maximum response concentrations.  
3.3.4 Novel findings regarding GPR120 arrestin recruitment and 
internalisation 
There were advantages and disadvantages to using the novel technique of 
ŝ&ƚŽŝĚĞŶƚŝĨǇƚŚĞĂƐƐŽĐŝĂƚŝŽŶďĞƚǁĞĞŶ'WZ ? ? ?ĂŶĚɴ-arrestin2. Firstly, the 
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subcellular localisation of these components increased the specificity of the 
experiment. This is because the receptor was localised at the plasma 
ŵĞŵďƌĂŶĞ ?ǁŚŝůƐƚɴ-arrestin2 was in a diffuse pattern in the cytosol (Bychkov 
et al., 2012), thus remain separated until agonist had been added. It also used 
live cells at the physiologically relevant temperature and gave quantitative 
pharmacological data for comparison of potency values obtained in the 
internalisation assay. A disadvantage to this system was that the YFP 
maturation step is slow, so measurements are not real time, and also the 
formation of the BiFC complex is irreversible, so all interactions were caught 
with no indication whether the interaction was a transient or more long 
lasting one (Kilpatrick et al., 2010; Rose et al., 2010). 
The first interesting finding here was that GPR120S more readily interacted 
ǁŝƚŚ ɴ-arrestin2 than FFA1. Also, in contrast to the results from studying G 
protein mediated responses, agonist stimulated GPR120L also interacted with 
ɴ-arrestin2 in an equivalent manner to GPR120S. This suggests that the DMR 
ĂƐƐĂǇĚŽĞƐŶŽƚĂƉƉĞĂƌƚŽƉŝĐŬƵƉ'WZ Pɴ-arrestin interactions, consistent with 
findings in Schroder et al., (2010) ? &ŽůůŽǁŝŶŐ ŽŶ ĨƌŽŵ ƚŚĞ ɴ-arrestin assay, 
agonist induced endocytosis was then measured. This gave the similar results 
ƚŽ ɴ-arrestin BiFC, that both GPR120 isoforms underwent internalisation in 
contrast to the assays that measured G protein mediated responses, and also 
in contrast to the fact that FFA1 did not undergo agonist induced endocytosis 
to such a clear extent as GPR120. 
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These internalisation assays used the SNAP-tag to visualise GPR120 and FFA1 
receptors, having verified that when compared to the FLAG-tagged receptors, 
there was no functional impact upon calcium signalling. A key advantage of 
the SNAP-tag modification is that it allows the receptor to be labelled with any 
wavelength SNAP-surface label and can be used on live cells (Keppler et al., 
2003). Both membrane permeant and impermeant labels are available, and an 
advantage of using the impermeant label (SNAP-surface) is that it only labels 
cell surface expressed receptors capable of undergoing agonist stimulated 
internalisation. The reaction which attaches the label to the receptor is 
specific, rapid and irreversible, and the label is fairly photostable. Another 
advantage of the SNAP-tag system over other visualisation methods like GFP, 
is that the SNAP-tag modification is on the amino terminus, compared to the 
carboxyl tail for GFP, and so it avoids potential effects on phosphorylation 
sites on the carboxyl tail, or on interactions with other intracellular effector 
proteins. Disadvantages of the SNAP-tag are that it still requires genetic 
modification of the receptor, and the large (~20kDa) modification is on the 
amino terminus, which could potentially affect ligand binding. However, here 
the SNAP-tagged receptor was as equally functional as the FLAG-tagged 
receptor. 
The BiFC and internalisation assay potency values are slightly right shifted 
relative to calcium and DMR assays. This could be because of the varying 
degrees of receptor reserve in each assay, for example a lower receptor 
ƌĞƐĞƌǀĞ  ?ĞǆƉĞĐƚĞĚ ŝŶ ƌĞĐĞƉƚŽƌ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ Žƌ ĚŝƌĞĐƚ ƌĞĐĞƉƚŽƌ Pɴ-arrestin 
interaction assays) results in agonists being less potent, with EC50 values closer 
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to the 50 % occupancy level for the receptor Kd. In contrast assays that 
measure downstream effects of G protein signalling measure an endpoint that 
has undergone signal amplification, and are therefore predicted to show 
increased receptor reserve, and agonist potency. There was a correlation 
between the pEC50 values acquired ĨƌŽŵ ɴ-arrestin binding and 
ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ? ǁŚŝĐŚ ŵĂǇ ďĞ ĂƐ ĞǆƉĞĐƚĞĚ ŝĨ 'WZ ? ? ? ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ŝƐ ɴ-
arrestin dependent, but this mechanism was not explicitly identified. 
Confocal imaging in conjunction with the use of intracellular markers 
transferrin (to label recycling compartments) and lysotracker red (to label 
lysosomes) was undertaken to determine the intracellular sorting of GPR120 
following internalisation. These images showed colocalisation with lysotracker 
red, suggesting a non-recycling trafficking profile. This was investigated 
further using a recycling protocol on the platereader, which further confirmed 
this non-recycling profile. 
3.3.5 Potential molecular basis for GPR120 isoform specific signalling 
These experiments showed an interesting result of the short isoform 
ƵŶĚĞƌŐŽŝŶŐďŽƚŚ'ƉƌŽƚĞŝŶĚĞƉĞŶĚĞŶƚĂŶĚɴ-arrestin2 mediated endocytosis, 
ǁŚŝůƐƚ ƚŚĞ ůŽŶŐ ŝƐŽĨŽƌŵ ŽŶůǇ ĞůŝĐŝƚĞĚ ɴ-arrestin2 mediated endocytosis. This 
must be due to the 16 residues inserted into ICL3 of GPR120L (Figure 3.10).  
How does such a small change make such a large difference to the protein-
protein interactions? Similar to GPR120, a 29 residue insert in ICL3 is all that 
differs between the long and short isoforms of the dopamine D2 receptor. 
Point mutations within ICL3 of the short dopamine D2 receptor changed G 
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protein coupling specificity, suggesting that this area is important for G 
protein interactions (Senogles et al., 2004). Also, a study in which the 
dopamine D3 receptor had 12 residues from the carboxyl tail of ICL3 replaced 
with equivalent residues from the long dopamine D2L receptor, found that this 
chimera then acquired promiscuity in G protein coupling, similar to WT D2L 
(Lane et al., 2008). Additionally, mutation of residues at the M2 muscarinic 
receptor TM5:ICL3 interface (close to the insert position in GPR120L) altered 
its G protein coupling specificity (Kostenis et al., 1997), again showing the 
importance of residues within this region for G protein coupling. Meanwhile, 
the ICL3 fragment of the glucagon-like peptide-1 receptor stimulated all G 
proteins tested (Bavec et al., 2003) ?ĂŶĚƚŚĞ /> ?ŽĨƚŚĞʅ-opioid receptor is 
thought to mediate interactions with its G protein (Chaipatikul et al., 2003).  
/ŶƚĞƌĞƐƚŝŶŐůǇ ? ďŽƚŚ ŝƐŽĨŽƌŵƐ ŚĂĚ ĞƋƵŝǀĂůĞŶƚ ɴ-arrestin and internalisation 
profiles, which is backed up by previous work showing no difference in agonist 
induced phosphorylation of the isoforms (Burns and Moniri, 2010). This shows 
that the ICL3 insert does not affect interactions with ɴ-arrestin. The classical 
model of receptor desensitisation is of threonine and serine residues in the 
carboxyl tail and intracellular loops becoming phosphorylated by GRKs and 
protein kinases, which then allow ɴ-ĂƌƌĞƐƚŝŶƚŽďŝŶĚ ?dŚĞďŝŶĚŝŶŐŽĨɴ-arrestin 
prevents G proteins binding, thus preventing signalling; ĂŶĚ ɴ-arrestin also 
acts as a scaffold for the proteins required for internalisation and 
desensitisation of the receptor (Ferguson et al., 1996). However there are also 
examples that show that for some receptors, ICL3 or carboxyl tail 
phosphorylation is not an absolute requirement for arrestin recruitment. In 
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ƚŚĞʅ-opioid receptor, serine and threonine residues in the carboxyl tail and 
ICL3 were not required for arrestin mediated desensitisation (Celver et al., 
2001).  
Instead, there is some evidence to suggest that there is a contiguous 
recognition site of ten proximal residues in intracellular loop 2 of GPCRs, 
termeĚ ƚŚĞ  “ĂĐƚŝǀĂƚŝŽŶ ƐĞŶƐŽƌ ? ? ƚŚĂƚ ŽŶĞ ƉĂƌƚ ŽĨ ɴ-arrestin2 binds to in a 
phosphorylation independent manner (Marion et al., 2006). This is in 
ĐŽŶũƵŶĐƚŝŽŶǁŝƚŚĂƐĞĐŽŶĚƐŝƚĞ ?ĚƵďďĞĚƚŚĞ “ƉŚŽƐƉŚŽƌǇůĂƚŝŽŶ ?ƐĞŶƐŽƌ ?ƚŚĂƚɴ-
arrestin2 also recognises and binds to in a phosphorylation dependent 
manner. For most GPCRs, both sites must be engaged for internalisation 
(Gurevich and Gurevich, 2006). 
/ŶƚŚĞƐƚƵĚǇŽŶƚŚĞʅ-opioid receptor, ICL2 was also the site of the critical GRK 
phosphorylation site (Thr180) required for arrestin recruitment, again 
ƐŚŽǁŝŶŐ Ă ƌŽůĞ ĨŽƌ /> ? ŝŶ ŵĞĚŝĂƚŝŶŐ ƌĞĐĞƉƚŽƌ ŝŶƚĞƌĂĐƚŝŽŶƐ ǁŝƚŚ ɴ-arrestin 
(Celver et al., 2001). 
A previous study has shown that GPR120 activates two independent signalling 
pathways. In adipocytes, agonist treatment activated signalling through Gq to 
cause glucose uptake, whilst in the macrophage, agonist treatment instead 
elicited anti-ŝŶĨůĂŵŵĂƚŽƌǇ ĞĨĨĞĐƚƐ ƚŚƌŽƵŐŚ ɴ-arrestin2 (Oh et al., 2010). 
Another GPCR, PAR2 has also been shown to activate two signalling pathways, 
ǀŝĂ 'Ƌ ĂŶĚ ɴ-arrestin2 independently (Zoudilova et al., 2007), as has the 
ĂƌĐŚĞƚǇƉĂů'WZɴ2AR (Drake et al., 2008). Perhaps GPR120 activation of  
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Figure 3.30 The structure of GPR120 showing the position of sites of interest. 
This structure of GPR120 shows the potential sites of phosphorylation at 
Ser/Thr residues (shown in blue) and potential ubiquitination sites at Lys 
(shown in red), together with the position of the 346 truncation. 
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these two pathways is isoform specific. Future work should determine 
whether GPR120L is endogenously expressed in different cell types in an 
isoform specific manner, and if so, where, and to confirm whether these 
pathways are isoform specific. These expression studies are critical, because 
some work has shown no evidence for the expression of the long isoform in 
humans (CP, Briscoe, Janssen Pharmaceuticals, private communication). 
3.3.6 Role of the GPR120 carboxyl tail 
Ɛ ƚŚĞƌĞ ǁĂƐ ŶŽ ĞĨĨĞĐƚ ŽĨ ŝƐŽĨŽƌŵ /> ? ĚŝĨĨĞƌĞŶĐĞƐ ǁŚĞŶ ƚŚĞ ɴ-arrestin 
interactions and internalisation responses were measured, the carboxyl tail 
was examined as an alternative regulatory domain in GPR120. This was 
achieved by truncating the tail at amino acid position 346, to remove 5 
Ser/Thr residues (Figure 3.30). The carboxyl tail was found to be critical for 
GPR120 G protein signal desensitisation, as the calcium data demonstrated. 
This also revealed that GPR120S calcium responses undergo rapid 
desensitisation. This may account for the difference in profile observed 
between GPR120S and FFA1, even though they both predominantly couple to 
the same class of G protein, Gq/11. Following removal of the carboxyl tail, i.e. 
the desensitisation domain, the peak response of GPR120S became as robust 
as that of FFA1. 
Additionally, these residues in the distal carboxyl tail also appear critical for 
internalisation, as their removal reduced the extent of internalisation but 
interestingly did not prevent internalisation. These results were unusual, 
because they suggest a separation of desensitisation and internalisation that 
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is in contrast to the dogma that desensitisation and internalisation are 
ƐĞƋƵĞŶƚŝĂůĂŶĚďŽƚŚĚĞƉĞŶĚĞŶƚƵƉŽŶɴ-arrestin proteins. 
Previous work on the follicle stimulating hormone receptor has shown it to 
have separate sites for phosphorylation required for uncoupling 
(desensitisation) present on ICL3, whilst phosphorylation sites for 
internalisation are thought to be on ICL1 predominantly, with a little 
involvement of sites on ICL3 (Nakamura et al., 1998a). Also, agonist induced 
activation and phosphorylation were found not to be essential for 
internalisation (Malecz et al., 1998) ?ǁŚŝůƐƚĂŶŝŶƚĞƌĂĐƚŝŽŶǁŝƚŚɴ-arrestin was 
required for internalisation (Nakamura et al., 1998b). Also, one residue, S421 
found in the carboxyl tail of the 5HT2A serotonin receptor has shown to be key 
for facilitating desensitisation (Gray et al., 2003). ZĞĐĞŶƚ ĞǀŝĚĞŶĐĞ ĨŽƌ ɴ2AR 
ƐƵŐŐĞƐƚƐĂ “ƉŚŽƐƉŚŽƌǇůĂƚŝŽŶďĂƌĐŽĚĞ ?ƐǇƐƚĞŵ (Butcher et al., 2011; Nobles et 
al., 2011), where differential phosphorylation signals for different receptor 
outcomes (Budd et al., 2001). Another example of differential 
phosphorylation is found with the melanocortin 1 receptor. When GRK2 
phosphorylated, it did not undergo internalisation (only desensitisation), 
whilst GRK6 caused internalisation (Sanchez-Laorden et al., 2007). Another 
study, on the N-formyl peptide receptor demonstrated no correlation 
between tŚĞ ďŝŶĚŝŶŐ ŽĨ ɴ-arrestin and the processes of receptor 
desensitisation and internalisation (Potter et al., 2006). 
Taken together, perhaps something similar is also true for GPR120, suggesting 
a paradigm of differential phosphorylation, whereby phosphorylation of 
residues in the distal carboxyl tail are responsible for desensitisation and 
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uncoupling, whilst residues elsewhere in the proximal carboxyl tail or on the 
ŝŶƚƌĂĐĞůůƵůĂƌ ůŽŽƉƐĂƌĞƌĞƋƵŝƌĞĚĨŽƌƌĞĐĞƉƚŽƌ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ?tŚŝůƐƚɴ-arrestin 
dependent mechanisms of internalisation are expected to predominate, 
'WZƐ ĐĂŶ ĂůƐŽ ŝŶƚĞƌŶĂůŝƐĞ ƚŚŽƵŐŚ ɴ-arrestin independent mechanisms 
(Mundell et al., 2006). 
3.3.7 Pharmacology of constrained fatty acid receptor dimers 
The BiFC technique was again utilised to test the influence of fatty acid 
receptor dimerisation of pharmacology, by creating constrained dimers. The 
key advantage of using BiFC is that it allowed specific GPR120S homo- or 
hetero-dimers to be visualised and their pharmacology assessed in the 
internalisation assay in comparison to the overall SNAP-GPR120S-vYNL 
population in the same cells. There are also limitations to this technique, 
chiefly that BiFC is an irreversible process and thus has potential to generate 
dimers that might otherwise not exist (or exist transiently) for endogenous 
receptors. The extent of measured dimerisation can vary depending on the 
GPCR being studied and the technique used, for example reconstitution of 
GPCRs into lipid discs discovĞƌĞĚ ƚŚĞ ʅ ŽƉŝŽŝĚ ƌĞĐĞƉƚŽƌ ƚŽ ďĞ ŝŶ ŵŽŶŽŵĞƌŝĐ
form (Kuszak et al., 2009); whilst TIRF found only a proportion of antagonist-
occupied M1 muscarinic receptors formed dimers (Hern et al., 2010). 
ĚĚŝƚŝŽŶĂůůǇ ? ƚŚĞƌĞ ŝƐ ĞǀŝĚĞŶĐĞ ĨŽƌ ďŽƚŚ ɴ1AR transient dimerisation and 
ƐƵƐƚĂŝŶĞĚɴ2AR dimer formation (Dorsch et al., 2009), discussed in more detail 
in section 1.6.5. 
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This study of constrained FFA dimers was important, because in 
pharmacologically relevant and important tissues, for example the colonic L 
cells in the gut, GPR120S (Hirasawa et al., 2005) and FFA1 (Edfalk et al., 2008) 
are both expressed. If these receptors undergo heterodimerisation in these 
sites, with altered pharmacology, any drugs designed to target either receptor 
may have limited effectiveness. Alternatively, this BiFC assay could be used to 
ĚŝƐĐŽǀĞƌŵŽƌĞĞĨĨĞĐƚŝǀĞ “ŚĞƚĞƌŽ-ĚŝŵĞƌ ?ƐƉĞĐŝĨŝĐĐŽŵƉŽƵŶĚƐ ?
In the calcium assay, when measuring responses of the co-expressed receptor 
populations, the receptor subtypes could be acting independently, e.g. in 
GPR120S:GPR120L, the presence of GPR120L does not prevent calcium 
mobilisation, but the calcium signal could be due to GPR120S acting alone. 
Also, the GPR120S:FFA1 cells had a 2 component calcium response to 
GW9508, with both components approximately fitting to the pEC50 values for 
each receptor when expressed alone i.e. 7.1 at FFA1 and 5.5 at GPR120S. 
In the internalisation assay, GW9508 was found to be more potent in the 
'WZ ? ? ?^ P&& ?  “ĚŝŵĞƌ ? ? ǁŚŝĐŚ ŝƐ ŶŽƚĞǁŽƌƚŚǇ ďĞĐĂƵƐĞ && ? ĚŽĞƐ ŶŽƚ ƌĞĂĚŝůǇ
undergo agonist induced endocytosis alone (data not shown). These data 
suggest binding of GW9508 to the higher affinity FFA1 binding site can 
support greater internalisation of the BiFC heterodimer, but require further 
work for confirmation.  
Future work on the heterodimerisation cell lines could be to use more ligands, 
for example GW1100 is an antagonist at FFA1 but is inactive at GPR120 
(Briscoe et al., 2006). GW1100 would therefore be interesting to use on 
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GPR120S:FFA1, to see what pharmacology it produced in terms of both 
calcium and internalisation responses. It would also be interesting to use 
additional more selective agonists that have differing orders of potency at 
ĞĂĐŚ ƌĞĐĞƉƚŽƌ ? ƚŽ ƐĞĞ ǁŚĂƚ ĞĨĨĞĐƚ ƚŚĞ  “ĚŝŵĞƌ ? ŚĂƐ ŽŶƚŚĞŝƌ responses, for 
example Met36 (Chapter 4) (Ma et al., 2010). The use of a biophysical 
technique, such as FRET (Herrick-Davis et al., 2004) or BRET (Babcock et al., 
2003) has also been popular in the study of dimerisation, in conjunction with a 
biochemical technique such as Western blotting. BRET is advantageous 
because it can be done in living cells without the use of laser excitation, whilst 
FRET can be utilised to determine the subcellular localisation of the signal 
(Herrick-Davis et al., 2004). TR-FRET has also been shown to be undertaken 
successfully in native tissues (Albizu et al., 2010), which was of great 
importance because other techniques, including the ones used here, rely 
upon overexpression of a receptor in an artificial, recombinant system and 
may also require a good native antibody or a good fluorescent ligand (Chapter 
5). 
3.4 Future work 
A crucial next step in this work will be to determine the expression of 
endogenous human GPR120 isoforms, confirm that the longer isoform is 
expressed, and whether the isoforms have differential expression to 
physiologically match their different signalling profiles in various cell types. 
Future work could also be undertaken on the role 'ɲŐƵƐƚĚƵĐŝŶ (a Gi related 
protein) plays in relation to FFA receptors. Gustducin was originally found in 
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the taste cells, but has also been found in gut enteroendocrine K and L cells 
and has been implicated in the secretion of GLP-1 (Jang et al., 2007), which is 
intriguing as GPR120 is known to promote the release of GLP-1 (Hirasawa et 
al., 2005) and CCK (Tanaka et al., 2008a). Perhaps gustducin is the link 
between FFA receptors and incretin secretion, as gustducin was found to be 
co-expressed in 17 % of GPR120 cells and 40 % of FFA1 cells (Li et al., 2013). 
Additionally, lipids suppress ghrelin levels post prandial to promote satiety. 
Further work could be to ascertain whether this signalling involves FFA 
receptors because one study has found that GPR120 may also be involved in 
ghrelin signalling to cause cessation of ghrelin initiation of hunger sensations 
(Janssen et al., 2012). 
Another area of interest is to ascertain the domains involved in GPR120 
signalling and trafficking. To continue the interesting results from the carboxyl 
tail data, a more targeted study could be undertaken to ascertain the roles of 
individual Ser/Thr residues within the carboxyl tail region of deletion, and see 
ǁŚĞƚŚĞƌ ƚŚĞǇ ĐŽƵůĚ ƌĞƉƌĞƐĞŶƚ Ă  “ƉŚŽƐƉŚŽƌǇůĂƚŝŽŶ ďĂƌĐŽĚĞ ? ? ůƐŽ ? 'WZ ? ? ?
internalisation could be further studied by confirming GPR120 internalisation 
ŝƐɴ-arrestin2 dependent using siRNA approaches (Abrisqueta et al., 2013). In 
addition to that, further analysis could be carried out on the confocal images 
depicting trafficking of the receptors to the lysosomes, by applying a 
colocalisation algorithm.  
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Chapter Four: Investigation of the GPR120 binding site 
using mutagenesis 
4.1 Introduction 
FFA1 and GPR120 are potential therapeutic targets for type II diabetes and 
obesity (chapter 1). So far, a number of synthetic ligands have been 
developed and tested, but these are mainly agonists at FFA1. This has mostly 
been carried out in the absence of any detailed knowledge of the FFA 
receptor family binding site, aside from theoretical modelling. Therefore, 
elucidating more detail about these binding sites especially for GPR120 is key, 
and this will potentially allow for the design of ligands with greater selectivity 
for GPR120. 
4.1.1 Structure activity relationships for synthetic ligands at FFA1 and 
GPR120 
Generally, both FFA1 (Briscoe et al., 2003) and GPR120 (Hirasawa et al., 2005) 
are activated by long chain fatty acids, 6 W22 and 14-22 carbons in length 
respectively. Other synthetic ligands such as GW9508 and Metabolex 
compound 36 (Met36; Figure 4.1) have a similar length of the ligand 
backbone, suggesting that there is an optimum carbon chain length, 
presumably for sitting correctly within the binding pockets. 
The key characteristic of both FFAs and most synthetic agonists at FFA1 and 
GPR120 is the requirement for a carboxylate group (Figure 4.1; Table 4.1). This 
is particularly shown by comparison of the activity of fatty acids to the 
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inactivity of the corresponding FFA esters that lack this group, e.g. in GPR120 
(Hirasawa et al., 2005), see also Chapter 1). Interestingly, TZDs do not contain 
a carboxylate, but have a 2,4-dione group that does the same function for 
FFA1 (Smith et al., 2009) and GPR120 agonism (see Chapter 3). In addition 
both Banyu patented GPR120 agonists lack functional acid groups entirely 
(Arakawa et al., 2010; Hashimoto et al., 2010). 
Moving along the structure, the majority of FFA1 and GPR120 agonists then 
contain an aromatic moiety (e.g. phenyl ring) at a structurally defined 3 
carbon position from the terminal carboxylate group. For example, this phenyl 
group in GW9508 was proposed to mimic the conformational restriction of 
carbon double bonds in unsaturated FFAs, such as linolenic acid (Briscoe et al., 
2006). An equivalent aromatic-dione spacing is also shared in TZDs, which 
formed the structural template for FFA1 agonists such as Merck compound B 
(Figure 4.1). A central oxygen (ether) or nitrogen (amino) links this 
pharmacophore with a second bulky aromatic group in majority of agonists, 
including TZDs and the Banyu derivatives (Figure 4.1). In the TUG series of 
FFA1 agonists however (e.g. Christiansen et al., 2008), this is substituted by an 
ethyne triple bond.  
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Figure 4.1 Chemical structures of example FFA GPCR agonists (A) and 
antagonists (B). Information on agonist pharmacology, with references, is 
provided in Table 1. The structure of Met36 is reproduced from the relevant 
GPR120 agonist patent (Ma et al., 2010) and two Banyu compounds are 
shown from isoindolin-1-one derivativesa (cpd 2; Arakawa et al., 2010) and the 
phenyl-isoxazol-3-ol seriesb (cpd 15; Hashimoto et al., 2010). GW1100 (Briscoe 
et al., 2006), Pfizer compound 15i (Humphries et al., 2009) and DC260126 (Hu 
et al., 2009) inhibited agonist stimulated FFA1 receptor calcium responses in 
transfected cells with respective pIC50 values of 6.0, 7.7, and 6.0. 
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Agonist FFA1 pEC50 GPR120 pEC50 Selectivity and comments References 
Example FFAs     
Palmitic Acid (C16:0) 5.2-5.3 4.3 Several actions as nutrients and 
signalling molecules. Potency observed 
highly dependent on assay constituents 
(e.g. BSA) 
(Briscoe et al., 2003; Hirasawa 
et al., 2005; Itoh et al., 2003) 
 Oleic Acid (C18:1) 4.4-5.7 4.5 
DHA(C22:6) 5.4-6.0 5.4 
PPARɶ agonists     
Rosiglitazone 5.0-5.6a N.D. GPR40 activity shared by related TZDs 
such as Troglitazone, Ciglitazone and 
Pioglitazone. Low potency GPR120 
agonism for Rosiglitazone (at 100 µM) 
(Hara et al., 2009a; Kotarsky et 
al., 2003; Smith et al., 2009; 
Watson et al., 2012) 
 
FFA1 agonists     
MEDICA16 5.5-5.9a <5.0  (Hara et al., 2009b; Kotarsky et 
al., 2003) 
 
GW9508 6.6-7.3 5.5 GPR40 activity 100 fold selective over a 
panel of 360 other targets. pEC50 values 
ĨŽƌWWZɲ ?ɷĂŶĚɶǁĞƌĞ ? ? ? ? ? ? ?ĂŶĚ
4.9 respectively 
(Briscoe et al., 2006; Smith et 
al., 2009; Sum et al., 2007) 
 
Cpd B 7.1 N.D. Lead compound of series inactive at 
PPARs (< 10 µM). GPR40 knockout 
abolished effects of Cpd B and C on 
insulin secretion in vivo 
(Tan et al., 2008; Zhou et al., 
2010) 
 
Cpd C 6.8 
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TUG424 7.5b N.D. No activity at FFA2 and FFA3 reported 
(TUG424). Cpd 37 has  100 fold 
selectivity for FFA1 over FFA2, FFA3 
and PPARs, with improved 
pharmacokinetic properties owing to 
reduced lipophilicity 
(Christiansen et al., 2012; 
Christiansen et al., 2008) 
 
Cpd 37 7.1b 
TAK-875 7.1c N.D.  (Sasaki et al., 2011; Tsujihata 
et al., 2011) 
 
AMG-837 
 
 
7.9a > 5.0 Partial agonist at FFA1, increases GSIS 
and lowered post-prandial glucose 
levels (0.05 mg / kg) in normal rats 
(Lin et al., 2011) 
Cpd 40 7.7 N.D.   (Christiansen et al., 2013) 
GPR120 agonists     
Grifolic acid N.D. N.D. Weak GPR120 partial agonist without 
GPR40 activity (at 100 µM). 
(Hara et al., 2009b) 
NCG21 (Cpd 12)  4.7 5.9 Lacks PPARɲ ?ɶ ?ɷ agonist activity (at 
100 µM) 
(Sun et al., 2010; Suzuki et al., 
2008) 
Isoindolin-1-one series (Cpd 2) N.D. 6.7 Banyu patent (Arakawa et al., 2010) 
Phenyl-isoxazol-3-ol series (Cpd 
15) 
N.D. 7.2 Banyu patent (Hashimoto et al., 2010) 
Met36 (Cpd 36) N.D. > 6.0 Cpd 36 (100 mg / kg) reduced glucose 
excursion by 45 % after an oral glucose 
tolerance test in lean C57Bl/6J mice 
(Ma et al., 2010) 
TUG 891 (Cpd 43) 4.2 7.4 No activity at FFA2 and FFA3 (Shimpukade et al., 2012) 
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Table 4.1 Summary of long chain FFA GPCR agonist pharmacology 
Agonist pEC50 values quoted were obtained from fluorescent indicator measurements of Ca
2+
 mobilization, except aSmith et al.(2009) compared 
TZD agonism for FFA1 ERK activation, while Kotarsky et al.(2003) and Lin et al (2011) measured FFA1 Ca2+ signalling using an aequorin reporter 
gene; bmeasurement of insulin secretion/DMR assay; cmeasurement of inositol phosphate accumulation; Shimpukade et al (2012) used a BRET 
assay. N.D. not determined; pEC50 values have not been published.  
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All agonists contain a terminal aromatic group (phenyl or biphenyl group) 
which connects to the rest of the molecule via the phenylproprionic acid 
moiety (the ether or amino group). There is limited information on this 
terminal aromatic group; for example TUG-424 and compound 42 (Figure 4.1) 
had the highest potency in their compound series, thought to be due to the 
methyl group being in the ortho position (Christiansen et al., 2008). 
Interestingly, as far as can be deduced, GPR120 selective compounds such as 
Met36 and TUG-891 appear to be characterised by the bulky aromatic groups 
in the ortho position ? ǁŚŝĐŚ ĐƌĞĂƚĞƐ Ă ƐƚƌƵĐƚƵƌĂů  “ŬŝŶŬ ? ŝŶ ƚŚĞ ƐƚƌƵĐƚƵƌĞ ŝŶ
contrast to the FFA1 selective GW9508 (Figure 4.1). 
Conversely, there are very few antagonists for the FFA receptors, with 
micromolar affinity, for example GW1100 at FFA1 (Briscoe et al., 2006). The 
three antagonists in the public domain (Figure 4.1) are structurally diverse, 
thus there is no clear SAR yet. Additionally, there are no antagonists for 
GPR120. 
Allosteric modulation of FFA receptors may also be possible. Allosteric 
compounds target an alternative binding site to the orthosteric FFA binding 
site to influence receptor activation (e.g. by the endogenous agonist) and they 
have the advantage of improving receptor selectivity, e.g. between FFA1 and 
GPR120 (May et al., 2007). Allosteric compounds have been discovered for 
another receptor in the FFA family, FFA2 (Lee et al., 2008), and as will be 
discussed in Chapter 5, an allosteric component to the action of some existing 
FFA1 agonists (e.g. GW9508) has been suggested. 
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4.1.2 Ligand binding to lipid GPCRs 
Although no FFA receptor has yet been crystallised, a high resolution structure 
of one lipid GPCR, the sphingosine-1-phosphate (S1P) receptor, has been 
obtained (Hanson et al., 2012). This structure showed that the amino 
terminus appears to fold over the top of the receptor, which in combination 
with the positions of ECL1 and 2, forms a barrier that appears to limit 
 “ĚŽǁŶǁĂƌĚƐ ? ůŝŐĂŶĚ ĂĐĐĞƐƐ ƚŽ ƚŚĞ ďŝŶĚŝŶŐ ƉŽĐŬĞƚ ?Uniquely this suggested 
that the ligand access is only through partitioning into the hydrophobic 
environment of the plasma membrane, through a gap between TM 1 and TM 
7 ? KŶĐĞ ƚŚĞ ůŝŐĂŶĚ ŝƐ  “ĚŽĐŬĞĚ ? ŝŶƚŽ ƚŚĞ ďŝŶĚŝŶŐ ƉŽĐŬĞƚ (located in the 
extracellular half of the receptor transmembrane domains), the polar 
phosphate headgroup is orientated towards the top of the binding pocket, 
coordinating with positive polar TM residues of Asn and Arg. This parallels the 
models of ligand binding with FFA1 (Sum et al., 2007) and GPR120 (Suzuki et 
al., 2008), as suggested by the inactivating effects of mutations of these 
residues (e.g. Arg 258 in FFA1, Chapter 3) The hydrophobic tail of the S1P 
(identical to a FFA carbon chain) sits in the binding pocket (Hanson et al., 
2012), reaching the highly conserved residue W6.48 (Ballesteros-Weinstein 
numbering system (Figure 4.2)) that is thought to play a key role in GPCR 
activation (see Chapter 1) (Holst et al., 2010).  
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Figure 4.2 The structure of GPR120 showing the position of the most 
conserved residue in each TM helix and the sites of mutation in this study. 
The Ballesteros-Weinstein system of numbering allows comparison of a 
residue in an equivalent position between different GPCRs, The most 
conserved residue is set as  “x. ? ? ?(shown in squares), with this number 
decreasing for residues closer to the amino terminus or increasing if closer to 
the carboxyl terminus (Ballesteros and Weinstein, 1995). The sites of mutation 
made in this study are in green, and the sites of other residues of interest in 
the Ulven model are shown in blue (Shimpukade et al., 2012).  
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4.1.3 The key features of the FFA1 receptor binding site 
Although the crystal structure of FFA1 or GPR120 has not yet been 
determined, homology studies have developed models of the binding sites by 
mapping the receptor sequences onto crystal structures of other class A 
GPCRs, such as ɴ2AR. For FFA1, recent investigations have also begun to test 
such models using site directed mutagenesis. 
4.1.3.1 Docking of carboxylate on the ligand into the binding site 
The negatively charged carboxylate group present on the majority of agonists 
was proposed to dock into the positive residues Arg183 and Arg258 on FFA1 
(Sum et al., 2007; Tikhonova et al., 2007), although one study suggests that 
Arg258 is thought to be solely important for binding linoleic acid (Takeuchi et 
al., 2013). The importance of Arg258 for oleic acid and GW9508 FFA1 
responses was confirmed in Chapter 3. In the Sum et al. (2007) investigation, 
mutation of Arg183 (TM 5), Asn244 (ECL3) and Arg258 (TM 7; Figure 4.2) all 
reduced the magnitude of response to linoleic acid, whilst mutation of R183A 
or R258A removed all responses to GW9508. The positive Arg residues, 
located at the top of the TM domains are thought to play a role in orientation 
of the agonist so that the lipophilic portion sits in the lower hydrophobic 
binding pocket (Sum et al., 2007; Sun et al., 2010). There is thought to be 
additional anchorage from His137 for GW9508, because the 3-phenoxy 
portion of GW9508 forms a hydrophobic interaction with His137 (Tikhonova 
et al., 2008; Tikhonova et al., 2007), and/or His86 and His 98 (Sum et al., 
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2007), but this is not universally agreed (Smith et al., 2009), highlighting the 
difficulty of using mutagenesis studies to determine and confirm binding sites. 
4.1.3.2 Role of ECL2 in ligand binding at FFA1 
From an FFA1 homology model based on the inactive ɴ2AR, ECL2 residues 
Glu145 and Glu172, along with aforementioned Arg183 and Arg258 were 
found to control FFA1 activation by agonists (Sum et al., 2009). Glu145 (ECL2; 
postulated to face into the binding pocket) formed a constraining hydrogen 
bond with Arg183 (TM 5), whilst Glu172 (ECL2) formed a hydrogen bond with 
Arg258 (TM 7). These residues appear important because these interactions 
hold the receptor in an inactive state and so are disrupted following the 
binding of GW9508 or linoleic acid. Then the negatively charged carboxylate 
of the ligand instead undergoes interactions with the positively charged 
binding site of Arg183, Arg258 and Asn244, causing the receptor to adopt the 
active conformation. It was also suggested that perhaps antagonists, without 
the requisite carboxylate groups, are unable to cause release of this ionic lock 
(Sum et al., 2009). Other GPCRs also contain a negatively charged Glu or Asp 
residue in ECL2 (a Cx(E/D) motif) which corresponds to Glu172 to FFA1. It has 
been postulated that these negative charges form a counter ion to the 
positively charged residues in the agonist binding pocket. This extracellular 
loop ionic lock also appears to be conserved in other class A purinergic and 
muscarinic GPCRs (Costanzi et al., 2005; Scarselli et al., 2007). Such residues 
thus appear to be involved in receptor activation, but not in direct ligand 
binding interactions (Sum et al., 2009). 
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4.1.3.3 Published models of GPR120 binding site 
In contrast to FFA1 with its multiple Arg sites in the receptor binding site, 
GPR120 contains a single predicted coordinating residue, Arg99 at the top of 
TM 2 (Suzuki et al., 2008). Two untested homology models have been 
published on GPR120, one using bovine rhodopsin (Sun et al., 2010) and the 
ŽƚŚĞƌƵƐŝŶŐƚŚĞɴ2AR structure as the template (Shimpukade et al., 2012). The 
ɴ2AR  “hůǀĞŶ ?model shows Met118, Thr119, Gly122, Phe211, Asn215, Trp277, 
Ile280, and Ile281 forming a narrow lipophilic binding pocket (Figure 4.2). 
Met, Ile and Val are hydrophobic residues, predicted to make hydrophobic 
contacts with the biphenyl moiety on the ligand, whilst Trp277 is the Trp 6.48 
that is highly conserved throughout class A GPCRs, and appears to be key for 
forming a hydrogen-bond with the ether-oxygen present in the agonist TUG-
891 (Figure 4.1). Additionally, the phenylpropionate group present in some 
agonists is predicted to interact with Phe304 on the top side and Phe311 on 
the bottom side (Shimpukade et al., 2012). 
In the rhodopsin-based model, the hydrophobic residues that were suggested 
to form interactions between the ligand and the binding pocket were Met115, 
Leu187 and Phe202 which interacted with the phenyl ring on the ligand. Also 
in this model, ECL2 was modelled showing contact with the ligand, perhaps 
through Trp198 (Sun et al., 2010), whilst ECL2 was not mentioned in the Ulven 
model (Shimpukade et al., 2012). 
Of note with both GPR120 models and the sphingosine 1-phosphate receptor 
structure, was that the agonist compounds penetrated quite deeply into the 
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TM domains of the receptor, which contrasts with the antagonist carazolol, 
which was bound at a relatively shallow position ǁŝƚŚŝŶƚŚĞdDŚĞůŝĐĞƐŽĨɴ2AR 
(Cherezov et al., 2007). 
4.1.4 AstraZeneca model of GPR120 binding site 
In this study, the AstraZeneca (AZ) model of GPR120 was used (provided by 
Dr. Graeme Robb, CVGI, Alderley Park), based on the crystal structure of the 
active 2-adrenoceptor (Rasmussen et al., 2011) and docked with various 
agonists including Met36 (Figure 4.1). Using the active structure has the 
potential advantage that in studying agonist binding to an activated receptor, 
this will give more relevant information for the design of therapeutically 
relevant GPR120 agonists. 
This model also defined the narrow lipophilic pocket as containing Met118, 
Thr119, Gly122, Phe211, Asn215, Ile280, Ile281 and Trp277, similar to the 
Ulven model (Shimpukade et al., 2012). The AZ model also contained Trp277, 
the highly conserved Trp 6.48, which was thought to interact via a water 
molecule to the nitrogen in the ring of Met36. As with the Ulven model of 
GPR120, the phenylpropionate moiety of Met36 forms stacking interactions 
with both Phe311 in the AZ model (Figure 4.3, 4.4), and Phe304 (G. Robb, 
personal communication). 
Finally, Asn215 was implicated in a second form of the AstraZeneca model, in 
mediating polar interactions with the pyrazole ring of Met36 instead of the 
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There are also similarities between the AstraZeneca model and the crystal 
structure of S1PR (section 4.1.5). The S1PR ligand, ML056 sits in the binding 
pocket in the same orientation as the postulated orientation of oleic acid in 
GPR120 in the AZ model, with the phosphate head interacting with Arg120 in 
TM 3. The phenyl acyl tail of ML056 also sits in a hydrophobic pocket that is 
lined with aromatic residues, 4 of which predicted to interact with the ligand 
(Hanson et al., 2012), which is also similar to the AZ model of GPR120 (Figure 
4.5). 
4.1.5 Aims 
Currently, with the exception of GPR120 Arg99 (Sun et al., 2010; Watson et 
al., 2012), all evidence for GPR120 ligand binding is based on modelling, whilst 
the FFA1 models have been tested by mutagenesis. Therefore, the aim of this 
work was to re-address this situation, by mutating key interactions, as 
identified by the AZ model, and study their effects upon GPR120S receptor 
activation using calcium signalling and internalisation assays with 4 
representative agonist compounds. The residues studied were Arg99 (2.64), 
Arg178 (4.65), Asn244 (5.46), Trp277 (6.48) and Phe311 (7.43), with the 
numbers in brackets referring to their Ballesteros-Weinstein numbering. In 
the rest of the chapter, the mutants will be referred to by their numbering 
from the GPR120S sequence (Figure 4.2).  
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Figure 4.3 Model of Met36 within the GPR120 binding site. 
The known interaction of Arg99 with the carboxylate is shown. Another 
interaction is Trp277 (Trp293 in figure) and Gly122 (a backbone residue in 
GPR120) with a water molecule interacting with the pyrazole (the nitrogen 
containing ring) present in Met36. The model also implicated Phe311 (Phe327 
in figure, which uses GPR120L numbering) in forming an aromatic stacking 
interaction with the ligand. An alternative hypothesis had Asn215 as an 
interaction in place of the water molecule. Figure provided by Dr G. Robb (AZ). 
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Figure 4.4 GW9508 docked into GPR120 binding site, with key residues from 
model highlighted. 
This shows the synthetic ligand, GW9508 (green stick figure, with space filling) 
undergoing interactions with the three residues to be tested from the mode: 
Asn215, Trp277 (labelled as Trp293) and Phe311 (labelled as Phe327, for 
GPR120L isoform). Figure provided by Dr. G. Robb (AZ).  
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Figure 4.5 Oleic acid docked into GPR120. 
This shows oleic acid (space filling) sitting within the whole homology 
modelled receptor. Figure provided by Dr. G. Robb (AZ).  
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4.2 Results 
4.2.1 Quantification of GPR120S mutant expression levels 
Alanine SNAP-GPR120S mutants were constructed at Arg99 (R99A), Arg178 
(R178A), Asn215 (N215A), Trp277 (W277A) and Phe311 (F311A) and Trp277 
was also substituted with a more conservative amino acid, phenylalanine 
(W277F). Receptor cDNAs were stably and inducibly expressed as mixed 
populations in HEK293TR cells, and their function compared with the cell line 
expressing WT SNAP-GPR120S (see Chapter 3). The expression levels of the 
mutants reaching the plasma membrane were determined using platereader 
imaging of SNAP-surface labelled receptors (Figure 4.6) and quantified using a 
cell scoring algorithm (see section 2.2.9.3.2 and chapter 3). In Figure 4.7 (and 
in the images used for quantification, Figure 4.6), the same acquisition 
settings were used (and brightness/contrast image adjustments) to compare 
cell lines. As the SNAP-surface fluorophore used is membrane impermeant, 
fluorescent labelling of the receptor indicates that it has the ability to reach 
the cell surface. This was done to ascertain that the mutation had not 
prevented receptor folding and expression, and so that any functional effects 
were relevant with respect to ligand binding and/or activation.  
The R99A mutant had reduced cell surface expression and also underwent 
constitutive internalisation. W277A also had significantly lower cell surface 
expression than WT. Conversely, W277F had significantly increased expression 
relative to WT (Figure 4.7; representative images Figure 4.6). All other 
receptor mutants had similar expression levels to WT, were predominantly 
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cell surface localised when vehicle treated and underwent some agonist 
induced endocytosis.  
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Figure 4.6 Representative images of GPR120S mutant expression levels. 
Images were acquired on the IX Ultra of HEK293TRs stably transfected with 
the SNAP-GPR120S mutant as indicated, following SNAP-surface AF-488 
labelling (0.1 µM) and ƚƌĞĂƚŵĞŶƚǁŝƚŚǀĞŚŝĐůĞŽƌ ? ? ?ʅDoleic acid for 60 min 
at 37oC. Images (here showing 25 % of the original Ultra image) were acquired 
using the same laser power and gain settings, and have undergone identical 
level adjustments to enable comparison between cell lines ?^ĐĂůĞďĂƌA? ? ?ʅŵ ? 
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Figure 4.7 Relative expression levels of the SNAP-GPR120S mutants. 
Using images acquired on the IX Ultra of HEK293TRs stably transfected with 
the mutants (Figure 4.5), relative expression levels of each mutant relative to 
WT could be determined using a multiwavelength cell scoring algorithm. The 
mutant data from each experiment shown was normalised (%) to GPR120S 
WT cells on the same plate, and then pooled from 4 - 6 individual 
experiments, mean ± S.E.M. SignificancĞǁĂƐŵĞĂƐƵƌĞĚƵƐŝŶŐ^ƚƵĚĞŶƚ ?Ɛt test; 
*** p < 0.001.  
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4.2.2 Calcium responses of GPR120 mutants 
Next, the mutants were tested in a traditional signalling assay, for their ability 
to elicit calcium responses in response to unsaturated oleic acid (C18:1), 
saturated myristic acid (C14:0), GW9508 or Met36. Concentration response 
curves to the four agonists were constructed from peak responses and 
expressed as fold over basal levels. 
R99A and W277A substitutions completely inhibited SNAP-GPR120S calcium 
responses to all agonists, whilst the R178A mutant stimulated calcium 
mobilisation in an equivalent manner to WT (Figure 4.8; Figure 4.9; Table 4.2). 
Interestingly (and in contrast to the effects of W277A), W277F increased 
GPR120S responses to FFAs (significantly for  ? ? ? ʅD ŵǇƌŝƐƚŝĐ ĂĐŝĚ), had no 
effect on GW9508 concentration response curves, and reduced the potency of 
Met36. Equally the N215A mutant had a significantly decreased response to 
 ? ? ? ʅDMet36, reducing its potency, but had no significant effect on 
responses to other agonists. F311A substitution did not alter SNAP-GPR120S 
calcium responses significantly, but there was a slight right shifting in the 
response curve to Met36 (Figure 4.8; Table 4.2; n = 4). 
The time courses of GPR120S calcium responses were also compared to 
maximum agonist concentrations (myristic acid responses omitted for clarity). 
N215A responses to oleic acid and GW9508 were more transient than WT 
(significant at 60 s); whilst W277F responses to GW9508 was also significantly 
reduced at 60 s compared to WT (Figure 4.10; Table 4.3; n = 4).  
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Figure 4.8 The effects of the SNAP-GPR120S mutations upon the calcium 
concentration responses to oleic acid, myristic acid, GW9508 and Met36. 
HEK293TRs expressing SNAP-GPR10S WT, R99A, R178A, N215A, W277A/F or 
F311A were treated with oleic acid (A-B), myristic acid (C-D), GW9508 (E-F) or 
Met36 (G-H). The peak calcium responses were measured by changes in Fluo4 
fluorescence on a FlexStation III, were analysed as fold over basal and pooled 
from 4-6 individual experiments, mean ± S.E.M.  
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Calcium 
       
 
pEC50 Rmax (fold over basal) 
Agonist Oleic Acid Myristic Acid GW9508 Met36 Oleic Acid Myristic Acid GW9508 Met36 
WT 4.2 ± 0.3 N.D. 5.4 ± 0.2 4.7 ± 0.1 1.5 ± 0.2 1.6 ± 0.2 1.9 ± 0.2 3.5 ± 0.1 
Mutant 
   
  
    R99A N.D. N.D. N.D. N.T. 1.1 ± 0.1 1.1 ± 0.1 1.1 ± 0.1* N.T. 
R178A N.D. N.D. 5.2 ± 0.2 N.T. 1.7 ± 0.1 1.8 ± 0.1 2.2 ± 0.1 N.T. 
N215A 4.4 ± 0.4 N.D. 5.2 ± 0.1 N.D. 1.9 ± 0.3 2.1 ± 0.2 2.4 ± 0.1 1.9 ± 0.1*** 
W277A N.D. N.D. N.D. N.T. 1.1 ± 0.1 1.1 ± 0.1 1.1 ± 0.1* N.T. 
W277F 4.8 ± 0.2 4.9 ± 0.2 5.4 ± 0.2 N.D. 1.1 ± 0.1 2.5 ± 0.1*** 2.0 ± 0.3 2.3 ± 0.1*** 
F311A 4.8 ± 0.3 4.4 ± 0.3 5.2 ± 0.2 4.8 ± 0.1 2.1 ± 0.3 2.1 ± 0.2 2.8 ± 0.2** 2.9 ± 0.1** 
Table 4.2 Potency and maximal calcium responses of GPR120S mutants to different agonists. 
EC50 values and maximal responses of GPR120 mutants in response to agonist as measured using the calcium assay (see concentration 
response curves in Figure 4.8). The responses shown were analysed as fold over basal, and pooled from 4 - 5 individual experiments, mean ± 
S.E.M. Statistical significance was ĚĞĨŝŶĞĚƵƐŝŶŐŽŶĞǁĂǇEKsĂŶĚƵŶŶĞƚƚ ?ƐƉŽƐƚƚĞƐƚ ?P < 0.05; ** P < 0.01. N.D.-not determined, N.T.-not 
tested. 
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Figure 4.9 The effect of R99A or R178A mutations upon the time course of 
SNAP-GPR120S stimulated ĐĂůĐŝƵŵŵŽďŝůŝƐĂƚŝŽŶŝŶƌĞƐƉŽŶƐĞƚŽ ? ? ?ʅDŽůĞŝĐ
ĂĐŝĚĂŶĚ ? ? ?ʅD't ? ? ? ? ? 
HEK293TRs expressing SNAP-GPR120S WT, R99A or R178A were treated with 
 ? ? ? ʅDŽůĞŝĐĂĐŝĚŽƌ  ? ? ? ʅD't ? ? ? ?and their calcium response recorded 
over 165 s. Dotted line indicates the time of agonist addition. The data shown 
were pooled from the raw fluorescence values (as relative fluorescence units, 
RFU) from 4-5 individual experiments, mean ± S.E.M. N.B. these data were not 
normalised in the same way as Figure 4.10 because of the lack of response at 
R99A.  
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Figure 4.10 The effect of N215A, W277F and F311A mutations upon the time 
course of GPR120S stimulated calcium mobilisation in response to agonists 
compared to WT. 
HEK293TRs expressing SNAP-GPR120S WT, N215A, W277F or F311A were 
ƚƌĞĂƚĞĚǁŝƚŚ ? ? ?ʅDŽůĞŝĐĂĐŝĚ ? ? ? ?ʅD't ? ? ? ?Žƌ ? ? ?ʅDMet36, and the 
calcium response followed over 165 s. Dotted line indicates the time of 
agonist addition. For clarity, W277F responses to oleic acid and Met36 are 
shown with error bar above, whilst F311A response to oleic acid and N215A 
response to Met36 are shown error bar below. The data shown were 
normalised to peak response, pooled from 4 - 5 individual experiments, mean 
± S.E.M.  
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Time Course 
  Agonist Oleic Acid GW9508 Met36 
Mutant 
   N215A ** * N.S. 
W277F N.S. *** N.S. 
F311A N.S. N.S. N.S. 
 
Table 4.3 Summary of statistical significance between calcium responses at 
60 s time point in Figure 4.10. 
Statistical significance between the calcium time course of GPR120S WT and 
mutants, N215A, W277F and F311A ŝŶƌĞƐƉŽŶƐĞƚŽ ? ? ?ʅDŽůĞŝĐĂĐŝĚ ? ? ? ?ʅD
't ? ? ? ?Žƌ ? ? ?ʅDMet36 (Figure 4.10) was determined at 60 s using 1 way 
EKsA?ƵŶŶĞƚƚ ?ƐƉŽƐƚƚĞƐƚƐ ?E ?^ ?-not significant, * P < 0.05, ** P < 0.01, *** 
P < 0.001.  
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4.2.3 Internalisation responses of GPR120 mutants 
The GPR120S mutants were then imaged on the automated IX Ultra 
platereader, and receptor internalisation was quantified by SNAP-surface AF-
488 labelling and 60 min agonist treatment as previously described (section 
2.2.3.4; representative images of receptor internalisation are shown in Figure 
4.11). Concentration response curve data (Figure 4.12) were expressed as fold 
over basal instead of normalisation to a reference compound, to allow 
comparison between different cell lines and thus different mutants. Potency 
and maximal responses for the different agonists are summarised in Table 4.4.  
The R99A mutant underwent low levels of agonist stimulated internalisation 
compared to WT in response to the highest concentrations of oleic acid and 
myristic acid, but did give a small concentration response curve to GW9508 
(Table 4.4; Figure 4.12; n = 5).  
Meanwhile, R178A, N215A and F311A did not significantly alter agonist-
promoted GPR120S internalisation (Figure 4.12; Table 4.4; n = 4 - 6). 
Interestingly, only agonist promoted internalisation of SNAP-GPR120S W277A 
and W277F mutants, compared to WT were significantly inhibited (Table 4.4; 
Figure 4.12; n = 6). 
For the responses where agonist pEC50 values could be determined, none 
were significantly altered by mutation (Figure 4.12; Table 4.4; n = 4). 
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Figure 4.11 Representative images of GPR120S mutant internalisation in 
ƌĞƐƉŽŶƐĞƚŽǀĞŚŝĐůĞŽƌ ? ? ?ʅDoleic acid. 
Images (25 % of total image shown here) were acquired on the IX Ultra of 
HEK293TRs stably transfected with the SNAP-GPR120S mutant as indicated, 
after SNAP-surface AF-488 labelling and ƚƌĞĂƚŵĞŶƚ ǁŝƚŚ ǀĞŚŝĐůĞ Žƌ  ? ? ? ʅD
oleic acid for 60 min at 37oC. In contrast to Figure 4.6, image level 
adjustments were kept constant for vehicle and oleic acid images within each 
mutant, to highlight agonist-stimulated receptor internalisation if present. 
^ĐĂůĞďĂƌA? ? ?ʅŵ ? 
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Figure 4.12 Internalisation of the GPR120 mutants in response to agonists. 
HEK293TRs expressing SNAP-GPR120S WT, R99A, R178A, N215A, W277A, 
W277F or F311A were treated with oleic acid (A-B), myristic acid (C-D), 
GW9508 (E-F) or Met36 (G-H) and internalisation concentration response 
relationships were measured by image granularity analysis (as described in 
277 
 
section 2.2.9.3.1). The responses shown were analysed as fold over basal and 
pooled from 4 - 6 individual experiments, mean ± S.E.M. (Met36 data set 
provided by N. Holliday).  
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Internalisation 
       
 
pEC50 Rmax (fold over basal) 
Agonist Oleic Acid Myristic Acid GW9508 Met36 Oleic Acid Myristic Acid GW9508 Met36 
WT 4.0 ± 0.2 4.3 ± 0.1 5.0 ± 0.1 5.3 ± 0.2 1.6 ± 0.1 1.6 ± 0.1 1.6 ± 0.1 2 ± 0.1 
Mutant 
   
  
    R99A 3.5 ± 0.5 N.D. 5.0 ± 0.3 N.D. 1.3 ± 0.1 1.4 ± 0.1 1.4 ± 0.1 1.1 ± 0.1 
R178A 4.2 ± 0.4 4.2 ± 0.4 5.0 ± 0.3 N.T. 1.4 ± 0.1 1.5 ± 0.1 1.5 ± 0.1 N.T. 
N215A 4.2 ± 0.6 4.3 ± 0.3 4.6 ± 0.3 4.2 ± 0.3 1.2 ± 0.1 1.5 ± 0.1 1.6 ± 0.1 1.7 ± 0.3 
W277A 5.5 ± 1.5 4.4 ± 1.8 N.D. N.D. 0.8 ± 0.1*** 1.1 ± 0.2** 1.2 ± 0.2 1.0 ± 0.1 
W277F N.D. 3.9 ± 0.4 4.1 ± 1.3 N.D. 1.2 ± 0.1 1.2 ± 0.1* 1.1 ± 0.1* 1.3 ± 0.1 
F311A 3.4 ± 0.6 4.0 ± 0.3 4.7 ± 0.5 5.2 ± 0.1 1.4 ± 0.1 1.3 ± 0.1 1.3 ± 0.1 2.1 ± 0.1 
Table 4.4 Potency and maximal internalisation responses of GPR120 mutants to agonists. 
EC50 values and maximal responses of GPR120 mutants (from Figure 4.12) undergoing internalisation in response to agonist as measured using 
the confocal plate reader assay. The responses were analysed as fold over basal and pooled from 4 - 6 individual experiments, mean ± S.E.M. 
Statistical significance was ĚĞĨŝŶĞĚƵƐŝŶŐŽŶĞǁĂǇEKsĂŶĚƵŶŶĞƚƚ ?ƐƉŽƐƚƚĞƐƚ ? P < 0.05; ** P < 0.01, *** P < 0.001. N.D.-not determined. 
N.T. - not tested (Met36 data provided by N. Holliday). 
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4.3 Discussion 
4.3.1 Key points from mutagenesis study of GPR120S binding site 
The key findings were that R99A abolished GPR120S calcium signalling to both 
FFAs and synthetic agonists, therefore supporting its role in docking the 
negative carboxylate group on the ligand, whereas R178A had no effect upon 
signalling and as such does not play this role. Asn215 appears to be key for 
interacting with Met36 but not other ligands, whilst F311A had a small non-
significant effect on activation, but not as dramatic as perhaps the AZ model 
suggested. W277A and W277F both suggest that Trp277 has a significant role 
in GPR120S ligand binding and activation. It should be kept in mind that there 
are limitations to studying binding sites by comparing signalling responses in 
different cell lines, even when normalised as fold over basal. Many factors can 
affect agonist potency and maximum response, such as receptor expression 
level (which has been monitored in this study) and the efficiency of a receptor 
coupling to a response can vary, for example in the calcium versus 
internalisation assays. Other limitations will be covered later in the discussion. 
4.3.2 Arg99: the residue that interacts with the acid group of ligands 
The R99A mutation, present at the top of TM 2, was postulated to be key for 
coordination of the carboxylate group on both FFAs and the synthetic 
GW9508 into the binding site (Sun et al., 2010; Suzuki et al., 2008). As 
expected, this mutation abolished all calcium signalling. Interestingly, R99A 
had small fold over basal responses in the internalisation assay. Perhaps this 
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mutation still allowed some ligand entry bilaterally from the membrane to 
allow receptor activation as seen in the lipid receptor S1P (Hanson et al., 
2012). Additionally, the Banyu compounds lack this carboxylate group (Figure 
4.1) but still act as GPR120 agonists. Therefore, there must be other 
interactions in the agonist binding site that still support binding and 
activation, so Arg99 may not be essential for all ligands. R99A did affect 
receptor expression and this would have impacted upon the signalling assays, 
especially in reducing the receptor reserve which results in agonists being less 
potent and having reduced maximal responses. However, some GPR120 R99A 
receptors were still cell surface expressed, so it is therefore unlikely that R99A 
would have abolished signalling by expression effects alone (Schwartz et al., 
1997). However, the low level of R99A expression and the high levels of basal 
endocytosis might have had an impact upon assessing the agonist-stimulated 
internalisation of this mutant reliably. 
4.3.3 Arg178 does not play a similar role to Arg99 
The rationale for creating the R178A mutation was that it was the only other 
positive residue in the upper half of the GPR120 TM domains, at the top of TM 
4 (aside from R99A), and it was thought that perhaps this residue could play a 
similar role to R99A. In the AZ model, this residue was found to point 
outwards from the TM bundle and away from the putative binding site, and 
therefore it was of no surprise that this mutation had no significant effect 
upon signalling. Therefore this residue does not play a role in interacting with 
the agonist carboxylate groups. Additionally, this also appears to rule out the 
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possibility that agonists can interact with different positively charged residues 
in GPR120 in a ligand selective manner, as has been suggested for the 
multiple Arg contact points present in FFA1 (Sum et al., 2009; Sum et al., 
2007; Tikhonova et al., 2008). 
4.3.4 Phe311 was predicted to interact with the phenyl group in the ligand 
In the model, Phe311 was shown to be an important feature of the ligand 
binding site, forming either pi-pi stack interactions (aromatic face to face) in 
combination with Phe304 either side of the phenyl ring present in nearly all 
synthetic agonists, or (C-H)-pi donation (edge to face). In the experimental 
study, this residue made relatively little difference to GPR120S calcium 
signalling or endocytosis. It may still contribute to docking the ligand into the 
correct orientation in the pocket and stabilising it there, but has a small effect 
when compared to other key residues such as Arg99. These small effects 
included somewhat more transient calcium timecourses in SNAP-GPR120S 
F311A cells, for example to oleic acid. Perhaps the AZ model overestimates 
the importance of this residue, for example by basing the structure on a 
ƉĂƌƚŝĐƵůĂƌ  “ĂĐƚŝǀĞ ? ɴ2AR conformation, rather than the inactive GPCR 
structures used previously (Shimpukade et al., 2012; Sun et al., 2010). Another 
issue could be that signal amplification in the calcium assay might compensate 
for mutation effects, but equally the F311A mutation had no significant effect 
in the internalisation assay where lower receptor reserve is expected. 
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4.3.5 The highly conserved Trp277, implicated in class A GPCR activation 
Trp277 (Trp 6.48) is in the highly conserved CWxW  “ƌŽƚŽŵĞƌ ? ƐǁŝƚĐŚ, which 
has been implicated in GPCR activation. When this residue was mutated in 
ɴ2AR, NK1, ghrelinR, GPR119 and GPR39 (Holst et al., 2010), the 5-
hydroxytrytamine 4 receptor (Pellissier et al., 2009) and the A3 adenosine 
receptor (Gao et al., 2002) it abolished agonist induced receptor activation. 
Interestingly, mutation of this residue in the B2 bradykinin receptor affected 
antagonist, but not agonist binding, thought to be due to the antagonist 
undergoing aromatic interactions with Trp (Marie et al., 2001). 
The Trp277 also appears to be an important interaction in the AZ model of 
GPR120, forming either a hydrogen-bond with the ether-oxygen present in 
GW9508 or undergoing a charge-donation effect from the pi-orbital of the 
central aromatic ring present in other synthetic agonists. Additionally, 
mutation of Trp269 (6.48) in the S1P receptor abolished ERK signalling 
mediated by CYM-5442 but not S1P, suggesting an interaction between the 
phenyl ring in the synthetic CYM-5442 structure and the aromatic ring in 
Trp269 (Hanson et al., 2012). 
The W277A mutation had significantly reduced expression levels, but as with 
R99A, some mutant receptor still reached the plasma membrane, so the lack 
of function appears to be a real result, and suggests that Trp277 is a key 
residue in the binding site, in agreement with the AZ model and the previously 
published model (Shimpukade et al., 2012). This agrees with the idea that 
agonists are agonists because they have the ability to reach down into the 
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ďŝŶĚŝŶŐƉŽĐŬĞƚĂŶĚ “ŬŶŽĐŬ ?ƚŚĞdƌƉƌĞƐŝĚƵĞ ?ĐĂƵƐŝŶŐƌĞĐĞƉƚŽƌĂĐƚŝǀĂƚŝŽŶ ?ƐĞĞ
section 1.5.1). 
Interestingly the more conservative substitution W277F had no effect on FFA 
or GW9508 activation of GPR120S calcium signalling, but reduced the potency 
of Met36 in this assay. This implies the Phe substitution can still undergo pi-pi 
interactions and maintain receptor activation for some agonists, but was less 
able to do so with Met36. These decreases in Met36 responses were despite 
GPR120S W277F receptors being more highly expressed than wild type. 
Larger effects of the W277F mutation, for all agonists, were observed when 
receptor internalisation was the endpoint rather than calcium responses. This 
may be a consequence of receptor reserve, because for example in Ă ɴ-
arrestin dependent internalisation, 50 % receptors may need to be occupied 
for a 50 % endocytosis response, if using the canonical stoichiometry ŽĨŽŶĞɴ-
arrestin to one activated receptor (Bayburt et al., 2011; Hanson et al., 2007). 
In contrast, only a small percentage of the receptors being activated may be 
required for a full calcium response due to signal amplification, which may 
mask some mutation effects. Another possibility is that W277F had a greater 
pathway-dependent effect upon the internalisation pathway, for example like 
a D2 dopamine mutant that still mediated G protein signalling, but was 
ŝŶĐĂƉĂďůĞŽĨɴ-arrestin binding (Lan et al., 2009). 
4.3.6 Asn215 supports an alternative model for Met36 binding 
The original AZ model (Figure 4.3) incorporated a water molecule interacting 
with the pyrazole (nitrogen ring) of Met36, but in an alternative arrangement 
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this interaction was mediated by direct contact with Asn215. A previous 
GPR120 model also implicated this residue in TUG-891 binding (Shimpukade 
et al., 2012). In addition, this Asn residue flanks the TM 5 Phe216 residue 
thought to involved in forming and stabilising an interaction with the Trp277 
(6.48) rotomer toggle in TM 6, and the N215A mutation could also influence 
this (Holst et al., 2010). 
Consistent with a role for N215A in the calcium signalling assay, N215A 
selectively inhibited Met36 responses, whilst GW9508 and FFA responses 
were relatively unaffected (although interestingly all the calcium time courses 
showed GPR120S N215A desensitising more rapidly than WT). The model 
supports the idea that GW9508 and Met36 have different conformations of 
the bi-aromatic rings in the GPR120S binding site. Perhaps, the pyrazole-
phenyl of Met36 ƐŝƚƐ  “ĐůŽƐĞƌ ?ƚŽAsn215 than the biphenyl of GW9508. Also, 
perhaps this difference could be key to the change in selectivity from FFA1 
selective ligands (such as GW9508) to the GPR120 selective ligands such as 
Met36 and TUG-891 (Figure 4.13). There was little effect of the N215A mutant 
in the receptor internalisation assay. This was unexpected because with a 
reduced receptor reserve in this assay there should have been a greater 
effect, for example in inhibiting Met36 responses. Perhaps there was a 
greater level of basal endocytosis of N215A compared to WT, which 
influenced the results. Another explanation could be that this mutation had a 
pathway specific effect, that this time was directed against the G protein 
mediated pathway but not the internalisation pathway. 
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Figure 4.13 The GPR120 binding site with both GW9508 (purple) and Met36 
(green) within. 
Shows the position of GW9508 (purple ball and stick) versus the position of 
Met36 (green ball and stick) within the binding pocket of GPR120. Figure 
provided by Graeme Robb (AZ).  
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Overall these data broadly support the AZ model of ligand binding, suggesting 
that Trp277 is implicated in the activation of GPR120 in response to all types 
of ligand as expected, whilst Asn215 is more involved in interacting with 
Met36 than fatty acids and GW9508, and Phe311 had relatively little effect. 
4.3.7 Limitations of modelling 
In one previous study of FFA1, the mutation of Tyr12 abolished all responses 
to GW9508 and linoleic acid. It was suggested that it does not interact directly 
with the ligand, but instead contributes to holding the receptor in the correct 
conformation required for activation (Sum et al., 2007). This brings in the 
interesting points of if an agonist no longer activates the receptor following 
mutation, it could be that the mutation has had an effect upon multiple things 
such as: preventing receptor folding and expression, conformation changes 
required for activation, coupling between the receptor and effector; or has 
affected the binding site. This highlights the difficulty of using mutagenesis to 
study binding sites, whereas a direct binding assay would be better (Chapter 
5). 
Some of these limitations were controlled for in this study, by monitoring 
receptor expression; and using two assays to measure two signalling 
pathways, that had both different levels of receptor reserve and were 
dependent upon coupling with different effectors. 
Also, these results have shown that another limitation of receptor modelling is 
that it is good at defining the overall site, but can sometimes overstate one 
the importance of one residue, for example Phe311. This may be because the 
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ŵŽĚĞůŝƐďĂƐĞĚŽŶƚŚĞĂŐŽŶŝƐƚĂĐƚŝǀĂƚĞĚɴ2AR (Rasmussen et al., 2011a), which 
ŐŝǀĞƐ ƚǁŽ ŵĂŝŶ ŝƐƐƵĞƐ ? &ŝƌƐƚůǇ ? ƚŚĂƚ ɴ2AR is not necessarily that similar to 
GPR120; and also that protein modifications were introduced ŝŶƚŽ ɴ2AR to 
allow for crystallisation, ƚŚĞƌĞĨŽƌĞŵĂǇŚĂǀĞĂůƚĞƌĞĚŽŶĞŽĨƚŚĞŵĂŶǇ “ĂĐƚŝǀĞ ?
conformations of the receptor. 
This also brings up the question of whether activated receptors undergo 
conformational induction or conformational selection, and so which structural 
template (inactive versus active) is most appropriate for studying agonists 
which stimulate such conformational changes. Conformation induction is 
when the agonist plays a role in changing the inactive conformation of the 
receptor into the active one. Mutations could prevent the agonist from 
inducing the active conformation of the receptor. Meanwhile, conformational 
selection is when the receptor spontaneously adopts the active conformation 
and the ligand binding to this increases the proportion of active 
conformations, leading to a response. Mutations could alter the equilibrium at 
which the receptor spontaneously forms the active conformation (Kenakin, 
1995). This shows the complications of the use of mutagenesis in the study of 
binding sites, because effects measured from functional assays may be due to 
issues such as above, rather than the mutation knocking out the actual 
binding site per se. Arguably though, whilst this study was based upon an 
active structural template, and a previous study was based upon an inactive 
one (Shimpukade et al., 2012), a similar range of residues were identified as 
key in both models, albeit with different agonists used in their identification. 
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Again, this demonstrates why binding assays are crucial for these types of 
studies (chapter 5), rather than solely relying on read outs from functional 
assays. 
4.4 Future work 
Future work could be to test the effects of the mutations on additional 
GPR120 ƐŝŐŶĂůůŝŶŐ ƉĂƚŚǁĂǇƐ ? ƐƵĐŚ ĂƐ 'dWɶ^ ĂƐ Ă ŵĞĂƐƵƌĞ ŽĨ ' ƉƌŽƚĞŝŶ
activation, or ERK activation, as GPR120 has been shown previously to signal 
through ERK (Hirasawa et al., 2005), to give better evidence on whether 
W277F or N215A substitutions are pathway specific. For example W277F had 
a greater effect upon agonist stimulated internalisation in comparison to its 
selective action on Met36 calcium signalling. Additionally, the internalisation 
results could be complemented by measuring the association of the mutant 
receptorƐǁŝƚŚɴ-arrestin2. 
Similarly, it would be of interest to test further GPR120 selective compounds, 
such as the Banyu compounds, to see if compounds without the carboxylate 
retain activity at R99A. Additionally, other compounds such as NCG21 (Sun et 
al., 2010) and TUG-891 (Shimpukade et al., 2012) could also be tested, 
particularly in evaluating the selective effects of N215A on Met36 signalling, in 
comparison to GW9508. GW9508 and Met36 were shown by the model to 
have different conformations due to the position of the biphenyl rings (the 
end phenyl of Met36 ƐŝƚƐ  “ĐůŽƐĞƌ ? ƚŽ ƚŚĞ WŚĞ ? ? ? ĂŶĚ ƐŶ ? ? ? ƚŚĂŶ ƚŚĞ ĞŶĚ
phenyl ring of GW9508), which might explain these differences. Therefore 
future work could also be to generate a double mutant of N215A and F311A 
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to give more information on the difference in results between GW9508 and 
Met36. Mutation of Phe216 could also test the theory that N215A has effects 
due to affecting the interaction between Phe216 in TM 5 and the Trp277 in 
TM 6. 
Further analysis of the model showed two more key interactions that are 
predicted to be selective for GW9508 (and not Met36) binding. Phe88 is 
predicted to undergo phenyl-phenyl ring stacking with the GW9508 biphenyl 
moiety and Thr310 may interact with the amine linker specific to GW9508.  
In the absence of a large effect of F311A, Phe304 could also be mutated, to 
test the theory that this residue, in conjunction with Phe311, forms stacking 
interactions with the phenyl proprionic acid pharmacophore of the synthetic 
ligands. Other residues mentioned in the literature such as Met118 (3.32), 
Thr119 (3.33), Gly122 (3.36), Phe211 (5.42), Ile280 (6.51) and Ile281 (6.52) 
imply a large hydrophobic patch, and point mutation of these residues 
individually may have limited effects.  
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Chapter Five: Development and characterisation of a 
novel fluorescent FFA1 agonist 
5.1 Introduction 
Ligand binding techniques are important for the study of receptor 
pharmacology because they are one of the main ways to attain the affinity of 
a ligand for the receptor, by determining Kd, the equilibrium dissociation 
constant. This is fundamental to the comparison of the activity of different 
ligands in the drug discovery process, or in exploring the way that a ligand 
binds to its receptor. 
For FFA receptors such as FFA1 and GPR120, using traditional radioligands is 
difficult, but not impossible as shown by a recent study on determining the 
binding sites of FFA1 (Lin et al., 2012). This difficulty of determining binding 
was highlighted in the previous chapter, whereby the binding site of GPR120 
had to be investigated indirectly using signalling assays, rather than being able 
to measure the affinity of the mutant receptors for their agonists directly 
(Chapter 4). A possible solution to this is using fluorescent ligands. These 
ligands potentially offer a way of visualising ligand binding at these receptors, 
and allowing ƐĞƉĂƌĂƚŝŽŶ ŽĨ  “ƐƉĞĐŝĨŝĐ ? ďŝŶĚŝŶŐ ĨƌŽŵ ŶŽŶ-specific interactions 
such as with cellular membranes. 
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5.1.1 Advantages of fluorescent ligands for studying GPCR pharmacology 
5.1.1.1 The opportunity for single cell pharmacology 
The ability to visualise fluorescent ligands, using various microscopy 
techniques, helps fulfil Ă ŶĞĞĚ ĨŽƌ ƉŚĂƌŵĂĐŽůŽŐǇ Ăƚ ƚŚĞ  “ƐŝŶŐůĞ ĐĞůů ? ůĞǀĞů
rather than a whole population study. This is useful because receptor 
populations can be heterogeneous, both within cell populations, and even 
within single cells. For example GPCRs have been shown to exist in signalling 
scaffolds associated with microdomains such as lipid rafts (Padgett and 
Slesinger, 2010). FCS is advantageous for measuring these microdomains in 
the membrane (Cordeaux et al., 2008; He and Marguet, 2011), because it 
measures the diffusion of a labelled species, and this diffusion can be altered 
due to the presence of these lipid rafts or other cytoskeletal structures in the 
plasma membrane, which then allows the extraction of biological information 
about the underlying receptor interactions. 
Fluorescent ligand imaging can also be used to study cell heterogeneity in 
receptor expression levels, for example in native tissues, and still be able to 
derive data from the subpopulation of receptor expressing cells (Pramanik et 
al., 2001). In addition to this, fluorescent ligands have also previously been 
employed to determine binding kinetics (May et al., 2011), and in high 
content screening (Stoddart et al., 2012). 
5.1.1.2 The study of ligand-receptor complexes 
Firstly, fluorescent ligands can be used in the place of a radiolabelled ligand as 
a probe in a traditional binding assay. A high content screening format is used 
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on an automated platereader, resulting in images which are then analysed to 
produce competition curves to obtain IC50 estimates for the unlabelled ligands 
(Stoddart et al., 2012). Additionally, fluorescent ligands can be used in the 
measurement of binding kinetics on single cells, which in this case also 
provided additional information about allosteric interactions across a homo-
dimer interface (May et al., 2011). 
FCS (section 2.2.8), in conjunction with a fluorescent ligand, can also be 
applied to studying ligand-receptor interactions, due to the nature of the 
differing speeds of diffusion of different species (Pramanik et al., 2001). As 
discussed below, this is because the free fluorescent ligand in solution moves 
faster than ligand in complex with the receptor, which diffuses more slowly 
through the plasma membrane (Briddon and Hill, 2007). FCS can even be used 
to undertake binding style studies (Pramanik et al., 2001), and derive 
dissociation kinetics (Pramanik and Rigler, 2001). FCS has been used to study 
ƚŚĞ ĚŝĨĨƵƐŝŽŶ ŽĨ Ă ǀĂƌŝĞƚǇ ŽĨ 'WZƐ ŝŶ ĐŽŵƉůĞǆǁŝƚŚ Ă ůŝŐĂŶĚ ? ŝŶĐůƵĚŝŶŐɴ2AR 
(Hegener et al., 2004), the galanin receptor (Pramanik et al., 2001) and the 
adenosine family of receptors (Briddon et al., 2004; Cordeaux et al., 2008). 
FCS can also be carried out without the use of modified receptors, for 
example by measuring the fluorescent ligand instead, because receptors 
labelled using GFP, SNAP-tag or an antibody are a larger species, with 
potentially different interactions with cell partners such as the cytoskeleton, 
which then impact on their diffusion speed. This, together with the fact that 
FCS is a sensitive technique, also offers potential to measure native receptors 
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in native cells, such as the A3 adenosine receptor in neutrophils (Dr. R. 
Corriden, University of Nottingham, personal communication). 
5.1.1.3 Discrimination between modes of binding 
FCS also has the ability to discriminate between different modes of binding 
(Pramanik et al., 2001), especially when using fluorescent ligands compared to 
the more traditional pharmacology of using radiolabelled ligands. One 
example of this is where a fluorescent antagonist for the H1 histamine 
receptor was demonstrated to significantly associate with the plasma 
membrane lipids, as well as binding to the receptor (Rose et al., 2012). This is 
particularly relĞǀĂŶƚ ĨŽƌ ƚŚĞ ƐƚƵĚǇ ŽĨ ůŝƉŝĚ 'WZ ďŝŶĚŝŶŐ ? ǁŚĞƌĞ  “ƐŝĚĞǁĂǇƐ ?
entry of the ligand by first entering the cell membrane has been suggested by 
the crystal structure of the S1P receptor (Hanson et al., 2012). 
5.1.2 Principles of fluorescent ligand design 
There can be some difficulty in designing fluorescent ligands for GPCRs, which 
will be discussed in this section. The basic considerations when designing a 
fluorescent ligand are in 3 parts: pharmacophore, linker and fluorophore 
(Kozma et al., 2013). 
5.1.2.1 Pharmacophore 
The pharmacophore represents the molecular features of a ligand that allow it 
to bind to the binding site of the receptor. This affinity should be maintained 
when designing a fluorescent ligand, but there is difficulty with designing 
fluorescent ligands for GPCRs. This is because some receptors have a TM 
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localised binding site combined with a ligands of low molecular weight, with 
one example of this being the design of XAC-BY630 for the A1 adenosine 
receptor (Briddon et al., 2004). Both the fluorophore and the linker 
significantly increase the size of the ligand, and this may disrupt the binding of 
the pharmacophore, or may even form interactions of its own with receptor 
proteins and other cell constituents. 
Additionally, especially for receptors such as the adenosine family, the desired 
receptor selectivity should be maintained (Kozma et al., 2013). The choice of 
linker point in the parent compound is also an important consideration, 
because this chemical manipulation should aim to disrupt affinity as little as 
possible (Briddon et al., 2011; Kozma et al., 2013). 
5.1.2.2 Fluorophore 
There are a few determining factors for consideration when choosing a 
fluorophore for a fluorescent ligand. Firstly, the fluorophore can influence the 
receptor-pharmacophore interaction due to its size, which can be in the 
region of 400 to 1,000 Da, and can double the size of the molecule (Briddon et 
al., 2011). Also, at the A1 adenosine receptor, it was found that different 
fluorophores can significantly alter receptor binding of the resultant ligands, 
whereby a BODIPY labelled ligand was found to have the greatest affinity 
(Baker et al., 2010). Also, the choice of fluorophore may be dependent upon 
the experiments that it will be used for, for example the colour may be 
important if the ligand will be used in conjunction with a labelled receptor. 
295 
 
Also, for FCS, photo physical properties such as excitation and emission 
spectra are important considerations (Briddon et al., 2011). 
Other properties of the fluorophore may be advantageous, for example 
BODIPY fluorophores are quenched in aqueous solution, which is preferable 
for live cell experiments;  ?ĨƌĞĞ ?K/Wz-based fluorescent ligands in solution 
emit less fluorescence that receptor-bound ligands in a hydrophobic 
environment (Briddon et al., 2011). BODIPY fluorophores also have a low rate 
of photobleaching, and there are derivatives (such as BODIPY-630/650), which 
like Cy5, have far-red fluorescence clearly distinguishable from cellular auto 
fluorescence (Kozma et al., 2013). Cy5 is less lipophilic than BODIPY630/650, 
which could be advantageous in minimising non-specific ligand binding to the 
plasma membrane and other cell lipid environments. 
5.1.2.3 Linker 
In most cases, the linker region has to be long enough to extend beyond the 
pharmacophore binding pocket, which can vary from receptor to receptor. For 
example, peptide receptors have a binding domain on the extracellular amino 
terminus or extracellular loops, whilst aminergic receptors have binding sites 
buried deep within the TM helices, that would require a longer linker region. 
The linker can also influence the pharmacophore, alter affinity or efficacy 
(Vernall et al., 2012), and influence the intensity of fluorescent labelling 
(Middleton et al., 2007). For example, during the design of a fluorescent 
ligand used at the A1 adenosine receptor, the linker length was found to affect 
its pharmacology, whereby ligands derived from the agonist N-ethyl 
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carboxamido adenosine (NECA) conjugated to a dansyl fluorophore had an 
increase in affinity and/or efficacy as the linker chain length increased, whilst 
was opposite was true when the fluorophore was BODIPY-630/650 (Baker et 
al., 2010). 
In summary, fluorescent ligands have their own pharmacological properties 
such as affinity, efficacy, and subtype selectivity if applicable, which may differ 
considerably from the parent pharmacophore. They must therefore be 
treated and characterised as entirely new ligands (Briddon et al., 2011; 
Middleton et al., 2007). 
5.1.3 Principles of FCS and PCH analysis 
5.1.3.1 FCS 
In FCS, the confocal spot focuses on a small area of interest, such the plasma 
membrane (area 0.1  W 0.3 ʅŵ2), defining a detection volume (~0.25fl), which 
is Gaussian in shape. Within this volume, fluctuations in fluorescent intensity 
are measured as for example fluorescently labelled receptor or ligand diffuse 
through (Figure 2.15). Autocorrelation analysis of these fluctuations gives 
quantitative data on the fluorescent particles present. This includes the 
ĂǀĞƌĂŐĞ ŶƵŵďĞƌ ŽĨ ƉĂƌƚŝĐůĞƐ ĂŶĚ ƚŚĞŝƌ ĂǀĞƌĂŐĞ ĚǁĞůů ƚŝŵĞ ? ʏD, which in 
conjunction with knowledge of the size of the confocal volume can then be 
used to calculate the particle concentration and diffusion co-efficients (D) of 
the fluorescent species respectively. Autocorrelation analysis is covered in 
more depth in section 2.2.9.5.1. 
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Briefly, autocorrelation analysis takes the size of the deviation in a fluctuation 
 ?ɷ/ ) ĨƌŽŵ average intensity at time T and compares it with a subsequent 
ĨůƵĐƚƵĂƚŝŽŶ Ăƚ ƚŝŵĞ d A? ʏ ? hƐŝŶŐ ƚŚĞ ǁŚŽůĞ ƌĂŶŐĞ ŽĨ ʏ ǀĂůƵĞƐ ŐŝǀĞƐ the 
autocorrelation function, ' ?ʏ ) ?which is normalised to the square of the mean 
intensity, <I>, resulting in an autocorrelation decay curve (see Figure 2.15 C). 
dŚĞĚǁĞůůƚŝŵĞ ?ʏD ?ŝƐĚĞƌŝǀĞĚĨƌŽŵƚŚĞŚĂůĨǁĂǇƉŽŝŶƚŽĨƚŚĞ' ?ʏ )ĚĞĐĂǇŽĨƚŚĞ
autocorrelation function, whilst the particle number, N, is derived from its 
inverse relationship to the amplitude of G0 (Briddon and Hill, 2007). In an 
experiment, calibration with a fluorophore of a known diffusion co-efficient, 
e.g. Cy5 (D 3.16 x10-10 m2 s-1 ) ? ĂůůŽǁƐ ƚŚĞ ĐŽŶĨŽĐĂů ǀŽůƵŵĞ ĂŶĚ ƌĂĚŝƵƐ  ?ʘ0 = 
4DCy5ʏD)1/2 to be calculated. This then allows the diffusion co-efficient of the 
labelled receptor or ůŝŐĂŶĚƚŽďĞĐĂůĐƵůĂƚĞĚĨƌŽŵŝŶĚŝǀŝĚƵĂůʏD values using the 
ĞƋƵĂƚŝŽŶ A?ʘ20 ? ?ʏD; and the particle concentration can be calculated using 
N ? ?ʋʘ20). These ǀĂůƵĞƐ ĂƌĞ ƚŚĞƌĞĨŽƌĞ  “ŶŽƌŵĂůŝƐĞĚ ? ĂŶĚallow comparison 
between data sets. 
Where multiple fluorescent species are present, with sufficiently different 
diffusion rates, the resultant autocorrelation curves can be modelled with 
additive components to obtain estimates of the relevant particle 
concentrations and dwell times (e.g. D1, D2, D3). In particular these 
quantitative data are useful because they give information on both the free 
and receptor bound fluorescent ligand, and multiple receptor diffusing 
components if present. For example, Cordeaux et al. (2008) used a fluorescent 
agonist in FCS studies of the adenosine A3 receptor, in which autocorrelation 
curves showed three components: ʏD1 (~ 60 µs) representing diffusion of the 
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free ligand; together with receptor bound components ʏD2, usually in the 
region of 1-10 ms, and ʏD3 is >50 ms (Cordeaux et al., 2008). Generally, there 
are also additional short lived components to be accounted in the 
autocorrelation curves, that derive from fluorophore photophysics. These can 
range from 1  W 10 µs (for fluorophores such as Cy5), to up to 1 ms (for 
fluorescent proteins such as GFP or YFP). 
There are some limiting factors to measuring receptor diffusion. When 
studying membrane localised receptors, there is also a limit to the two 
dimensional model because it assumes Ă “ĨůĂƚ ? ?ƉůĂƐŵĂŵĞŵďƌĂŶĞ ?ƚŚĂƚŝŶ
reality is a more complex three dimensional structure with molecules that 
diffuse in 3D within it. Additionally, there is a limit to the separation of species 
with differing diffusion rates based solely on molecular weight, due to the 
cube root relationship between the change in mass causing a change in 
diffusion co-efficient (Briddon and Hill, 2007). For example an 8 fold change in 
molecular mass of the species being measured will only result in a ~2 fold 
change in the diffusion co-efficient. For small molecular weight fluorescent 
ligands, the diffusion co-efficient can distinguish between free ligand and 
ligand-bound to receptor, because this change in molecular mass is large 
enough to cause a detectable change in the diffusion co-efficient. However, 
FCS is not generally appropriate to determine the presence of receptor dimers 
versus monomers (2 fold change in mass). However this is also why small 
changes in measured D can still result from significant changes in the 
molecular composition of receptor complexes. The measurement of particle 
concentration works best at low particle concentrations (because the 
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fluctuations in intensity are relatively larger and generate a higher amplitude 
of the autocorrelation curve), and this means FCS is sensitive enough to study 
low fluorescent ligand or receptor concentrations, for example in native cells, 
where more traditional binding methods would be challenging. Finally, the 
largest limitation with FCS is that in order to be detected, the fluorescent 
species must be moving to generate fluctuations. Therefore, stationary 
receptors, for example attached to the static cytoskeleton, would not be 
detected by FCS. 
5.1.3.2 PCH 
From the same fluorescence intensity data set collected over time (e.g. 15 s), 
photon counting histogram (PCH; covered in depth in section 2.2.9.5.2) 
analysis can also be applied. Briefly, PCH analysis depends upon the variation 
in amplitude rather than over time (in comparison to FCS autocorrelation 
analysis) and can provide a different calculation of the particle concentration. 
In addition, it also gives information on molecular brightness ( ), the 
brightness of each species (Chen et al., 1999). 
This analysis is useful because it is perhaps more sensitive in determining the 
stoichiometry of the fluorescent complexes, because if the fluorescent species 
contains 2 labelled receptors instead of 1, the diffusion co-efficient might not 
change significantly (see above), but  is expected to double. 
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5.1.4 Aims 
One of the issues with fatty acid receptor drug discovery, for example at FFA1 
and GPR120, is the highly lipophilic nature of their ligands which poses 
problems in the generation of specific, high-affinity radiolabelled ligands. 
Without these, traditional pharmacology such as radioligand binding is more 
challenging, preventing generation of data key to drug discovery such as 
equilibrium dissociation constants measuring ligand affinity. This study hoped 
to address this for FFA1 and GPR120, by replicating the traditional binding 
assay through characterisation of a novel fluorescent ligand based on 
GW9508, before exploring the mechanism of fluorescent ligand:receptor 
interactions by FCS and PCH techniques.  
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5.2 Results 
5.2.1 Ligand characterisation in terms of calcium responses 
CellAura technologies (Nottingham, UK) synthesised a number of analogues of 
GW9508 with 3 different types of linker and 2 different fluorophores 
(BODIPY630/650 and Cy5). These were screened for FFA1 activity in 
preliminary calcium signalling assays (data not shown). This process led to the 
choice of the ligand 40Ag-Cy5, which was then examined in more detail. The 
detailed structure of 40Ag-Cy5 is not shown for confidentiality reasons. 
Firstly, this ligand, along with its precursor congener (the ligand without the 
fluorescent Cy5 addition; abbreviated to 40Ag-Cg) were both tested for their 
ability to stimulate calcium responses via both FFA1 and GPR120. Calcium 
responses were observed in HEK293TR FLAG-tagged FFA1 cells to 40Ag-Cy5 
and its congener (in HBSS in the absence of BSA), with pEC50 values of 5.7 ± 
0.1 and 7.8 ± 0.4 respectively, compared to a pEC50 of 8.3 ± 0.6 for GW9508 
responses. No responses were observed to 40Ag-Cy5 when cells were not pre-
treated with tetracycline to induce FFA1 expression (Figure 5.1 A; n=4). The 
presence of 0.02 % BSA in this assay, had little effect on the ligand pEC50 
values at FFA1 (Figure 5.1 B; Table 5.1; n=4). In contrast 40Ag-Cy5 was inactive 
at FLAG-tagged GPR120S, at up 10 µM, compared to the GW9508 pEC50 of 
6.0±0.2 (Figure 5.1 C; n=4). This showed that 40Ag-Cy5 retained GW9508 
selectivity for FFA1 over GPR120S.  
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Figure 5.1 Calcium mobilisation responses of FLAG-tagged FFA1 and 
GPR120S to 40Ag-Cy5, its congener and GW9508 show 40Ag-Cy5 selectivity 
at FFA1 over GPR120S. 
The ability of 40Ag-Cy5 and its congener to elicit intracellular calcium 
responses at FFA1, both in the absence (A) and presence (B; 0.02 %) of BSA 
and also at GPR120 (C) was measured in tetracycline (tet) inducible HEK293TR 
ĐĞůůƐďǇ&ůƵŽ ?ŵŽďŝůŝƐĂƚŝŽŶ ?dŚĞ&& ?ĚĂƚĂǁĞƌĞŶŽƌŵĂůŝƐĞĚ ?A? )ƚŽƚŚĞ ? ?ʅD
40Ag-Cy5 response, whilst the GPR120S data were normalised (%) to the 100 
ʅD't ? ? ? ? ƌĞƐƉŽŶƐĞ ?dŚĞƐĞƉĞĂŬƌĞƐƉŽŶƐĞƐǁĞƌĞƉŽŽůĞĚ ĨƌŽŵĂŵŝŶŝŵƵŵ
of 4 individual experiments, mean ± S.E.M.  
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pEC50 with 0.02 % 
BSA 
pEC50 without 
BSA 
40Ag-Cy5 5.8 ± 0.2 5.7 ± 0.1 
40Ag-Congener 7.5 ± 0.3 7.8 ± 0.4 
GW9508 8.1 ± 0.5 8.3 ± 0.6 
 
Table 5.1 Potency values of 40Ag-Cy5, its congener and GW9508 at FLAG 
tagged FFA1 receptors from the characterisation of the fluorescent ligand in 
the calcium assay. 
pEC50 values were obtained from the concentration response curves in Figure 
5.1 A and B, pooled from a minimum of 4 individual experiments, mean ± 
S.E.M.  
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5.2.2 Using the fluorescent ligand 40Ag-Cy5 in a binding assay format 
Next 40Ag-Cy5 was used in a binding assay using HEK293TR FLAG-FFA1 cells, 
to test the theory that this fluorescent ligand could be used in an assay 
analogous to radioligand binding. The principle is similar to radioligand 
binding. HEK293TR FLAG-FFA1 cells were first briefly pre-treated (5 min; to try 
to ensure true equilibrium conditions) with a non-fluorescent competing 
ligand. 40Ag-Cy5 was then added and allowed to reach equilibrium binding 
(optimised as 30 min at 37°C, data not shown), then the cells were imaged live 
on an automated plate reader (Stoddart et al., 2012). From the images (Figure 
5.2), it can be seen that as the concentration of the competing ligand 
increased, fluorescent 40Ag-Cy5 binding decreased. To these images, a 
modified version of the granularity analysis was applied to maximise the signal 
to ŶŽŝƐĞƌĂƚŝŽǁŚĞŶƋƵĂŶƚŝĨǇŝŶŐĨůƵŽƌĞƐĐĞŶĐĞŝŶƚĞŶƐŝƚǇ ?^ŵĂůů “ƉŝƚƐ ?ƋƵĂŶƚŝĨŝĞĚ
cell-bound fluorescent ligand, predominantly localised to the cell surface 
(granules 1- ? ʅŵ ŝŶ ĚŝĂŵĞƚĞƌ) ? ǁŚŝůĞ ůĂƌŐĞƌ  “ǀĞƐŝĐůĞƐ ? ĞǆĐůƵĚĞĚ ƚŚĞ ůĂƌŐĞƌ ?
non-bound aggregates of ligĂŶĚ  ?ŐƌĂŶƵůĞƐ AN  ? ʅŵ ŝŶ ĚŝĂŵĞƚĞƌ ? &ŝŐƵƌĞ  ? ?3).
Cells without tetracycline treatment displayed low levels of fluorescent ligand 
binding and were used to set the negative control (0 %), whilst the totals (tet 
treated cells, with no competing ligand) were set as the positive control 
(100%; Figure 5.2, 5.3). 
Firstly, the assay was optimised, by comparing 40Ag-Cy5 binding and its 
displacement in HBSS buffer with 0.02 % BSA and without BSA. Interestingly, 
in comparison to the calcium signalling assay, in which 0.02 % BSA had no 
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effect upon ligand potency, here it can be seen that the addition of BSA, 
reduced total cellular binding in the presence of 100 nM 40Ag-Cy5 (Figure 
5.2). Subsequently, binding experiments were performed in the absence of 
BSA, unless otherwise stated. Following this, paired competition curves were 
carried out using the antagonist GW1100 (Figures 5.3, 5.4). This allowed for 
the estimation of the dissociation constant of 40Ag-Cy5. Two sets of 
displacements were carried out (in the absence of BS )ƵƐŝŶŐ ?ʅDŽƌ ? ? ?ŶD
40Ag-Cy5. This gave two IC50 values for GW1100, of 2.2 ± 0.2 and 1.1 ± 0.2 µM 
respectively, from the pooled data (Figure 5.4). This allowed for the 
simultaneous solution of the Cheng-Prusoff equation (section 2.2.9.4) for each 
curve ?ƌĞƐƵůƚŝŶŐŝŶĂŶĞƐƚŝŵĂƚŝŽŶŽĨ ? ? ?ʅDĨŽƌƚŚĞĚŝƐƐŽĐŝĂƚŝŽŶĐŽŶƐƚĂŶƚ (KFL) 
of 40Ag-Cy5 at FFA1 receptors. This knowledge of the dissociation constant of 
40Ag-Cy5 at FFA1 in principle allowed for Ki values to be estimated for the 
competing ligands, again using the Cheng-Prusoff equation for conversion 
from the IC50s of the displacement curves. A selection of known FFA1 
synthetic agonists (GW9508, TZDs) and an antagonist were tested as 
competing ligands in this assay to test for their displacement of 40Ag-Cy5 
binding (Figure 5.5), and pIC50 values and Kis were calculated (Table 5.2). 
Interestingly, oleic acid did not displace 40Ag-Cy5 binding at concentrations 
ƵƉƚŽ ? ? ?ʅD ?ĂŶĚŝŶĨĂĐƚƚŚĞƉƌĞƐĞŶĐĞŽĨoleic acid led to increased 40-AgCy5 
binding in the assay. Increasing the oleic acid pre-treatment time (to either 15 
min or 30 min) did not alter the lack of 40Ag-Cy5 displacement observed (data 
not shown).  
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Figure 5.2 A representative plate map showing increasing concentrations of GW1100 displacing 40Ag-Cy5 from binding. 
HEK293TR FLAG-FFA1 cells were pre-treated with unlabelled ligand for 5 min at 37°C, followed by 1 µM 40Ag-Cy5 for 30 min at 37°C in HBSS in 
the presence or absence of 0.02 % BSA. Cells were immediately imaged live on the IX Ultra platereader (2 horizontal sites / well, < 10 min read 
time), without an intervening wash step. The top section shows the plate map (10 wells (20 sites) x 6 wells), with the top 3 rows in the presence 
of BSA and the bottom 3 rows in the absence of BSA. The far left column shows low fluorescent ligand binding in the absence of receptor 
expression (-ƚĞƚ ) ?ǁŚŝůƐƚƚŚĞŶĞǆƚĐŽůƵŵŶĚĞƉŝĐƚƐƚŚĞ “ƚŽƚĂůƐ ?ǁŚŝĐŚŝƐ ? ?Ő-Cy5 binding in the absence of any competing ligand. The following 7 
columns show the displacement of 40Ag-Cy5 binding in the presence of increasing concentrations of GW1100 (indicated as log M). The bottom 
section shows enlarged individual images, with identical level adjustments, to show 40Ag-Cy5 binding and its displacement with greater clarity. 
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Figure 5.3 Representative images and quantitative analysis of specific 40Ag-Cy5 binding to FFA1 receptors. 
Images illustrate an example experiment performed as described in Figure 5.3, using 100 nM 40AG-Cy5 and incubation media lacking BSA. The 
top row shows (L-R) (i) HEK293TR FLAG-FFA1 cells that have not undergone tetracycline induction of FFA1 expression; (ii) tetracycline-induced 
cells labelled by 40AG-Cy5 that have not undergone competing ligand treatment (totals) and (iii) competition for 40Ag-Cy5 binding by 
increasing concentrations of GW1100 as indicated. The bottom row shows representative granularity analysis applied to these images. This 
ĂŶĂůǇƐŝƐ ŵĞĂƐƵƌĞĚ ĨůƵŽƌĞƐĐĞŶƚ ůŝŐĂŶĚ ďŝŶĚŝŶŐ ĂƐ ƚŚĞ Ɖŝƚ ĐŽƵŶƚ  ? “ǁŚŝƚĞ ĚŽƚƐ ? ? ŐƌĂŶƵůĞƐ  ?- ? ʅŵ ŝŶ ĚŝĂŵĞƚĞƌ ) ǁŚŝůƐƚ ĞǆĐůƵĚŝŶŐ ƚŚĞ ůĂƌŐĞƌ
ĂŐŐƌĞŐĂƚĞƐ ? “ƌĞĚĚŽƚƐ ? ?AN ?ʅŵŝŶĚŝĂŵĞter). When quantifying and pooling data, binding in the absence of tetracycline was set as the negative 
control (0 %), whilst the totals were set as the positive control (100 %). 
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Figure 5.4 Paired GW1100 competition curves enable estimation of  40Ag-
Cy5 dissociation constant at FFA1 receptors. 
Two displacement curves (no BSA) were performed by pre-treating 
tetracycline induced HEK293TR cells expressing FFA1 with increasing 
concentrations of GW1100 for 5 min at 37oC, followed by 30 min treatment at 
37oC with 1 µM or 100 nM 40Ag-Cy5. These paired curves gave GW1100 IC50 
values of 2.2 and 1.1 µM respectively. Simultaneous solution of the Cheng-
Prusoff equations for each curve (shown in text, section 2.2.9.4), gave an 
estimate of the 40Ag-Cy5 dissociation constant for FFA1 receptor (KFL) of 0.6 
µM ?dŚĞĚĂƚĂǁĞƌĞŶŽƌŵĂůŝƐĞĚ  ?A? )ƚŽƚŚĞ  ?ʅD ? )Žƌ  ? ? ?ŶD  )  ? ?Ő-Cy5 
 “ƚŽƚĂů ? ƌĞƐƉŽŶƐĞ ĂŶĚ ǁĞƌĞ ƉŽŽůĞĚ ĨƌŽŵ  ? ŝŶĚŝǀŝĚƵĂů ĞǆƉĞƌŝŵĞŶƚƐ ? ŵĞĂŶ± 
S.E.M.  
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Figure 5.5 Binding curves show the displacement of 40Ag-Cy5 binding to 
FLAG-tagged FFA1 receptors following the pre-treatment of a competing 
ligand. 
HEK293TR cells induced to expressing FFA1 were pre-treated for 5 min at 37oC 
with competing ligands: oleic acid, GW1100, GW9508 or 40Ag-congener (A) or 
the thiazolidinediones troglitazone, rosiglitazone and ciglitazone (B). They 
were then treated with 40Ag-Cy5 for 30 min at 37oC and were immediately 
imaged live. The data were normalised (%) to the 100 nM 40Ag-Ǉ ?  “ƚŽƚĂů ?
response and were pooled from a minimum of 3 individual experiments, 
mean ± S.E.M. Fitted IC50 curves yielded the affinity estimates in Table 5.2. 
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Ligand pIC50 (-Log M) Ki  ?ʅD ) 
GW1100 5.8 ± 0.3 1.42 
40Ag-Congener 6.1 ± 0.2 0.66 
GW9508 6.8 ± 0.2 0.13 
Troglitazone 6.1 ± 0.2 0.62 
Rosiglitazone 4.8 ± 0.2 13.5 
Ciglitazone 4.8 ± 0.2 14.6 
Oleic Acid N.D. N.D. 
 
Table 5.2 pIC50 and Ki values of competing ligands at the human FFA1 
receptor. pIC50 values were fitted from the pooled displacement (n = 3+) 
curves in Figure 5.5. The estimation of Kfl from the paired GW1100 
displacement curves (Figure 5.4) was also used to apply the Cheng-Prusoff 
conversion to competing ligand IC50 values, yielding the indicated Ki estimates. 
N.D. no displacement obtained.  
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5.2.3 Diffusion of FFA1 using FCS of SNAP-labelled receptors and bound 
40Ag-Cy5 
5.2.3.1 Optimisation of FCS at SNAP-surface labelled FFA1 receptors 
To obtain reference measurements of FFA1 receptor diffusion, FCS was first 
performed using SNAP-surface BG-647 (0.1 or 0.5 µM) labelled HEK293TR cells 
expressing SNAP-tagged FFA1 receptors (representative FCS read in Figure 
5.6). Firstly, the position of the upper and lower plasma membrane was 
determined by performing a confocal z scan by positioning the scan in xy on 
the nucleus (Figure 5.6 A). The confocal volume was placed on the upper 
plasma membrane for FCS readings (dotted line in 5.6 A). Next, the 
fluorescent fluctuations were recorded, typically 3 x 15 s reads at 0.7 % laser 
power, following a 15 s prebleach at 0.5 % laser power (Figure 5.6 B). These 
data were then fitted to an autocorrelation 2 component 2 dimensional 
model (Figure 5.6 C), and the deviation from this fit was also plotted (Figure 
5.6 D). 
In evaluating this mŽĚĞů ?ƚŚĞĨĂƐƚʏD1 component 1 (~100 µs dwell time) was 
interpreted as free SNAP-surface label that remained after washing the cells, 
ǁŚŝůƐƚʏD2 (component 2) was interpreted as labelled SNAP-FFA1 receptors in 
the membrane. From the autocorrelation analysis, diffusion co-efficients (D) 
were derived, which normalised the dwell time (ʏD1 or ʏD2) to the confocal 
ǀŽůƵŵĞĐĂůĐƵůĂƚĞĚŝŶƚŚĞĐĂůŝďƌĂƚŝŽŶĨŽƌƚŚĂƚĚĂǇ ?ƐĞǆƉĞƌŝŵĞŶƚ ?ĂŶĚĂůůŽǁƐĨŽƌ
comparison with estimates for other labelled receptors. As expected, D for 
component 1 or 2 did not alter when SNAP-surface fluorophore concentration 
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was increased from 0.1 to 0.5 µM (Figure 5.7 A&B). Interestingly, there was a 
statistically significant increase in particle concentration in component 2 
following the increase in SNAP-surface label concentration (Figure 5.7 D; 53  W 
69 cells from 5 individual experiments). 
In the course of these experiments, the laser power used to measure 
fluorescent fluctuations was also optimised. Four different laser powers at 
633 nm were used: 0.5 A? ? ? ? ? ? ?ʅt ) ? ? ? ? % (0.423 ʅt ) ? ? % (0.748 ʅW) and 2 
% (1.410 ʅt; laser power determination carried out by Dr. S.J. Briddon, 
University of Nottingham). Component 2 D, which measured the diffusion co-
efficient of SNAP-surface labelled FFA1 receptors, significantly increased when 
laser power was increased from 0.5 % to 2 %, as expected because higher 
laser powers would be predicted to increase fluorophore bleaching, and 
shorten the apparent dwell time of the species in the confocal volume (Figure 
5.8 B). Also, the particle concentration of component 2 significantly decreased 
when laser power was increased from 0.5 % to 2 % (Figure 5.8 D). From this, 
 ? ? ?ʅD^EW-surface BG-647 was the chosen concentration to label the SNAP-
FFA1 receptors, and 0.7 % laser power was subsequently used to measure the 
fluorescence fluctuations. Finally the effect of agonist (1 µM GW9508, pre-
treated for 5 min at 22°C) on SNAP-FFA1 receptor diffusion was assessed. This 
treatment significantly increased the particle concentration for this 
component (Figure 5.9 B; 58 cells from 4 individual experiments). 
These data were also analysed using a 2 component PCH analysis, which 
determined the molecular brightness and concentration of the diffusing 
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species. Representative traces show that the 2 component model fit the 
control data (receptors labelled with 0.1 µM / 0.5 µM SNAP-surface BG-647) 
better than the 1 component model (Figure 5.10 A). Since the bin time chosen 
(1 ms) should exclude the contribution of free SNAP-surface label to the PCH 
histogram (component 1 described in FCS traces above), both PCH 
components were interpreted as SNAP-surface labelled receptor-containing 
ƉĂƌƚŝĐůĞƐ ?/ŶƚĞƌĞƐƚŝŶŐůǇ ?ǁŚĞŶ ? ? ?ʅD SNAP-surface BG-647 was used to label 
FFA1, this shifted the curve further right, as would be expected with increased 
particle concentration (Figure 5.10 B). Indeed, the estimated particle 
concentration of both component 1 and 2 were found to be significantly 
ŝŶĐƌĞĂƐĞĚĨŽƌ ? ? ?ʅDSNAP-surface BG-647 labelled FFA1 (Figure 5.10 C & D). 
Also, the molecular brightness for component 1 (SNAP-surface labelled FFA1 
receptors) was found to almost double as the SNAP-surface BG-647 labelling 
ĐŽŶĐĞŶƚƌĂƚŝŽŶŝŶĐƌĞĂƐĞĚĨƌŽŵ ? ? ?ƚŽ  ? ? ?ʅD ?ĨƌŽŵ ? ? ? ?A?   ?ƚŽ ? ? ? ?A? ? ? ?
cpm s-1 (Figure 5.10 E & F; 59  W 66 cells from 5 individual experiments). PCH 
analysis found no significant difference when BG-647 labelled FFA1 was 
ƚƌĞĂƚĞĚ ǁŝƚŚ  ? ʅD 't ? ? ? ? ĐŽŵƉĂƌĞĚ ƚŽ ǀĞŚŝĐůĞ  ?&ŝŐƵƌĞ ? ? ?1; 58  W 61 cells 
from 4 individual experiments).  
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Figure 5.6 FCS measurements of the lateral mobility of SNAP-FFA1 receptors 
labelled with 0.5 ʅDSNAP-surface BG-647. 
A shows the confocal Z scan, which identified the upper and lower plasma 
membrane in SNAP-surface BG-647 labelled HEK293TR SNAP-FFA1 cells, with 
the dotted line showing where the confocal volume was placed for FCS 
readings. Next, fluorescent fluctuations were recorded 3 x 15 sec at 0.7 % 
laser power on the upper plasma membrane, following a 15 sec prebleach at 
0.5 % laser power, all at 22oC (an example record shown in B). Finally, the data 
were fitted to an autocorrelation curve using a 2 component 2 dimensional 
diffusional model (C) and also the deviation from the fit of the autocorrelation 
(D). This resulted in a SNAP-FFA1 receptor dwell time ( D2 of 71.3 ± 12 ms; 53 
cells from 5 individual experiments).  
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Figure 5.7 HEK293TR cells expressing FFA1 were labelled with either 0.1 or 
0.5 ʅDSNAP-surface BG-647, and their diffusion measured using FCS. 
Scatter plots show the pooled data points (individual values, and mean ± 
s.e.m.) for diffusion co-efficients (abbreviated to D) for component 1 (A, 
interpreted as free SNAP-surface label) and 2 (B, interpreted as SNAP-FFA1 
diffusion) derived from the model; and the particle concentrations for 
component 1 (C) and 2 (D) from FCS experiments in HEK293TR cells expressing 
FFA1 (53  W 69 cells from 5 individual experiments) and labelled with 0.1 and 
 ? ? ?ʅDSNAP-surface BG-647. Statistical significance was determined using a 
Matt-Whitney test, *** P <0.001.  
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Figure 5.8 HEK293TR ĐĞůůƐĞǆƉƌĞƐƐŝŶŐ&& ?ǁĞƌĞůĂďĞůůĞĚǁŝƚŚ ? ? ?ʅD^EW-
surface BG-647 and their diffusion measured using FCS at 0.5, 0.7, 1 and 2 % 
laser power. 
Scatter plots show the pooled data for diffusion co-efficients (abbreviated to 
D) for component 1 (A) and 2 (B) derived from the autocorrelation model; and 
the particle concentrations for component 1 (C) and 2 (D) from FCS 
experiments in HEK293TR cells expressing FFA1 (15  W 42 cells from 2 individual 
ĞǆƉĞƌŝŵĞŶƚƐ ) ĂŶĚ ůĂďĞůůĞĚ ǁŝƚŚ  ? ? ? ʅDSNAP-surface BG-647. Statistical 
ƐŝŐŶŝĨŝĐĂŶĐĞǁĂƐĚĞƚĞƌŵŝŶĞĚƵƐŝŶŐĂ<ƌƵƐŬĂůtĂůůŝƐ ƚĞƐƚǁŝƚŚƵŶŶ ?ƐŵƵůƚŝƉůĞ
comparisons post test, *** P < 0.001.  
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Figure 5.9 Effect of 1 µM GW9508 agonist treatment on the lateral mobility 
of SNAP-FFA1 receptors in HEK293TR cells, measured by FCS. 
Scatter plots show the pooled data for diffusion co-efficients for component 2 
(A) of the model; and the particle concentration for component 2 (B) from FCS 
experiments in HEK293TR cells expressing SNAP-FFA1 receptors (58  W 61 cells 
from 4 individual experiments), pre-ůĂďĞůůĞĚ ǁŝƚŚ  ? ? ? ʅDSNAP-surface BG-
647 ĂŶĚ ƚƌĞĂƚĞĚ ǁŝƚŚ ǀĞŚŝĐůĞ Žƌ  ? ʅD 't ? ? ? ? ? ^ƚĂƚŝƐƚŝĐĂů ƐŝŐŶŝĨŝĐĂŶĐĞ ǁĂƐ
ĚĞƚĞƌŵŝŶĞĚƵƐŝŶŐĂ<ƌƵƐŬĂůtĂůůŝƐƚĞƐƚǁŝƚŚƵŶŶ ?ƐŵƵůƚŝƉůĞĐŽŵƉĂƌŝƐŽŶƐƉŽƐƚ
test, *** P < 0.001.  
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Figure 5.10 Photon counting histogram (PCH) analysis estimates of particle 
concentration and molecular brightness of 0.1 or  ? ? ?ʅD SNAP-surface BG-
647 labelled SNAP-FFA1 receptors in HEK293TR cells. 
Representative 1 and 2 component fits of PCH analysis of HEK293TR cells 
expressing SNAP-&& ? ĂŶĚ ůĂďĞůůĞĚ ǁŝƚŚ  ? ? ? ʅDSNAP-surface BG-647 (A); 
whilst representative traces of the 2 component fits to data from SNAP-FFA1 
ĐĞůůƐůĂďĞůůĞĚǁŝƚŚ ? ? ?Žƌ ? ? ?ʅDSNAP-surface BG-647 labelled FFA1 (B).  From 
this analysis, scatter plots show pooled data for the PCH obtained particle 
concentrations for component 1 (C) and 2 (D)  W both of which were 
interpreted as SNAP-surface labelled receptor species; and the molecular 
brightness for component 1 (E) and 2 (F) (59  W 66 cells from 5 individual 
experiments). In the PCH analysis, bin time was set to 1 ms. Statistical 
significance was determined using a Matt-Whitney test, ** P < 0.01, *** P < 
0.001.  
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Figure 5.11 Photon counting histogram (PCH) analysis of particle 
concentration and molecular brightness of SNAP-FFA1 receptors in cells 
ƚƌĞĂƚĞĚǁŝƚŚǀĞŚŝĐůĞŽƌ ?ʅD't ? ? ? ? ? 
Scatter plots show the pooled data for particle concentrations for component 
1 (A) and 2 (B); and the molecular brightness for component 1 (C) and 2 (D) 
from FCS experiments in HEK293TR cells expressing FFA1 (58  W 61 cells from 4 
ŝŶĚŝǀŝĚƵĂů ĞǆƉĞƌŝŵĞŶƚƐ ) ? ůĂďĞůůĞĚ ǁŝƚŚ  ? ? ? ʅDSNAP-surface BG-647 and 
ƚƌĞĂƚĞĚǁŝƚŚǀĞŚŝĐůĞŽƌ ?ʅD't ? ? ? ? ?/ŶƚŚĞW,ĂŶĂůǇƐŝƐ ?ďŝŶ time was set to 
1 ms.  
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5.2.4 FCS studies of 40Ag-Cy5 at SNAP-surface labelled FFA1 
Next, diffusion of the fluorescent ligand, 40Ag-Cy5 was measured free in HBSS 
solution. The diffusion of both 10 and 100 nM 40Ag-Cy5 were measured in the 
absence and presence of 0.02 % BSA. As expected, a ten fold increase in ligand 
concentration from 10 nM (+ 0.02 % BSA) to 100 nM (+ 0.02 % BSA) caused a 
concomitant 10 fold increase in particle concentration, from 3.5 ± 0.2 to 33.7 
A? ? ? ?E ?ʅm2 (Figure 5.12; 31  W 45 cells from 3 - 5 individual experiments). At 
the highest concentration (100 nM), the presence of BSA increased the dwell 
time (Figure 5.12 A) and also reduced the diffusion co-efficient of 40Ag-Cy5 in 
solution. From these daƚĂ ?ƚŚĞĚǁĞůůƚŝŵĞŽĨ ? ? ?A? ? ?ʅs, as measured for 100 
ŶD ǁŝƚŚŽƵƚ ^ ? ǁĂƐ ƵƐĞĚ ĂƐ ƚŚĞ ĐŽŶƐƚĂŶƚ ĨŽƌ  “ĨƌĞĞ ůŝŐĂŶĚ ? ŝŶ ůĂƚĞƌ
autocorrelation data from cells. 
Then, HEK293TR cells expressing SNAP-FFA1 were labelled with 40Ag-Cy5 (5 
min at 22°C) in HBSS in the absence of BSA and FCS recordings made. Pre-
labelling of SNAP-FFA1 with SNAP-surface AF-488 was also undertaken to 
enable easy identification by initial epifluorescence microscopy, and to 
remove any bias in selecting fluorescent ligand labelled (or unlabelled) cells. 
This wavelength was also used to measure the confocal z scan and determine 
the position of the upper plasma membrane. In these experiments, the 
ĐŽŶĨŽĐĂůǀŽůƵŵĞǁĂƐƉůĂĐĞĚŽŶĞ ? ? ?ʅŵƐƚĞƉĂďŽǀĞƚŚĞƵƉƉĞƌŵĞŵďƌĂŶĞ ?ƚŽ
take into account the differences between 488 nm (SNAP-surface labelled 
FFA1) and 633 nm (40Ag-Cy5) laser lines. 
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Representative FCS traces from SNAP-FFA1 receptor cells treated with 100 nM 
40Ag-Cy5, in the absence or presence of 1 µM GW1100 (10 min at 22oC) are 
shown in Figure 5.13 and Figure 5.14 respectively. In each figure, the confocal 
z scan for a representative cell is shown (A), complete with the position of 
where the confocal volume was placed, which was offset slightly above the 
upper membrane (dotted line in A). Also shown are the raw fluorescent 
fluctuations of FFA1 treated with 100 nM 40Ag-Cy5 (B), the autocorrelation 
curve (C) of the data fitted to a model that encompassed 3 dimensional 
diffusion of the ligand with a single component 2 dimensional diffusion of the 
receptor (unless otherwise stated), and the dĞǀŝĂƚŝŽŶĨƌŽŵƚŚŝƐŵŽĚĞů ? ) ?ʏ ?
 ?ƚŚĞĨĂƐƚ ?ĐŽŵƉŽŶĞŶƚƌĞƉƌĞƐĞŶƚŝŶŐĨƌĞĞůŝŐĂŶĚ )ǁĂƐƐĞƚĐŽŶƐƚĂŶƚĂƚ ? ? ?ʅƐ
from earlier measurements of 40Ag-Cy5 in solution (Figure 5.11  )ǁŚŝůƐƚʏD2 
was interpreted as 40Ag-Cy5-bound receptor. 
In the pooled FCS data (Figure 5.15), increasing concentrations of 40Ag-Cy5, 
from 25  W 100 nM, resulted in higher observed particle concentrations for 
both free ligand (component 1) and bound ligand (component 2), but did not 
change the diffusion co-efficient of the FFA1 receptor bound ligand 
significantly (Figure 5.15 B). These diffusion co-efficient estimates were 
approximately 4 times faster than those measured for SNAP-surface BG-647 
labelled SNAP-FFA1 receptors (compare Figure 5.9 A). Pre-treatment with a Kd 
concentration of the antagonist, GW1100 (1 µM for 5 min), as expected 
reduced the percentage proportion of the autocorrelation curve represented 
ďǇʏD2 (compare Figure 5.13 and 5.14; pooled data in Figure 5.15), but this was 
not statistically significant; whilst the measured component 2 diffusion co-
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efficient remained unaffected (Figure 5.15; 31  W 45 cells from 3 -5 individual 
experiments). Unexpectedly there was also a significant increase in 
component 2 particle concentration for 40Ag-Cy5 labelled SNAP-FFA1 that 
had been pre-ƚƌĞĂƚĞĚǁŝƚŚ  ?ʅD't ? ? ? ?  ?&ŝŐƵre 5.15 F). PCH analysis, with 
bin time again set to 1 ms, showed large increases in both component 1 and 2 
particle concentration as the concentration of 40Ag-Cy5 was increased. The 
only conditions that did not have significant differences were from 25 to 50 
nM 40Ag-Cy5 and from 100 nM 40Ag-Cy5 to 100 nM 40Ag-Ǉ ? A?  ? ʅD
GW1100 (Figure 5.16 C & D; 34  W 54 cells from 4 individual experiments). As 
for SNAP-surface BG-647 labelled FFA1 receptors (Figure 5.10), there was also 
an approximate doubling in molecular brightness of component 1 when 
labelling SNAP-FFA1 receptors with 50 nM 40Ag-Cy5, compared to 25 nM, 
from 2453 ± 207 to 4400 ± 400 cpm s-1 (Figure 5.16 E; **, P < 0.01 from 
<ƌƵƐŬĂů tĂůůŝƐ ǁŝƚŚ ƵŶŶ ?Ɛ ŵƵůƚŝƉůĞ ĐŽŵƉĂƌŝƐŽŶ post test). Pre-incubation 
with 1µM GW1100 had no significant effect upon molecular brightness of 
component 1 (Figure 5.16 E), but did significantly reduce the brightness of 
component 2, in cells labelled with 100 nM 40Ag-Cy5 (Figure 5.16 F). 
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Figure 5.12 FCS measurements of 10 or 100 nM 40Ag-Cy5 freely diffusing in 
HBSS solution in the absence or presence of 0.02 % BSA. 
Scatter plots show the pooled autocorrelation data for dwell times calculated 
from a single component 3D autocorrelation model (A); the resultant diffusion 
co-efficients (B; abbreviated to D); and the calculated particle concentrations 
(C) from FCS experiments (60 readings from 4 individual experiments). 
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Figure 5.13 FCS measurements depicting the lateral mobility of 100 nM 
40Ag-Cy5 treated (5 min at 22
o
C) SNAP-FFA1. 
The confocal z scan identified the upper and lower plasma membrane based 
on SNAP-surface AF-488 labelling of the cells, with the dotted line showing 
where the confocal volume was placed for FCS readings (A). Fluorescent 
fluctuations were recorded 3 x 15 sec at 0.7 % laser power on the upper 
plasma membrane, following a 15 sec prebleach at 0.5 % laser power, all at 
22oC (example record, B). Finally, the data were fitted to an autocorrelation 
curve using a 2 component (1x 3D, 1x 2D) diffusional model (C; 45 cells from 4 
individual experiments), and also shown is the deviation from the fit of the 
ĂƵƚŽĐŽƌƌĞůĂƚŝŽŶĐƵƌǀĞ ? ) ?dŚŝƐƌĞƐƵůƚĞĚŝŶĂ “ůŝŐĂŶĚ-ďŽƵŶĚƌĞĐĞƉƚŽƌ ?ĚŝĨĨƵƐŝŽŶ
time of 7.6 ± 0.5 ms.  
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Figure 5.14 FCS measurements depicting the lateral mobility of SNAP-FFA1 
labelled treated with 100 nM 40Ag-Cy5 (5 min at 22
o
C) after antagonist, 1 
ʅD't ? ? ? ?ƉƌĞ-treatment (10 min at 22oC). 
The confocal z scan identified the upper and lower plasma membrane, with 
the dotted line showing where the confocal volume was placed for FCS 
readings (A). Fluorescent fluctuations were recorded 3 x 15 sec at 0.7 % laser 
power on the upper plasma membrane, following a 15 sec prebleach at 0.5 % 
laser power, all at 22oC (example record, B). Finally, the data were fitted to an 
autocorrelation curve using a 2 component diffusional model (1x3D, 1x2D, C; 
40 cells from 4 individual experiments), and also shown is the deviation from 
ƚŚĞ ĨŝƚŽĨ ƚŚĞ ĂƵƚŽĐŽƌƌĞůĂƚŝŽŶ  ? ) ?dŚŝƐ ƌĞƐƵůƚĞĚ ŝŶĂ  “ůŝŐĂŶĚ-ďŽƵŶĚ ƌĞĐĞƉƚŽƌ ?
(component 2) diffusion time of 7.0 ± 0.6 ms.  
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Figure 5.15 FCS measurements of HEK293TR cells expressing SNAP-FFA1 
treated with 25 and 50 nM 40Ag-Cy5; and 100 nM 40Ag-Cy5 (5 min at 22
o
C), 
with or without the pre-ƚƌĞĂƚŵĞŶƚŽĨĂŶƚĂŐŽŶŝƐƚ ?  ?ʅD't ? ? ? ? (10 min at 
22
o
C). 
Scatter plots show the pooled autocorrelation data for percentage proportion 
of the autocorrelation curve corresponding component 2 (A); the diffusion co-
efficient of component 2 (B); and the particle concentration of component 1 
(free ligand, with fixed diffusion co-efficient) (C) and 2 (D) from FCS 
experiments (31-45 readings from 4 individual experiments).  
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Figure 5.16 Photon counting histogram (PCH) analysis estimates of particle 
concentration and molecular brightness of FFA1 treated with 25 and 50 nM 
40Ag-Cy5; and 100 nM 40Ag-Cy5 (5 min at 22
o
C), with or without the pre-
treatment of antagonist GW1100 (10 min at 22
o
C). 
Representative 1 and 2 component fits of PCH analysis of FFA1 treated with 
100 nM 50Ag-Cy5 are shown in A and B respectively. Using the 2 component 
ĨŝƚƐ  ?ďŽƚŚ ŽĨ ǁĞƌĞ ŝŶƚĞƌƉƌĞƚĞĚ ĂƐ  “&& ? ďŽƵŶĚ ? ƐƉĞĐŝƐ ) ? ƐĐĂƚƚĞƌ ƉůŽƚƐ ƐŚŽǁ
the pooled data for particle concentrations obtained for component 1 (C) and 
2 (D); and the molecular brightness for component 1 (E) and 2 (F) from FCS 
experiments in HEK293TR cells expressing SNAP-FFA1 (34  W 54 cells from 4 
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individual experiments) and treated with the ligands as indicated. Bin time 
was set to 1 ms, to exclude contributions from the fast diffusing free ligand 
Statistical significance between all groups was defined using a Kruskal-Wallis 
ƚĞƐƚǁŝƚŚƵŶŶ ?ƐŵƵůƚŝƉůĞĐŽŵƉĂƌŝƐŽŶƉŽƐƚ-tests; whilst comparison between 
100 nM 40Ag-Cy5 and 100 nM 40Ag-Ǉ ?A? ?ʅD't ? ? ? ?ǁĂƐĚĞĨŝŶĞĚƵƐŝŶŐĂ
^ƚƵĚĞŶƚ ?ƐƵŶƉĂŝƌĞĚƚƚĞƐƚ * P < 0.05, ** P < 0.01.  
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5.3 Discussion 
The objective of this study was to use a fluorescent ligand to measure and 
determine the binding affinities of ligands at FFA1. Following the synthesis of 
40Ag-Cy5, it was found to have sub-micromolar affinity and selectivity for 
FFA1. 40Ag-Cy5 was able to be used in imaging competition assays to identify 
the binding affinities of other FFA1 ligands. FCS studies using both SNAP-
surface and 40Ag-Cy5 labelled FFA1 seem to suggest that FFA1 receptors exist 
as oligomers as well as monomers. In the future, this study could be expanded 
to examine the route of association and dissociation of the fluorescent ligand, 
to identify whether the route is via the membrane, as is the case for the S1P 
receptor (Hanson et al., 2012) 
5.3.1 Advantages and disadvantages of the 40Ag-Cy5 fluorescent ligand 
A range of fluorescent fatty acids are already commercially available and 
examples of these ligands, such as BODIPY558/568-C12, act as FFA1 agonists 
(Dr N Holliday, personal communication). However, despite one report of a 
fluorescent fatty acid binding assay (Hara et al., 2009a), these ligands have 
several disadvantages when imaging their binding; for example they have low 
FFA1/GPR120 affinity, readily label cellular membranes in the absence of FFA1 
or GPR120 receptors non-specifically, and they are rapidly incorporated into 
other cellular lipids (such as triglycerides; Dr N Holliday, personal 
communication). 
Thus the rationale for using a more stable synthetic high affinity ligand, 
GW9508, as the starting point for fluorescent ligand generation was to 
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improve the ultimate selectivity and affinity of 40Ag-Cy5 for FFA receptors. 
Indeed this ligand was a selective FFA1 agonist, with potency and estimated 
affinity in the low µM range. In imaging studies it also had greater apparent 
selectivity for binding FFA1, rather than binding to other hydrophobic 
elements present in the plasma membrane such as fatty acid binding proteins, 
or partitioning into the lipid bilayer. This may be a consequence of reduced 
40Ag-Cy5 lipophilicity due to the use of the more hydrophilic Cy5 fluorophore, 
compared to BODIPY630/650, which may also make the ligand more 
membrane impermeant. 
There were some limitations with this study. 40Ag-Cy5 was still 100 fold less 
potent that GW9508 at FFA1 (pEC50 is 10 nM), and was completely inactive at 
GPR120 (compared to GW9508 pEC50 of  ?ʅD ) ?dŚŝƐŵĞĂŶƚƚŚĂƚƵŶĨŽƌƚƵŶĂƚĞůǇ
40Ag-Cy5 could not be used to complement the GPR120 mutagenesis study 
(chapter 4). Additionally, 40Ag-Cy5 is an agonist, therefore it could be 
ƐƵŐŐĞƐƚĞĚ ƚŚĂƚ ŝƚ ŵŝŐŚƚ ůĂďĞů Ă ƐƵďƐĞƚ ŽĨ  “ĂĐƚŝǀĞ ? ƌĞĐĞƉƚŽƌ ĐŽŶĨŽƌŵĂƚŝŽŶƐ ?
Also, it could potentially result in FFA1 internalisation which would complicate 
the binding studies, but there were no observations of this, as the ligand 
stayed on the plasma membrane during the 37oC incubations (and as 
discussed in Chapter 3, relatively little agonist stimulated SNAP-FFA1 receptor 
internalisation could be detected). Finally, there is also the possibility that 
40Ag-Cy5 does not still hit the same binding site as either free fatty acids or 
even the parent compound GW9508 (Lin et al., 2012), which will be discussed 
later. 
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5.3.2 Imaging analysis of 40Ag-Cy5 binding 
Using this fluorescent ligand, successful competition binding assays could be 
performed at FFA1 with high content imaging approaches (Stoddart et al., 
2012). This assay showed 40Ag-Cy5 had specific FFA1 receptor binding, 
because whole cell membrane binding was largely (though not exclusively) 
dependent upon the tetracycline induction of the expression of FFA1. This 
was in direct comparison to high levels of non specific binding that occurred 
when using a radioligand, [3H]TAK-875 at FFA1 (Dr A.J.H. Brown, AZ, personal 
communication) (Negoro et al., 2012). Also, two radiolabelled compounds, 
partial agonist [3H] AMG837 and agonist [3H] AM1638 were successfully used 
to study FFA1 binding, but details of any non-specific binding were not 
included in the published data (Lin et al., 2012). 
Another key advantage to using a fluorescent ligand instead of a radioligand, 
is that the fluorescent ligand did not require washing off to measure the 
binding. TŚĞƌĞĨŽƌĞ ďŝŶĚŝŶŐ ĐŽƵůĚ ďĞ ŵŽŶŝƚŽƌĞĚ ŝŶ ƌĞĂů ƚŝŵĞ Ăƚ  “ƚƌƵĞ ?
equilibrium, without first separating bound from free ligand. 
However, there was still some background 40Ag-Cy5 membrane staining 
present in the no tetracycline controls and in the presence of high 
concentrations of competing ligand, suggesting some residual non-specific 
background binding into the plasma membrane. Also, as expected, total 
binding of 40Ag-Cy5 was reduced by the presence of BSA, because albumin 
has multiple fatty acid and drug binding sites (Krenzel et al., 2013), and was 
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confirmed by the FCS solution studies (Figure 5.12) to interact with 100 nM 
40Ag-Cy5. 
This binding assay was also validated because both the IC50 value for GW1100 
that was determined with this assay; and the rank order of potency of the 
thiazolidinediones of troglitazone > rosiglitazone, ciglitazone; were both 
comparable to results previously published using other functional assays 
(Briscoe et al., 2006; Smith et al., 2009) (e.g. GW1100 pKb in the same FFA1 
cell line calculated in Chapter 3). 
There were some unusual findings from the FFA1 competition binding assay, 
which will now be discussed. Firstly, competition with synthetic ligands did 
not in general displace 40Ag-Cy5 binding to 0 % levels, as defined by cells in 
the absence of tetracycline induction of the FFA1 receptor. For agonists such 
as TZDs, GW9508 or the 40Ag-Cy5 congener, the maximum competition 
observed was greater than this. This might be explained (given the GW9508 
pharmacophore of the 40Ag-Cy5 ligand) by the presence of additional non-
FFA1 membrane binding sites for 40Ag-Cy5, which can be competed for by 
these ligands. 
In contrast, the antagonist GW1100 did not fully displace 40Ag-Cy5 binding to 
the low levels seen in no tet controls. This might arise because the presence 
of FFA1 itself elevates non-specific membrane binding in these cells (e.g. 
because dissociation of 40Ag-Cy5 from FFA1 provides a route for this ligand 
into the plasma membrane). Alternatively, it might indicate allosteric 
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interactions between GW1100 and the 40Ag-Cy5, discussed further below (Lin 
et al., 2012).  
Most interestingly, the endogenous free fatty acid agonists (oleic and myristic 
acid) did not displace 40Ag-Cy5 binding at concentrations up to 300 µM. 
While this could perhaps be due to low mM affinity of FFAs, one could argue 
that there was actually an increase in 40Ag-Cy5 binding with increasing oleic 
acid concentration (and potentially, this was also evident with low 
concentrations of TZDs). This suggests perhaps that oleic acid binds to a 
different site on FFA1 to 40Ag-Cy5 and there is positive allosteric co-
operativity between these two binding sites. Recent findings from an FFA1 
binding study support the existence of such mechanisms (Lin et al., 2012). 
Using radiolabelled partial agonist [3H]AMG837, or full agonist [3H]AM1638, 
these authors uncovered complex allosteric interactions at FFA1 between 
these ligands, other members of the compound series (e.g. AM8182; 
structurally related to GW9508 (chapter 4)), and endogenous FFAs (DHA). A 
summary of the postulated FFA1 binding interactions found in Lin et al., 
(2012) is shown in Figure 5.16. In particular, the authors demonstrated that 
the free fatty acid DHA increased [3H]AM1638 binding at FFA1 (Lin et al., 
2012), in an identical fashion to the observations between oleic acid and 
40Ag-Cy5 in this study. 
This possibility of allosteric interactions thus requires further experiments to 
investigate (section 5.4).  
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Figure 5.16 Three postulated FFA1 binding sites and the potential allosteric 
modulation between them 
Based on the recent Lin et al. (2012) study, the partial FFA1 agonist AMG837 
binds to a site different to full agonists AM1638 and AM8182, and positive 
and negative cooperative binding effects are shown as green or red lines 
respectively. A point to note is that although there is negative binding co-
operativity between the AMG837 site and the AM8182 site shown here, a 
contrasting positive cooperative effect is observed in the functional Ca2+ 
signalling assay (Lin et al., 2012).  
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5.3.3 FCS and PCH analysis of SNAP-FFA1 receptor diffusion 
SNAP-surface BG-647 was used to label SNAP-tagged FFA1 receptors and 
measure their diffusion using FCS. The advantages of this method, compared 
to the use of GFP-tagged receptor proteins, are that there are less effects 
from fluorophore photophysics; and that the far red fluorophore is resistant 
to photobleaching compared to fluorescent proteins, at a wavelength which 
minimises cellular auto fluorescence compared to at 488 nm (Kozma et al., 
2013). Using SNAP-surface BG-647 labelled proteins also allowed more direct 
comparison with the 40Ag-Cy5 ligand data, as acquisition involved the same 
calibration and beam path settings, from the same confocal volume. The 
optimisation of the laser power was also important, because higher laser 
powers can cause shorter dwell times, for example of ʏD2, due to the fact that 
the fluorophore is more likely to become bleached before the labelled 
molecules can fully traverse the confocal volume, resulting in the shorter, 
artificially  “ĨĂƐƚĞƌ ?dwell times. This was demonstrated by the component 2 
diffusion co-efficient, interpreted as the SNAP-surface BG-647 labelled 
receptors, undergoing a significant increase when laser power was increased 
from 0.5 % to 2 %. The particle concentration of component 2 also 
significantly decreased when laser power was increased from 0.5 % to 2 %, 
and this may also have been due to bleaching. 
The decrease in diffusion coefficient from component 1 to component 2 of 
SNAP-surface BG-647 labelled FFA1 is to be expected, and is in line with the 
proposal that component 1 measured the fast moving free SNAP-surface label 
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(with similar D to freely diffusing fluorophores such as Cy5 used for 
calibration), whilst component 2 measured the SNAP-surface labelled 
receptor which would diffuse much slowly. Component 1 particle 
concentration increased when SNAP-surface BG-647 concentration was 
ŝŶĐƌĞĂƐĞĚĨƌŽŵ ? ? ?ƚŽ ? ? ?ʅD ?Equally there was also a significant increase in 
component 2 particle concentration when increasing SNAP-surface BG-647 
ĨƌŽŵ  ? ? ? ƚŽ  ? ? ?ʅD ?which indicates that not all SNAP-tagged FFA1 receptor 
proteins were labelled at the lower concentration. 
The calculation of diffusion co-efficients allows for comparison with other 
receptors and other labels, and it was found that the diffusion co-efficient for 
SNAP-FFA1 was comparable to other GPCRs expressed in the same cell line, 
even though these studies used fluorescent protein tags fused to the 
receptors. Such examples include the neuropeptide Y Y1 receptor (Kilpatrick 
et al., 2012) and bradykinin 2 receptor (Philip et al., 2007). 
Diffusion rates derived from other methods, such as fluorescence recovery 
after photobleaching (FRAP) are still consistent with other methods, for 
ĞǆĂŵƉůĞ ƚŚĞ ŵŽďŝůŝƚǇ ŽĨ ɴ2AR (Hegener et al., 2004; Kaya et al., 2011). 
However, some diffusion rates from FRAP (e.g. for the Y1 receptor) have been 
found to be an order of magnitude lower than those from FCS. This is thought 
to be because FRAP measurements cover a larger area of the plasma 
membrane compared to FCS, therefore cytoskeletal factors limiting diffusion 
might become more noticeable (Kilpatrick et al., 2012).  
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The addition of 1 ʅD't ? ? ? ?ĐĂƵƐĞĚĂdecrease in the diffusion co-efficient 
of the receptor mediated component 2. This would be expected if the binding 
of GW9508 increased the mass of FFA1 receptor complexes sufficiently, or 
changed the interactions with cellular components such as the cytoskeleton 
to slow their diffusion. The extent with which agonists can affect receptor 
diffusion is very variable, for example NPY slowed the receptor diffusion of 
the neuropeptide Y1 receptor (Kilpatrick et al., 2012); meanwhile, agonist 
treatment resulted in two differently diffusing populations of the A3 
adenosine receptor (Cordeaux et al., 2008); whilst agonists had no effect upon 
the diffusion of the A1 adenosine receptor (Briddon et al., 2008) or opioid 
receptors (Golebiewska et al., 2011). However, in Kilpatrick et al., (2012), this 
slowing in receptor diffusion was thought to be associated with receptors 
clustering prior to endocytosis. This is unlikely here because FFA1 less readily 
undergoes endocytosis. 
The observed SNAP-FFA1 particle concentration also significantly increased 
following GW9508 treatment. This could be explained either by dissociation of 
receptor clusters into smaller units, or the agonist increasing the mobility of 
an inactive pool of immobile FFA1 receptors invisible to FCS. PCH analysis of 
SNAP-surface ůĂďĞůůĞĚ && ? ƌĞĐĞƉƚŽƌ ƌĞĐŽƌĚƐ ƌĞǀĞĂůĞĚ ƚǁŽ  “ƌĞĐĞƉƚŽƌ ?
components of very different molecular brightness, with a minority of very 
ďƌŝŐŚƚ && ? ƌĞĐĞƉƚŽƌ  “ĐůƵƐƚĞƌƐ ?  ? ? ?ǆ ƚŚĞ ĐŽŵƉŽŶĞŶƚ ?  “ƵŶŝƚ ? ďƌŝŐŚƚŶĞƐƐ ) ?
However  ? ʅD 't ? ? ? ? did not alter the relative proportions of these PCH 
components.  
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The calculated particle concentration for the predominant FFA1 receptor 
component in PCH analysis (component 1) was ~5 fold higher than that 
estimated by FCS as component 2, but the PCH analysis still showed the same 
increase ŝŶƉĂƌƚŝĐůĞĐŽŶĐĞŶƚƌĂƚŝŽŶďĞƚǁĞĞŶ ? ? ?ĂŶĚ ? ? ?ʅDSNAP-surface BG-
647 labelled FFA1 as was found in the FCS analysis. The difference in 
calculated values may be due to the fact that the FCS data are fitted to a 2D 
model, whilst the PCH data is fitted to the currently available 3D model (Chen 
et al., 1999). There are limitations to either model because the model is based 
on a 2D bilayer that in reality will also contain components diffusing in 3D. In 
addition, the PCH analysis may also incorporate some measurement of 
immobile particles, but this would not contribute to the FCS time dependent 
fluctuation data (Kilpatrick et al., 2012). 
5.3.4 FCS analysis of 40Ag-Cy5 diffusion 
5.3.4.1 Free diffusion of 40Ag-Cy5 in solution 
Diffusion of the free 40Ag-Cy5 ligand (100 nM) was affected by the addition of 
0.02 % BSA, which was as expected because BSA contains binding sites for 
drugs and fatty acids (Krenzel et al., 2013), and the parent compound 
GW9508 binds albumin (Dr. G. Robb, AZ, personal communication). 
Theoretically, there would a 64 fold change in mass upon the ligand binding 
BSA because the molecular mass of ligand is 1,038 Da, whilst BSA is ~66,000 
Da, therefore should result in a 4 fold change in dwell time, but the observed 
result was only a ~2 fold change in dwell time which suggests a mix of free 
ligand and ligand bound to BSA was present. Other things that may cause this 
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discrepancy are that the ligand in solution may not all be monomeric, and that 
the ligand may not bind BSA in a 1:1 stoichiometry. 
5.3.4.2 40Ag-Cy5 binding to HEK293TR cells expressing FFA1 
Membrane binding of 100 nM 40Ag-Cy5 to cells expressing FFA1 receptors 
was clearly observed as the appearance of an additional slow diffusing 
component ( D2 ~ 8 ms) in the autocorrelation curve, interpreted as FFA1 
receptor bound 40Ag-Cy5, in addition to free ligand. However a discrepancy in 
the studies of 40Ag-Cy5 binding to FFA1 was that the apparent diffusion co-
efficient of FFA1 bound 40Ag-Cy5 was 5-6 times faster than the 
measurements using the SNAP-labelled receptor alone. One suggestion for 
this could be that the fluorescent agonist selectively labels a fast moving 
population of receptors when compared to SNAP-surface which labels all 
receptors ?ĂƐƐƵŐŐĞƐƚĞĚƚŽĞǆƉůĂŝŶƚŚĞ  “ĨĂƐƚ ? D2 and  “ƐůŽǁ ?D3 components 
described for A3 receptor bound fluorescent agonists (Cordeaux et al., 2008). 
A more likely scenario (given the relatively low affinity of the ligand) is that 
40Ag-Cy5 only binds to the FFA1 receptor for short time before dissociating, 
and this length of time is less than the time taken for the receptor molecules 
to diffuse completely across the confocal volume. This is also the latest theory 
for the A3 adenosine receptor data (Dr S.J. Briddon, University of Nottingham, 
personal communication). The addition of 1µM GW1100, expected to displace 
40Ag-Cy5 binding by ~ 50 %, did decrease the proportion of the ʏD2 bound 
component slightly without significantly changing the diffusion co-efficient, 
which could suggest that 40Ag-Cy5 was partly displaced. However, this was 
not significant, and there was also no change in particle concentration of 
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component 2. To exclude artefacts from experimenter bias, cells were not 
chosen on the basis of their 40Ag-Cy5 labelling in these studies, but on the 
basis of the SNAP-surface AF-488 labelling of FFA1. The apƉĂƌĞŶƚ  “ĨƌĞĞ ?
concentration of 40Ag-Cy5 as determined from component 1 particle 
concentration did increase following GW1100 treatment, though not 
significantly, suggesting some displacement of 40Ag-Cy5 from FFA1. 
Interestingly, there was also a significant increase in component 2 particle 
concentration following GW1100 (and this was evident in the PCH analysis for 
receptor bound components), showing that GW1100 does appear to have 
some sort of effect upon 40Ag-Cy5 binding to FFA1, though these early data 
are not entirely consistent with the clear competition observed in the binding 
study. 
Perhaps these less than conclusive results are due to the experiment not 
being carried out at equilibrium, because in contrast to the binding studies, 
the cells were treated with 40Ag-Cy5 for only 5 min at 22oC, compared to 30 
min at 37o ?ůƐŽ ?ŝŶƚŚĞďŝŶĚŝŶŐĞǆƉĞƌŝŵĞŶƚƐ ?ʅD't ? ? ? ?ŽŶůǇ ŐĂǀĞ ? ?-50 
% displacement of 40Ag-Cy5, which could result in the limited effect seen 
here in the FCS data, therefore, the experiments should be repeated with an 
increased GW1100 concentration. Another limitation with this study is that a 
ŵŝŶŽƌŝƚǇŽĨǀĞƌǇďƌŝŐŚƚƉĂƌƚŝĐůĞƐŵĂǇƐŬĞǁƚŚĞʏD2 parameter, and the relative 
contributions to different D components, and one effect of GW1100 was to 
increase the proportion of these large 40Ag-Cy5 bound clusters observed as 
component 2 in PCH analysis. 
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5.3.5 PCH data suggests presence of FFA1 dimer/oligomer formation 
PCH analysis applied to either SNAP-surface BG-647 labelled FFA1, or 40Ag-
Cy5 labelled FFA1 receptors, also measured the molecular brightness of the 
SNAP-FFA1 receptor containing particles. /Ŷ ĂĚĚŝƚŝŽŶ ƚŽ ĚĞĨŝŶŝŶŐ ďŽƚŚ  “ƵŶŝƚ ?
(component 1) and clustered, very bright particles (component 2), in both 
cases tŚĞďƌŝŐŚƚŶĞƐƐŽĨ ƚŚĞ  “ƵŶŝƚ ?ĐŽŵƉŽŶĞŶƚ  ?ǁĂƐ ŝŶĐƌĞĂƐĞĚďǇ ŝŶĐƌĞĂƐŝŶŐ
the concentration of the SNAP label or 40AG-Cy5 ligand. Thus, when the 
SNAP-surface ĐŽŶĐĞŶƚƌĂƚŝŽŶǁĂƐ ŝŶĐƌĞĂƐĞĚĨƌŽŵ ? ? ?ƚŽ  ? ? ?ʅD'-647 there 
was almost a doubling in molecular brightness of component 1, though this 
was not found to be statistically significant. Equally, the molecular brightness 
of component 1 was significantly increased when FFA1 cells were exposed to 
100 nM 40Ag-Cy5 compared to 25 nM 40Ag-Cy5. In both cases, this increase 
suggests the presence of dimers or higher order receptor oligomers within the 
membrane. If FFA1 receptors were only monomeric, it would either be 
labelled (by SNAP-surface or 40Ag-Cy5) or not, i.e. 1 or 0, thus increasing label 
concentration would increase particle concentration but not brightness. If in 
contrast, some FFA1 receptors were oligomers (e.g. a dimer) one or two 
protomers within a particular particle could be labelled, i.e. the brightness 
could be 1 or 2, theoretically causing an approximate doubling in molecular 
brightness for the particle as the labelling concentration is increased, and an 
increase in molecular brightness overall for the population. This is the first 
evidence for dimerisation occurring in the FFA receptor family. It also 
indicates another way in which FCS and PCH can be used to determine the 
oligomerisation of receptors in conjunction with the use of SNAP-surface 
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labels, in comparison to other studies, in which PCH measurements for Y1 or 
opioid receptors have been altered in the presence of agonists (Golebiewska 
et al., 2011; Kilpatrick et al., 2012). 
Additionally, this demonstration of FFA1 dimerisation indicates another 
ƉŽƐƐŝďůĞ ĞǆƉůĂŶĂƚŝŽŶ ĨŽƌ ƚŚĞ ĂůůŽƐƚĞƌŝĐ  “ĐƌŽƐƐ-ƚĂůŬ ? ďĞƚǁĞĞŶ ďŝŶĚŝŶŐ ƐŝƚĞƐ ŝŶ
each protomer (Lin et al., 2011). This allosteric co-operativity across a 
homodimer has previously been demonstrated for both the A3 adenosine 
(May et al., 2011) and D2 dopamine receptor (Han et al., 2009). Another 
interesting example is with the chemokine receptor, where it was found that 
the binding of a specific ligand to one receptor in the oligomer prevented 
radiolabelled chemokine binding to the other protomer. Additionally, there 
was evidence of negative co-operativity across a heterodimer, where the 
binding of a specific antagonist to one protomer inhibited chemokine binding 
to the other protomer (Sohy et al., 2009). 
5.4 Future work 
5.4.1 Binding 
Future studies on the binding assay would be to carrying it out using a native 
tissue such as pancreatic islet ɴĐĞůůƐ, immune cells or colonic endocrine cells, 
as this would show the applicability of using a fluorescent ligand to study 
native FFA1 receptors in the absence of suitable antibodies and could also 
ůŽĐĂůŝƐĞ ƌĞĐĞƉƚŽƌƐ ƚŽƐƉĞĐŝĨŝĐĐĞůůƐ ? ĨŽƌĞǆĂŵƉůĞɲŽƌɴĐĞůůƐ ŝŶ ƚŚĞƉĂŶĐƌĞĂƚŝĐ
islets, in addition to studying pharmacology by binding assays. 
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5.4.2 FCS 
Future work is necessary to determine that component 2 identified in 40Ag-
Cy5 FCS studies is definitively FFA1 receptor bound. One option would be to 
carry out FCS measurements on HEK293TR cells that have not undergone 
tetracycline induction of FFA1 expression. The expected result from treating 
these cells with 40Ag-Cy5 would be that component 2 disappears. This was 
attempted unsuccessfully (results not shown) by using DiO labelled cells to 
locate the membrane, but hopefully with further optimisation these issues 
could be resolved. 
Another further FCS experiment that could be carried out would be to pre-
treat with GW9508 as a competing ligand, then treat with 40Ag-Cy5. This is 
because GW9508 would be expected to bind at the same site as 40Ag-Cy5, 
therefore this could then be compared with the GW1100 data. Additionally, 
the GW1100 studies could be repeated using a higher concentration of 
GW1100, predicted to fully displace the 40Ag-Cy5 ligand. These studies might 
also lead to greater understanding of potential allosteric interactions between 
these ligands, but also begin to determine whether 40Ag-Cy5 binds FFA1 
through the extracellular, aqueous solution or via the membrane as was 
suggested for the S1P receptor (Hanson et al., 2012). 
A future study that would complement the FCS work, would be to carry out 
FRAP on the SNAP-labelled receptors. This technique measures the proportion 
of receptors that are immobile, because a limitation of FCS is that it only 
detects moving species (Kilpatrick et al., 2012). 
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5.4.3 Testing allosteric interactions 
The possibility of allosteric interactions could be investigated using other 
radio- or fluorescently labelled ligands (Leach et al., 2011; Lin et al., 2012). 
These ligands could also be used in the technique of perfusion (May et al., 
2011). In this study, perfusion was used to detect allosteric interactions by 
comparing the dissociation kinetics of a fluorescent ligand using infinite 
dilution conditions, or in the presence of other ligands. Cells expressing the 
receptor of interest were imaged under constant switchable perfusion in 
buffer, buffer with fluorescent ligand or buffer with unlabelled ligand. Images 
were then analysed to quantify association and dissociation kinetics of the 
fluorescent ligand binding. Allosteric interactions between protomers were 
detected by the fact that the unlabelled ligand accelerated the dissociation 
rate of the labelled ligand (May et al., 2011), compared to infinite dilution 
conditions.  
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Chapter Six: Overall discussion 
6.1 Discussion 
Investigating the pharmacology of FFA receptors is important because there is 
a rising worldwide prevalence of both obesity (Ogden et al., 2006; Rennie and 
Jebb, 2005) and type II diabetes (Wild et al., 2004), and particularly for 
obesity, a very limited amount of pharmacological options licensed for 
treatment. Therefore the investigation of novel therapeutic targets in these 
area is a key element to meeting this growing need. 
Since their deorphanisation, both GPR120 (Hirasawa et al., 2005) and FFA1 
(Briscoe et al., 2003) have been researched for their possibility as novel 
targets for obesity and type II diabetes. FFA1 has already been validated as a 
target for type II diabetes, due to the success of the agonist TAK-875 in 
ongoing clinical trials (Kaku et al., 2013), and is known for modulating GSIS in 
the presence of FFAs, due to it predominantly being expressed in the 
ƉĂŶĐƌĞĂƚŝĐɴĐĞůů(Briscoe et al., 2003). GPR120 is also of interest because it is 
predominantly expressed in the gut and its activation causes the release of 
incretins, aka satiety hormones, such as GLP-1 (Hirasawa et al., 2005) and CCK 
(Tanaka et al., 2008a). It is also expressed in the tongue (Matsumura et al., 
2009), suggesting the possibility of GPR120 acting as a dietary fat sensor. 
Although GPR120 exists in 2 splice isoforms, no full isoform specific 
characterisation had been carried out. This study aimed to readdress this 
situation (chapter 3). Using a variety of assays, it was found that GPR120S can 
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respond in a G protein dependent manner, as measured using calcium and 
dynamic mass redistribution (DMR; (Schroder et al., 2010)), whilst GPR120L 
gave no responses. Additionally, the G protein mediated responses by 
GPR120S were insensitive to the effects of PTx, therefore these responses are 
mediated independently of Gi, probably through Gq as previously hinted at 
(Hirasawa et al., 2005). Unfortunately, although DMR is known for giving 
unique signatures depending upon the G protein coupling of the receptor 
(Schroder et al., 2010), the GPR120S responses did not correlate precisely to 
one of these signatures. 
Interestingly, it was found that both GPR120S and GPR120L signal in a G 
protein independent manner, as elucidated using both an internalisation 
ĂƐƐĂǇĂŶĚŝ&ƚŽŵĞĂƐƵƌĞƚŚĞ ŝŶƚĞƌĂĐƚŝŽŶƐďĞƚǁĞĞŶƌĞĐĞƉƚŽƌĂŶĚɴ-arrestin 
(Kilpatrick et al., 2010). Additionally, as part of this work, the novel finding 
that GPR120S undergoes calcium signalling and internalisation in response to 
nuclear PPAR  agonists, thiazolidinediones, was discovered.  
Following internalisation, both receptors were also observed to undergo 
trafficking, predominantly to the lysosomes and did not undergo significant 
recycling back to the cell surface. All that differs between the isoforms is a 16 
residue insert in the third intracellular loop, which must result in the selective 
difference in G protein dependent signalling. 
Following on from this, a mutant of GPR120S was created, to examine the 
possibility that the carboxyl tail was an alternative regulatory domain in 
GPR120, because both isoforms had similar trafficking profiles therefore there 
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must be no effect of the ICL3 insertion upon this pathway. This mutant was 
truncated at the carboxyl tail at residue 346, thus removing 5 Ser/Thr 
residues. This mutation resulted in a lack of desensitisation in calcium 
signalling, resulting in larger calcium responses of the same magnitude of 
FFA1 expressed in the same cell background. Interestingly, in contrast to the 
dogma of sequential desensitisation and internalisation, this mutation 
appeared to have less of an effect upon the internalisation pathway. 
Further work needs to be carried out to determine if GPR120L is expressed in 
humans, in which tissues, and under what circumstances (e.g. adult versus 
during development). Some preliminary data has struggled to find any 
evidence of its expression (Dr C.P. Briscoe, Janssen Pharmaceuticals, personal 
communication). If it is expressed in humans, further work then needs to 
determine whether the expression profiles of the isoforms differ, to see if 
these findings of differential signalling have in vivo relevance. An intriguing 
study found that GPR120 underwent differential signalling depending on 
which tissue it is expressed in. In the adipocyte GPR120 signalled through Gq 
ƚŽ ĐĂƵƐĞ ŐůƵĐŽƐĞ ƵƉƚĂŬĞ ? ǁŚŝůƐƚ ŝŶ ƚŚĞ ŵĂĐƌŽƉŚĂŐĞ ŝƚ ƐŝŐŶĂůůĞĚ ƚŚƌŽƵŐŚ ɴ-
arrestin2 to mediate anti-inflammatory effects (Oh et al., 2010). It could be 
tantalising to postulate that this is due to GPR120S being expressed in the 
adipocyte, whilst GPR120L was expressed in the macrophage; but there is no 
evidence for this so far. If it turns out that such an expression profile exists, 
this gives additional possibilities for GPR120 as a therapeutic target, and 
potenƚŝĂů ƵƐĞ ŽĨ  “ďŝĂƐĞĚ ? ĂŐŽŶŝƐƚƐ ? One example could be if GPR120S was 
expressed in a tissue that required glucose uptake, a ligand could be used to 
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target this G protein mediated effect; or if on the other hand, an anti-
ŝŶĨůĂŵŵĂƚŽƌǇĞĨĨĞĐƚǁĂƐƌĞƋƵŝƌĞĚ ?ĂůŝŐĂŶĚƚŚĂƚǁĂƐďŝĂƐƚŽǁĂƌĚƐɴ-arrestin2 
signalling could be used to target that pathway instead. 
Additionally, GPR120 and FFA1 are known to have some overlapping sites of 
expression in the GI tract (Hirasawa et al., 2005; Stoddart et al., 2008). This 
degeneracy is interesting, considering they are activated by a similar range of 
FFAs. Therefore, these receptors were constrained into heterodimers to 
investigate whether they underwent novel pharmacology in response to 
agonist, because if so, this could complicate designing drugs to target these 
receptors in the gut. However these results ĚŝĚ ŶŽƚ ƐŚŽǁ  “ŚĞƚĞƌŽĚŝŵĞƌ ?
specific pharmacology for the limited range of ligands tested. There is also the 
ƉŽƐƐŝďŝůŝƚǇŽĨ&& ?ĂŶĚ'WZ ? ? ?ĐŽƵƉůŝŶŐƚŽƚŚĞ'ɲƉƌŽƚĞŝŶ ?ŐƵƐƚĚƵĐŝŶǁŝƚŚŝŶ
these endocrine cells in the GI tract (Kinnamon, 2012). 
This characterisation of GPR120 showed it to still be an exciting drug target, 
but to design drugs to target GPR120, more information on the binding site is 
required. This is especially relevant to design drugs to be selective for GPR120 
over FFA1, considering their overlap in human expression sites, and this is 
what led to the rationale to investigate the GPR120 binding site (chapter 4). 
Firstly, two modelling studies, with the model based on rhodopsin, identified 
R99 placed at the top of TM 2, to be the positive counter ion to the negative 
carboxylate group found on the endogenous agonists, FFAs (Sun et al., 2010; 
Suzuki et al., 2008). Along with R99, R178 was also tested, because like R99, it 
is at the top of a TM helix 4, and may also have been a counter ion to the 
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carboxyl group. It was found that R99 was key for this role, whilst R178 was 
not. In addition to this, a later modelling study, this time based on the active 
sƚƌƵĐƚƵƌĞŽĨɴ2AR (Rasmussen et al., 2011a), indentified a hydrophobic pocket 
comprised of Met118, Thr119, Gly122, Phe211, Asn215, Ile280, Ile281 and 
Trp277. This study also identified F304 and F311 to form interactions with the 
phenylpropionate moiety of the ligand (Shimpukade et al., 2012). 
Meanwhile, Graeme Robb (AZ) also modelled the GPR120 binding site, again 
ƵƐŝŶŐ ƚŚĞ ĂĐƚŝǀĞ ĐƌǇƐƚĂů ƐƚƌƵĐƚƵƌĞ ŽĨ ɴ2AR (Rasmussen et al., 2011a), and 
identified Asn215, Trp277 and Phe311 as being important for ligand binding. 
Therefore, a mutagenesis study was carried out, comprising of testing the 
SNAP-tagged GPR120S mutants N215A, W277A, W277F and F311A on both a 
calcium and an internalisation assay, in the same background. It was found 
that N215 interacts selectively with the synthetic agonist Met36, and is 
suggested to be key for this class of ligands which have selectivity for GPR120 
over FFA1. W277 meanwhile, is highly conserved in all class A GPCRs and is 
implicated in the toggle switch activation of receptors (Holst et al., 2010). It 
was found to be important for stabilising both endogenous FFA activation and 
synthetic ligands, for example either hydrogen bonding with the ether-oxygen 
group present in GW9508, or undergo charge-donation effect from the pi-
orbital of the central aromatic ring present in Met36. On the other hand, F311 
was found to be overestimated by model, because its mutation had little 
effect on agonist activation of GPR120S. It was postulated to contribute to 
docking the ligand in the binding site in combination with F304 (Shimpukade 
et al., 2012), so perhaps this is an explanation for the lack of effect by itself. 
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The residue Phe311 being overestimated by the model shows some 
limitations in the modelling approach and mutagenesis to determine the 
binding site. Firstly, the model is flawed because there is no x-ray structure of 
'WZ ? ? ? ? ĂŶĚ ŝƐ ŝŶƐƚĞĂĚ ďĂƐĞĚ ŽŶ ƚŚĞ ĐƌǇƐƚĂů ƐƚƌƵĐƚƵƌĞŽĨ ɴ2AR (and as 
discussed in Chapter 1, there may be significant differences in this template, 
even for class A GPCRs). Secondly, the effects of the mutants are measured by 
signalling assays, which is also flawed because results can be affected by cell 
surface expression levels of the receptor (though this was monitored in this 
study). Additionally, using a signalling assay such as measuring calcium also 
has flaws because the effect of a mutant may be hidden by the fact that the 
calcium signalling assay has signal amplification, but this is why the 
internalisation assay was also employed in this study for comparison. If a 
mutant is found to have an effect upon signalling, there are still limitations to 
interpretation because if an agonist no longer activates the receptor following 
mutation, this could be due to a myriad of factors. The mutation, e.g. Trp 
 “ƚŽŐŐůĞ ƐǁŝƚĐŚ ?could have prevented receptor conformational changes 
required for activation, or prevented the coupling between the receptor and 
effector protein. These factors may be in addition to or instead of the role of 
the residue in mediating ligand-receptor interactions in the binding site. This 
highlights the difficulty of using mutagenesis and signalling assays to study 
GPCR binding sites, and a ligand binding assay would be another way to 
investigate this. 
This example of the need for a binding assay at FFA receptors is also 
emphasised by the current lack of information about ligand affinity for these 
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receptors (rather than indirect potency estimates). Normally, affinity 
estimates are key for drug discovery (chapter 5), for example in considering 
structure activity relationships. 
Since there are no radiolabelled ligands of suitable selectivity or affinity, a 
fluorescent ligand 40Ag-Cy5, based on a known agonist at FFA1 was 
synthesised (by CellAura, Nottingham) and characterised. 40Ag-Cy5 was found 
to be selective for FFA1 (sub µM affinity) over GPR120. 40Ag-Cy5 was used 
successfully in a whole cell ligand binding imaging assay, and could be 
specifically competed from the FFA1 receptor by a collection of known ligands 
at FFA1 (Stoddart et al., 2012). This also showed that a traditional radioligand 
binding assay could be replicated using a fluorescent ligand, because its 
results agreed with those already in the literature, such as the order of 
potency of TZDs (Smith et al., 2009); and the pIC50 of the antagonist GW1100 
(Briscoe et al., 2006). 
Then, to further confirm ligand binding, the technique of FCS was used. This 
firstly measured the diffusion of the SNAP-tagged receptor alone (dwell time 
71 ± 12 ms). Then FFA1 was treated with 40Ag-Cy5, which was demonstrated 
to bind to the receptor (dwell time 7.6 ± 0.5 ms), and that this binding could 
be partly displaced by the pre-treatment of FFA1 with an antagonist, GW1100 
without affecting the dwell time. The apparent formation of FFA1 dimers was 
shown by the fact that the molecular brightness assumed to correspond to 
the main receptor component, as measured from PCH analysis, appeared to 
almost double, when either increasing SNAP-surface BG-647 labelling 
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concentration (labelling the SNAP-tagged receptor irreversibly) or increasing 
the concentration of 40Ag-Cy5. This in conjunction with the findings from the 
constrained dimers (chapter 3), suggests that perhaps FFA1 can indeed exist 
as oligomers, and potentially heterodimers, e.g. with GPR120. 
In the future, if a fluorescent ligand for GPR120 were to become available, it 
would be of interest to test ligand binding at the mutants created in this study 
(chapter 4), and also to determine the Ki values for ligands at the wild type 
receptor. Also, the existence of GPR120:FFA1 dimers could be validated using 
either a FRET based assay or the perfusion system. 
6.2 General conclusion 
In conclusion, this investigation into the FFA receptors GPR120 and FFA1 has 
found novel findings regarding the differential G protein signalling of the 
GPR120 isoforms, even though they underwent similar intracellular 
trafficking. The ligand binding site of GPR120 was also probed using a 
mutagenesis study, validating the proposed molecular model for the general 
mode of binding of the different types of GPR120 agonists, but with some 
limitations. A binding assay would be a better approach to identifying residues 
key for ligand binding, and measuring ligand affinity at these receptor directly 
(for example to generate structure activity relationships during drug 
discovery). A traditional pharmacological binding assay was achieved at FFA1 
using a fluorescent ligand in lieu of a radiolabelled ligand. This ligand was then 
also utilised to investigate the binding of FFA1 using another technique, FCS, 
as well as to define its diffusion characteristics.  
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Therefore, this investigation shows the utility of using a fluorescent ligand in 
the place of a radiolabelled ligand to characterise FFA receptors. Overall, it 
has revealed new avenues for exploiting FFA receptors as pharmacological 
targets. In particular, this has been by validating a new mechanism for 
measuring ligand binding at these receptors using fluorescent tools. It has also 
revealed future possibilities to increase FFA ligand selectivity by targeting FFA 
receptor dimers or  isoform-specific signalling pathways.  
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